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ABSTRACT 
To improve the outcomes of drug therapy, there is increasing interest in the 
community pharmacist providing medicines management services (MMS) 
(Department of Health, 2000b, 2003a). In 2001, the Department of Health 
funded the Community Pharmacy Medicines Management Project (CPMMP) to 
evaluate the introduction of a community pharmacy led MMS. 
This thesis set out to critically assess the views and experiences of community 
pharmacists and general practitioners (GPs) participating in the CPMMP; 
exploring how relationships and perceptions of each other could influence 
community pharmacists carrying out a MMS, from the viewpoint of both 
community pharmacists and GPs. 
This is a qualitative study whereby eight focus groups were conducted with 
thirty five community pharmacists, and semi-structured telephone interviews 
were carried out with twenty one GPs and twenty eight community 
pharmacists. Data was analysed using the broad principles of Grounded 
Theory (Glaser and Strauss, 1967). 
Almost all pharmacists and GPs stated they had a good working relationship 
with each other prior to the MMS commencing, although a number of 
attitudinal barriers were identified. These included professional hierarchy, GPs' 
lack of awareness of a pharmacist's training and role in health care, and 
concerns that commercial interests could potentially affect a community 
pharmacist's advice. However, these data suggested that where there was an 
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established relationship between the two professions, the most positive 
feedback about the MMS was reported. 
These data also suggested that some GPs were not supportive for community 
pharmacists to undertake a MMS and were generally unwillingly for the 
community pharmacist to have full access to patients' medical records. There 
were also some concerns around boundary encroachment. 
The project had a limited impact on improving relationships between 
community pharmacists and GPs, with relationships and GPs' perceptions 
remaining unaltered in many instances. This piece of research has highlighted 
that attitudinal barriers need to be addressed in order to accomplish effective 
collaborative working between community pharmacists and GPs. 
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1. INTRODUCTION 
1.1 Origins and development of the thesis 
This thesis grew out of a commissioned piece of health services research 
(HSR), and an interest in how community pharmacists and general 
practitioners (GPs) relationships and perceptions of each other affected the 
ability of community pharmacists to develop new roles. 
There have been drivers from within the pharmacy profession alongside 
external factors such as Government policies, which have called for community 
pharmacists to develop new roles beyond dispensing medication (Nuffield 
Foundation, 1986; Joint Working Party, 1992; Department of Health, 2000b, 
2003a; Pharmaceutical Services Negotiating Committee, 2004). For example, 
the Department of Health (DoH) document 'Pharmacy in the Future-
Implementing the NHS Plan' (Department of Health, 2000b), set a target date 
of 2004 for the implementation of schemes within primary care that allowed 
people to get more help from pharmacists in using their medicines. To provide 
this 'targeted support for patients' and to improve the outcomes of drug 
therapy, there is increasing interest in community pharmacists providing 
medicines management services (MMS) (Department of Health, 2000b, 
2003a). MMS can include all aspects of the supply and use of medicines, from 
an individual patient medication review to a health promotion programme 
(National Prescribing Centre, 2002). 
Inevitably, community pharmacists need to communicate and collaborate 
more extensively with GPs if they are to successfully accomplish this role 
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extension. Likewise, the support of GPSl is essential for pharmacists to 
successfully deliver a collaborative MMS, and to ensure the successful 
implementation of health care policies concerning community pharmacists, 
such as the new community pharmacy contract in England (Pharmaceutical 
Services Negotiating Committee, 2004). It is therefore important to 
understand how the relationship between community pharmacists and GPs, 
along with their perceptions of one another, could influence the ability of 
community pharmacists to develop new roles. 
There are many empirical studies that have explored the feasibility of 
coordinating patient care between pharmacists and physicians in order to 
manage specific, chronic disease states (Bogden et ai, 1998; Weinberger et ai, 
2002; Tsuyuki et ai, 2002; Clifford et ai, 2002) or aid health promotion 
incentives (Bond et ai, 1999; Zermansky et ai, 2001; Maguire et ai, 2002). 
Many of these studies have concluded that pharmacists' interventions can 
have a positive impact on clinical outcomes (for example, improved blood 
pressure control), economic outcomes (for example, rationalising a patient's 
medication to reduce drug costs), and improve patient satisfaction regarding 
their treatment. However, few of these have explored in depth, or commented 
on how the relationship between the two professions, or attitudinal factors had 
impacted on the success of the outcomes described above. 
Whilst it could be hypothesised that improving the relationship or contact 
between the pharmacist and physiCian would have a positive effect on 
collaborative working, the literature is conflicting. Some studies have 
I The term 'GP' has been used in this thesis when the literature has specifically stated that GPs 
were involved in the study. Where the literature has not clarified this, the term 'physician' has 
been used. 
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concluded that improving relationships between physicians and pharmacists 
had a significant, positive, impact on the attitude of physicians towards 
pharmacists extending their role (Bogden et ai, 1998; Muijrers et ai, 2003). 
However, other authors (Adamcik et ai, 1986; Chen, 2001a; Hughes and 
McGann, 2003) have concluded that improving relationships has an 
insignificant or negative effect on collaboration, as it can threaten social 
relationships or reinforce the physicians' existing and sometimes negative view 
of the community pharmacist. 
Furthermore, the available literature suggests that there are significant 
attitudinal barriers shaping the scope for collaboration between physicians and 
pharmacists. These include professional hierarchy (Hughes and McGann, 
2003), physicians' lack of awareness of a pharmacist's training and role in 
health care (Smith et ai, 2002; Hughes and McGann, 2003) and concerns that 
commercial interests could potentially affect a community pharmacist's clinical 
advice (Adamcik et ai, 1986; Spencer and Edwards, 1992; Ellis et ai, 1992; 
Hughes and McGann, 2003). 
The literature also suggests that physicians have often seen the extension of 
the pharmacist's role as boundary encroachment (Eaton and Webb, 1979; 
Adamcik et ai, 1986; Gilbert, 1997, 1998a-c, 2001; Edmunds and Calnan, 
2001). Some SOCiologists have argued that community pharmacists may 
challenge medicine's autonomy and dominance by trying to extend their roles 
into more clinical domains such as prescribing and medicines management 
(Elston, 1999; Britton, 2001). Consequently, as pharmacists have tried to 
extend their role, physicians have opposed this and exercised a tight control 
over their task boundaries (Adamcik et ai, 1986; Gilbert, 1998a-c, 2001). This 
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is supported by literature that has investigated GPs' views on the extension of 
the community pharmacist's role into more clinical areas, such as monitoring 
blood pressure or deciding appropriate prescription medication for a patient 
(Ritchey and Raney, 1981; Spencer and Edwards, 1992; Ellis et ai, 1992; 
Bleiker and Lewis, 1998; Ewen and Triska, 2001; Hughes and McCann, 2003). 
These studies demonstrated that whilst GPs generally favoured community 
pharmacists extending their roles and often welcomed a greater degree of 
collaboration with them, GPs often identified roles which they believed were 
appropriate for community pharmacists to become more involved with. In 
these studies there was a general trend for GPs to be least supportive of tasks 
that allowed the pharmacist the opportunity to make independent, 
autonomous decisions regarding treatment. This led to a view that pharmacy's 
professional development has been hindered largely because of medicine's 
control over its clinical autonomy (Edmunds and Calnan, 2001; Gilbert, 1998a-
c, 2001). This research set out to explore these arguments in more depth 
using data from a specific piece of commissioned research involving 
collaboration between community pharmacists and GPs. 
1.2 The project and its framework 
This thesis is based on an evaluation of a specific service which involved 
collaborative working between community pharmacists and GPs. This service 
was named the Community Pharmacy Medicines Management Project 
(CPMMP). The CPMMP was developed by the Pharmaceutical Services 
Negotiating Committee (PSNC), funded by the DoH and evaluated by an 
independent research team. This project aimed to evaluate the provision by 
community pharmacists of a MMS for patients with coronary heart disease 
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(CHD), primary and secondary objectives are detailed in Chapter 3. I was 
employed as a Research Fellow to investigate specific objectives relating to the 
evaluation of this service. I also had the opportunity to undertake a part-time 
PhD and used the data collected as part of the evaluation, in order to explore 
specific questions about collaborative working. 
The specific questions driving the research were how relationships and 
attitudinal factors between community pharmacists and GPs impacted on the 
success of community pharmacists conducting a MMS. I also wanted to 
establish whether relationships and perceptions altered between the two 
professions during the course of the project. Finally, I wanted to frame this 
research using concepts from the sociological literature. For example, did the 
partiCipating pharmacists and GPs view the extended role that the community 
pharmacists were undertaking in this project as boundary encroachment, or as 
tasks that GPs were delegating to them? 
1.3 Structure of the thesis 
The thesis is laid out in a conventional format. Chapter 2 is the first of two 
literature review chapters. This chapter explores the factors that have 
influenced pharmacists to redefine their role and how this in turn has affected 
their relationships with physicians. Firstly, I discuss the literature about how 
pharmacists have attempted to redefine their role in response to changes from 
the pharmaceutical industry and other developments, such as increased 
consumerism. An overview of contemporary health policy developments is 
then provided and I discuss the factors which have shaped health policies and 
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how this has impacted on the community pharmacist's role and in turn how 
this has affected their professional status. 
In the final part of this chapter the literature on how the medical profession 
has responded to both pharmacists and nurses extending their clinical role is 
examined. An overview of physicians' views regarding the extension of the 
pharmacist's role is detailed in order to ensure a thorough grounding for what 
follows. 
Chapter 3 provides details about the National Services Framework (NSF) for 
CHD and highlights the potential medicines management role for community 
pharmacists. The chapter then looks at studies conducted where pharmacists, 
usually community pharmacists, have had a medicines management role in 
CHD. These studies generally demonstrated that pharmacists have had a 
beneficial effect on clinical outcomes, and have improved patient satisfaction 
concerning their treatment. Again, few of these studies have explored how the 
relationship and attitudinal factors between the pharmacist and physician have 
impacted on the success of the collaborative intervention. Finally in this 
chapter, the CPMMP will be discussed. An overview of the project is detailed, 
as the project provided the subjects and time frames from which I collected 
my data. 
Chapter 4 sets out the aims and objectives for this piece of research. Chapter 
5 goes on to detail the methods used to address the specific research 
questions, with justifications about why they were used, and the practicalities 
and problems experienced in using these methods. 
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Chapter 6 is the first of three data chapters exploring the relationship and 
attitudinal factors between the community pharmacists and GPs participating 
in the CPMMP. In this first data chapter, findings from focus groups with thirty-
five community pharmacists and telephone interviews with two community 
pharmacists are reported. The data collection focused on the working 
relationship between community pharmacists and GPs prior to, and during the 
first four months of the MMS commencing, establishing how community 
pharmacists thought GPs perceived them. Pharmacists also report their 
experiences and views about undertaking a MMS role, helping to establish any 
potential and actual barriers which could limit them from conducting this role. 
Chapter 7 explores GPs' perspectives of community pharmacists conducting 
this MMS. This chapter presents data from telephone interviews with twenty-
one GPs, conducted six months after the introduction of the MMS. The chapter 
reports on GPs' relationships with and, perceptions of community pharmacists, 
along with their experiences and views about community pharmacists 
conducting a MMS. 
Chapter 8 is the final data chapter and turns its attention back to community 
pharmacists' views of collaborative working at the end of the MMS. This 
chapter presents data from telephone interviews with twenty-eight 
pharmacists and explores whether the MMS impacted on their working 
relationship with their local GPs and their overall views about community 
pharmacists conducting a MMS. 
Chapter 9 discusses the issues raised from my findings. Also discussed are my 
reflections upon being involved in a large randomised controlled trial, the 
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research methods used, and how my professional background may have 
impacted on the data collected. I draw together the material put forward in 
the three data chapters to consider how the initial research questions can be 
answered. The chapter further expands on the barriers identified by the 
community pharmacists and GPs to the extension of the community· 
pharmacist's role, and how they differ from and support the existing literature. 
Finally, I conclude this chapter by discussing whether community pharmacists 
and GPs saw this role extension for community pharmacists as boundary 
encroachment or task delegation. 
Chapter 10 is the final chapter of this thesis, and looks at the lessons that may 
be learnt from this piece of research. It aims to highlight the importance of 
breaking down potential attitude and relationship barriers between 
pharmacists and physicians before commencing collaborative work. I support 
this argument by exploring the literature on different initiatives and strategies 
which have been suggested, or used to break down attitudinal barriers and 
enhance collaborative working between pharmacists and physicians. 
29 
2. RE-DEFINING THE COMMUNITY 
PHARMACIST'S ROLE 
2.1 Introduction 
This chapter explores the factors that have influenced the profession of 
pharmacy, in particular community pharmacy to attempt to redefine its 
role, and in turn how physicians have responded to these attempts at role 
extension. Firstly, I explore the literature looking at how community 
pharmacy has responded to changes from the pharmaceutical industry 
surrounding the manufacture and distribution of medicines, along with 
other potential factors such as greater 'consumerism' in health. I then aim 
to give an overview of health policy developments that have occurred 
during the last twenty-five years that have affected the profession of 
pharmacy. I discuss the key factors which have shaped health policy over 
this period, and how this in turn has impacted on community pharmacy. I 
provide an overview of the main medicine management initiatives piloted 
in the United Kingdom (UK). Also considered is how these changes have 
affected pharmacy's professional status. 
Historically, physicians have diagnosed and prescribed, while pharmacists 
have compounded and dispensed medications (Smith et ai, 2002). 
However, with changing Government reforms, other healthcare professions 
extending their roles, and greater consumerism, it is argued that this right 
has been challenged (Britten, 2001). In the final part of this chapter, the 
literature exploring how the medical profession has responded to both 
pharmacists and nurses attempting to extend their roles in health care will 
be discussed. 
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2.2 Literature review on the community pharmacist's role 
publications on MEDLINE, EMBASE, CINAHL, PHARMLINE and the British 
Nursing Index, were searched from January 1966 to present day. This 
broad time frame was chosen to capture any medical and sociological 
literature looking at how community pharmacists' roles had changed, and 
to incorporate any initiatives which had resulted from Government and 
independent policy recommendations for the pharmacy profession. A 
combination of the following terms were used: General Practitioners, GPs, 
physician(s), collaboration, role extension, prescribing, medical profession, 
power, nurses/nursing, pharmacists/pharmacy, community pharmacists, 
relationships, interdisciplinary relationships, professional relationships, 
professions, deprofessionalisation, consumerism and professionalism. 
Inclusion terms were English language and studies (from any country) 
which involved the following: 
• Relationship/collaboration between physicians and pharmacists 
• Relationship/collaboration between physicians and nurses 
• Extending the role of pharmacists and nurses 
• The perception of the community pharmacist from the viewpoint of 
community pharmacists, physicians and nurses 
Studies that involved collaboration between physicians, pharmacists and 
nurses were discarded if the primary outcomes/objectives were not 
concerned with the interaction or relationship element to the collaboration. 
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2.3 The origins of the community pharmacist's role 
In the UK, the modern day pharmacist has roots dating back to a specialist 
sub-group (the apothecaries) set up within the Company of Grocers in the 
Middle Ages. In the 16th century, a Society of Apothecaries was formed, 
giving them a monopoly in compounding and dispensing (Traulsen et ai, 
2004). It became customary for an apothecary to accompany a physician 
on his house call. The physicians would diagnose and prescribe, whilst the 
apothecary would compound the remedy in their shop and return to the 
patient to administer it. The apothecaries acquired a great deal of medical 
knowledge from working with a phYSician and gradually began to prescribe 
for patients who frequented their shops. Gradually, the apothecaries 
extended their activities to visiting the sick at home, and began to 
diagnose and prescribe for them. They made no charge for medical advice 
but charged for the medicine. Consequently they treated most of the 
population, as only the rich could afford the service of a physician. Until the 
creation of the National Health Service (NHS) in 1948, community 
pharmaCists often remained the first port of call for healthcare advice 
(Silcock et ai, 2004). However, with the formation of the NHS they became 
independent contractors to this organisation, with their payments coming 
chiefly from dispensing rather than selling over-the-counter (OTC) or 
proprietary medicines (Silcock et ai, 2004). 
2.4 The effects of large scale manufacturing on the 
community pharmacist's role 
The pharmacist's traditional role of compounding and formulating 
medicines, involved an understanding of and control of an exclusive field of 
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knowledge surrounding the chemistry, pharmacology and formulation of 
drugs. However, the role of community pharmacy has changed in recent 
years and their once exclusive field of knowledge, largely in compounding 
and formulating medicines has diminished. This has been due to the advent 
of large-scale manufacturing of medical products in the latter half of the 
twentieth century, medical specialisation and increased medical 
technology. The predominance of original patient pack dispensing has 
diminished the pharmacist's compounding and formulating skills. The 
presence of patient information leaflets supplied with medication (these 
leaflets contain information about dosage, dosage frequency and possible 
adverse effects) has further reduced the advice function of the pharmacist. 
Increased computerisation in GP practices and pharmacies, mean that 
individual patient records and product information are produced. These 
programmes highlight potential drug interactions and produce appropriate 
warnings, again restricting and diminishing the ability of pharmacists to 
exercise clinical judgment. It has been argued that the community 
pharmacist's work has become increasingly routine and deskilled, and has 
limited their scope to utilise their own unique knowledge and skills in their 
day-to-day tasks (Harding and Taylor, 2002). The main health-related 
services community pharmacists now provide is the dispensing of 
prescriptions and supervising the sale of OTC medicines (Hibbert et ai, 
2002). 
2.5 Increased 'consumerism' in health 
Another factor that is thought to potentially have had impacted on the role 
of the community pharmacist is the present day 'consumer' of health care 
services. Historically, the patient has been regarded as occupying a 
submissive position, with implications of dependency and unquestioning 
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compliance with medical instructions. However, this emphasis on social 
control and the 'docile' body is felt to be less appropriate when considering 
the present day 'consumer' of health care services (Williams and Calnan, 
1996). The rise of consumerism is regarded as one of the fundamental 
developments shaping health service delivery within the UK (Nettleton, 
1995). Government reforms and polices endorsed a view that service users 
should become more empowered in their relationships with health 
professionals. This has led to a more demanding consumer and empowered 
patient, who is more able and willing to question the practices of the health 
care professionals (Varnish, 1998). 
Higher levels of education, greater media coverage of medical issues, and 
an increased availability of medical information have also reduced the 
knowledge gap between the pharmacist and patient. The increased 
deregulation of Prescription Only Medicines (POMs) has increased the range 
of medicines available for purchase. This has offered new opportunities for 
the self-treatment of ailments by the consumer (Blenkinsopp and Bradley, 
1996). 
There have been limited studies conducted regarding how the general 
public, perceive community pharmacists. However, those studies that have 
looked into this, confirm that the general public view community 
pharmacists as having little autonomy and often state that they would not 
consult them first line for advice (even regarding minor ailments). They 
also had clear ideas of suitable roles that community pharmacists should 
undertake (Varnish, 1998; Bell et ai, 2000; Iverson et ai, 2001). For 
example, the general public was in favour of community pharmacists 
providing advice in areas such as 'healthy living' or 'minor ailments' but 
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were less in favour of roles where the pharmacist would have access to 
patient medical records (Bell et ai, 2000; Iverson et ai, 2001). 
In Varnish's study (1998), there was a question over the autonomy of the 
pharmacist's work, particularly in the area of the interprofessional 
boundary between a pharmacist and a doctor. The participants often saw 
the pharmacist as having 'expert knowledge of drugs', which was often 
considered to be superior to a doctors but the doctor was still seen as 
being ultimately responsible for the patient's health. Therefore the 
pharmacist was perceived to be answerable to the doctor and had little 
responsibility for the choice of medication or freedom to exercise their 
professional judgement. 
2.6 Reprofessionalisation 
In response to the potential de-skilling brought about by the processes 
described above, representatives of the pharmacy profession have tried to 
redefine the community pharmacist's role (Edmunds and Calnan, 2001). 
Pharmacists have tried to promote themselves as providers of a broader 
range of services than has previously been the case. The profession's 
response to their loss of function and role ambiguity was a movement 
towards 'reprofessionalisation', which began in the 1960s and has 
continued today (Birenbaum, 1982). 
The concept of reprofessionalisation reflects the strategies used by 
pharmacists to enhance their professional status. The process of 
reprofessionalisation took on different forms, but had a common thread of 
moving away from an emphasis on technical tasks e.g. compounding, 
towards a closer interaction with physicians and other health professionals 
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and a stronger pharmacist-patient relationship (Adamcik et ai, 1986). The 
development of 'clinical pharmacy' in the hospital setting has been of the 
major achievements of pharmacy reprofessionalisation (Hepler, 1985; 
Cotter et ai, 1994). More active involvement in patient care has been less 
successful in the community setting, due to geographical isolation from the 
rest of the primary healthcare team and a lack of access to patients' 
medical records (Cotter et ai, 1994). 
Hospital pharmacists had the advantage of being less isolated from the rest 
of the secondary health care team and had greater accessibility to patient's 
medical records, allowing them to make more informed pharmaceutical 
decisions and become integrated in the secondary health care team by 
attending ward rounds and clinics (Cotter et ai, 1994). Likewise, as 
community pharmacists' main payment came from dispensing, their day-
to-day role had more structural and contractual restraints, with less 
freedom to develop clinical roles (Silcock et ai, 2004). 
Another factor that potentially has made it difficult for community 
pharmacists to implement new roles has been supervision restrictions 
placed on them. The Medicines Act 1968 required that pharmacy and POMs 
be sold or supplied by a pharmacist, or by someone acting under the 
supervision of a pharmacist. However, the Act did not specify that the 
pharmacist had to be physically present in the pharmacy to do this, but 
supervision was interpreted to mean that the pharmacist must be aware of 
the transaction and be in a position to intervene. It could be argued that 
pharmaCists were partly responsible for this restriction placed on them. In 
1989, a special general meeting was held to discuss whether or not a 
pharmacist always needed to be a final checker in the dispensing process. 
Pharmacists against the recommendations of the then Royal 
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Pharmaceutical Society of Great Britain (RPSGBP) Council voted to remain 
the final checkers. This action immediately restricted the individual 
pharmacist's freedom to ensure responsible and accountable dispensing 
and supply in ways to suit his or her practice. This confirmed the policy 
that pharmacists should never leave their premises for long. It is now 
hoped that these requirements are to be changed under the Health Bill, to 
allow registered and suitably trained staff to supervise dispensing and 
medicines sales without direct supervision by a pharmacist. This would 
enable pharmacists to leave their pharmacies and offer a wider range of 
services (Anon., 2005). 
As the next section of this chapter demonstrates there have been drivers 
from within the pharmacy profession alongside external factors such as 
Government health policies, which have called for community pharmacists 
to develop their roles beyond dispensing (Nuffield Foundation, 1986; Joint 
Working Party, 1992; Department of Health, 2000b, 2003a; 
Pharmaceutical Services Negotiating Committee, 2004). These will be 
detailed and discussed in chronological order, starting with health policy 
developments under the Conservative government. 
2.7 Health policy under the Conservative government 
In 1979 the Conservative government came into office. Over the next 15 
years health policy changed as a consequence of both economic and 
political influences on the NHS. This halted the rapid expansion of public 
services and public expenditure that had occurred since the setting up of 
the NHS. The consequence for the NHS in the first part of the 1980's was 
that budgets grew much more slowly, with the emphasis on making the 
NHS more business like using existing budgets more efficiently (Ham, 
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2004). This led to a series of polices intended to increase efficiency 
including the requirement that Health Authorities (HAs) should generate 
efficiency savings every year, to release funds from existing budgets to 
support new service developments. 
In relation to the profession of pharmacy, during this period the Nuffield 
Report (Nuffield Foundation, 1986) was published. This was a landmark 
report on the future development of the pharmacy profession, that 
specifically recognised that pharmacists were a highly trained and under 
utilised healthcare resource. The report acknowledged that the community 
pharmacist's role had failed to develop, and recommended structural and 
contractual changes to free community pharmacists from dispensing. Few 
of the report's recommendations were implemented, although new 
activities that were implemented included keeping pharmacy-held patient 
medication records, health promotion and pharmaceutical advice for 
residential care homes. However, it could be argued that these activities 
were generally not contentious in nature and posed little threat to GPs' 
autonomy. 
The major reforms made by the Conservative government left community 
pharmacists virtually untouched in the creation of the internal market, trust 
status hospitals and fund-holding GPs. However, these reforms did affect 
pharmacy practice services as primary care started to become a higher 
priority due to HAs and fundholders undertaking a reassessment of 
expenditure patterns. As HAs began allocating drug budgets, fund-holders 
saw the need for help to make their prescribing more cost effective and 
clinically appropriate. This opened up new strategic and operational 
opportunities for many pharmacists (Silcock et ai, 2004). This was the start 
of primary care pharmacy, as individual pharmacists (either employed by 
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GP practices, the HAs or self employed) started to help GPs switch to 
generic prescribing, manage repeat prescribing and implement evidence-
based practice within the GP practice. 
During the 1990s there were several reports published, which again made 
recommendations about further developing the role of the community 
pharmacist. In 1992, the pharmacy profession discussed formal 
development of community pharmacy contractors with the DoH via a joint 
working party (joint Working Party, 1992). This resulted in a long list of 
agreed recommendations and new roles for community pharmacists. 
However, implementation was once again poor, primarily because the 
legislation and contractual changes were never brought forward (Silcock et 
ai, 2004). 
In 1995, the RPSGB began a consultation exercise 'Pharmacy in a new age' 
(PlANA). They aimed to gather evidence of good practice and stimulate 
pharmacy development to help develop a strategy for pharmacy in the 21st 
century (Royal Pharmaceutical Society of Great Britain, 1996 & 1997a). 
The results were formally passed over to individual pharmacists in 1998 
that had expressed an interest to engage in service development (Royal 
Pharmaceutical Society of Great Britain, 1998). There have been some 
service development achievements by the creation of local Pharmacy 
Development Groups (PDGs), for example, the provision of the emergency 
hormonal contraception services. These groups of pharmacists (made up of 
a cross-section of pharmacists) worked with Local Pharmaceutical 
Committees (LPCs) to develop new services and respond to policy 
initiatives. However, once again PDGs do not exist in all areas and some 
have been more successful than others in funding and implementing new 
services (Silcock et ai, 2004). 
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2.8 Health policy under New Labour 
In 1997, the Labour government was elected into office ending 18 years of 
a Conservative government, which led to another period of reforms and 
reorganisation of the NHS. Over the next three years, the Government 
published a series of proposals regarding modernising the NHS 
(Department of Health, 1997, 2000a). The overall aim was to improve 
health and tackle health inequality in England (Department of Health, 
1997). In July 2000 'The NHS Plan: a plan for investment, a plan for 
reform' was published (Department of Health, 2000a). This described a 
programme of reforms and consisted of 10 core principles and aimed to re-
shape care around the patient, improve quality and make better use of the 
skills and dedication of the NHS staff. 
In July 1999 the Government published their white paper 'Saving Lives: 
Our Healthier Nation' (Department of Health, 1999a). It placed greater 
emphasis on the social, economic and environmental causes of illness and 
formally acknowledged the importance of inequalities in health (Ham, 
2004). It was designed as a wide public health strategy for England, 
proposing a national contract for better health in which Government, local 
communities and individuals would work in partnership to improve health. 
It proposed four priority areas: cancer, heart disease (& stroke), mental 
health and older people. 
2.9 Pharmacy in the Future 
'Pharmacy in the Future-Implementing the NHS Plan' was published in 
September 2000 (Department of Health, 2000b). It gave a detailed review 
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of how pharmacy would fit into the NHS Plan. The fundamental change that 
affected community pharmacists was the change in responsibilities from 
HAs to Primary Care Groups initially and then Primary Care Trusts (PCTs). 
PCTs would now have to take the lead on the development of all primary 
care services, assessing need, planning and commissioning all health 
services. As a consequence, pharmacists would need to support improved 
prescribing, help people get the best use out of their medicines and 
develop methods to reduce medicine waste. By 2004, this document stated 
that every PCT across the country should have schemes in place so that 
people could get more help from pharmacists in using their medicines 
effectively (Department of Health, 2000b). 
Implementing 'Pharmacy in the Future' included introducing schemes such 
as: 
• Repeat dispensing arrangements 
• Pharmacist prescribing arrangements 
• One stop primary care centers 
• Provision of emergency contraception 
• Local pharmacy services 
• Smoking cessation 
• Medicines management & concordance 
In July 2003, the Government published a new pharmacy strategy for 
England. "A vision for pharmacy in the new NHS" was designed as a follow-
up document from "Pharmacy in the Future". The document focused on 
community pharmacy and was essentially a progress report, stating what 
had been achieved and a summary of previous announcements. The paper 
however provided a vision of the ten key roles for pharmacy, which were 
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intended to underpin the future direction of pharmacy (Department of 
H e a ~ h , , 2003a).These induded: 
• To provide convenient access to prescriptions and other medicines 
• To advise patients and other health professionals on the safe and 
effective use of medicines 
• To be a point of first contact with health care services for people in 
the community 
• To provide medicines management services, especially for people 
with enduring illness 
• To promote patient safety by preventing, detecting and reporting 
adverse drug reactions and medication errors 
• To contribute to seamless and safe medicines management 
throughout the patient's journey 
• To support patients as partners in medicines taking 
• To prescribe medicines and to monitor dinical outcomes 
• To be a public health resource and provide health promotion, 
improvement and harm reduction services 
• To promote value for money in the use of medicines to reduce 
wastage 
One area that appeared to have moved up the Government's agenda for 
pharmacy was pharmacists' role in public health. It suggested that 
pharmaCists were well placed to improve public health and the wider 
promotion of health (Bellingham, 2003). In 2005, the Government 
published a pharmaceutical public health strategy 'Choosing health through 
pharmacy' (Department of Health. 2005a). The guidance identified public 
health targets that pharmaCists could have an impact in, such as smoking, 
obesity and sexual health, and described how pharmaCists could become 
health champions over the next ten years. For example, the Government 
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has pledged to reduce smoking rates, the programme stated that in 
addition to pharmacists providing opportunistic advice, pharmacists should 
actively participate in local and national stop-smoking campaigns and 
become one of the main providers of specialist NHS stop-smoking services 
(Department of Health, 200Sa). 
2.10 Medicines management initiatives within the UK 
In response to 'Pharmacy in the Future - implementing the NHS Plan' 
(Department of Health, 2000b) and 'A Vision for Pharmacy in the new NHS' 
(Department of Health, 2003a) there have been numerous medicines 
management initiatives piloted throughout the UK. These schemes aimed 
to extend the role of the community pharmacist by allowing the community 
pharmacist to provide clinical medicines management services, such as the 
assessing, monitoring and review of prescriptions, patient medication 
reviews and improving repeat dispensing (National Prescribing Centre, 
2002). Medicines management services potentially enable patients to have 
a greater involvement in their medication, for example through the 
discussion of medication taking and help them get the most from their 
medicines. An overview of these schemes follows. 
There were three main medicines management initiatives in England, 
supported by the DoH. These were the PSNC project (this project will be 
discussed in more detail in Chapter 3), the Medicines Management Services 
Collaborative Programme, co-ordinated by the National Prescribing Centre 
(NPC) in Liverpool, and the Task Force on Medicines Partnership. 
The National Medicines Management Services Collaborative Programme 
was launched in July 2001. It had an initial £1.9 million to support up to 25 
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pilot sites based in PCTs and their GP practices (Department of Health, 
2001). Between 2001 and 2004 it has had four waves of activities, inviting 
pilot sites on to the programme each time. Each pilot site recruited local 
facilitators to work closely with local GPs, pharmacists and primary 
healthcare teams. The participating sites set their own objectives relevant 
to local circumstances. The aims of this programme were to identify 
existing good practice and facilitate change over a two-year period. 
Key themes from the first wave of pilot sites included prescription review, 
medication monitoring, improvement of GP computer and repeat 
prescribing systems, better prescription collection and delivery services, 
and development of concordance between patients and health care 
professionals (National Prescribing Centre, 2002). The programme 
diversified further and in December 2003 hospitals were also invited to join 
in a pilot wave of the Hospital Medicines Management Collaborative 
(Bellingham, 2004a). 
The Task force on Medicines Partnership was a two-year initiative, which 
formed the next phase of the work begun by the Concordance Co-
ordinating Group. It was based at the RPSGB and included representatives 
from health professions, patient groups and the pharmaceutical industry. 
The aim was to encourage concordance between health care professions 
and patients, to share models of good practice and to develop a strategy 
for integrating medicines partnerships into the NHS (Royal Pharmaceutical 
Society of Great Britain, 1997b). 
A further initiative in England was Barking's Medicine Management Project 
for the Elderly. This was launched in February 2002 and like the PSNC 
project was based in community pharmacy. It aimed to investigate the 
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impact of community pharmacists reviewing patients over 65 years on four 
or more medicines. Particular targets were cardiovascular disease (CVD), 
diabetes and asthma. The project is still ongoing but the evaluation will 
look at drug related problems before and after pharmacists' interventions, 
expenditure in certain therapeutic areas, and interactions between 
pharmacists and GPs, along with patients' views. The collaborative team 
evaluating the project includes researchers from Robert Gordon University, 
the University of London and the academic pharmacy practice unit at Barts 
and the London NHS Trust (Anon., 2002a; Morrow, 2002). 
2.1.0.1. Medicines management initiatives in Northern Ireland 
In Northern Ireland pharmacists were paid for reviewing medication under 
a new elective contract operating in health and services board areas 
(Morrison et ai, 2001). This was the first UK scheme to have gone beyond 
the pilot stage into general availability. The service 'Managing Your 
Medicines' first targeted CHD patients but as the scheme widened it 
included other medical conditions such as diabetes. The main aims of this 
pharmacy-based medication review service were to educate patients about 
their medication, ensure medicines were used appropriately and to 
promote communication between all members of the primary healthcare 
team. Patients were recruited for the service either by the pharmacist or 
via referral from the patient's GP. The review involved compilation of a 
medication list (which was completed pre-medication review), followed by 
a medication review in the pharmacy or at the patient's home. It was a 
requirement that participating pharmacists attended training evenings and 
completed a distance learning course. 
45 
A second scheme in Northern Ireland was an integrated medicines 
management programme that involved both the hospital and community 
sector. The project was set up in September 2001 and aimed to implement 
standardisation of products between the hospital-community interface. It 
also aimed to improve communication between the GP, hospital and 
community pharmacist regarding medication on a patient's admission and 
discharge to and from hospital (Anon., 2002b). 
2.10.2 Medicines management initiatives in Scotland 
In 1999, the Scottish Health Department allocated half a million pounds to 
be spent on pilot projects on pharmaceutical care in the community. These 
projects focused on three main areas: the elderly, palliative care and 
mental illness, with payments made to pharmacists providing these 
services (Anon., 1999a). One such example was the Dumfries and 
Galloway Primary Care NHS Trust Frail Elderly project, which investigated 
compliance in the frail elderly. The setting up of a team of pharmacist 
facilitators located across Scotland in October 2001 enabled these pilot 
schemes and others to be rolled out throughout Scotland. 
A second scheme was a minor ailment service. This was a pilot scheme run 
in 176 community pharmacies which demonstrated how community 
pharmacists could effectively supply medication to non-fee paying patients 
who would otherwise have visited their GP or not sought help at all 
(Bellingham, 2004b). 
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2.1.0.3 Medicine management Initiatives in Wales 
In Wales, a pharmacist has been appointed to lead the Welsh Medicines 
Management Collaborative. The programme was launched in June 2004 
and is expected to run for 20 months (Royal Pharmaceutical Society of 
Great Britain, 2004). An expert advisory group consisting of patients and 
professionals (including pharmacists) identified as having 
experience/interest in medicines management has been established to 
provide advice throughout the programme. The overall aims of the 
programme are to: 
• Identify and address unmet pharmaceutical needs 
• Help patients make better use of their medicines 
• Develop innovative approaches to medicines management 
• Provide convenient access to a range of medicines management 
services through multidisciplinary working, building on the strengths 
of pharmacists 
Fifteen Local Health Board sites (each has developed a project team) have 
begun working on this initiative. The Local Health Boards funds and 
supports local medicines management schemes. These can be short-term 
projects or incentives aimed at local issues or a service development to 
improve health in their area. 
2.11 Other health policy developments affecting the 
pharmacy profession 
In response to 'Pharmacy in the Future - implementing the NHS Plan' 
(Department of Health, 2000b) and 'A Vision for Pharmacy in the new NHS' 
(Department of Health, 2003a) there have been other health policy 
47 
developments that potentially affect community pharmacists' roles. 
Developments to pharmacists' prescribing rights and changes to their 
contractual framework, could allow community pharmacists to have greater 
flexibility and a larger role in the management of patients within the 
primary care setting. Each of these health policy developments will be 
discussed in turn. 
2.11.1 The Crown Reports 
In 1998, the first of two reports on 'The Review of Prescribing, Supply and 
Administration of Medicines' was published (Department of Health, 1998). 
The Crown report stated that pharmaCists should be part of the 
multidisciplinary team reviewing group protocols for the administration of 
medicines. Following the recommendations in the final report of 'The 
Review of Prescribing, Supply and Administration of Medicines' 
(Department of Health, 1999b), pharmaCists were granted the opportunity 
to become supplementary (or dependent) prescribers. This opportunity 
became a reality with the passing of the Health and Social Care Act in May 
2001. 
Supplementary prescribing was introduced in April 2003 and was available 
for allied health professionals. It was a voluntary prescribing partnership 
between the independent prescriber (physician) and supplementary 
prescriber, to implement a patient specific Clinical Management Plan (CMP), 
with the patient's agreement (NHS Modernisation Agency, 2005). Following 
finalisation of the CMP, the supplementary prescriber could prescribe 
medication for the patient that had been referred to in the CMP, until the 
next review by the independent prescriber. 
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In November 2005, the DoH announced (after consultation) that they 
would extend pharmacists and nurses prescribing rights, to enable them to 
become independent prescribers (Department of Health, 2005b). From 
Spring 2006, suitably trained pharmacists and nurses will be able to 
prescribe any licensed drug, with the exception of controlled drugs. 
2.11.2 Contractual frameworks for community pharmacists and GPs 
In the last few years, both the contractual frameworks for community 
pharmacists and GPs have undergone major reviews in order to provide 
greater flexibility, in terms of developing and funding services provided to 
PCTS. 
In 2003, negotiations took place on the new contractual framework for 
community pharmacists. The guidelines were drawn up by the NHS 
confederation, the DoH and PSNC, in response to the Government's 
'Pharmacy in the Future' document that stated the existing national 
contractual framework for community pharmacy would be modernised to 
establish minimum standards and to promote and reward high quality 
services (Department of Health, 2000b). 
The contract established a new structure for pharmacy services, which 
incorporated three levels of service (essential, advanced and enhanced). 
The overall aim of the new contract was to enable community pharmacists 
to be rewarded for their professional services, rather than the number of 
NHS prescriptions dispensed. The new contract for community pharmacists 
took effect from 1 April 2005 (Pharmaceutical Services Negotiating 
Committee, 2004). 
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Essential services had to be provided by all pharmacies before they could 
start other services. Essential services included dispensing, repeat 
dispensing (which included maintaining the records of each patient and 
ensuring that there was no reason for them to be referred back to their 
GP), promotion of healthy lifestyles, compliance support for people with 
disabilities, and clinical governance. In addition, the minimum hours of 
opening of a community pharmacy was increased from 30 to 40 hours a 
week. 
Advanced services, could be provided by all community pharmacists once 
they had met the accreditation requirements i.e. undergone the required 
training and had a consultation area in the pharmacy. The proposed 
advanced services include medicines use review and prescription 
intervention. 
Community pharmacists could provide enhanced services if the PCT 
decided to commission them, the decision being based on identifying the 
needs of the population. Such services could include smoking cessation 
services, care home support and supervised administration of prescribed 
medication (Pharmaceutical Services Negotiating Committee, 2004). 
In 2004, a new general medical services (GMS) contract was also 
implemented (Department of Health, 2003b). This contract provided new 
mechanisms to allow GP practices greater flexibility to determine the range 
of services they wished to provide, including opting out of additional 
services and out-of-hours care. The new contract also enabled peTs to 
commission local services to meet local needs. 
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Both these contractual changes mean that community pharmacists could 
potentially be commissioned by PCTs to playa greater part in providing 
essential services to the local population. For example, to provide 
medicines management services to people with chronic diseases. 
2.12 Summary 
Health policy over the last thirty years has largely been shaped by the 
state of the economy and Government decisions on priorities about 
spending programmes. Health policy reforms under the Conservative 
government aimed to make the NHS more businesslike and efficient. The 
NHS under New Labour, acknowledged the importance of inequality on 
health, and policy changes have seen the shift of focus of care onto the 
patient, with the emergence of guidelines of care. These aimed to ensure 
best care for patients were implemented wherever they resided in the UK. 
The community pharmacist's role has been slow to develop, despite several 
reports (during both the Conservative and New Labour government), which 
recognised the greater role they could have within in the primary 
healthcare team. It is unclear why few of these reports were implemented, 
but lack of contractual changes may have been a factor (Silcock et ai, 
2004). 
With the new contractual changes, potential changes to pharmacy 
supervision, Government reforms and with new prescribing opportunities, it 
is arguable that community pharmacists are now in a much stronger 
position to extend their role. However, despite attempts at 
reprofessionalisation there is an ongoing debate whether pharmacy is a 
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'profession' due to the potential deskilling brought about by processes such 
as increased medical technology. 
2.13 Is pharmacy a profession? 
The pharmacist's traditional role of compounding and formulating 
medicines, involved an understanding of and control of an exclusive field of 
knowledge surrounding the chemistry, pharmacology and formulation of 
drugs. This led pharmacy to enjoy a status comparable with occupations 
such as medicine, as they had access to and control of an unique body of 
specialist knowledge, one of the factors which is thought to determine the 
social standing of professions such as medicine (Edmunds and Calnan, 
2001). 
Harding and Taylor (2002) state, the functions and evolution of a 
profession, together with its relationships with the state and public, are key 
elements in any strategy to secure a privileged (and well remunerated) 
social position for its members. Technological advances have diminished 
the pharmacist's traditional activities in the compounding and dispensing of 
medicines, and sociologists state that this challenges their claim to a 
professional status due to an associated decline in their social and 
economic status (Harding and Taylor, 1997). Furthermore, an occupation's 
claim to professionalism is partly dependent on the power relationship 
between the occupation's members and those served by them to create 
social distance or 'mystification', The increasing dependence on technology 
has caused the 'mystique' the public has traditionally associated with 
pharmacists to largely disappear, with the practical aspects of dispensing 
being viewed as technical activities largely carried out by pharmacy 
technicians rather than by pharmacists (Taylor et ai, 2003). 
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There have been a number of theoretical approaches used in the sociology 
of professions. One well-known approach was the functionalist approach, 
which began with Talcott Parsons. His approach viewed the professions as 
fulfilling useful and necessary social functions. According to Parsons, 
professionals exercised their important social function through 
"mechanisms of social control", by applying scientific and rational 
knowledge to particular cases. Professionals ensured and maintained 
progress in society by deploying certain features that made their actions 
distinctive from those of non professionals (Parsons, 1954). Other writers 
in this tradition have emphasised the professions' functional traits, such as 
altruism and the obligation of service. These writers adapted what is known 
as the 'trait approach', listing the characteristics in which a profession 
should have, for example a code of ethics regulating that profession. 
Another major theoretical approach that has dominated sociological work 
on the professions has looked at power. Sociologists focused on how 
professions, in particular medicine, instead of holding society together with 
their invaluable activities, were exerting their powers to preserve their 
privileged place in society (Harding and Taylor, 2002). The three key 
concepts in this approach was power over the social object, social 
stratification and monopoly. These concepts, according to the power 
approach were what a profession should strive for. A major focus of this 
approach was the relation, in terms of relative power to other healthcare 
professionals. Not being subordinate to another profession was considered 
crucial for professionals to succeed. 
Within sociological writing on pharmacy, many attempts have been made 
to define the practice of pharmacy as either a profession or non-profession. 
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The two main areas of critique are that as a profession, pharmacy is torn 
between a professional approach and a business approach (Denzin and 
Mettlin, 1968). The second area centres on the fact that the power of the 
working environment is not contained solely within the profession, but is to 
a large extent in the hands of the medical profession. 
Knapp and Knapp (1968) addressed pharmacy practice at both the macro 
and micro level in the community pharmacy setting. Their conclusion was 
that pharmacy had not been able to clearly define and accept its 
professional function and role. Drug control was in the hands of the medical 
profession and pharmacies were torn between commercialism and 
professionalism. Pharmacy had the potential to become a health 
profession, but had failed to become one. 
Denzin and Mettlin (1968), argued that pharmacy had become an 
'incomplete' or 'quasi- profession', over-trained for what they did and 
under utilised in relation to what they knew. They argued pharmacy had 
taken on some of the characteristics necessary to be a profession but was 
still incomplete. Pharmacists had failed to gain control over their social 
object, the drug. In the retail setting of pharmacy, pharmacists viewed the 
drug as a product to be sold instead of an object at which to direct 
services. Their paper argued that pharmacy lacked control over the social 
object of its practice (the medicine) and that pharmacists were guided by 
commercial interests, at odds with the supposedly altruistic, service 
orientation of professions. 
In 1995, Dingwall and Wilson criticised Denzin and Mettlin over their 
analysis of the incomplete pharmacy profession. They argued the reason 
Denzin and Mettlin concluded that the pharmacy profession was incomplete 
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was because they had analysed the pharmacy profession from standards of 
the medical profession instead of defining it on its own terms. Dingwall and 
Wilson (1995) acknowledged that pharmacists were technically oriented, 
but they argued the pharmacist had a distinctive role in the symbolic 
transformation of drugs from natural into social objects. They argued 
Denzin and Metlin had failed to acknowledge the drug as a basis for social 
action. They further argued that commercialism might not be the real 
problem, concluding that a new approach should be taken in the sociology 
of professions that identified the true values of the pharmacy profession. 
Harding and Taylor (1997) addressed the new roles of community 
pharmacists in the UK. In line with Dingwall and Wilson, they argued that 
pharmacy has the necessary knowledge base to control the symbolic 
transformation of drugs (the pharmacological entity), into medicines (the 
social object). They believed that by pharmacists trying to redefine their 
role and promote themselves as providers of a broader range of services, 
they served to deprofessionalise the pharmacy profession further. They 
argued pharmacists had failed to capitalise on their unique social function 
in supplying drugs. This social function had not been fully realised but was 
central to pharmacists successfully attempting to define their professional 
role, and preserving their claim to a privileged occupational status. 
Gosselin and Robbins (1999) made a recent analysis of the pharmacy 
profession. They detailed the evolution of the pharmacist from 
compounder-dispenser to advisor-counselor, and described the dilemma for 
the pharmacy profession. They believed pharmacists were torn between 
being business people and professional practitioners. They identified the 
primary role of the pharmacist today as dispensers and concluded that the 
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criterion for pharmacy professionalism lay in its consultative role to 
patients concerning drugs and rational ising drug use. 
2.14 Summary 
It is generally agreed that the current role of the community pharmacist 
has changed in recent years due to the advent of large scale manufacturing 
of medical products, increased medical technology and increased 
consumerism. These changes have diminished many of the traditional 
functions associated with pharmacists, for example compounding and 
formulating medicines. Sociologists state that this challenges their claim to 
a professional status due to an associated decline in their social and 
economic status (Harding and Taylor, 1997). 
The professional status of the pharmacist remains a contentious issue. 
Whilst representatives of the pharmacy profession have tried to redefine 
the pharmacist's role to promote them as providers of a broader range of 
services, this process has been less successful in the community setting. I 
believe until the community pharmacist can re-establish roles where they 
can be seen to be exerting their expertise, whether or not they are deemed 
to be a 'true professional' by sociological classifications will be an on-going 
debate. 
Y. 2.15 The changing role of the physician 
The final part of this chapter focuses on physicians, looking at the factors 
that have challenged their autonomy and in turn, how they have responded 
to other members of the primary health care team attempting to extend 
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their role. The literature on physicians' responses to both pharmacists and 
nurses attempting to extend their roles in health care will be discussed. 
Sociological literature during the 1960s and 1970s emphasised the 
professional dominance of medicine within the health care division of 
labour (Friedson, 1970). The concept of power has been central to the 
sociology of medicine for over 30 years, with Friedson (1970) arguing that 
there were two inter-related components to medicine's power: autonomy 
and dominance. Medicine had the ability to control its own work activity 
(autonomy), but it could also define the limits of the work of other 
occupational groups (dominance). Elston (1991) further differentiated 
between medicine's autonomy, stating they had economic autonomy (the 
right of physicians to determine their remuneration), political autonomy 
(the right of physicians to make policy decisions as the legitimate experts 
on health matters), and clinical autonomy (the right of the medical 
profession to set its own standards and control clinical performance). 
/' Since the 1970s onwards, sociologists have generally agreed that 
medicine's autonomy and dominance has been challenged, and have 
evaluated the impact of changes of health service reforms and other 
challenges to their autonomy such as increased consumerism and other 
health professionals trying to extend their role. Sociologists argue that two 
distinct processes pose challenges to medical dominance: 
deprofessionalisation and proletarianisation (Elston, 1991; Annandale, 
1998). 
Proponents of the proletarianisation thesis have argued that the medical 
profession, along with other professional groups, is losing control over their 
working conditions as a result of the economic requirements of advanced 
capitalism. Proponents of the deprofessionalisation thesis argue that 
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medicine is losing its professional status and in particular that this is being 
challenged by consumerism (Britten, 2001). 
It is argued that in British general practice, prescribing is a battleground on 
which the cause of clinical autonomy is defended, with prescribing being 
one of the core activities that demarcate the medical profession from other 
groups (Britten, 2001). Physicians work within increasingly complex 
organisational structures, and their work is becoming ever more 
rationalised. In the UK, the introduction of the National Institute for Health 
and Clinical Excellence (NICE) recommendations, the developments of 
NSFs for the treatment of chronic diseases, the drive to change prescribing 
behaviour from PCT boards and the deregulation of POM to pharmacy 
medicines have all helped to reduce the medical profession's autonomy to 
prescribe. 
/ Deregulation of medicines has had the effect of reducing the range of 
medicines over which physicians have exclusive control, and may therefore 
be seen as a reduction of clinical jurisdiction (Britten, 2001). Deregulation 
of POMs has given the consumer more choice and in doing so, the 
responsibility of the pharmacist is increased (as OTC medicines are free of 
medical control), thus allowing pharmacists a greater degree of control 
over the supply of medicines to consumers. However, a study by Erwin et 
al (1996) found that the proportion of GPs agreeing to drugs becoming 
available OTC had increased from an earlier study, which had looked at 
GPs' views on the deregulation of POM medicines. Although a small scale 
study, the authors concluded the change in attitude may have reflected 
greater awareness of the cost of prescriptions to the NHS and the need for 
cost containment. Other reasons put forward included GPs encouraging 
self-medication for relatively minor ailments due to increased pressures on 
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their time, more awareness of the community pharmacist's role within the 
primary health care team and being more supportive of pharmacists' role 
extension. 
Patient demands are also thought to be challenging the medical 
professions' exclusive right to prescribe. Drawing on qualitative interviews 
with GPs, Weiss and Fitzpatrick (1997) have carried out work exploring the 
deprofessionalisation and proletarian thesis in relation to prescribing. They 
argued that the greatest threat to GPs' clinical autonomy was from 
deprofessionalisation through lay challenges to GP prescribing. The advent 
of the Internet and wide spread information sources, along with 
Government polices endorsing greater consumerism had caused patients to 
challenge GPs' prescribing decisions. However, their work was based on the 
prescriber's perspective rather than on an analysis of consultations or 
patients' views (Britten, 2001). 
By contrast, Britten (2001) took the view that the literature did not suggest 
that the challenge to clinical autonomy came from articulate, well-informed 
consumers. She argued that physicians cited patients' inappropriate 
demands as problematic, although physicians often did not give patients 
the information about their medicines that they required. She believed 
when the medical profession was in conflict with the state, patients' needs 
and expectations may be cited in support of professional claims, while in 
other professionally defined contexts, patients' demands may be seen as a 
threat to clinical autonomy. As a form of resistance, non-compliance 
reflected the patient's autonomy without necessarily reducing the 
physician's autonomy or power. 
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Work by Lupton (1997) also showed mixed views about the effect of 
consumerism on medical autonomy. She attempted to find out what 
physicians thought of the changing social position and status of the medical 
profession. The findings from the study suggested physicians were highly 
aware of, and sensitive to changes that have taken place regarding the 
public perception of their profession. Most of the interviewed physicians 
believed that their profession in general was not considered quite as 
powerful as perhaps they once were, although they did not mind greater 
consumerism on the part of the patients. Female and younger physicians 
interviewed were particularly positive about changes they believed had 
occurred in relation to patient's attitudes to their physicians. However, 
specialist practitioners (who tended to be older and male) noted that they 
still found patients willing to be guided by their medical expertise. 
A recent survey of more than 2000 trainee physicians and medical 
students, found that eight out of ten respondents thought medical 
professionalism to be under threat largely due to external factors 
(Kmietowicz, 2005). They believed that high public expectations of what 
medicine could do and too many Government targets were reducing 
physician' autonomy and could ultimately drive physicians out of the 
profession. 
~ ~ Whilst sociologists agree medicines autonomy and dominance is being 
challenged, they disagree why these changes are occurring and what this 
means for the medical profession. Both Friedson (1985) and Elston (1991) 
concluded that despite some erosion of clinical freedom, current challenges 
to the medical profession could not be described as bringing about either 
proletarianisation or deprofessionalisation. 
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2.16 Physicians' response to the extension of the 
pharmacist's role 
The professions of pharmacy and medicine have a long history of 
competition and rivalry, which have included times of good will and 
conversely times of friction and antipathy (Cowen, 1992). Whilst the 
Nuffield Report, Crown Reports and recent Government polices have 
recommended that pharmacists extend their roles into areas such as 
supplementary and independent prescribing, medicines management 
schemes and providing greater support to patients on their medication in 
general, implementing these health policy recommendations has raised 
issues about professional status and inter-professional rivalry. As 
pharmacists have tried to extend their role, physicians have opposed this 
and exercised a tight control over their task boundaries (Adamcik et ai, 
1986; Gilbert, 1998a-c, 2001). Edmunds and Calnan (2001) have argued 
that in recent years pharmacy's 'quasi-status' may also have been linked to 
its relationship with medicine, as their professional development has been 
hindered, largely because of medicine's control over their clinical 
autonomy. 
Some time ago, Eaton and Webb (1979) referred to the extended role of 
community pharmacy as 'boundary encroachment', claiming that it was an 
attempt to extend the boundaries of pharmacy practice into the territory of 
the medical profession. They found hospital pharmacists had extended 
their roles into areas where physiCians had previously tended to take short 
cuts or had neglected entirely. For example, patient counselling, 
monitoring of drug side effects and the provision of drug information 
services. However, Eaton and Webb (1979) maintained that the activities 
of clinical pharmacists were not viewed as encroachment by the medical 
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profession because physicians had either willingly delegated or relinquished 
control over certain tasks. Therefore, the medical profession had officially 
controlled encroachment and as a consequence pharmacists had gained 
some increase in clinical tasks rather than status. Ritchey and Sommers 
---_. " 
(1990) also claimed like Eaton and Webb that clinical pharmacy involved a 
few new tasks and these had been delegated by physicians. However, 
Mesler (1991) stated that the bipolar perceptions of pharmacy's clinical role 
(e.g. had they encroached clinical tasks or had they been delegated clinical 
tasks) did not do justice to the interactive processes of role expansion and 
boundary construction, as it was a dynamic process. He concluded that 
often clinical pharmacist's expertise was unsolicited and provided 
autonomously, but it was provided discretely or in such a manner that 
nurses and physicians were left 'in charge'. A further conclusion was many 
nurses and physicians had become aware of the need for such assistance 
from pharmacy and were therefore relinquishing some tasks. This 
demonstrated a slow process of encroachment and delegation taking place 
simultaneously. 
Studies have shown that physicians often see the extension of pharmacists' 
roles as boundary encroachment (Adamcik et ai, 1986; Gilbert, 1997, 
1998a-c, 2001; Edmunds and Calnan, 2001). In 1997, the DoH sponsored 
a series of projects aimed at testing some form of extended roles for 
community pharmacists in the UK. Edmunds and Calnan (2001) reviewed 
these trials to ascertain the views of both community pharmacists and GPs 
towards these initiatives. T h ~ i r _ s t l . J d y y concluded that community 
pharmacists saw their new role as a means of survival and not as a chance 
to take power away from GPs, although GPs saw these initiatives in a 
different light. Many GPs were willing to accommodate some changes but 
saw some activities as a threat to their autonomy and control. They did not 
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approve of representative bodies on committees such as the Local Medical 
Committee, but were happy for pharmacists to have a larger role in areas 
such as repeat prescribing, where there were limitations and exclusion 
criteria for the community pharmacist. There was also some evidence that 
community pharmacists themselves (as well as GPs) were perhaps 
preventing community pharmacists from achieving professional status by 
attributing ultimate authority to GPs. 
Adamcik et al (1986), hypothesised (and the hypotheses was supported) 
that physicians would be more antagonistic towards an expansion of 
pharmacists' clinical activities in the community setting rather than in the 
hospital setting. They believed pharmacists working in a community setting 
typically exercised far more autonomy (both professional and 
administrative) and had freedom from direct supervision compared to 
x h Q ~ p i t ~ l p h ~ r m a c i s t s . . In hospitals, the activities performed by a clinical 
pharmacist were highly visible and could be more readily scrutinised, 
monitored or controlled by other health professionals. 
Literature that has investigated GPs' views on the extension of the 
community pharmacist's role into more clinical domains (Ritchey and 
Raney, 1981; Spencer and Edwards, 1992; Ellis et ai, 1992; Bleiker and 
Lewis, 1998; Ewen and Triska, 2001; Howard et ai, 2003; Hughes and 
McCann, 2003), shows that GPs identify roles which they believe are 
appropriate for community pharmacists to undertake. 
Ritchey and Raney (1981) looked at the factors associated with physicians' 
acceptance of pharmacy services. They found that physicians were least 
supportive of tasks that allowed the pharmacist to make independent 
technical-therapy decisions, such as deciding the choice of drug for a 
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patient, and were most favourable towards the pharmacists undertaking 
tasks with less autonomy, such as maintaining patient drug profiles. These 
findings have been mirrored in subsequent studies. For example, in 
Spencer and Edwards (1992) study, GPs deemed roles such as reporting 
adverse drug reactions, managing minor illness, and advising GPs about 
cost effective prescribing as appropriate roles. Inappropriate roles included, 
screening for high blood pressure (BP) and cholesterol levels. A third of 
GPs in their study believed that pharmacists should only dispense 
medication, although there was high agreement that communication 
between pharmacists and GPs was good and that pharmacists were ideally 
placed to provide health education. 
Ellis et al (1992) also aimed to assess opinions held by GPs on the role of 
the pharmacist, how involved they thought pharmacists should be in 
treating patients with common medical problems and whether they felt that 
pharmacists were becoming involved in tasks they were not qualified to 
undertake. Whilst most respondents (97%) reported a good or very good 
------ ~ ~ ~ ~ - -
working relationship with their local pharmacists and 75% cited a desire for 
greater cooperation between the two professions, GPs once again identified 
appropriate roles that they would be happy for the pharmacist to 
undertake. Appropriate activities included, preparation and dispensing of 
medicines, providing advice about OTC and prescribed medication and 
counselling patients about adverse reactions to OTC medications. 
Inappropriate activities included, pharmacy screening programmes of blood 
pressure, cholesterol, glucose and haemoglobin, with 37% of GPs 
indicating that pharmacists were expanding their role inappropriately. 
Ewen and Triska's (2001) study indicated that pharmacists' ability to 
expand their role depended largely on GPs' attitudes. GPs supported limited 
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expansion of the pharmacist's role but only if it did not threaten their scope 
of practice. There was strong agreement on more traditional services such 
as dispensing medication, providing medical information, counselling, 
verifying the patient's understanding of information and evaluating patient 
satisfaction. {ps did not support more non-traditional pharmacy services, 
were divided on life-style counselling and were less supportive about 
~ ~
pharmacists being involved in multidisciplinary meetings. 6ver half the GPs 
did not believe that pharmacists had the required knowledge and skills to 
provide pharmaceutical care. 
Howard et al (2003) aimed to ascertain the views of specially trained 
expanded role pharmacists (ERPs) and GPs involved in a programme, in 
which they worked together to optimise drug therapy for elderly patients. 
*-ERPs and GPs differed in their perceptions of appropriate roles for ERPS. 
Whilst ERPs saw the programme as an opportunity to take on new 
professionals roles, GPs stated they did not want ERPs to directly counsel 
their patients about their m e d i c a t i o ~ . . GPs stated they appreciated the 
information they received from ERPs about their patients' adherence and 
use of OTC medications, and they did not see a problem with ERPs advising 
patients about OTC products. Both ERPs and GPs identified the need to 
work out professional role relationships before undertaking collaboration 
more fully. 
These studies demonstrated that although GPs generally favoured 
community pharmacists extending their roles (and often welcomed a 
greater degree of collaboration with them), they all identified roles which 
they believed were appropriate for community pharmacists to become 
more involved with. It can be concluded that there was a general trend 
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that GPs were least supportive of tasks that allowed the pharmacist the 
opportunity to make independent decisions regarding treatment. 
Physicians defending their prescribing rights have also been demonstrated 
at a national level. Following the publishing of the second Crown report 
(this suggested that pharmacists be allowed legal authority to become 
supplementary prescribers), the British Medical Association (BMA) 
expressed caution and stated that it would prefer community pharmacists 
to do what they always have done, counter prescribe (Anon, 1999b). This 
was illustrated by the following quote: 
" We would prefer to see high street pharmacists becoming independent 
prescribers taking full responsibility for their decisions in prescribing 
general sale list and pharmacy medicines where they have the skills". 
The announcement by the DoH to extend pharmacists' and nurses' 
prescribing rights so they could become independent prescribers was again 
met with dismay by the BMA. Their concerns centered around non-medical 
prescribers' ability to diagnose, as illustrated by the following quote (Day, 
2005). 
"While we support the ability of suitably trained nurses and pharmacists to 
prescribe from a limited range of medicines for specific conditions, we 
believe only doctors have the necessary diagnostic and prescribing training 
that justifies access to the full range of medicines for all conditions". 
This is not an issue that has just occurred within the UK. For example, 
Gilbert (1998a-c) has described the South African situation where 
community pharmaCists have tried to expand their role, taking into account 
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aspects of professional dominance and boundary encroachment. The 
papers demonstrated that pharmacists could have an extended role. 
However, it also showed that the medical profession was strongly opposed 
to the pharmacist's role extension, particularly when it related to a 
pharmacist's ability to prescribe. Pharmacists were often only permitted to 
extend their role when the medical profession did not see a task as its 
exclusive domain. For example, physic!ans were unhappy for pharmacists 
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to undertake a prescribing function, as they believed this was a sole 
function for their profession to undertake. The developments made showed 
a partial success for the community pharmacist to extend their role. 
Special permits were granted to a selection of pharmacists, although these 
were restricted to pharmacists based in rural or under-served areas. 
It is interesting to note that boundary encroachment may also be occurring 
to community pharmacists by physicians threatening the dispensing 
function of community pharmacists. In Spencer and Edwards (1992) study, 
fifty per cent of GPs thought they should be able to dispense medication. 
Likewise, Gilbert (2001) has described the situation in South Africa where 
most community pharmacists see the 'dispensing doctor' as the primary 
problem facing their profession, due to the large and increasing numbers of 
physicians who dispense medication as part of their practice. Physicians 
have successfully managed to protect their role from encroachment but 
have managed to encroach on pharmacy's main function (Gilbert, 2001). In 
South Africa, pharmacy's lack of success to extend its role has resulted in 
additional attempts to broaden the scope of the services offered within the 
community pharmacy. One such successful scheme was the formation of a 
'therapeutic alliance' with the nurse (Gilbert, 1997). The partnership 
developed between these two professions allowed the pharmacists to 
expand their professional activities without invading the nurse's 
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professional domain but the alliance between these two professions 
presented an 'united front' against the medical profession. However, 
Adamcik et al (1986) found that nurses would not support pharmacists 
undertaking clinical activities, if these activities threatened their role. 
2.17 Effects of collaboration on relationships between physicians 
and pharmacists 
The literature is conflicting about how improving the relationship or contact 
between physicians and pharmacists positively affects the attitude of 
physicians towards pharmacists undertaking extended roles. Muijrers et al 
(2003) concluded that improving the relationship between GPs and 
pharmacists would have a significant, positive effect on the attitude of GPs 
towards the pharmacist's care-providing function. Adamcik et al (1986), 
found that physicians who had worked with a clinical pharmacist were 
significantly more likely to support clinical role activities in the community 
but not in the hospital setting. However, overall levels of support for 
pharmacists to extend their role remained negative. 
Chen (2001a) argued that when there was an established relationship 
between a GP and a community pharmacist, the relationship might extend 
to being a social relationship, particularly in small communities. Whilst 
community pharmacists acknowledged that contacting GPs was easier 
when they knew the GP, they were often reluctant to try and extend their 
role due to the fear that it may antagonise their relationship and impact on 
their relationship outside of work. In these instances, pharmacists valued 
their social relationship more than their professional relationship and 
preferred to remain in a traditional role. 
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Hughes and McGann (2003) concluded that GPs who had previous contact 
with pharmacists through interdisciplinary projects did not have a more 
positive view of community pharmacists. They argued that contact with 
pharmacists in prescribing support roles may have just reinforced the GPs' 
perceived view of the community pharmacist, for example that of a 
'shopkeeper', and they continued to be resistant against community 
pharmacists undertaking roles such as prescribing. 
Studies also indicate that poor communication between pharmacists and 
physicians could have a negative effect on how physicians perceived 
collaborative schemes with pharmacists (Wilson et ai, 2002; MacRae et ai, 
2003; Brook & Doucette, 2004). For example, MacRae et al (2003) 
reported that limited GP-pharmacist contact was deemed to be a problem 
by GPs in their study, which looked at the views of GPs to a pharmacist-led 
medication review (PLMR) service. 
Wilson et al (2002) also stated that poor communication was reported 
between the community pharmacists and GPs in their community 
pharmacy repeat dispensing project. At the beginning of their project there 
were positive relationships between the pharmacists and GPs. However, 
GPs reported that they had high expectations of what could be achieved 
but overall were disappointed that there was not more communication with 
the pharmacists. Likewise, community pharmacists confirmed that 
communications with the medical practices had not improved noticeably 
during the study, although the study did not provide explanations 
regarding this issue. 
Brook & Doucette (2004) concluded developing an effective system for bi-
directional communication facilitated the development of a collaborative 
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working relationship. Face-to-face communication was often important to 
develop open channels of communication between the physician and 
pharmacist. 
2.18 Physicians' response to the extension of the nursing role 
In order to shed more light on how the medical profession has responded 
to other healthcare professional taking on new roles, that literature 
exploring the nursing profession extending their role has been explored in 
the final part of this chapter. 
Nurse and physician conflict has gone on for centuries, with the nurse-
physician game well documented in the literature (Stein 1967). In the 
formative years it was a mainly a one-sided relationship, where nurses 
played a largely subservient and supportive role to the physician. These 
conflicts were based to a large extent on factors such as the education of 
the physician and nurse, differences in status and prestige, gender 
imbalance, and social class differences (Kappeli, 1995; Blickensderfer, 
1996). The two professions had distinct professional identities. The nurse's 
professional identity was framed in terms of communication and 
compassion, responsible for managing the healing process of a patient. 
They were taught to have a more holistic view of the patient, which set 
different goals for patient care than the physician. Conversely, physicians 
were taught to be decisive, independent problem solvers who diagnosed 
and prescribed (Blickensderfer, 1996). 
British nursing has undergone radical reform in the past decade, with 
nursing education shifting from a task centred approach towards 
personalised care (Salvage, 1995). For years, dependent on physicians for 
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their education and training, nurses had been in a long struggle to 
establish epistemological demarcation from medicine. In the UK, 'Project 
2000' resulted in changes to the nursing curriculum that freed it from the 
dominance of the medical model. 'Project 2000' also saw nursing move into 
higher education (Allen, 2001). 
Government reforms have allowed nursing to have a role in prescribing 
medication. Likewise, the need for general practice to respond to 
Government policy (which called for increased efficiency and 
accountability) has also led to nurses having a larger role within the 
primary care team. As the role of the nurse began to expand, the 
boundaries between medical care and what was deemed nursing care 
become less obvious (Blickensderfer, 1996). It is argued that the 
delegation of responsibilities has challenged the professional identities of 
GPs and nurses (Charles-Jones et aI, 2003). 
A number of studies have looked at the effect of redistributing medical 
work to nurses (Bond et ai, 1987; Svensson, 1996; Allen, 1997; Willis et 
ai, 2000; Snelgrove and Hughes, 2000; Blue and Fitzgerald, 2002; 
Charles-Jones et ai, 2003). The majority of these studies suggested the 
nursing-physician relationship had not significantly changed, and 
physicians still remained the more dominant position within the healthcare 
system. 
Svensson (1996) argued that the traditional models of medical dominance 
were deterministic and provided an inappropriate basis for understanding 
the physician-nurse relationship on contemporary hospital wards. He 
suggested that the 'negotiated order perspective' as the most appropriate 
theoretical framework for understanding patterns of physician-nurse 
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interaction, changes within the health care system had created 'negotiation 
space' for nurses, which had led to an evolution of new working 
relationships with physicians. 
He attributed this shift in the physician-nurse relationship to three key 
changes in the negotiation context, which had given nurses 'space' for 
directly influencing patient care decisions and interpreting organisational 
rules. Firstly, the increased prevalence of chronic illness had resulted in a 
shift of emphasis from preventing death to handling life, introducing a 
social dimension into health care. Nurses were powerfully placed to 
contribute to this patient management. Secondly, that the shift from a 
system of task allocation to team nursing had facilitated a closer nurse-
patient relationship because the nurse was responsible for fewer patients. 
Likewise, the nurse's knowledge of the patient was no longer exchanged 
via the ward sister, but presented directly to the physician. Thirdly, that 
the introduction on many wards of the 'sitting round', where the physician 
and nurse discussed their patients before the traditional 'ward round' 
offered nurses an opportunity to converse with the doctor and influence 
patient management decisions in a more informal setting. 
A criticism of Svensson's work (and one in which he conceded) is that 
whilst he was concerned with patterns of interaction between nurses and 
physicians, he argued this theory by drawing on interview data undertaken 
with nurses only, thus we are given only a partial view. 
Allen (1997) aimed to further the debate on the 'negotiated order 
perspective' and increase the sociological understanding of physician-nurse 
relationships, by examining the ways in which nurses' accomplished 
occupational jurisdiction in the course of their every day work. She aimed 
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to analyse features of nursing and medical work that inhibited inter-
occupational negotiations but nevertheless led to the blurring of the 
nursing-medical division of labour. 
Data was generated on a surgical and a medical ward in a UK, District 
General Hospital. She observed and participated on wards for ten months, 
collecting data via observation, semi focused interviews and spontaneous 
extended conversations, carried out with ward nurses, physicians, clinical 
managers, health care assistants and auxiliaries. 
The main areas where nurses were extending their skills were in the 
administration of intravenous (IV) antibiotics, venepuncture, male 
catheterisation and IV cannulation. Physicians were happy for nurses to 
take over what they regarded as low status menial activities, e.g. IV 
antibiotic administration but they were less clear about activities such as 
diagnostic investigations, which came closer to the focal tasks of medicine. 
There was an expectation of the need for inter-occupational negotiations 
and associated boundary tensions between nursing and medical work due 
to the nurse's role extension and policy developments. These expectations 
were confirmed by the interview data, which revealed uncertainty and 
disagreement about the changing division of labour in health care. 
However, this data were not supported by Allen's ward observations, which 
revealed little evidence of negotiations or inter-occupational strains on the 
ward. 
In attempting to explain the findings, Allen suggested that the strategies 
staff developed in order to manage the tensions associated with the social 
organisation of hospital work, meant that non-negotiated informal 
boundary-blurring was a taken-for-granted feature of normal nursing 
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practice. Although there was little face-to-face negotiation of the division of 
labour between nursing and medicine on the ward, often negotiations had 
taken place in other areas, such as hospital management meetings. 
It also raised some methodological issues relating to the clarity of the 
concept of negotiation and how 'negotiated orders' could be best studied. 
The discrepancy between nurses' accounts of their work and their observed 
daily practice illustrated the dangers that were raised in relation to 
Svensson's work and the unquestioning reliance on interview data. 
Snelgrove and Hughes (2000) investigated the changing nature of 
physician-nurse relations, and in particular, how far the notion of the 
physician-nurse game remained relevant to contemporary hospital work. 
They reported that nurses were generally reluctant to challenge physicians' 
authority, although some used the notion of patient 'advocacy' to frame 
and justify their questioning of particular decisions. Whilst physicians 
valued experience in nurses and saw experienced nurses as the group who 
might most legitimately move into physicians' territory, they drew a sharp 
distinction between medical and nursing roles. Medical roles identified 
again emphasised medicine's desire to control its autonomy in diagnosing 
and prescribing. The authors concluded that some boundary blurring was 
occurring and nurses were having greater roles according to the clinical 
areas in which they were located, but generally that physicians and nurses 
continued to see their roles in largely traditional terms. 
Charles-Jones et al (2003) concluded that as medical work was being 
transferred to nurses, it began to change the GP's identity to that of a 
consultant in primary care and it now mirrored the hierarchy found in 
hospitals. This had come about by delegating patients that had 'minor 
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ailments' to nurses, so the GP began to just see the more complex 
patients. This act had allowed GPs to maintain their dominant position 
within the primary care team. 
However, Willis et al (2000) and Blue and Fitzgerald (2002), concluded that 
the working relationship between GPs and nurses was more constructive 
than the literature on the physician-nurse game suggested. These studies 
also showed a clear division of labour, with the GP as the initiator and 
supervisor, and the nurse being largely dependent on the flow of work from 
the GP. Blue and Fitzgerald (2002) found that relationships between the 
GPs and nurses were very co-dependent ones, in which neither rural nurse 
nor GP could operate successfully without each other. GPs indicated their 
strong support of nurses, encouraging them to develop their skills and 
abilities to use them whenever possible because it reduced their workload. 
Both parties indicated that they were happy with the division of labour and 
saw no need for a radical change. 
2.19 Summary 
Due to Government reforms and greater consumerism the traditional roles 
of physicians, community pharmacists and nurses have all changed. Whilst 
community pharmacists and nurses have attempted to extend their roles 
into areas such as prescribing, the medical profession has struggled to 
defend its autonomy and have exercised a tight control over their task 
boundaries. 
The literature suggests that physicians are willing for community 
pharmacists and nurses to have an extended role, but identify specific roles 
which they feel are appropriate for them to undertake. These roles are 
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usually in areas where there is limited autonomy, allowing the physician to 
remain in a dominant position. This suggests that pharmacists and nurses 
have not managed to encroach into traditional physician territory but 
instead are being delegated tasks that physicians are happy to relinquish. 
However, what can be concluded is that the extension of the community 
pharmacist's role is unlikely to happen fully, or successfully if GPs are 
unwilling to co-operate with community pharmacists. This is further 
complicated by the fact that the majority of community pharmacists are 
not based within the GP practice, meaning relationships may not be 
established with each other and communication may be poor. 
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3. THE POTENTIAL ROLE OF THE COMMUNITY 
PHARMACIST IN MEDICINES MANAGEMENT 
INITIATIVES 
3.1 Introduction 
As I discussed in the previous chapter, recent health policy changes have 
acknowledged the importance of addressing inequalities in health. This has 
led to the development of care guidelines for different disease states, 
which have aimed to implement best care for patients wherever they reside 
in the UK. The National Service Framework for CHD, was published in 
March 2000 and formed part of this modernisation strategy for the NHS. In 
line with these changes, the DoH document 'Pharmacy in the Future -
Implementing the NHS Plan' set a target date of 2004 for the 
implementation of medicines management schemes in all primary care 
organisations (Department of Health, 2000b). Such schemes aimed to 
improve health outcomes, reduce medication waste and allow patients to 
get more help regarding their medicines. If community pharmacists could 
contribute to improved health outcomes in CHD through a MMS, it could 
provide a cost-effective method of addressing a national priority. 
The first part of the chapter provides a brief overview of CHD, looking at 
why reducing the incidence of CHD is a national health priority. The aims of 
the NSF will be discussed, with particular focus on standards three and four 
of the document, and emphasising the role of the primary care team within 
these two standards. The role of aspirin, statins and beta-blockers in CHD, 
along with the clinical evidence for their use will be investigated. The 
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potential role that the community pharmacist could play at assisting in the 
targets laid down in the NSF for the use of these medications will also be 
discussed. 
The chapter then looks at the concept of pharmaceutical care and 
medicines management. It explores the literature and reports the findings 
of randomised controlled trials (RCTS) and controlled clinical trials (CCTs) 
where pharmacists have had a medicines management role within CHD. 
Finally, the CPMMP will be discussed. An overview of the CPMMP's aims, 
objectives and protocol will be given, along with the focus that I have 
decided to undertake in this thesis. 
3.2 Coronary heart disease 
Coronary heart disease can be pathologically defined as the narrowing, or 
the blockage of the coronary arteries by atheroma (fatty-fibrous plaques), 
leading to angina, coronary thrombosis or heart attack, heart failure and/or 
sudden death (Department of Health, 2000c). Despite a fall in CHD 
mortality since the late 1970's, the UK death rate is still amongst the 
highest in Western Europe. It is the most common cause of death and 
premature death (death before the age of 75) in the UK, accounting for 
approximately 117,000 deaths in 2001 (Peterson et ai, 2004). Therefore, 
the reduction in mortality and inCidence of CHD is a major public health 
goal. 
Within the UK there is also significant regional, gender, socioeconomic and 
ethnic differences in CHD mortality. Deaths from CHD are higher in 
Scotland, Northern Ireland and the North of England than in Wales or the 
South of England. The highest mortality rates are primarily concentrated in 
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urban areas. CHD has a higher incidence in males than females; currently 
it is responsible for 1 in 5 deaths in males and 1 in 6 deaths in women 
(Peterson et ai, 2004). CHD is three times more common amongst 
unskilled male workers, compared with men in managerial or professional 
positions, and is twice as common in wives of manual workers compared 
with the wives of non-manual workers (McGlynn et ai, 2000). South Asians 
living in the UK (Indians, Bangladeshis, Pakistanis and Sri Lankans) have a 
higher premature death rate from CHD than average (Peterson et ai, 
2004). 
3.3 Risk factors for CHD 
The 20th century has seen a rise and decline in the death rate of CHD in 
most developed countries. Studies such as the international WHO 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) 
were designed to answer epidemiological questions about this decline. 
From the early 1980s the 'WHO MONICA' project, monitored the trends in 
CHD of 37 populations in 21 countries over a ten-year period. 
The project concluded that in most developed countries the death rate from 
CHD was falling, although the rate of decline varied widely. The main factor 
reducing CHD mortality rates was a decrease in event rates, rather than a 
reduction in the fatality of these events (Tunstall-Pedoe et ai, 1999). What 
has driven this decline in CHD events is still not fully understood. However, 
reducing known cardiovascular risk factors is likely to be very important 
(National Prescribing Centre, 2000). 
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The major modifiable risk factors for the development of CV02 are 
generally accepted as smoking, high blood pressure, poor diet, high 
cholesterol levels, obesity, lack of exercise and excess alcohol intake. Non-
modifiable risk factors include family history of premature CHO, advancing 
age, male gender, ethnicity and diabetes mellitus (McGlynn et ai, 2000). 
The absence of established risk factors does not guarantee freedom from 
CHO. 
3.4 The National Services Framework for coronary heart 
disease 
In March 2000, the NSF for CHO was published (Department of Health, 
2000c). The framework aimed to provide uniformity of care and set out 
plans to ensure that the best care regarding prevention, diagnosis and 
treatment of CHO was available for everyone in the UK. The NSF consisted 
of twelve standards of care which covered the whole management 
spectrum of CHO, including prevention of CHO, medical and surgical 
interventions of established CHO, and cardiac rehabilitation. Heart failure 
was also included in the framework. 
One of the highest priorities of the NSF was the reduction of CHO in the 
general population and the prevention of CHO in high-risk patients. 
Standards three and four of this NSF aimed to address these issues and 
centred around GPs and primary care teams identifying all people with 
either established CVO (secondary prevention3 ), or those who were at 
2 Cardiovascular disease: heart and circulatory disease, for example CHD plus stroke, 
peripheral vascular disease and heart failure. 
3 Secondary prevention is defined as the prevention of the progression of the disease in 
symptomatic patients (Stevens and Williams, 2002). 
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significant risk of developing it (primary prevention4 ) and offering them 
appropriate advice and treatment to reduce their risks. 
To address these aims, CVD registers and risk assessment tools were 
required to facilitate the identification and assessment of people at high 
risks. To calculate cardiovascular risk, assessment tools required the 
following patient data: age, sex, smoking status, diabetic status and blood 
pressure. Most assessment tools also required cholesterol measurements 
(serum total cholesterol and high density lipoprotein cholesterol). Risk 
assessment tools did not need to be applied to individuals with established 
CVD as these people were deemed to have a very high risk of a further 
CVD event (>30% CHD risk over 10 years) and therefore required 
management using appropriate drug treatment. 
3.4.1 Primary interventions 
The NSF stated the following interventions that patients with diagnosed 
CHD or other occlusive arterial disease should receive unless 
contraindicated: 
• Advice on stopping smoking 
• Information and personal advice about other modifiable risk factors 
• Advice and treatment to maintain blood pressure (BP) below 140/85 
mmHg 
• Low dose aspirin (75mg daily) 
• Statins and dietary advice to lower serum cholesterol concentrations 
EITHER to less than 5.0mmol/L (Low density lipoprotein (LDL)-
Cholesterol to below 3mmol) OR by 30% (whichever was greater) 
4 Primary prevention can be defined as using strategies to reduce the risk of cardiovascular 
events in people without CHD but who are at high risk of developing it (Williams et ai, 2003). 
5 The NSF defined a high-risk threshold, as a CHD event (not disease) risk greater than 30% 
over 10 years (Department of Health, 2000c). 
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• 
• 
• 
ACE inhibitors for left ventricular dysfunction 
Warfarin or aspirin for people over 60 years for atrial fibrillation 
Meticulous BP and glucose control in diabetics 
3.4.2 Secondary interventions 
The following interventions were stated in the NSF for patients without 
diagnosed CHD or other occlusive arterial disease with a CHD event risk 
greater than 30% over ten years: 
• 
• 
• 
• 
• 
Advice on stopping smoking 
Information and personal advice about other modifiable risk factors 
Advice and treatment to maintain BP below 140/85 mmHg 
Statins and dietary advice to lower serum cholesterol concentrations 
EITHER to less than 5.0mmol/L (LDL-Cholesterol to below 3m mol) 
OR by 30% (whichever was greater) 
Meticulous BP and glucose control in diabetics 
3.5 The use of aspirin, statins and beta-blockers in clinical 
practice 
One of the other immediate NSF priorities was to improve the use of 
effective medicines after heart attack which included the use of aspirin, 
statin and beta-blockers. The Government set a target that 80-90% of 
patients discharged from hospital following a heart attack would receive 
these medications by April 2002 (Department of Health, 2000c). 
Aspirin has been shown to decrease mortality and non-fatal reinfarction 
and stroke when given as a short-term therapy for acute MI (ISIS-2 
Collaborative Group, 1988). Many trials have shown the beneficial effects 
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of aspirin in secondary prevention of CHD (The Antiplatelet Trialists 
Collaboration, 1994; Antithrombotic Trialists Collaboration, 2002). Low 
dose aspirin (75-150mg daily) is an effective antiplatelet regimen for long-
term use and unless contra-indicated or not tolerated, aspirin should be 
given prophylactically to all CHD patients. 
The role of aspirin in primary prevention is less clear. A meta-analysis of 
four RCTs of aspirin for primary prevention (Sanmuganathan et ai, 2001), 
concluded that aspirin treatment for primary prevention was safe and 
worthwhile if the risk of a CHD event was greater than 15% over 10 years. 
It was safe but of limited value with a CHD risk of 10% over 10 years. 
However, it was unsafe when a CHD risk was 5% over 10 years, as the risk 
of hemorrhagic complications potentially outweighed the benefits of aspirin 
therapy. 
The aim of lipid lowering therapy is to reduce the progression of coronary 
atherosclerosis and to stabilise and induce regression of existing plaques. 
Statins have been shown to reduce coronary events and death in both 
primary (Shepherd et ai, 1995; Downs et ai, 1998) and secondary 
prevention trials (Scandinavian Simvastatin Survival Study Group, 1994; 
LIPID Study Group, 1998; Sacks et ai, 1996). These trials demonstrated 
that statins reduced cholesterol significantly compared to placebo, with 
LDL-cholesterol being reduced to 20 to 30% of the baseline level. A 
reduction in cardiovascular mortality and morbidity of about 20-40% was 
also noted in patients receiving a statin. 
Statin treatment should be started or adjusted to achieve target total 
cholesterol of less than 5mmol/litre or a LDL-cholesterol, below 
3mmol/litre (or a 30% decrease, whichever was the greatest) (Department 
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of Health, 2000b) and was recommended for both primary and secondary 
prevention of CHD in the NSF. 
Beta-blockers have been shown to be effective post myocardial infarction 
(MI) and in angina. Unless there are contraindications, such as 
uncontrolled heart failure, beta-blockers should be given as secondary 
prevention following MI and as first-line therapy for those with angina. 
There are data available to indicate that the beneficial effects of beta-
blockers is maintained for at least six years after infarction with continued 
oral, administration (Olsson et ai, 1988). Therefore, it has been suggested 
that patients who tolerate these drugs, this treatment should continue 
indefinitely (Goldstein, 1996). 
Research has shown that aspirin, statins and beta-blockers are under-
utilised or inappropriately used in clinical practice (Viskin et ai, 1995; 
Campbell et ai, 1998; White, 1999; McCallum, 1997; Welton et ai, 1999; 
Abbokire et ai, 2001; Fonarow, 2002; Smith, 2000). For example, 
Campbell et al (1998) set out to determine secondary preventive treatment 
amongst primary care patients with CHD in the Grampian area. They 
identified 1921 patients with CHD from GP registers, of these 825 (63%) 
patients took aspirin, and 133 (17%) patients had lipid levels managed 
according to current guidelines. Of the 414 patients that had a recent MI, 
only 131 (32%) took beta-blockers. The study concluded half of the 
patients had a least two aspects of their medical management that were 
sub optimal in terms of secondary prevention. 
Likewise, studies have shown that pharmacists could have a role in 
identifying patients on sub-optimal therapy. For example, Reilley and 
Cavanagh (2003) implemented a secondary heart disease prevention clinic 
that was run by a practice pharmacist and nurse. Analysis of the first 100 
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patients that had attended the clinic showed that the percentage of 
patients taking aspirin 75mg had risen from 39% to 92%, compared with 
the current population. Similarly, the number of angina patients receiving a 
beta-blocker had increased from 24% to 50%. 
McGovern et al (2001) also demonstrated the potential role that 
community pharmacists could have in the management of angina. Patients 
who presented to a community pharmacy requiring sublingual glyceryl 
trinitrate (GTN) were interviewed after consent, about their angina 
medication and whether they took aspirin. The results of the study 
indicated that only 73% of patients were receiving low dose aspirin, and 
only 35% were receiving a beta blocker as part of their medical treatment. 
In addition, only 69% of patients had satisfactory knowledge of how to use 
sublingual GTN to relieve an angina attack. 
As indicated in these studies, pharmacists could have a potential role in 
alerting physicians to CHD patients that were either not receiving the 
appropriate drugs, or those not receiving therapeutic doses. For example, a 
MMS from community pharmacists could help address these issues of sub 
therapeutic medication in CHD patients and in doing so assist in the 
attainment of the national targets laid down in the NSF for CHD. 
I now wish to explore the literature on previous medicines management 
services conducted by pharmacists, to provide an overview of the roles that 
pharmacists have had in managing patients with CHD. To frame this work, 
an overview of the concepts 'pharmaceutical care' and 'medicines 
management' are provided. 
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3.6 The concept of pharmaceutical care 
Over the past three decades the term 'pharmaceutical care' has been 
increasingly used to describe the greater role pharmacists have taken 
beyond dispensing medicines. The concept of pharmaceutical care first 
evolved in the United States of America (USA) as part of the clinical 
pharmacy movement, with Mikael et al (1975) introducing the concept into 
pharmacy practice. Pharmaceutical care is a patient centred concept, 
whereby pharmacists take responsibility for the management and 
outcomes of the patients' medicines and their associated drug-related 
needs. For example, it dealt with the way people should receive and use 
medication, medication surveillance, counselling and outcomes of care. In 
some countries the concept also covered the way in which people should 
obtain information about disease states and lifestyle issues (Van Mill et ai, 
1999). 
For the next fifteen years, different definitions of pharmaceutical care were 
put forward, each addressing the concept in slightly different ways. Van Mill 
et al (1999) addressed the difficulties of defining pharmaceutical care at an 
individual level, arguing that for an observer, what pharmaceutical care 
was and how it fitted into healthcare was not clear. Based on a literature 
review, they argued that different approaches were embedded in practice 
and stated that when defining pharmaceutical care, the culture, language 
and healthcare practice of the country had to be taken into account. 
Likewise, Barber (2001) argued that whilst pharmaceutical care was a 
patient centred concept, the definitions used talked of the patient's clinical 
condition, rather than the patient and were therefore not patient centred. 
The aims of pharmaceutical care were therefore stated in terms of the 
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disease rather than the patient. He argued that the principles of 
pharmaceutical care were not adequately developed, and that this had 
caused problems when people tried to apply them in practice. Likewise, the 
inadequacy of the original definition of pharmaceutical care was why a 
wider range of definitions had since been developed. Van Mil et al (2001) 
also concluded that lack of time and money were major barriers for the 
implementation of pharmaceutical care in European countries. 
Hepler and Strand (1990) came up with the most widely accepted 
definition for pharmaceutical care, and defined it as: 
..... the responsible provision of drug therapy for the purpose of achieving 
definite outcomes that improve a patient's quantity of life. These outcomes 
are (i) cure of a disease; (ii) elimination or reduction of a patient's 
symptomatology; (iii) arresting or slowing of a disease process; or (iv) 
preventing a disease or symptomatology. 
Over time Strand stated that this definition was not complete and redefined 
pharmaceutical care as, 'A practice in which the practitioner takes 
responsibility for a patient's drug related needs and holds him or herself 
accountable for meeting these needs' (Simpson, 1997). 
Therefore the practitioner (hopefully a pharmacist) working to this new 
definition ascertains all the medicines that a patient is taking, from 
whatever source, assesses them for reasonableness and effectiveness in 
the light of the patient's condition, develops a care plan and follows up 
their progress on a regular basis. 
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3.7 The concept of medicines management 
The concept of medicines management is not as well defined but seems to 
originate from organisations which paid for drugs, and therefore wanted to 
'manage' them (Barber 2001). The term medicines management has 
become increasingly popular over the last ten years, with numerous 
definitions cited in the literature (Department of Health, 2000c; National 
Prescribing Centre, 2002; The Community Pharmacy Medicines 
Management Evaluation Team, 2004). The term medicines management, 
tends to be used more frequently in England, rather than the term 
pharmaceutical care, which is used in other countries including Scotland 
(Simpson, 2001). Various suggestions have been made as to why England 
uses the term medicines management instead of pharmaceutical care. One 
of these involves the possible sensitivities of doctors regarding the phrase 
'taking responsibility for the patients' drug related needs and being 
accountable for meeting those needs', who may regard this as an invasion 
of territory (Simpson, 2001). 
Medicines management is a concept that encompasses a range of activities 
intended to improve the way that medicines are used, both by patients and 
by the NHS. Medicine management schemes can include all aspects of the 
supply and use of medicines, from an individual medication review to a 
health promotion programme. Examples of common medicines 
management activities include prescription review, medication monitoring, 
pharmacist led clinics, management of repeat prescribing, services to 
nursing and residential homes, domiciliary services, primary/secondary 
care interface management, and patient education (National Prescribing 
Centre, 2002). 
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As of yet there is no commonly agreed definition of medicines 
management. In the CPMMP, the definition used was 'The process of 
optimising beneficial outcomes and minimising harm from medicines, 
including medication review (appropriateness), monitoring and advice to 
patients and prescribers' (The Community Pharmacy Medicines 
Management Project Evaluation Team, 2004 ). This will be the definition 
used throughout this thesis. 
There have been attempts to explain the differences between 
pharmaceutical care and medicines management. Simpson (2001) 
suggested that pharmaceutical care is a type of medicines management, 
but medicines management is not pharmaceutical care. Simpson (2001) 
suggests that medicines management should be viewed as an 'umbrella' 
term', as it allows for a variety of practices and processes to fall within it. 
Jenkins and Ghalamkari (2001) have also endorsed this view and have 
suggested that most patients will receive medicines management without 
pharmaceutical care and this creates the dilemma of the ability to target 
those who need full pharmaceutical care. 
3.8 Previous medicine management services conducted by 
pharmacists 
The literature shows that community pharmacists have been involved in a 
selection of medicine management and pharmaceutical care initiatives in 
many different disease states. These include initiatives in asthma and 
chronic obstructive pulmonary disease (Weinberger et ai, 2002), diabetes 
(Clifford et ai, 2002), hypertension (Bogden et ai, 1998), 
hypercholesterolaemia (Tsuyuki et ai, 2002; Donaldson & Andrus, 2004), 
congestive heart failure (Gattis et ai, 1999) and angina (Ryan-Woolley et 
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ai, 2000). Pharmacists have also begun to develop roles in health 
promotion (Anderson, 1995), for example, smoking cessation (Maguire et 
ai, 2001), repeat prescribing schemes (Bond et ai, 1999; Wilson et ai, 
2002), the supply of emergency hormonal contraception via patient group 
directions (O'Brien and Gray, 2000; Bissell and Anderson, 2003), managing 
anticoagulant clinics (Macgregor et ai, 1996) and reviewing medication in 
the elderly population (Zermansky et ai, 2001; Sellors et ai, 2003) These 
initiatives have ranged from being small scale service developments to 
large scale RCTs. 
publications on MEDLINE, EMBASE, CINAHL, PHARMLINE and the Cochrane 
database, were searched from January 1990 to present day. This time 
frame was chosen to incorporate any pharmacy initiatives which had 
resulted from Government and Independent health policy recommendations 
for the pharmacy profession (as discussed in Chapter 2). Likewise, the 
literature suggests the concept of pharmaceutical care and medicines 
management started to fully evolve in the 1990s (Hepler and Strand, 
1990: Barber 2001). I hoped this time frame would identify pharmacy 
initiatives which had resulted from these processes of care. 
The following search terms were used: pharmacist(s), community 
pharmacists, health promotion, community pharmacy, pharmacy, coronary 
heart disease, coronary disease(s), cardiovascular disease(s), general 
practitioners, GPs, physicians, patient compliance, blood pressure, 
cholesterol, and smoking cessation. Inclusion criteria used included RCTs 
and CCTs looking at CHD from any country, English language, and studies 
which involved pharmacists having interventions that involved the 
following: 
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• 
• 
• 
Target drugs, which are used in the treatment of CHD e.g. lipid-
lowering agents, beta-blockers and aspirin. 
Studies which involved collaboration with GPs/physicians 
Studies which involved lifestyle factors affecting CHD e.g. smoking 
cessation or hypertension control 
Exclusion criteria included studies involving heart failure, anticoagulation, 
and drug costs as their primary outcomes. 
Also consulted was a literature review of RCTs and CCTs of community 
pharmacists and medicine management for patients with CHD (Watson et 
ai, 1999). This review identified and described 25 trials (14 RCTs and 11 
CCTs) from January 1994 to August 1999, which met their inclusion 
criteria. The authors concluded that the reported studies clearly 
demonstrated the potential of pharmacists to improve medicine 
management at both an individual patient and global level. 
3.8.1 Pharmacists and hypertension trials 
Trials have been identified (both RCT and CCT) where pharmacists have 
had a role in evaluating interventions for hypertensive patients (Park et ai, 
1996; Carter et ai, 1997; Gourley et ai, 1998; Bogden et ai, 1998; 
Blenkinsopp and Phelan, 1999; Chisholm et ai, 2002; Garcao et ai, 2002; 
Borenstein et ai, 2003). Table 1. provides details of the trial characteristics. 
With the exception of Carter et al (1997), all studies found that the 
pharmacist intervention resulted in a significant reduction in blood pressure 
compared to the control group. When measured, patient compliance also 
increased in the intervention group. 
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Patient satisfaction was measured in three of the studies; all reported that 
this had increased in the intervention group after seeing the pharmacist. 
However, the studies did not give any indication why their levels of 
satisfaction had increased, nor did they indicate the patients' previous 
relationship with the pharmacist. 
Park et al (1996) reported the percentage of recommendations made by 
pharmacists, which had been implemented by physicians. However, they 
gave no indication of the interprofessional barriers between the two 
parties, nor whether the working relationship impacted on whether 
interventions were followed by the physician. Bodgen et al (1998) did 
address relationship issues between pharmacists and physicians, and 
suggested that considerable emphasis should be placed on the interaction 
between the pharmacist and physician in determining how successful a 
pharmacist intervention study could be. They stated in their study, that 
there was a sustained positive rapport among the physicians, pharmacists 
and patients, and concluded this was likely to be an important factor in 
achieving success. They also concluded that pharmacists and physicians 
were aware of each other's roles, and this may have helped them to 
cooperate and respect divergent opinions. 
3.8.2 Pharmacists and angina trials 
There were fewer studies identified in the literature regarding pharmacists' 
impact in delivering a MMS to patients with angina (O'Neil et ai, 1996; 
Ryan-Woolley at ai, 2000; McAlistair et ai, 2001). However, the trials 
available suggest that the pharmacist could have (or potentially could 
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have) a positive impact on the care management of this group of patients6 • 
Table 2. provides details of the trial characteristics. 
Ryan-Woolley et al (2000) looked at both evidence-based interventions 
made by community pharmacists and the interprofessional perspectives of 
the GP-pharmacist collaboration. Although a small-scale feasibility study, 
the pharmacists and GPs interviewed expressed a high level of satisfaction 
about the service and viewed it as a positive experience. The key themes 
from the GP interviews were the high level of confidence in, and 
acceptance of the pharmacist in the management of patients with angina. 
Pharmacists stated they had gained more confidence in the actual and 
potential role they could have in managing patients with angina. The 
authors concluded that although positive results were obtained from the 
study, they acknowledged that the study may have shown a lack of 
representativeness. A convenience sample was used and the participating 
pharmacists had been involved in a previous, successful GP-pharmacist 
collaboration study. 
The other angina studies identified, did not measure or comment on the 
effect of a MMS on pharmacist and physician satisfaction, nor did they 
comment on how relationships and attitudinal factors between these 
parties may have affected the outcomes. 
6 The trial conducted by O'Neil concluded that community pharmacists could deliver a 
successful MMS to angina patients, although their actual study was conducted with Health 
Visitors. 
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3.8.3 Pharmacists and Lipid Management 
Table 3. details the studies identified where pharmacists had assisted 
patients with managing their hypercholesterolaemia (HC) in a range of 
settings (Shaffer and Wexler, 1995; Gardner et ai, 1995; Konzem et ai, 
1997; Bogden et ai, 1997; Tsuyuki et ai, 2002; Straka et ai, 2005; Paulos 
et ai, 2005). All identified studies, demonstrated a significant reduction in 
the cholesterol levels of the intervention patients compared with the 
control patients. Straka et al (2005) and Yamada et al (2005)7 also 
demonstrated that the reduction in cholesterol and target levels achieved 
in the intervention patients were maintained for up to 18 months post 
intervention. The study by Gardner et al (1995) demonstrated that 
community pharmacists could have a role in identifying patients at risk of 
developing He, by viewing target drugs that the patient was taking. 
7 Yamada et al (2005) was not a RCT. It has been included in this review as it was a follow-
up study of the intervention patients involved in the study conducted by Tsuyuki et al (2002). 
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I,Q 
VI 
Study 
Park et al (1996) 
USA 
Bogden et al 
(1998) 
USA 
Gourley (1998) 
USA 
Carter (1997) 
USA 
Table 1. Trial Characteristics - Pharmacists and Hypertension Management 
Participants Interventions Outcomes 
To determine the effect of pharmaceutical BP measurements 
64 patients with care on blood pressure (BP) control & quality Quality of Life 
hypertension of life. Patients in intervention group received Compliance (%) 
education & advice about their medication, Patient & physician 
Community pharmacists along with BP measurements at four acceptance of pharmaCiSts' 
scheduled visits with a community recommendations 
pharmaCist. 
Thirty-minute interview with pharmacist Percentage of patients who 
100 subjects with before seeing a physician. The pharmacist reached BP goals 
uncontrolled hypertension took a medication history, emphasised 
compliance and provided diet & lifestyle 
PharmaCists + physicians advice. PharmaCists also made 
recommendations to physicians regarding 
cost effective therapy. 
To determine the effect of pharmaceutical BP, Pulse 
133 outpatients with care on clinical, economic & humanistiC Medication compliance 
hypertenSion outcomes for patients with hypertension. Patient satisfaction 
Six month treatment period with scheduled Quality of life 
Clinical pharmacists visits for intervention group at 4 - 6 week 
intervals for a total of 5 visits. During visit, 
pharmacist recorded BP, weight, pulse & 
compliance. 
Trained community pharmacists (had access BP 
51 Clinic attendances with to medical notes + lab data) had face -to - Quality of life 
hypertension (BP ~ ~ face interviews with physicians & patients. Quality of care 
140/90) Patient satisfaction 
Number of anti-hypertensive 
Community pharmaCists medication 
Mean drug charges 
GPs Mean visits charges 
I 
Results 
Improvements in patient compliance in 
intervention group compared with control 
group. 
52% intervention group had normal BP at 
end of trial compared with 17% of this 
group at the start of trial. 
Recommendations followed up 53% with 
physicians & 60% with patients. 
55% intervention group reached BP goals 
compared with 20% in control group. 
Authors suggest that rapport between 
pharmacist and physician may influence 
outcomes. 
-
BP significantly reduced in intervention 
group. 
Medication compliance improved 
Significantly in interventions group. 
No significant differences in BP between 
intervention + control group. 
Hypertension services cost more for 
intervention group. 
Patient satisfaction values + quality of life 
scores higher in intervention group. 
\0 
0\ 
Study 
Blenkinsopp + Phelan 
(1999) 
UK 
Chisholm et al (2002) 
USA 
Garcao & Cabrith 
(2002) 
Portugal 
Borenstein et al 
(2003) 
USA 
Table 1. Trial Characteristics - Pharmacists and Hypertension Management Continued. 
Participants Interventions Outcomes Results 
251 subjects with hypertension To test the effects of a community BP Statistically significant BP improvement in 
identified by participating pharmacy based intervention on BP in intervention group. 
community pharmacists. improving patient adherence in Compliance Increased satisfaction in intervention 
hypertension. Pharmacist group. 
25 X Community pharmacists administrated a patient questionnaire Medication problems identified Statistically significant self-reported 
(either face-to-face or via telephone), adherence in intervention group. 
on 3 occaSions, 2 months apart to Patient satisfaction & acceptability 
intervention group. Written /verbal of pharmacists interventions 
information + referral to GP occurred if 
appropriate. Patient information needs 
23 African-American patients Whether pharmaceutical care could BP Significant differences in systolic BP 
> 18yrs who had received a impact on BP management over 12 between intervention & control group in 
renal transplant, with or at risk months. Intervention patients received 2nd, 3rd, & 4th quarter. 
of developing hypertension a quarterly BP assessment & education Significant differences in diastolic BP 
by pharmacists. between intervention & control group in 
Pharmacists 2nd and 4th quarter. 
82 patients with essential Whether pharmaceutical care could Variation of BP between Significant BP improvement in the 
hypertension & taking impact on hypertension management intervention & control group intervention group. 
antihypertensive medication over 6 months. 
Community pharmacists 
197 patients with uncontrolled Whether a physician-pharmacist co- BP measurements Both intervention & control groups had 
hypertension management group (PPCM) could help Number of visits significant reductions in BP, but 
reduce BP in patients with uncontrolled Cost per patient reductions greater in intervention group. 
39 x primary care physicians hypertension. Patients in PPCM group More patients achieved BP control in 
received education & recommendations intervention group. Patient costs higher in 
4 x clinical pharmacists from the pharmacist, with follow-up control group. 
from the physician. 
\0 
'-.l 
Study 
O'Neil et al (1996) 
UK 
Ryan-Woolley et al 
(2000)** 
UK 
**This study was not a 
RCT but has been 
included, as it looked 
at both a CHD 
intervention and the 
impact of the 
pharmacist-physician 
relationship on 
collaboration. 
McAlistair et al. (2001) 
Canada 
Table 2. Trial Characteristics - Pharmacists and Angina Management 
Participants Interventions Outcomes Results 
Number of prescription drugs Reduction in drug usage in 
688 patients with angina Trained health visitors made 3 home visits per Visit to GP intervention group. 
Health visitors* year to discuss way of living with disease and Smoking Cessation Episodes of angina decreased in 
reducing risks of future events. BP intervention group. 
* Authors conclude this Personal health education from trained health Cholesterol level No significant differences in the 
intervention could also be visitor every 4 months. Exercise use of the health services. 
delivered by a community Visits to Hospital 
pharmacist 
To determine whether community pharmacists 6 Evidence-based interventions 93 out of 105 therapeutic 
208 patients with stable could contribute to the management of patients 0 smoking cessation interventions accepted by GP. 
angina with stable angina. Patients received 2X face-to- o dietary adVice 
face interviews with the pharmacist at the 0 exercise PharmaCiSts, GP + patients 
5 community pharmacists beginning +end of the intervention +2 brief - aspirin reported high levels of satisfaction 
interim telephone interviews over a 5 month 0 beta blockers with the service. 
8 GP practices! 17 GPs period. Patients referred to GP if appropriate. 0 statins 
Patient, pharmacist +GP 
satisfaction to service 
To determine whether multidisciplinary disease Whether received efficacious drugs Disease management programmes 
SystematiC review of 12 RCTS management programmes for patients with Quality of life had positive impacts on processes 
(9803 patients with CHD) CHD, improved the process of care & reduced Cost of interventions of care, patients more likely to be 
morbidity & mortality. Risk factor profiles prescribed efficacious drugs. Five 
out of 7 trials evaluated risk factor 
profiles, these showed significant 
improvement compared with usual 
care. Five out of 8 trials evaluated 
quality of life, better out comes in 
intervention group. 
Favorable results have also been shown from a multidisciplinary 'lipid clinic' 
team, which included a pharmacist (Shaffer and Wexler, 1995). Patients 
attending the lipid clinic were four times more likely to reach national goals 
for LDL-cholesterol. However, although the multidisciplinary composition is 
discussed, it is not stated how the intra-professional interaction may have 
impacted on the success of the study. Likewise, no other studies identified 
(refer to Table 3.) made any reference to relationship or attitudinal aspects 
between the participating pharmacists and physicians, and in turn how this 
may have impacted on the intervention. 
3.8.4 Pharmacists and smoking cessation 
Table 4. details the studies identified where community pharmacists have 
had a role in smoking cessation (Anderson, 1995; Sinclair et ai, 1998; 
Sinclair, 1999; Maguire et ai, 2001). The studies concluded that a higher 
smoking cessation rate amongst smokers was achieved when community 
pharmacists had received training in smoking cessation. This training 
varied from health promotion training to a structured smoking cessation 
programme. Customers also reported a greater satisfaction with the advice 
they received about smoking cessation from pharmacists who had received 
training. 
3.9 Summary 
The majority of studies identified showed that pharmacist and physician 
collaboration had a positive, impact on patient care in terms of clinical and 
economical outcomes. However, few of the identified studies had 
considered or specifically explored in depth how relationship or attitudinal 
factors between the participating pharmacists and physicians may have 
98 
affected the success of the collaborative interventions. In the final part of 
this chapter, attention is turned to the CPMMP, along with the focus that I 
have decided to undertake in this thesis. An overview of the project is 
detailed, as it provided the subjects and time frames from which I collected 
my data. 
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o 
Study 
Shaffer and Wexter 
(1995) 
USA 
Gardner et al (1995) 
USA 
, Konzem et al (1997) 
USA 
Table 3. Trial Characteristics -Pharmacists and Lipid Management 
Participants Interventions Outcomes Results 
Patients with fasting total serum To compare the effect of the lipid Cholesterol levels After four clinic visits, patients attending the 
cholesterol level> 6.85mmol on clinic team vs routine physician Education level assessed lipid clinic were four times more likely to 
two occasions care in treating patients with high Diet + education evaluation reach national goals for LDL cholesterol. 
cholesterol. Patient attended the Behaviour + lifestyle changes I Lipid Clinic Team: 1 registered lipid clinic and received medical Weight + BP 
nurse, clinical pharmacist, counseling, with follow up visits 
dietician, psychologist, cardiologist every 3 months. 
+nurse practitioner 
185 subjects at risk of HC To compare the effectiveness of Cholesterol levels Cholesterol readings were higher in the I 
selectively screening pharmacy intervention group. Higher % of borderline 
4 community pharmacists databases to identify patients with cholesterol levels in control group. Authors 
potential high HC Intervention conclude identification of target drugs by 
patients identified vs mass HC pharmacists could detect individuals with risk 
screening. Intervention patients factors for HC compared to random screening. 
identified with one or more clinical 
indicator from pharmacy 
databases. Control group, 
pharmacists advertised free 
cholesterol tests to anyone by 
word of mouth. 
40 subjects with HC To determine whether Reduction in total cholesterol LDL After 52 weeks, achievement of LDL 
pharmaceutical care with + HDL cholesterol cholesterol was higher in the intervention 
Pharmacist + physician. pharmacist & physician team could Cholesterol group. 
increase patient acceptance & Achievement of LDL Cholesterol No significant differences in compliance but 
compliance with colestipol therapy goals 65% in intervention group still taking drug at 
& improve outcomes. one year compared with 40% in control 
Intervention patients met group. 
pharmacist for one hour before 
start of cholesterol therapy for 
intensive counselling. 
Compliance encouraged at 2, 4 + 
6 weeks by telephone and follow 
up visit at 8 weeks. 
Telephone contact at 26 and 52 
weeks. 
Table 3. Trial Characteristics - Pharmacists and Lipid Management Continued. 
Study Participants Interventions Outcomes Results 
To determine the effect of a pharmacist/physician Total cholesterol levels Total Cholesterol reduced by 43% in 
Bodgen et al (1997) 94 outpatients with a team on lowering cholesterol. Intervention intervention group compared with 21 % in 
total cholesterol of patients met pharmacist prior to seeing % patients who achieved control group. 
USA 6.2mmol/L (240mg/dl) physician. Patient provided with education & National Cholesterol Education 90% pharmacist recommendations accepted by 
or higher clinical recommendations passed to physician. Programme (NCEP) the physician. 
Pharmacists % interventions accepted by 
-o 
physician 
To determine the effect of a community Total fasting cholesterol 57% of intervention patients reached cholesterol 
-
Tsuyuki et al (2002) 675 patients at high pharmacist intervention, on the process of measurement goals compared with 31% in control group. 
risk of cardiovascular cholesterol risk management in patients at high 
Canada events risk for cardiovascular events. Intervention % of patients receiving a % of new prescriptions for cholesterol -lowering 
patients received education, referral to their prescription for a new drug 10% intervention group vs 4% control 
54 community physician and regular follow up for 16 weeks, cholesterol - lowering group. Increased medication use in 3% 
pharmacies. with recommendations sent to physician. medication or an increase in intervention group vs 1 % control group. 
dosage of a cholesterol-
lowering medication Study terminated early due to beneficial effects. 
Medication use 
481 patients with CHO To compare the results of a collaborative Changes in LDL levels LDL levels reduced by 27.5% in intervention 
Straka et al (2005) and non-target LDL approach with pharmacists vs usual care for group compared with 4.6% in control group. 
levels achieving LOL levels of 100mg/dl or less. In Sustainability of the impact, 
USA intervention group pharmacist assigned to a observed up to 18 months When active programme discontinued for 18 
4 clinics (of which patient to develop & implement a patient-specifiC after discontinuation of the months, 65% of intervention patients vs 42% 
clinical pharmacists care plan & to provide information. intervention control patients remained at target LDL level. 
made un team) 
To implement a pharmaceutical care programme Total cholesterol level Total cholesterol (77% vs 23%) & triglyceride 
Paulos et al (2005) 42 patients being for dyslipidemic patients within a community Triglyceride level levels (77% vs 22% increase) decreased more 
treated for dyslipidemia pharmacy setting. Intervention over 16 weeks. in the intervention group compared with control 
Chile Intervention patients received 5 interviews during Body Mass Index (BMI) group.26 ORPs detected in intervention group 
lx community this time to receive education & clinical (24 resolved) compared with 26 in control group 
pharmacist measurements. Control group received 2 Drug Adherence (5 resolved). 
interviews during intervention period. BM! decreased more in intervention group 
Number of drug related Quality of life improved in intervention group 
problems (ORPs) High drug costs & failure to remember to take 
drug most common cause of non drug 
Quality of life adherence. 
..... 
o 
tv 
Study 
Anderson (1995) 
UK 
Sinclair et al (1998) 
UK 
Sinclair et al (1999) 
UK 
Maguire et al (2001) 
UK 
Table 4. Trial Characteristics - Pharmacists and Smoking Cessation Management 
Participants Interventions Outcomes Results 
40 community pharmacies (20 control To evaluate whether training in health Availability of smoking 
+ 20 involved In a health promotion promotion affected what happened In cessation therapy & Information Greater satisfaction with the trained pharmacists' 
scheme) pharmacy practice. consultations. I 
Duration of Interview 
1x covert participant researcher Training to pharmacists improved the advice given, 
Willingness of the pharmacist counselling & communication skills & handling of 
to help provide advice health promotion leaflets. 
Overall satisfaction 
492 customers who sought advice on To evaluate the effect of a training Smoking cessation rate No significant difference between the proportion of' 
smoking cessation or bought an OTC workshop for community pharmacy quitters' In the Intervention & control group, but the 
anti-smoking product personnel on smoking cessation. Intervention group was associated with an increased 
and more useful counselling and higher smoking 
Community pharmacists and cessation rate. 
community pharmacy personnel 
134 community pharmacy personnel To monitor the duration of the training Attitudinal differences Training on smoking cessation had a significant 
effect on smoking cessation from effect on knowledge for at least 3 years, since at 
community pharmacy personnel. both 24 + 36 months the intervention pharmacy 
teams had a significantly greater knowledge + 
understanding of the model than the controls. 
Evaluation on whether a structured Self - reported smoking cessation for Smokers in the PAS group had a higher smoking 
124 Community Pharmacists community pharmacy -based smoking 12 months with continued cessation at cessation rate than the control group. 
cessation programme (the Pharmacists' a 12 month follow-up 
484 Smokers Action on Smoking (PAS) model) gave 
rise to a higher smoking cessation rate. 
The PAS intervention involved a 
structured counselling programme, an 
information leaflet & follow-up weekly 
for the first few weeks, then monthly as 
needed. 
-
3.10 The Community Pharmacy Medicines Management 
Project 
As reported previously in this chapter, the reduction of CHD is a national 
priority, with the use of aspirin, beta blockers and statins often being 
under-utilised in CHD patients. There is also evidence that pharmacists can 
contribute to patient care through medicines management initiatives in 
CHD. In addition, they can have a positive effect through lifestyle changes, 
particularly smoking cessation. A further consideration is that many 
patients with CHD have other conditions for which they are prescribed 
repeat medication and are receiving polypharmacy regimens, which 
pharmacists could review. With this evidence available that community 
pharmacists can have a beneficial impact, the CPMMP was proposed. 
The CPMMP was developed by the PSNC, funded by the Department of 
Health, and evaluated by an independent research team. The project was 
implemented in nine pilot sites throughout England and involved 1493 
patients (980 intervention and 513 control), 62 pharmacists and 164 GPs. 
3.11 Aims and objectives 
The aim of the study was to evaluate the introduction of a MMS by 
community pharmacists for patients with CHD (defined as previous MI, 
angina, coronary artery by-pass graft (CABG) and angioplasty). 
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The primary objectives of the CPMMP were to: 
• 
Compare the proportion of patients receiving appropriate treatment 
(as defined by current available evidence and guidelines) between 
intervention and control groups, at baseline and at the end of the 
intervention period. 
• Quantify 'health gain' by describing the change in patients' overall 
health status after the intervention period, as defined by standard 
• 
measures. 
To conduct an economic evaluation of the medicines management 
intervention (including estimates of drug cost changes). 
The secondary objectives of the CPMMP were to: 
• 
• 
Describe the opinions of the community pharmacists, patients, GPs 
and their staff about a MMS before and after its introduction. 
Describe the barriers to implementation and make 
recommendations for change. 
• Describe the role of OTC medicines in the overall patient 
management of this condition. 
3.12 The research team 
The Universities of Aberdeen, Keele and Nottingham and the College of 
Pharmacy Practice were responsible for evaluating the project. The 
research team consisted of a Research Project Manager (based in 
Aberdeen), three Research Fellows (one in each University), and nine local 
research co-coordinators «LRCs), one based in each project site). The 
principle grant holder and investigator was Professor C. Bond (based in 
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Aberdeen). Key academic staff at each of the institutions made up the 
Steering Group and were responsible for the delivery of the research 
(Appendix 1 provides details of who made up the Community Pharmacy 
Medicines Management Evaluation Team). Training for community 
pharmacists prior to the delivery of the intervention was designed and 
provided by the Centre for Pharmacy Postgraduate Education (CPPE). 
3.13 Project design and the medicines management 
intervention 
The project was a RCT (where the control group represented 'usual care' Vs 
the medicine management intervention). A RCT was chosen as the 
preferred project design, as if conducted appropriately the risk of bias 
should be minimised and the validity of the results optimised (Deeks et ai, 
1996). The primary subjects for the study were patients with CHD, and 
were identified from general practices computer systems. Secondary 
subjects were community pharmacists and health care professionals caring 
for the recruited patients, for example GPs and their staff. The main data 
source for both intervention and control patients were obtained from 
patients' medical records by audit clerks. 
Community pharmacists received training prior to the delivery of the 
intervention, which was provided by CPPE. Eligible patients were identified 
and invited on to the study by participating GP practices (see Figure 1.). 
Once the patient had returned the consent form indicating their intention to 
partiCipate, along with the name of the pharmacy that they used for their 
medicines, they were randomised by Aberdeen to either intervention or 
control group. To maximise the number of patients experiencing the 
intervention a 2: 1 intervention/control ratio was used. 
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Participating pharmacists were informed of the patients that had been 
allocated to the intervention group and they received a core set of medical 
information about these patient extracted from their medical records. The 
intervention comprised of an initial consultation with the community 
pharmacist to review the patient's medication, making recommendations 
and giving life style advice where appropriate. Appropriateness of therapy, 
compliance and concordance, lifestyle and social and support issues were 
to be addressed, all of which were communicated to the GP using a 
standard form (with duplicate forms being retained in the pharmacy). 
The pharmacist also followed up the progress of the patient over the 12-
month intervention period, determining the number of subsequent 
consultations, based on the needs of each patient. Control patients were 
advised that they would continue to receive their standard treatment. 
3.14 Primary and secondary outcome measures 
The effectiveness and efficiency of the intervention was assessed using 
primary and secondary outcome measures. These were derived from data 
in the medical records, information on the intervention form, and patient 
and healthcare professional questionnaires at baseline and follow-up. 
Interview and focus group data were also used. The primary outcome 
measures were appropriate treatment (derived from the NSF), health 
status and an economic evaluation. The secondary outcome measures were 
patient risk of death, role of OTCs, patient satisfaction, experiences and 
attitudes of patients and healthcare professionals. All measures were 
assessed at baseline and at twelve months. 
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3.15 Pilot sites 
Thirty-three sites expressed an interest to the PSNC and subsequently put 
in a bid to take part in the CPMMP. After discussion with the Project 
Manager and the relevant project group, nine sites were selected using 
purposive sampling to include a cross section of sites (e.g. rural, small city, 
city center), ethnicity, income, community pharmacies (e.g. multiple chains 
and independents) and general practice (e.g. large, small, dispensing & 
non-dispensing). 
The project was conducted in the following nine localities across England. 
• Lichfield 
• Nantwich 
• 
North Southwark (London) 
• North Tyneside 
• poole 
• Portsmouth 
• Salford 
• Shipley & Baildon 
• Walsall 
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Figure 1. Patient Recruitment Process in the Community Pharmacy 
Medicines Management Project 
Patients identified using READ 
codes for CHD & related cardiovascular diagnosis 
in the GP practice* 
.l-
Patient list presented to the GP 
GP applied exclusion criteria** to the patient list 
& provided authorisation for patient to be invited onto 
the study 
.l-
Letters sent to eligible patients inviting them to participate 
.l-
Patient returned consent form to Aberdeen 
indicating their intention to participate 
.l-
If patient participating, they asked to name pharmacy 
that they use for collecting their medicines 
.l-
Patients randomised (2: 1 intervention) 
.l-
Control Patients advised 
that they will continue to 
receive standard treatment 
.l-
.l-
Intervention patients sent 
registration card from 
Aberdeen, asking them to 
present the card to the 
pharmacist, initiating the 
intervention 
Pharmacists informed of intervention patients & received 
a set of medical information about each intervention patient 
*Inclusion criteria - Male & females (18 years and above) with CHD 
(defined as previous MI, angina, CABG or angioplasty) 
**Exclusion criteria - any patient, which was illiterate, innumerate, 
suffers from alcohol or drug misuse, terminally or seriously ill, severe 
mental illness, unable to give informed consent, or in the opinion of their 
GP is unsuitable to participate in the study 
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3.16 Data collection 
Both quantitative and qualitative data were collected in the CPMMP. All 
participants were sent postal questionnaires at baseline and follow-up. 
Qualitative interviews were undertaken with a sample of patients, 
community pharmacists and GPs. Focus groups were also undertaken with 
a sample of community pharmacists. 
Supplementing quantitative methods with qualitative techniques allowed 
the data to be checked for accuracy, content validity and relevance of the 
quantitative data that had been collected. Also, by combining different 
research methods and investigators in the same study, deficiencies or bias 
that came from an investigator or method could partially be overcome. 
The Research Fellow in Aberdeen was primarily responsible for developing 
and analysing patient, pharmacist and GP (and their staff) questionnaires. 
The Research Fellow in Keele was primarily responsible for selecting, 
conducting and analysing patient qualitative, semi-structured interviews. 
They were also responsible for developing, testing and validating a patient 
satisfaction and compliance and concordance questionnaire. The 
Nottingham Research Fellow (myself) was primarily responsible for 
conducting and analysing interviews/focus groups with pharmaCists, GPs 
and patients. 
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3.17 Rationale for this thesis 
As detailed earlier on in this chapter, there have been many studies that 
have looked at collaboration between pharmacists and physicians to 
evaluate the impact on patient care in terms of clinical and economic 
outcomes. However, few studies have commented or specifically explored 
in depth the effect of relationships and attitudinal factors between 
pharmacists and physicians to gain an understanding of how this affects 
collaborative work, and ultimately the success of role development for the 
pharmacist. 
With recent Government reforms and changes to the community 
pharmacist contract, community pharmacists extending their role beyond 
dispensing medication is becoming an ever more realistic option 
(Department of Health, 2000b, 2003a; Pharmaceutical Services Negotiating 
Committee, 2004). To improve the outcomes of drug therapy, there has 
been an increasing focus on community pharmacists providing MMS 
(Department of Health, 200b). Inevitably, community pharmacists will 
need to communicate and collaborate more extensively with GPs, if they 
are to successfully accomplish this role extension. Likewise, the support of 
GPs is essential for pharmacists to successfully deliver a collaborative MMS. 
It is therefore important to understand how community pharmacists' and 
GPs' perceptions and working relationship with each other could affect the 
ability of community pharmacists to develop new roles. 
As discussed in chapter 2, the available literature suggests that there are 
significant attitudinal barriers between pharmacists and physicians 
(Adamcik et ai, 1986; Spencer and Edwards, 1992; Ellis et ai, 1992; Smith 
et ai, 2002; Hughes and McGann, 2003). Likewise, the literature also 
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suggests that physicians have often seen the extension of the pharmacist's 
role as boundary encroachment (Eaton and Webb, 1979; Adamcik et ai, 
1986; Gilbert, 1997, 1998a-c 2001; Edmunds and Calnan, 2001). I believe 
positive perceptions and good relationships between community 
pharmacists and GPs are key components to successful collaborative 
working. However, as the available literature indicates it is an area that is 
rarely given much consideration. I therefore believe it is an area that needs 
to be addressed and researched as these findings could help inform and 
facilitate future collaborative ventures between community pharmacists 
and GPs. 
The specific questions driving the research were how relationships and 
attitudinal factors between the participating community pharmacists and 
GPs impacted on the success of the community pharmacist conducting a 
MMS. I also wanted to establish whether perceptions and relationships 
between the two professions altered during the course of the project. 
Finally, I wanted to frame this research using concepts from a sociological 
perspective. For example, did the participating pharmacists and GPs view 
the extended role that the community pharmacists were undertaking in this 
project as boundary encroachment, or as tasks that GPs were willing to 
delegate to them? 
The participating pharmacists and GPs in the CPMMP were ideal subjects to 
use, as they had varying clinical experiences (this ranged from being newly 
qualified to having over thirty years of clinical experience), worked in a 
variety of settings (from single handed to large GP practices and similarly, 
small independent community pharmacies to large multiple chain 
pharmacies), and had different degrees of working relationships with each 
other (these ranged from no prior relationship with each other to 
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established relationships, where the pharmacist and GP socialised 
together). I hoped this diversity of subjects would help me gain some 
insight and draw some conclusions to my research questions. 
3.19 Summary 
CHD is currently the most common cause of death in the UK and therefore 
the reduction in mortality and incidence of CHD is a major public health 
goal. Previous pharmaceutical care and medicine management initiatives in 
CHD have shown that pharmacists can have a positive impact in managing 
patient care. The majority of these studies have mainly focused on the 
impact the pharmacist could have on clinical outcomes (such as a reduction 
in blood pressure or cholesterol levels), economic outcomes and patient 
satisfaction levels. However, few studies have considered or specifically 
looked at the effect of the relationship or attitudinal factors between the 
pharmacist and physician to gain an understanding of how this affects 
collaborative schemes, and ultimately the success of the role extension for 
the pharmacist. 
In an aim to address this public health goal the CPMMP was developed. 
This project aimed to evaluate the introduction of a MMS by community 
pharmacists for patients with CHD. This thesis was an exploration of the 
relationships and attitudinal factors between the community pharmacists 
and GPs participating in the CPMMP, to see how these affected the 
community pharmacist having an extended role. 
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4. AIMS AND OBJECTIVES 
4.1 Aims of the Study 
To critically assess the views and experiences of community pharmacists 
and GPs involved in a MMS after its introduction; exploring how 
relationship and perceptions of each other may influence community 
pharmacists carrying out a MMS, from the view pOint of both community 
pharmacists and GPs. 
4.2 Objectives 
The specific objectives for the qualitative work with community 
pharmacists were to: 
1. Describe community pharmacists' current working relationship with 
GPs. 
2. Determine whether a MMS had altered community pharmacists' 
working relationship with GPs. 
3. Determine how community pharmacists thought GPs perceived 
them. 
4. Determine whether involvement in a MMS had altered these 
perceptions. 
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5. Assess the attitudes and experiences of community pharmacists 
towards their participation in a MMS after its introduction and at the 
end of the twelve month intervention period. 
6. Identify barriers to community pharmacists' involvement in a MMS. 
The specific objectives for the qualitative interviews with GPs were to: 
1. Describe GPs' current working relationship with community 
pharmacists. 
2. Determine whether a MMS had altered GP's working relationship 
with community pharmacists. 
3. Determine GP's knowledge about community pharmacists. 
4. Describe the views of GPs about collaborating with community 
pharmacists. 
S. Identify barriers to community pharmacists' involvement in a MMS 
from the viewpoint of GPs. 
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5. METHODOLOGY 
5.1 Introduction 
This chapter gives an overview of qualitative research, discussing the broad 
intellectual traditions on which it is based, the differences and similarities 
between qualitative and quantitative research, and criticisms of its use. 
Also discussed are the principles of focus groups and semi-structured 
interviews. The analysis of qualitative data will then be considered, 
particularly focusing on the 'Grounded Theory' approach, explaining its use 
within this project. Finally, the theory and epistemological orientation of 
this piece of research will be discussed, along with justifications on why 
focus groups and semi-structured interviews were chosen as the data 
collection methods for this piece of research. 
5.2 Differences and similarities between qualitative and 
quantitative research 
Qualitative research has its origins in the social, rather than the natural 
sciences. There have been many attempts to define qualitative research 
and it is important to pOint out that it is not a unified set of techniques or 
philosophies, but has grown out of a wide range of intellectual and 
disciplinary traditions (Mason, 2002). It has been used extensively within 
disciplines such as sociology, anthropology, history, and psychology 
(Harding and Gantly, 1998). Strauss and Corbin (1998:21) define it as: 
"Any type of research that produces findings not arrived at by statistical 
procedures or other means of quantification. " 
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It is argued that there are certain common, characteristics of qualitative 
research that distinguish it from quantitative research strategies (see Table 
5). However, it should be noted that these characteristics are better viewed 
as tendencies within qualitative research rather than hard and fast 
differences, as the qualitative/quantitative research paradigms have 
become less polarised than in the past (Harding and Gantley, 1998). 
Table 5. Differences and Contrasts between Quantitative and 
Qualitative Research Strategies 
Quantitative Qualitative 
Principal orientation to Deductive; testing of Inductive; generation 
the role of theory in theory of theory 
relation to research e.g. Hypothesis testing e.g. Hypothesis 
generating 
Epistemological Natural science model, Interpretivism 
orientation in particular positivism 
Ontological orientation Objectivism Constructionism 
Relationship between Distant Close 
researcher & subject 
Research Strategy Fixed, structured FleXible, unstructured 
Image of social reality Static Processual 
Nature of data Hard, reliable data Rich, deep data 
Adapted from Bryman A. Social Research Methods 2nd Edition. Oxford University Press. 2004 
p.20 and p.287 
Qualitative research can be construed as a research strategy that usually 
emphasises words rather than quantification in the collection and analysis 
of data (Bryman, 2004). The rationale underpinning qualitative methods 
lies in an exploration of how people make sense of their social world, in 
order to provide insights into people's behaviour that is not readily 
116 
accessible through surveys (Harding and Gantley, 1998). It is usually 
carried out with small samples of individuals and has often been presented 
as attempting to understand events, actions, values and meanings from 
the individual's perspective, rather than the researcher's. These methods 
are often concerned with aspects of social reality such as interaction, as 
opposed to hypothesis testing aspects of social trends, and have a 
processual image of social reality (Bryman, 2004). Qualitative methods 
tend to have a less structured approach, to allow the researcher to pursue 
respondents' meanings and concepts as they emerge from the data. It is 
argued that the researcher often builds a close relationship with the 
subject, producing rich, deep data. 
Qualitative approaches tend to be inductive in which the emphasis is placed 
on the generation of theories. The researcher moves from observation to 
hypothesis, as opposed to starting with a research question or a hypothesis 
that precedes any data collection. A researcher undertaking qualitative 
work is encouraged not to separate the stages of design, data collection 
and analysis but to go backwards and forwards between the raw data and 
the process of conceptualisation, thereby making sense of the data 
throughout the period of data collection (Pope and Mays, 1995). 
From an epistemological position it is broadly interpretivist, which is in 
contrast to the adoption of a natural scientific model in quantitative 
research. Interpretivism (also known as symbolic interactionism) rejects 
the idea that social structures (or the needs of society) might influence or 
significantly shape the activities of humans (Bissell et ai, 2002). 
Interpretivists are interested in the processes in which indiViduals make 
sense of and attribute meaning to social events to try to get a sense of how 
the 'self' is managed, presented or influenced in the course of interaction. 
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They believe the 'self' is not some fixed entity that an individual is born 
with, but is emergent and continually developing. Interpretivism has 
produced a plethora of literature into the insights of individuals in the 
health care settings, regarding issues such as health beliefs and experience 
of health and illness (Bissell et ai, 2002). 
5.3 When to use qualitative research 
Qualitative research methods are considered particularly advantageous in 
studies where there is little pre-existing research, or the issues are 
sensitive or complex. The qualitative investigator has the advantage of 
getting close to the research material allowing an in depth exploration of 
the subject. A large quantity of in-depth information can be obtained, 
which can be tested in subsequent quantitative studies if necessary and 
appropriate. Often qualitative description is a prerequisite of good 
quantitative research, particularly in the initial stages of questionnaire 
design and scale construction (Bowling, 2002). Qualitative techniques have 
a wide range of applications in health care research and have commonly 
been used in documenting the experience of chronic illness, in investigating 
practitioners' and patients' attitudes, beliefs and preferences, as well as 
looking at how clinical evidence is turned into practice (Green and Britten, 
1998). 
5.4 Sampling in qualitative research 
Qualitative interviewing is usually based on small sample sizes, and the 
sampling techniques preferred include convenience sampling, purposive 
sampling, snowballing, and theoretical sampling (Bowling, 2002). Sample 
sizes are small because of the detailed and intenSive work that qualitative 
118 
studies usually entail and also due to the complexity of the data, which are 
expensive and time-consuming to analyse. The data also aims to provide 
in-depth insights in order to understand social phenomena rather than 
statistical information (Bowling, 2002). 
The application of mathematical rules to calculate sample size is generally 
not appropriate. Even if the sample were random, due to the small 
sampling fraction and resulting possibility of a high sampling error, the 
application of probability statistics would be inappropriate (Smith, 1998). 
The data obtained from qualitative interviews are used to increase our 
insight to social phenomena rather than assume representativeness. 
However, the issue of non representativeness of people, and hence the 
generalisability of the data is a criticism that is frequently encountered with 
qualitative data (Mays and Pope, 1995). 
5.5 Criticisms of qualitative research 
Three of the most prominent criteria for the evaluation of social research 
are reliability, replication (generalisability) and validity. Often qualitative 
research is criticised for lacking scientific rigour (Mays and Pope, 1995). 
Some argue that qualitative and quantitative research is very different and 
that it is not possible to judge qualitative research by using conventional 
criteria such as reliability, generalisability and validity (Mays and Pope, 
1995). However, various strategies are available within qualitative research 
to help protect against bias and enhance the reliability of findings. 
It is argued that qualitative findings are too impressionistic and subjective, 
as they rely too much upon on the researcher's views about what is 
significant and important (Mays and Pope, 1995). The close personal 
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relationships that the researcher may form with their subjects can make it 
too subjective, or can influence what is said in an encounter. However, it 
could be argued that the qualitative researcher aims to investigate people 
in their usual environments and seeks a close involvement with the 
subjects under investigation, as this allows an in depth exploration with an 
awareness of the social content in which data are collected. 
Reliability may also be a problem due to the way a researcher goes about 
categorising the events or activities described. When people's activities are 
tape-recorded and transcribed, the reliability of the interpretation of 
transcripts may be weakened by a failure to record apparently trivial but 
often crucial, pauses and overlaps (Silverman, 2000). Silverman (2000) 
argued that transcription of interview tapes should be carried out using the 
standards required by conversation analysis. This included revealing 
features such as hesitations, breaths and pauses in conversation. These 
authors also argued that in order to improve reliability and validity, 
qualitative researchers should support generalisations by counts of events 
(quasi-statistics) and they should use computer-assisted qualitative data 
analysis software (CAQDAS) to help with coding and analysis. Mays and 
pope (1995) suggest that organising an independent assessment of 
transcripts by additional researchers and comparing agreement between 
the raters can enhance the reliability of the analYSis of qualitative data. 
Anecdotalism can also be a criticism in which researchers report a few 
'examples' of some apparent phenomenon without any attempt to analyse 
less clear (or even contradictory) data. This questions the validity of much 
qualitative research because the researcher has clearly made no attempt to 
deal with contrary cases and is strongly subject to researcher bias 
(Silverman, 2000 and 2001). 
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Qualitative research can also be criticised for its lack of transparency. Often 
the process of qualitative analysis is unclear (Bryman and Burgess, 1994) 
and it is difficult to establish from the research what the researcher has 
done and how they have arrived at their conclusions (Bryman, 2004). 
However, this is one criticism that can be addressed by the qualitative 
researcher, simply by providing a detailed methodology in their report 
(although it should be noted it is often difficult for researchers to provide a 
detailed methodology due to the tight word restriction placed by journals 
on research papers). Proponents of qualitative research have also 
described various methods and techniques that they assert in order to 
make qualitative research more rigorous (Pope and Mays, 1995; Pope et ai, 
2000; Hoddinott and Pill, 1997a). For example, Hoddinott and Pill (1997a) 
have published a list of criteria and suggest that if such methodological 
detail were included in every paper, a reader would be able to 'replicate' 
the study and confirm the 'findings'. However, replicating a qualitative 
study can be difficult as it is often reliant upon the qualitative researcher 
being the main data collection instrument. What a qualitative researcher 
decides to focus on may not be what other researchers see as significant. 
The responses of the subjects are also likely to be affected by the 
characteristics of the researcher, for example their gender, age, personality 
and profession. Qualitative data is often conducted with a small number of 
individuals in a certain organisation or locality. Qualitative methods often 
have an unstructured approach so that the possibility of exploring 
meanings and concepts emerging out of data can be enhanced and may be 
used to explore 'insights' in an ever changing surrounding. Therefore, 
replication may not be possible or appropriate for some qualitative 
research as it is impossible to know how the findings can be generalised to 
other settings. 
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There is a variety of validation strategies sometimes used in qualitative 
research. These include triangulation, in which data collection is 
deliberately sought from a wide range of different, independent sources 
and means. Feeding the findings back to the participants to see if they 
regard the findings as a reasonable account of their experience, and to use 
interviews or focus groups with the same people so that their reactions to 
the evolving analysis become part of the emerging data (Mays and Pope, 
1995, 2000; Smith, 1999). 
5.6 The collection of qualitative data 
Qualitative data may be collected by a variety of techniques; these include 
participant observation, interviews, group interviews and focus groups, 
language-based approaches (such as discourse and conversation analysis), 
and analysis of historical and contemporary records, documents and 
cultural products (Bowling, 2002). 
5.6.1 Qualitative interviews 
The interview is probably the most widely employed method in qualitative 
research, as it allows the researcher to glean the ways in which research 
participants view their social world (Bryman, 2004). Qualitative interviews 
may take the form of being either unstructured (these tend to be very 
similar in character to a conversation) or semi-structured (the interviewer 
will have a list of questions or topics to be covered). Semi-structured 
interviews are conducted on the basis of a loose structure consisting of 
open-ended questions that define the area to be explored (Britten, 1995). 
These are useful if the researcher is beginning the investigation with a 
fairly clear focus, rather than with a general notion of wanting to do 
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research on a topic, so that more specific issues can be addressed. 
Questions may not follow on exactly in the way outlined in the schedule 
and the interviewee will have a great deal of freedom in their reply. This 
allows the researcher to ask things not on their list but in response to 
emerging information given to them by the interviewee. However, by and 
large, all the questions will be asked and a similar wording will be used 
from interviewee to interviewee. Semi-structured interviewing is also 
preferred where there is more than one person carrying out the fieldwork 
in order to ensure a small quantity of comparability in interviewing style 
(Bryman, 2004). Interviews should be tape recorded (after gaining the 
interviewee's permission) in order that they can be analysed in detail later. 
Interviews may be carried out face-to-face or by telephone, each method 
having its own set of advantages and disadvantages. For example, 
telephone interviews have the advantage of being impersonal, which some 
interviewees may prefer as they feel more comfortable than answering 
questions face-to-face. As a consequence they may reveal more on the 
telephone than they would in person and richer data may be collected. 
conversely, from the interviewer's perspective, the interviewee's body 
language (which is often very revealing) can not be observed and it may be 
harder for the interviewer to build any rapport with their interviewee. It is 
also much easier for the interviewee to terminate a telephone interview by 
hanging up. Telephone interviews are often used as second or follow-up 
interviews to face-to face interviews. In this situation, the interviewee 
'knows' to whom they are speaking, having previously met the interviewer. 
Telephone interviews, like face-to-face interviews, are usually recorded 
(Grbich, 1999). 
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Problems often encountered when carrying out qualitative interviews 
include interruption during the interview, particularly if the interview is 
carried out in the participant's home or workplace. The interviewee may 
have 'stage fright' or jump from one topiC to another. This may be 
precipitated by the use of a tape recorder, as it may alarm or make the 
interviewee self-conscious and the researcher should be aware and 
sensitive of this. The interviewer should try to use language that is relevant 
to the people that they are interviewing. Care must be taken in developing 
suitable open and non-leading questions. The use of closed questions may 
direct the interview down a path of interest to the researcher, but not 
necessarily of importance to the interviewee (Smith, 1998). The 
interviewee should be careful not ask leading questions or give their 
opinions as this could lead to a biased interview. They must also maintain 
control of the interview and need to be flexible in their questioning. Finally, 
all qualitative researchers need to consider how interviewees perceive 
them and how the interviewer's characteristics such as class, race, sex and 
profession may affect the interview (Britten, 1995). The main practical 
problems associated with semi-structured interviews are that they are 
expensive and time consuming to conduct, transcribe and analyse. This is 
particularly pertinent in projects with wide geographical locations. 
5.6.2 Focus groups 
Focus groupS are semi-structured interviews with small groups of 
individuals (typically between six to twelve people), which rely on the 
interaction between each other and the group leader (e.g. the researcher) 
in order to produce data. A group leader (usually the researcher) runs the 
focus group and is expected to guide the session but not be too intrusive 
(Morgan, 1998). Focus groups are particularly useful for exploring people's 
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knowledge and experiences and can be used to examine not only what 
people think, but also how and why they think that way. They have been 
widely used to examine people's experiences of disease and of health 
services (Kitzinger, 1995). 
Focus groups are believed to be most effective when the participants share 
some common background characteristics, thereby allowing the researcher 
to identify group norms and gain an understanding of the varying 
perspectives and concerns of different groups of people (Smith, 1999). 
potential advantages of using focus groups as a means of data collection 
include: 
• They do not discriminate against people who cannot read or write. 
• They can encourage participation from those who are reluctant to 
be interviewed on their own (such as those intimidated by the 
formality and isolation of a one to one interview). 
• They can encourage contributions from people who feel they have 
nothing to say or who are deemed 'unresponsive' (but engage in the 
discussion generated by other group members). 
• Participants are allowed to bring to the fore issues in relation to a 
topic that they deem to be important and significant. Although this 
is an aim in an individual interview, the researcher has to relinquish 
a certain amount of control to the participants in a focus group, 
allowing the issues that concern the interviewee to surface more 
easily. 
potential limitations of carrying out focus groups include: 
• The researcher probably has less control over proceedings than with 
an individual interview. The researcher will often have to find a 
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• 
• 
• 
balance between letting the focus group 'take-over' the running of 
proceedings, and the researcher prompting and asking questions. 
There may be problems with the group dynamics, with overly 
prominent participants and those who participate very little. Equally, 
the opinions of group norms may silence individuals with differing 
opinions. 
The presence of other research participants compromises the 
confidentiality of the research session. 
A huge amount of data can be very quickly produced, often making 
data difficult to analyse. The transcribing time is often more time-
consuming than equivalent recordings of individual interviews. 
• They are difficult to organise and persuade people to turn up at the 
same time. 
5.7 Qualitative data analysis 
One of the main difficulties with qualitative data is that it generates large 
amounts of data, but unlike the analysis of quantitative data there are few, 
well established rules for its analysis. Grounded Theory has become the 
most widely used framework for conducting and analysing qualitative data 
(Bryman, 2004). Originally developed in 1967 by Glaser and Strauss, it is a 
theory that is derived from data systematically gathered and analysed 
through the research process. Grounded theorising represents a particular 
version of the link between data and theory statements, emphasising their 
interdependence and proposing that theory can be generated from close 
examination of data (Seale, 1999). 
It is concerned with the development of theory out of data and the 
approach is iterative. The researcher starts with a general research 
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problem and relevant sampling takes place. The data are collected and 
coding begins, breaking the data down into potential concepts and 
categories. There is a constant movement backwards and forwards 
between these steps with early coding suggesting the need for new data, 
which results in the need for further sampling. More concepts and 
categories are developed during the process, more data are collected, 
concepts and categories tested and so on until an understanding of the 
phenomenon is achieved. The analysis is redesigned during the process as 
new themes emerge which need to be explored. This eventually leads to 
categories becoming saturated during the coding process and when 
theoretical saturation has been reached, this process stops, as additional 
sampling, adds nothing more to the topic of Interest (Bryman, 2004). 
Relationships between categories are then explored so hypotheses about 
connections between categories emerge. This prompts further sampling 
with the generation of more data. This collection of data is likely to be 
governed by the theoretical saturation principle and by the testing of the 
emerging hypotheses, which leads to the development of a substantive 
theory. The substantive theory will be explored using Grounded Theory 
processes in relation to different settings from that in which it was 
generated, which may lead to the development of a formal theory (see 
Figure 2). 
5.7.1 Theoretical sampling and theoretical saturation 
Theoretical sampling is the process of data collection that involves the 
generation of theoretical categories during the research progression 
whereby the researcher jOintly collects, codes and analyses the data and 
decides what data to collect next, in order to develop their theory as it 
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emerges. The aim of this sampling strategy is to collect data to develop 
and challenge emerging hypotheses. As the process of theoretical sampling 
is potentially limitless, Glaser and Strauss (1967) proposed a criterion for 
judging when to stop sampling. They proposed that sampling stopped when 
no analytical insights were emerging, at which pOint theoretical saturation 
had been achieved. 
5.7.2 constant comparison 
The constant comparative method is used as a systematic tool for 
developing and refining theoretical categories and their properties (Seale, 
1999). This method proceeds in four stages. First, data are coded into 
categories so that the different incidents that have been grouped together 
by the coding process can be compared. This helps to generate ideas about 
the properties of the category. The second stage of this method involves 
the integration of categories and their properties, noting how properties 
interact. The third stage is represented by theoretical saturation, in which 
no new properties or categories appear and no new interactions occur. The 
fourth stage is to form a theoretical framework from the well-developed 
categories (Seale, 1999). 
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Figure 2. The Processes and Outcomes In Grounded Theory 
Research Problem 
Theoretical Sampling 
,1. 
Data Collection 
,1. 
Coding 
,1. 
~ ~ Concepts 
Constant Comparison ~ ~ Categories 
,1. 
Saturation of Categories 
,1. 
Explore Relationships between Categories 
,1. 
Theoretical Sampling 
,1. 
Collect Data 
,1. 
Saturate Categories 
,1. 
Test Hypothesis 
,1. 
~ ~ Hypotheses 
~ ~ Substantive Theory 
Collection and Analysis of Data in other Settings ~ ~ Formal Theory 
From Bryman A. Social Research Methods 2nd Edition. Oxford University Press. 2004 pA04 
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5.7.3 Criticisms of Grounded Theory 
There are a number of criticisms to Grounded Theory despite its wide use 
for analysing qualitative data. There are practical difficulties in carrying out 
a genuine Grounded Theory analysis. Attempting to get interviews 
transcribed and conducted, whilst carrying out constant interplay of data 
collection and conceptualisation is particularly difficult if researchers have 
tight deadlines. The data analysis approach to this theory is associated with 
data being coded into chunks. This is criticised as It results in a loss of a 
sense of context and of narrative flow. 
It is doubtful whether Grounded Theory in many instances results in a 
theory being generated (Bryman, 2004). Its process is vague on certain 
points such as the difference between concepts and categories, with 
different writers using the key terms in different ways, which contributes to 
a reduced understanding of the process of carrying out Grounded Theory. 
Grounded Theory advocates an initial theory-neutral observation. It is 
argued that this is not feasible as the way researchers conduct a study is 
conditioned by many factors, one of which is what they already know about 
the social world (Seale, 1999). 
5.7.4 Computer-assisted qualitative data analysis (CAQDAS) 
The last twenty years has seen the emergence of computer software, which 
can assist in qualitative data analysis. CAQDAS such as NVivo, Ethnograph 
and ATLAS are based on a code-and-retrieve theme. They remove most of 
the clerical tasks associated with the manual coding and retrieving of data, 
such as cutting out all chunks of texts relating to a code, and pasting them 
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together. The package however, does not help with decisions about the 
coding of transcripts, nor does it interpret the data, it merely saves on the 
manual labour involved in analysing this type of data (Pope et ai, 2000). 
Packages such as NVivo are also able to code the text into several different 
categories and to link between codes, retrieving segments of marked text 
by single codes or combinations of codes, for comparison. There can be 
multiple linkages between segments of texts, and this is essential for 
Grounded Theory approaches as they concentrate on extracting the 
meanings that emerge from the data and the type of coding used (Bowling, 
2002). 
The use of CAQDAS amongst qualitative data analysts is not universally 
accepted. The packages are criticised for the distance it puts between the 
researcher and their data, and the ease with which coded text may become 
quantified. It has also been suggested that the code-and-retrieve process 
results in a fragmentation of the textual materials, resulting in a loss of the 
narrative flow of interview transcripts and decontextualising data. It is also 
argued that researchers working in a team may experience practical 
difficulties in coding text when all are involved in one study (Bryman, 
2004). The researcher will also require a training period on the package 
and there will be the initial cost of having it installed. 
5.8 The research approach in this project 
The use of qualitative methods to produce analytical inSights from 
recounted experiences, beliefs and views in HSR is increasing. Often the 
'theory-orientated' approach in HSR analysis is secondary to assembling 
'facts' and descriptions in order to answer predefined problems. Therefore, 
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the chosen method of analysis In HSR sometimes becomes defined more by 
practical rather than theoretical considerations (Harding and Gantley, 
1998). These authors argue that in contrast to 'theory-orientated' social 
science research, HSR implicitly utilises 'common sense' as its theoretical 
basis for analysis. They state that to treat what people say and do as self-
evident, without having a theoretical framework in which to interpret facts 
or descriptions, reduces the power of subsequent qualitative analysis. 
However Chapple and Rogers (1998), whilst acknowledging the advantages 
for researchers having an understanding and knowledge of social theory, 
argue that health professionals should not be put off from conducting 
qualitative research as they bring their own special experience of dealing 
with patients and other health professionals to their interviews or 
observations. They conclude that to suggest that those involved in HSR 
cannot produce a detailed analysis of the meanings that people attach to 
their behaviour unless they are trained as social scientists could be 
suggestive of another form of sociological imperialism. 
Whilst the importance of a theoretical framework to qualitative research 
should be always be acknowledged, it is often difficult to address this when 
tight practical constraints are imposed on the researcher (which often is a 
reality with HSR). I believe there is a danger when social scientists claim 
that HSR often uses 'common sense' as its theoretical basis for analysis 
that HSR is seen as 'second rate research'. Healthcare professional are 
often in an ideal position to conduct research, and as Chapple and Rogers 
(1998) suggest are often able to use their professional experience to their 
advantage when conducting interviews. For example, access and 
subsequent interviews with healthcare professionals may be easier to 
achieve if the interviewer is a peer. Rather than creating a 'hierarchy' 
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approach to social sciences and HSR research I believe that healthcare 
professionals should seek where possible the advice of a social scientist, so 
both theoretical and practical considerations may be addressed when 
undertaking HSR. 
This thesis grew out of a commissioned piece of HSR looking at whether 
community pharmacists could undertake a MMS from a community 
pharmacy. My particular interest and the one on which this thesis centred 
on, was looking at whether the relationships and attitudinal factors 
between community pharmacists and GPs could affect community 
pharmacists from extending their role into more clinical domains. On 
reflection, the theory informed approach to this research was secondary to 
practical, rather than theoretical considerations when choosing the method 
of analysis to answer this pre-defined question. 
The sociological literature surrounding professional boundary encroachment 
and the HSR literature on physicians' responses to pharmacists extending 
their clinical role informed this research. This led to a specific focus 
throughout the research. Although I started this piece of research with 
defined research questions, from an epistemological position it was broadly 
interpretivist in its orientation, as it was important to have contact with the 
community pharmacists and GPs to understand their relationship with each 
other. This was imperative in order to investigate and interpret how 
pharmacists' and GPs' relationships and perceptions of each other could 
affect the progression of the community pharmacist's role. 
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5.9 The use of qualitative research methods within this 
research 
In order to meet the aims and objectives set out in this project, qualitative 
methods (namely focus groups and semi-structured interviews) were 
chosen. These were chosen as the evaluation methodology because they 
allowed an in-depth investigation into these objectives. These methods also 
provided respondents with a forum to offer their own accounts of being 
involved in the MMS, and gave me the opportunity to probe respondents in 
more detail about particular areas of interest. I believe obtaining this type 
of information would have been difficult using a quantitative data collection 
method, as information would have been lost using a standardised 
questioning technique. I would not have had the opportunity to clarify 
answers and question the individual further over more complex issues. 
These methods also met the practical constraints (for example, other 
research objectives, time and budget restrictions) imposed on me as a 
Research Fellow, employed to undertake the CPMMP. 
5.9.1 The use of focus groups within this research 
Focus groups were initially selected as the primary data collection 
technique for pharmacists, as the participants shared a common 
background and the group dynamics facilitated interaction and discussion 
between participants. It was also the most practical data collection method 
to obtain views from a number of the participating pharmacists without 
occurring large travelling costs to the multiple pilot sites. 
I initially intended to use this data collection method for both community 
pharmacists and GPs. However, due to the practical problems I 
experienced trying to organise focus groups in each of the pilot sites, 
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coupled with the restrictions placed on me as part of a larger research 
project (this is discussed further in chapter 9) it became apparent that this 
data collection method was not gOing to be feasible. 
5.9.2 The use of semi-structured Interviews within this research 
In the pilot phase of the project, too few pharmacists had carried out 
medication reviews on patients to feasibly conduct a focus group in each 
pilot site. It was therefore decided to carry out one-to-one interviews. 
Convenience sampling was used, with the pharmacist being invited for 
interview as soon as they had completed a patient review. This allowed in-
depth information to be gathered and enabled me to gain an insight about 
their views and perceptions towards GPs, and towards having an extended 
role. It also informed the question schedule to be used in the focus groups. 
Even though very small samples of pharmacists were interviewed, the 
disadvantages of carrying out individual interviews were highlighted to me 
and the Research Team. Pharmacists had little time to be interviewed, so 
all interviews were conducted during the pharmacist's lunch hour. As a 
result I was only able to carry out one interview per day, which was both 
an expensive and time consuming process. It was originally decided that in 
the main phase of the project focus groups would be used as the main data 
collection tool. However, as discussed previously, focus groups proved 
difficult to coordinate and it became apparent they were not a feasible data 
collection method. Despite the time and expense issues associated with 
individual semi-structured interviews, it became apparent that I would 
have to use this data collection method for some of the pharmacists and all 
of the GP data collection. I therefore decided to conduct individual , 
telephone interviews due to the limited time that community pharmacists 
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and GPs were likely to have available, and the cost of travelling to each 
pilot site. 
Individual, telephone interview still allowed me to obtain specific, in-depth 
information about the relationships and perceptions between the 
participating GPs and pharmacists. It also had the advantage of allowing 
the interview to be carried out in a more informal setting than a focus 
group. 
S.10 Ethics 
As this were a multi-centre study, an application for ethical approval was 
required from a Multi-Centre Research Ethic Committee (MREC). Ethics 
approval was granted from the Scottish MREC in December 2001. 
Subsequently, the nine Local Research Ethic Committees (LREC) gave 
consent during February to June 2002. Professor Christine Bond (the main 
grant holder and research project manager for the CPMMP) based at the 
University of Aberdeen submitted all ethics applications. 
S.ll Setting and participants 
All data was collected from pharmacists and GPs participating in the 
CPMMP. Sixty four community pharmacists and thirty seven GP practices 
(164 GPs) participated in the project. Data collection for pharmacists in the 
pilot phase of the project was only obtained from two of the pilot sites 
(Nantwich and Lichfield). This was due to pharmacists having completed 
medication reviews in these two sites first, and the time constraints that 
were dictated that data was required for the wider project to be collected 
as quickly as possible. In the main data collection period, pharmacist and 
GP data was collected in all nine pilot sites. 
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5.12 Pharmacist pilot data collection 
Qualitative, semi-structured interviews (for interview guide see Appendix 
2) were carried out with five community pharmacists. Pharmacists were 
approached for interview once they had completed at least one patient 
medication review during the pilot phase of the project. All pharmacists 
were interviewed in their work place and all worked for chain pharmacies. 
Interviews were taped-recorded (after gaining consent) and transcribed so 
emerging themes could be reported. Interviews lasted approximately 40-50 
minutes. The purpose of the interviews was to identify key emerging 
themes to help inform the question schedule to be used in the main data 
collection. 
5.13 Main data collection - focus groups with community 
pharmacists 
In the main phase of the project, focus groups were conducted in each pilot 
site (with the exception of Southwark), during the first four months of the 
intervention period. These were arranged in a pilot site once the majority 
of pharmacists had conducted at least one patient medication review, 
either in the pilot or main phase of the project. 
All pharmacists participating in the project were contacted via telephone to 
invite them to the focus group (for numbers of pharmacists contacted see 
Table 6.). This allowed me to explain the purpose of holding a focus group, 
find out how many medication reviews the pharmacist had conducted, 
discuSS convenient dates and times, and establish whether the pharmacist 
would be willing to attend. A confirmation letter was then sent out to all 
pharmacists who had stated they would be willing to attend (see Appendix 
3). For those pharmacists unable to be contacted via telephone, an 
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invitation letter was sent to them informing them of the purpose and 
details of the focus group (see Appendix 4). Where possible, all 
pharmacists (unless they had notified me that they were unable to attend) 
were contacted again prior to the focus group as a reminder and to double 
check attendance. 
All focus groups were held as early evening meetings, with food and 
refreshments provided. A question schedule was used at each focus group 
(for question schedule see Appendix 5) and two researches attended all but 
one focus group. This allowed one researcher (myself) to concentrate on 
guiding the discussion and encourage passive participants to interact, 
whilst the second researcher concentrated on making observational notes 
of the meeting. Once the focus groups had finished, the two researchers 
discussed the main themes to emerge from the focus groups. All focus 
groupS were taped (after gaining verbal consent from the participating 
pharmacists) and subsequently transcribed. They lasted between 60-90 
minutes. 
5.13.1 Southwark pilot site 
A focus group was not held in the Southwark pilot Site, as the patient 
response rate in this area was low, with only three pharmacists having the 
opportunity to conduct medication reviews with patients. It was therefore 
impractical and expensive to conduct this type of interview. To obtain 
feedback all three pharmacists were contacted to see if they would be 
willing to conduct an individual interview (either face-to-face or via 
telephone) at a time convenient to them. Two pharmacists agreed to be 
interviewed and stated that telephone interviews would be the most 
convenient method. Both interviews were conducted during the day, at the 
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pharmacist's workplace. A question schedule was used at each interview 
and both interviews were taped (after gaining consent from the 
pharmacist) and subsequently transcribed (for interview schedule see 
Appendix 6). Interviews lasted between 20-30 minutes. 
Table 6. The Number of Pharmacists Invited to the Focus Groups, 
the Number Which Stated They Were Willing to Attend, and the 
Number of Pharmacists, Who Actually Attended. 
Pilot Site Number of Number of Number of 
Pharmacists Pharmacists Pharmacists 
invited to the willing to attend actually 
Focus Group the Focus Group attending the 
Focus Group 
Lichfield 11 11 7 
Nantwich 7 5 5 
Newcastle - 9 7 6 
Upon - Tvne 
poole 4 4 3 
portsmouth 4 4 3 
Salford 11 7 2 
Shipley & 8 6 3 
Baildon 
Walsall 8 5 4 
* Details for Southwark are not included, as a focus group was not conducted in this pilot site. 
5.14 Main data collection - follow-up semi-structured 
interviews with community pharmacists 
In order to follow-up and assess the views of community pharmacists 
participating in the project, a series of one-to-one, semi-structured 
telephone interviews were conducted. Interviews were conducted with a 
sample of twenty-eight participating pharmacists at the end of the twelve-
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month intervention period. Telephone interviews were chosen because of 
the limited time that community pharmacists were likely to have available 
and the cost of travelling to each pilot site. 
A purposive sample of pharmacists was drawn from the sixty-one 
community pharmacists remaining in the project. The aim was to interview 
three to four community pharmacists from each pilot site. Pharmacists that 
had attended the focus groups conducted at the beginning of the 
intervention period were initially contacted by telephone to see if they 
would be willing to provide feedback. In pilot sites where more than four 
pharmacists had attended the focus group, pharmacists were chosen so 
there was a mixture of pharmacists working for independent and multiple 
chain pharmacies. Likewise, pharmacists were only asked to provide 
feedback if they had carried out a patient medication review. 
There were few recruitment difficulties encountered except in Southwark 
(see Table 7.). This was due to a low number of participating pharmacists 
in this pilot Site, which was further exacerbated by one pharmacist going 
on maternity leave and one pharmacist refusing to provide feedback as 
they were too busy. Two pharmacists from one other pilot site also refused 
to be interviewed because they were too busy. 
Interviews usually occurred during the pharmacist's lunch hour and at their 
workplace, although several interviews occurred at the pharmacist's home 
during the evening. A question schedule was used at each interview (for 
interview schedule see Appendix 7) and all interviews were taped (after 
obtaining verbal consent from the participating pharmacist) and the full 
interview transcribed. Interviews lasted between twenty to thirty minutes. 
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Table 7. Number of Community Pharmacists Interviews by Pilot 
Site 
Pilot Site Number of Community 
Pharmacists Interviewed 
Lichfield 3 
Nantwich 3 
Newcastle-Upon-Tyne 4 
poole 3 
portsmouth 3 
Salford 4 
Shipley & Baildon 3 
Southwark 1 
Walsall 4 
5.15 Semi-structured interviews with GPs 
A series of one-to-one, semi structured telephone interviews were 
conducted with a sample of twenty-one GPs during months six to twelve of 
the intervention period. Six months into the intervention period all 
participating GP practices were contacted via their practice managers 
requesting feedback from GPs. The intention was to interview two to five 
GPs from each pilot site. 
Participating GP practices were contacted initially by letter to their practice 
managers (see Appendix 8). The letter asked them to inform their GPs that 
they might be contacted and asked to volunteer to provide feedback (via a 
telephone interview) about being involved in a MMS. Letters were sent six 
months into the intervention period so the GPs would have had some 
experience of receiving recommendations from the community pharmacist. 
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Follow-uP telephone calls were then made to all the practice managers two 
to three weeks after they had received the letter, to confirm whether GPs 
within their practice would be willing to be interviewed. In nearly all cases 
the practice managers identified the lead GP involved in the project as the 
GP to provide feedback from that practice. Interview times were either 
arranged through the practice manager or by contacting the GP directly, at 
a time convenient to the GP. Both practice managers and GPs were 
informed the interviews would take approximately twenty minutes to 
complete. Table 8. shows the number of GPs willing to be interviewed, the 
number of GPs unable to be contacted, and those refusing to be 
interviewed. 
A question schedule was used at each interview (for question schedule see 
Appendix 9). As the data was obtained from the semi-structured interviews 
the transcripts were reviewed to allow refinement of the data and pursue 
emerging themes. As a consequence the question schedule was refined 
(see Appendix 10) for subsequent interviews. All but two of the interviews 
were taped (after gaining verbal consent from the participating GP) and 
subsequently transcribed. 
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Table 8. Number of GPs Interviewed 
Pilot Site Number of Number Number of Number of 
participating of GPs GPs GPs 
GPs unable to refusing to interviewed** 
be be 
contacted interviewed 
Lichfield 28 GPs (5 GP 7 GPs (1 14 GPs (2 2 GPs (2 GP 
Practices) Practice) GP Practices) 
Practices) 
Nantwich 6 GPs (2 GP N/A N/A 4 GPs (1 
Practices) Practice) 
Newcastle- 29 GPs (5 GP 2 GPs (2 N/A 3 GPs (3 GP 
upon -Tyne Practices) GP Practices) 
Practices) 
poole 6 GPs (2 GP N/A N/A 2 GPs (2 GP 
Practices) Practices) 
portsmouth 22 GPs (6 GP 1 GP (1 10 GPs (2 3 GPs (3 GP 
Practices) GP Practices) Practices) 
Practice) 
Salford 9 GPs (4 GP N/A 3 GPs (2 2 GPs (2 GP 
Practices) GP Practices) 
Practices) 
Shipley & 25 GPs (5 GP 3 GPs (3 N/A 2 GPs* (2 GP 
Baildon Practices) Practices) Practices) 
Southwark 15 GPs {3 GP 1 GP (1 N/A 2 GPs (2 GP 
Practices) Practice) Practices) 
Walsall 23 GPs (5 GP 2 GPs (2 2 GPs (2 1 GP (1 GP 
Practices) Practices) GP Practice) 
Practices) 
"'No formal interview was carried out to provide feedback with one GP 
*'" Usually only one lead GP was identified in a practice that was willing to be interviewed, 
therefore the other GPs within that practice were not approached to carry out an 
interview. 
143 
5.16 Data analysis and validation 
In its broad outline, the Grounded Theory approach (Glaser and Strauss, 
1967) has been used in the project to conduct and analyse data. I hoped 
this approach would allow me to extend and broaden any emerging 
theories regarding the relationships and attitudinal aspects between 
community pharmacists and GPs, and how these may have influenced 
community pharmacists from conducting a MMS. 
However, practical difficulties were experienced whilst trying to carry out a 
genuine Grounded Theory analysis. This mainly centered on time 
constraints in collecting the pharmacist and GP data, as it proved difficult 
to get interviews conducted and transcribed and to start conceptualising 
the data simultaneously. Likewise, due to time constraints and difficulties 
recruiting participants (particularly GPs), I was unable to continue 
interviewing participants until theoretical saturation occurred. I also 
acknowledge that due to this piece of research having a specific focus, 
there was sometimes a tendency to focus on data that related to my 
research questions rather than take a completely inductive approach to the 
data analysis. A description of how the data was analysed is now detailed. 
Interviews and focus groups were taped and the full interview transcripts 
transcribed. As previously stated, due to the practical difficulties 
experienced surrounding the collection of the data, it was not always 
possible to transcribe the data and then examine it immediately following 
data collection. Generally, the tape recordings of the interviews or focus 
groupS (rather than the full transcripts) were initially reviewed to provide 
an overview of their content. This allowed me to gain familiarity with the 
data and to pursue emerging themes for subsequent interviews or focus 
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groups. As the interviews and focus groups were transcribed, the 
transcripts were then reviewed in greater detail to allow refinement of the 
data. This process involved looking at patterns of responses and linking 
them together using key words and concepts identified in the 
transcriptions. 
To improve the consistency and reliability of the data analyses all the 
transcripts were coded separately by three researches (they were coded by 
both my supervisors and myself). To avoid the potential difficulties of three 
people trying to code data within a project, a basic coding system was then 
devised through discussion to allow an initial coding framework for the 
pharmacist and GP data. Key words and phrases were coded to capture 
frequently expressed concepts in the data and grouped Into categories that 
resulted in recurrent themes. The qualitative computer package, NVivo was 
used to assist in the analysis of the focus group data, due to the large 
amount of data generated from them. NVivo was not used in the analyses 
of semi-structured interviews as there was less data generated. 
These data were further analysed by one of my supervisors and myself to 
refine and consolidate the emerging themes. This process involved 
scrutinising the data for patterns and inconsistencies, similarities and 
differences in pharmacists' and GPs' views and perceptions of each other. 
All pharmacists and GPs were assigned an individual code to protect their 
identity. Sections of the transcripts have been included in the results 
sections (see Chapter 6, 7, 8) to illustrate the key themes identified. I have 
attempted to give 100% of views through the use of themes and quotes. 
However, this at times has been difficult particularly with the pharmacist 
focuS group data (these results are presented in Chapter 6), as despite 
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encouragement from the facilitators not all participants expressed their 
views. In order to support the themes identified I have used 'quasi-
statistics'to help the reader gain some perspective on the data reported. 
S.17 Summary 
In this chapter an overview of qualitative research and the Grounded 
Theory approach of analysing qualitative data have been given, along with 
strengths and criticisms of their use within research. In the later part of 
this chapter I have aimed to provide the reader with the theory and 
epistemological orientation of the research, along with justifications on why 
qualitative, semi-structured interviews and focus groups were chosen as 
the evaluation methodology. Whilst I have alluded to some of the 
difficulties encountered using focus groups and semi-structured interviews, 
a more in-depth discussion of the difficulties and limitations of my 
methodology (along with being part of a larger research project) will be 
provided in Chapter 9 of the thesis. 
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6. COMMUNITY PHARMACISTS' INITIAL 
EXPERIENCES OF UNDERTAKING 
COLLABORATIVE WORK WITH GPS 
6.1 Introduction 
This chapter presents data from eight focus groups and two individual 
telephone interviews, conducted with community pharmacists during the 
first four months of the MMS. The focus groups were conducted between 
January to May 2003. Thirty-three pharmacists (20 female and 13 male) 
took part in the focus groups, and two pharmacists (2 female) 
completed a telephone interview to provide feedback. The number of 
patient consultations completed by individual pharmacists varied; with 
up to seventeen consultations being carried out by several pharmacists, 
and six pharmacists having completed no patient consultations at the 
time of the focus groups being conducted. 
The data presented in the first part of this chapter focuses on the 
working relationship between community pharmacists and GPs prior to, 
and during the initial few months of the MMS commencing, establishing 
how community pharmacists thought GPs currently perceived them. Also 
explored were the community pharmacists' experiences and views about 
undertaking a medicines management role, establishing any potential 
and actual barriers which could limit them from doing this. The second 
half of this chapter concentrates on these data. 
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Where possible I have used numbers to help quantify and support the 
generalisations that I have reported, to give the reader some sense of 
perspective of the data. However, sometimes not all pharmacists 
expressed views about the MMS, despite encouragement from the 
facilitators. This has made it difficult at times to report the overall views 
of the pharmacists. The key themes are reported in the following 
sections. 
6.2 community pharmacists' current working relationship 
with GPs 
Community pharmacists were asked to provide feedback about their 
working relationship with GPs, prior to the MMS commencing. Twenty 
five pharmacists stated they had a good working relationship with their 
local GPs, although their contact with them was often limited and usually 
conducted via the telephone. Pharmacists stated they rarely had face-
to-face discussions with GPs over medication issues, due to the time 
constraints on both professions. 
"Well I don't see them that much, I mean they are busy people they 
don't. ... I never see them face to face very often." (P25jFG5) 
Pharmacists were also encouraged to talk about whether they had any 
concerns or issues about having more collaboration with their local GPs. 
Three pharmacists were dealing with GP practices in the project which 
were not local, so there was no prior working relationship. There were 
concerns held by four pharmacists that undertaking this type of service 
could be more difficult if the pharmacist and GP did not have an 
established relationship in place, as it would be difficult to liaise with 
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GPs. Two other pharmacists also acknowledged that If they already 
knew the GP, It was easier to liaise with them and build on existing 
relationships. However, one pharmacist believed the MMS was an 
opportunity to break down barriers between the two professions and 
gave the pharmacist an opportunity to speak to GPs regarding 
medication Issues. 
"I'm sort of lucky in a way that I work so closely with the GPs next door 
anyway, but there are a lot of pharmacists who don't. For them to have 
to liaise with GPs and things, if the study wasn't there, it would have 
actually been a little more difficult. So I suppose the study has actually 
helped to break barriers." (P34/TI1) 
It was also thought that difficulties could arise If the GP practice was not 
situated near the pharmacy, as communication between the two 
professions would be more difficult. 
"If you want to confirm something and speak with the doctor face-to-
face, then face-to-face is very difficult if it's 3 miles down the road!" 
(P03/FG1) 
However, two pharmacists stated that the locality of the GP practice was 
not a concern, as currently their local GP practices were not located near 
them, so communication was always conducted via the telephone. 
Four pharmacists stated they were concerned at having to see the GP 
face-to-face and potentially having to challenge their prescribing 
decisions. This was largely due to the pharmacists stating they lacked 
the confidence to do this, even though many of them believed they had 
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a good foundation of CHD knowledge. To circumvent these concerns 
pharmacists admitted they were using the practice pharmacist to liaise 
with the GP on their behalf. 
"No, I'm always a bit apprehensive about sort of face-to-face with the 
GP. It hasn't arisen but because I always go through, well I have gone 
through my own practice pharmacist at the minute." (P13/FG3) 
One pharmacist stated that unless a pharmacist knew how to speak with 
GPs in a confident manner and not be fearful of them, it was irrelevant 
whether they had good pharmaceutical knowledge as they would not 
instill confidence in the GP. This pharmacist believed younger 
pharmacists now received training at university on how to talk to 
doctors effectively. They believed speaking to GPs was largely a fear 
held by the 'older' generation of practising community pharmacists. 
"I think the new ones coming out of University already have been 
trained to do it and it's just the older generation that needs to go 
through learning how perhaps to talk to GPs and things and not see 
them as gods." (P34/TI1) 
Despite these concerns reported, nine pharmacists stated they had no 
concerns liaising with GPs as they currently worked in GP practices, or 
were used to forging relationships with trainee GPs in their local 
practice. Pharmacists acknowledged that relationships had to be built 
from both sides and GPs were often responsive to suggestions, it was a 
case of finding the 'right time' to speak with them, for example, 
speaking with the GP when they were not too busy or preoccupied with 
other tasks. 
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"I mean relationships are what we make them from both sides. Of 
course, the practice where I am they get registrars in all the time and 
they tend to be quite, you know, sort of interested in what we have to 
say and can be slightly difficult people to handle because they feel 
they're on trial anyhow. But I'm old enough to be their father most of 
the time so I don't get too much problem." (P28/FG7) 
Seven pharmacists saw this project as an opportunity to have a closer 
working relationship with GPs within their area. They hoped the MMS 
would allow GPs to see community pharmacists using their clinical skills 
and allow inter-professional working to develop, which they believed 
was currently missing. One pharmacist had been motivated to join the 
project in order to improve their relationship with their local GP and 
enable them to have a mentor for pharmacist supplementary 
prescribing. 
"I just thought it would be a good opportunity to work with doctors and 
get recognised in the city as a professional really." (P32/FG8) 
Whilst the majority of the pharmacists had a good relationship with their 
local GPs, these data suggest that some pharmacists had concerns 
liaising face-to-face with GPs, and viewed the GP as having the most 
authority in the relationship. The relationships described by the 
pharmacists can be compared to the literature on the nurse-physician 
relationship (Stein, 1967; Bond et ai, 1987; Svensson, 1996; Allen, 
1997; Willis et ai, 2000; Snelgrove and Hughes, 2000; Blue and 
Fitzgerald, 2002; Charles-Jones et ai, 2003). Traditionally, nurses have 
been seen to playa largely subservient and supportive role to the 
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physicians. Whilst a number of studies have looked at the effect of 
redistributing medical to work to nurses (Bond et ai, 1 9 8 7 ~ ~ Svensson, 
1996; Allen, 1997; Willis et ai, 2000; Snelgrove and Hughes, 2000; Blue 
and Fitzgerald, 2002; Charles-Jones et ai, 2003), the majority of these 
studies suggested the nursing-physician relationship had not 
significantly changed. 
6.3 Working relationship with GPs during the MMS 
Pharmacists were then asked to comment on whether being involved in 
the MMS had so far made any impact on their existing working 
relationship with GPs. Pharmacists gave a mixed response, with seven 
pharmacists holding concerns that the participating GPs were not taking 
the MMS very seriously, resulting in no impact on relationship building. 
"1 think we were led to believe that the GPs were really kind of up for all 
this, but I'm beginning to feel very disillusioned about it now. " 
(P18/FG6) 
Three pharmacists were ambivalent about whether the MMS had so far 
improved the relationships between them and their local GPs, due to the 
time delays which had occurred between the launch and delivery of the 
MMS. On the other hand, there were reports from six pharmacists that 
their GPs had responded to their clinical recommendations and they 
viewed the collaboration as a positive impact on their working 
relationship. 
"Excellent. I went to two GPs and it just so happened there was four 
(patients) from each and I actually made one appointment after I'd done 
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the whole lot (consultations) to go through the forms and it all worked 
out very well." (P28/FG7) 
Six pharmacists were unable to comment on this subject, due to them 
not having completed any patient consultations. The remaining 
pharmacists did not clarify their views despite encouragement from the 
facilitators. However, the data suggests that the MMS had so far had 
little or no impact on working relationship for some community 
pharmacists, mainly due to lack of GP engagement in the project. 
6.4 How community pharmacists believe GPs perceive 
them 
One of the objectives of this thesis was to determine how community 
pharmacists thought GPs currently perceived them, and whether the 
MMS had altered these perceptions. Hughes and McCann (2003) state 
that pharmacists are conscious of a hierarchical system between 
themselves and GPs, with GPs seeing community pharmacists as 
subordinate to them in professional terms. During the focus groups, 
whilst pharmacists discussed why GPs had not responded to their clinical 
recommendations, or did not welcome extra collaboration with them, 
some pharmacists stated that they believed GPs saw them as 
'shopkeepers' rather than health professionals. Pharmacists stated that 
this resulted in GPs not viewing them as having a similar professional 
status. The following quotes illustrate this. 
"They sort of think ... they still think that a pharmacist is a class down, 
like you know you think of a shopkeeper." (P31/FG8) 
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"Yes we work as a team but 1 think they still think they are the upper 
class; we are the lower class you know." (P33/FG8) 
Two pharmacists also believed that GPs held the attitude that 
community pharmacists should 'dispense medication', rather than 
having a clinical input into what medication should be prescribed. 
"1 get the feeling that their attitude is that we just dispense the tablets 
and they prescribe it. "(P23/FG5) 
As a consequence, GPs were not used to having their clinical decisions 
questioned and three pharmacists believed this might have accounted 
for some of the GPs not following the community pharmacists' 
recommendations over patients' medication regimens in this project. 
"Because they're so not used to having their judgment questioned, 
purely and simply. Not by people that they perceive as being 
shopkeepers." (P19/FG4) 
In addition, five pharmacists thought that GPs did not have a clear 
understanding of their current role. This was particularly pertinent 
regarding patient confidentiality. Pharmacists were frustrated and 
surprised by both the GPs lack of awareness of their current role 
(particularly when their role involved dealing with confidential, patient 
issues on a daily basis) and also their lack of trust regarding 
confidentiality issues. Pharmacists in one pilot site commented that a GP 
practice had withdrawn from the project, as they did not want 
pharmacists looking at patients' medical notes. The following quotes 
illustrate this. 
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"But the confidentiality issue was surfaced again and again and again at 
that meeting wasn't it? They were absolutely hitting the whole time, as 
though we were going to sell it to the News of the World or something 
they just kept all the time coming back to confidentiality .... It was almost 
as though we were just somebody in the street, you know" (P21/FGS) 
"They don't realise that what we do every day is confidential, isn't it?" 
(P24/FG5) 
However, four pharmacists stated their local GPs had increasingly 
started to ask their opinions regarding medication issues on a day-to 
day basis. 
"I think most of them are beginning to see us as sort of clinical 
professionals and the majority of them feel quite at ease to phone up 
and ask for help and advice." (P34/TI1) 
As a result, these pharmacists acknowledged that GPs' attitudes were 
starting to change and they were now beginning to view the community 
pharmacist as a fellow clinical professional. 
In a similar vein, pharmacists participating in the project hoped as GPs 
started to have more interaction with community pharmacists and 
gained confidence in the recommendations they were making, this 
would help change the GP's perception of them, from that of a 
'shopkeeper', to that of a health professional. 
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The data suggests that some pharmacists believed that GPs viewed 
them as a shopkeeper, or had concerns surrounding whether community 
pharmacists could uphold patient confidentiality. In both instances, 
some community pharmacists believed these perceptions could have 
accounted for why GPs had either not actioned their clinical 
recommendations or did not want to undertake collaborative work with 
them. 
6.5 General assessment of the MMS 
To assess the attitudes and experiences of community pharmacists 
undertaking a MMS, in each of the focus groups and interviews 
pharmacists were asked to provide a general assessment of their 
experience of being involved in the MMS. Pharmacists were also 
encouraged to discuss why they had wanted to become involved in the 
project, what they wished to achieve from taking part in the MMS, along 
with their experiences conducting medication reviews, stating the 
benefits and difficulties so far encountered by providing this new 
service. 
Whilst all pharmacists saw their involvement in the MMS as a positive 
experience, almost all of them thought they could not have participated 
without receiving clinical training. Only two pharmacists stated they 
were confident enough to do the MMS without clinical training and both 
of these had completed a clinical diploma. 
"No we definitely needed extra training really, more research and 
reading up of things, to feel confident really and able to do it you need 
the research." (P08/FG2) 
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The most significant benefit cited for being involved in the MMS was the 
opportunity to have a greater input into patient care. More specifically, it 
had allowed pharmacists the chance to build better relationship with 
patients and gave them the opportunity to use their clinical knowledge, 
while in turn increasing their job satisfaction. 
"It certainly is an extension of our role and a very worthwhile one, 
actually using our clinical skills for a change. 1/ (P16/FG4) 
In addition, six pharmacists identified a desire for greater job 
satisfaction and hoped that this MMS would allow them to move away 
from the community pharmacist's traditional role of dispensing 
medication to a more clinical approach. Some pharmacists reported that 
they currently did not have fulfillment in their current day-to day role, 
particularly surrounding clinical work. The follOWing quotes illustrate this 
theme. 
"What was the personal motivation? There has to be more to life in 
community pharmacy than checking scripts. 1/ (P28/FG7) 
"Satisfaction from - well yes, job satisfaction. Fulfilment from clinical 
work, which is something which has been missing from community 
practice - certainly from the community practice that I've had always. " 
(P19/FG4) 
Six pharmacists had seen the MMS as an opportunity to improve their 
clinical skills and knowledge regarding CHD. Three pharmacists reported 
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their clinical knowledge had diminished in recent years and the project 
was both a chance and a challenge to develop this. 
Overall, participants believed that community pharmacists needed to 
continue developing their roles, particularly in light of the new 
pharmaceutical services contract. 
"Because there is so much pressure to demonstrate that we can do 
more than just dispense, check and put in a bag. We have got to 
demonstrate that there are other services that we can offer. It's like the 
future of pharmacy and everything, rather than just a checker." 
(P26jFG5) 
This project was seen as an opportunity to have a greater clinical role 
and demonstrate that community pharmacists could undertake new 
roles and become more integrated into the primary healthcare team. 
"I hope more people can leave the dispensing side and get like 
technicians in to do all the dispensing work. Then we can be used more 
as the primary care team as opposed to being an outsider." (P03jFG1) 
The responses shown by the pharmacists suggest that currently they 
were not fulfilled by their current day-to-day role and hoped 
involvement in the MMS would allow them to have a greater clinical role 
into patient care, and become more integrated into the primary care 
team. 
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6.6 Motivation of community pharmacists 
Despite the reasons given by pharmacists to participate in the MMS, a 
third of the pharmacists stated the reason for participation was due to 
obligation. When questioned further, pharmacists expanded by saying 
that although they were interested in participating in the project, the 
primary motivation had been obligation because it was being carried out 
within their area. This could suggest that these pharmacists were not 
fully committed to changing their role despite stating a number of 
potential opportunities that this new role could provide. 
I thought it was a good opportunity to get involved. It is the way I 
would like to see things going, part of it and because it was in my area I 
felt obliged to do it, someone has to try it! (P01/FG1) 
Pharmacists also offered possible explanations why some pharmacists in 
their area did not want to participate in the MMS. Identified factors 
included fear of undertaking a more clinical role and time issues. 
"Possibly the ones who you know sort of have been chained to the 
dispensing bench for so long that they're probably frightened to come 
out." (P28/FG7) 
"And of course there are some who probably think "Why should I? I'm 
doing eleven hours in the day" (P33/FG8) 
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Likewise, pharmacists expressed disappointment that fellow peers would 
not attempt to undertake new roles, particularly younger pharmacists 
that had received a greater amount of clinical training at university. 
However, it was acknowledged that pharmacists who did not want to 
undertake new roles were in the minority. 
"1 think the ones who don't want to get involved are probably a dying 
breed. " (P28/FG7) 
When pharmacists were asked if they would have participated in the 
MMS without receiving a financial incentive, three of the pharmacists 
specifically stated they would not have participated, as they were giving 
up their time and would lose money if they required a locum. 
"As a company though or an owner you wouldn't want to do something 
that you weren't paid for because there's other jobs you could be dOing, 
because obviously we're funding locums while we're doing this service 
so we'll be out of pocket with this." (P13/FG3) 
Likewise, whilst thirteen pharmacists thought the fee they received for 
each patient consultation was adequateB, five pharmacists thought it 
was inadequate. These pharmacists argued when preparation and 
writing-up time, locum cover and follow-up interviews with the patients 
were taken into consideration the fee was small. However, they 
acknowledged as they gained more experience consultations would 
become easier. 
8 Community pharmacists received a capitation payment of £60 per intervention patient. 
This payment included ~ i m e e preparing f o ~ ~ the patient consultation, conducting the initial 
consultation, documenting recommendations and conducting any subsequent consultations 
that were required. 
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"But yes, I do feel it is expecting a bit much. ... I suppose the more you 
do, the quicker it does get, so perhaps if you are doing it regularly you 
will get to a stage where it is a reasonable remuneration." (P09/FG2) 
Due to the payment not being sufficient, two pharmacists specifically 
stated they had no intention of carrying out follow-up interviews on all 
the patients. 
"Because of that I'm only going to do follow ups with two actual 
interviews and I have sent a couple of compliance charts out through 
the post to people. But I still think I've probably put more effort in than 
some people would do for that payment, which I'm happy with because 
I'm interested." (P31/FG8) 
There were also mixed views from employee pharmacists about the 
employers getting the payment rather than the individual pharmacist. 
The majority of pharmacists working for companies stated that they had 
got involved for the professional aspect; therefore the payment was not 
important. However, it was acknowledged that if this project went 
nationwide then pharmacists might be reluctant to provide this type of 
service if the employee received the payment. 
"It didn't bother me but I would say 80% of pharmacists would expect 
to be reimbursed in someway for doing it." (P26/FG6) 
Again, this potentially highlights that some pharmacists were not fully 
committed to changing their role if they were not gOing to be adequately 
reimbursed. Therefore despite pharmacists citing reasons for changing 
161 
their current role, remuneration and lack of motivation may be a barrier 
for some pharmacists to fully commit to undertaking a MMS. 
6.7 Relationship with patients during the MMS 
Having a greater input into patient care was cited as the greatest benefit 
of being involved in the MMS. Pharmacists were therefore asked to 
comment how the MMS had impacted on their relationship with patients 
and how their patient consultations had gone. Although twenty-five 
pharmacists believed they had a good existing relationship with their 
patients, it was acknowledged that their current workload prevented 
them from forging relationships with them. Pharmacists thought the 
MMS had given them the opportunity to get closer to patients. In turn, 
this had allowed patients to see community pharmacists in a different 
capacity, moving away from the 'supplier role' to a more clinical and 
informative role. Pharmacists also hoped as a result of the MMS patients 
would feel that they were having an interest taken in them rather than 
being seen as just a customer. 
"Probably have a perception of more of a dispenser's role, you know 
typing of labels and filling the bottles and yes they can ask you 
questions and whatever but you know when you start explaining stuff to 
them, it's like your light comes on." (P29/FG7) 
The remainder of the pharmacists stated they had been reviewing 
patients that usually did not use their pharmacy, so there was not an 
established relationship. Three pharmacists believed this type of service 
was more beneficial when you had an established relationship with 
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patients because patient issues could just be focused on, rather than 
having to spend time explaining a community pharmacist's role. 
"Well the thing is where we are situated, I basically know all the faces 
that did come in and have known them for years, so there wasn't the 
problems you might have breaking a patient in, do you know what I 
mean? Like explaining the whole thing about your role and stuff like 
that. So it wasn't difficult but then I can see that there could be 
problems when you don't know a patient." (P34/Tl) 
Pharmacists also believed their confidence in dealing with patients and 
their clinical knowledge had improved as a result of being involved in the 
MMS. They stated they were now less intimidated and more 
authoritative when giving advice to patients. 
"I've gained a lot of knowledge and a lot of confidence. I don't feel quite 
so intimidated at going sort of to patients and talking to them in the 
shop whereas before you'd think, oh am I saying the right thing, you 
know." (P13/FG3) 
One pharmacist in particular, stated the confidence gained from the 
training had allowed them to develop their questioning skills on other 
people requesting advice in their pharmacy. 
"I feel like I'm making a difference though. In that respect it's been 
good doing the project, because we've got the consultation area and the 
extra training, and it just gives me the confidence to do a bit more. I 
mean I sat the other day and took a lady's blood pressure and she'd had 
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her medication changed and it isn't something that I'd normally offer to 
do, but she was in a right state. " (P10/FG3) 
Pharmacists were then asked to provide feedback about their 
experiences in conducting patient medication reviews. All the 
pharmacists who had had the opportunity to conduct medication reviews 
reported that their patient consultations had gone well. 
"I was up to now, happy with the way they've gone. I got quite a bit of 
feedback from people saying how much they'd enjoyed it and found it 
valuable and that sort of thing; we just don't have time to say this to 
our doctor. It's wonderful to be able to talk to people. I mean I've had 
four or five like that." (P21/FG5) 
Pharmacists pOinted out a further benefit of their consultations, in that it 
provided patients with the opportunity to talk to another health 
professional. This allowed patients to discuss medication issues which 
had been bothering them, which sometimes had not occurred with their 
GP. 
"I think it's noticeable when you're talking to the patients that they tell 
you things that you suspect they have never told their doctor, not 
because they wouldn't tell the doctor perhaps, but perhaps because the 
situation in which they can tell the doctor has not occurred. " (P25/FG5) 
Pharmacists also noted that patients perceived their consultations quite 
differently to that of the GPs, notably as the pharmacist having less 
power, being less threatening and having more time to talk than the GP. 
There was a general agreement that patients were often more likely to 
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speak to them about issues they would not broach with their GP. 
Pharmacists thought this was due to a variety of reasons. Firstly, 
patients often did not get the opportunity to discuss issues with their GP 
due to short GP consultations times. They also believed patients felt 
they could not bother the GP with issues that they deemed trivial 
because they did not want to waste the GP's time. 
"The one patient I had, I think he must have said three or four times 'I 
don't want to bother the doctor but can I ask you?" (P06/FG1) 
Pharmacists also believed some patients did not worry about 'pleasing' a 
pharmacist regarding their medication, as they might with the GP. 
Again, if patients had issues with their medication but were worried 
about 'upsetting' their GP because they were not taking it then they had 
the opportunity to discuss these issues with another health professional. 
"They're not trying to please us in the same way that perhaps they 
might be doing for the GPs. And we're not actually prescribing for them 
so it's not as if we're involved in that decision to the same extent. I'm 
not worried by that in the same way that the doctor would be. I'm 
worried about it from the compliance pOint of view but I don't feel as if 
I've been cheated out of something. I think it's important for a patient's 
decision; they have the opportunity to speak to somebody else, so that 
they can be more involved in their treatment than perhaps someone 
who can't do that. I think sometimes they take things because they're 
told to rather than because they understand the issues, because they've 
been involved in it. And maybe we can offer them that in the 
pharmacy." (P19/FG4) 
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The downside to patients feeling more relaxed towards the pharmacist 
often led to patients cancelling or not turning up for appointments. The 
data perhaps suggests that although patients welcomed the opportunity 
to discuss clinical issues that they would not normally broach with their 
GP, they did not have always have the same respect for pharmacists as 
they did for GPs. 
"They treat appointments with you, far more casual I think than they 
would with a doctor. They don't feel as bad when they're ringing up at 
the last minute saying I can't come and 'oh, I can come nine o'clock 
tomorrow. " (P17/FG4) 
Two pharmacists stated that carrying out medication reviews had given 
them an insight in the difficulties that a GP might face whilst carrying 
out patient consultations, due to time restrictions placed on them. As a 
result they could now empathise with their local GPs. Two pharmacists 
also feared carrying out this type of consultation service on a regular 
basis could make them more like GPs in terms of reducing a 
pharmacist's availability. This was seen to be detrimental because they 
would become less assessable to patients and pharmacists feared people 
would have to book apPointments to see them if they took on too much. 
"But the more of these things that we take on, the less available we are 
going to be. That's becoming a problem as people are having to book 
appointments." (P04jFG1) 
Whilst the data suggests that community pharmacists thought the MMS 
advantageous for patients, the down side was that patients often did not 
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turn up for appointments. Pharmacists acknowledged that they would 
not cancel appointments with GPs on such a regular basis. 
6.8 Community pharmacy Vs. GP practice as the setting for 
a MMS 
As the majority of pharmacists at the time of the focus groups had 
completed medication reviews, pharmacists were asked whether a 
community pharmacy or a GP practice was the most appropriate setting 
to conduct a MMS. Three pharmacists believed that the community 
pharmacy was the most appropriate setting, as it was easier for patients 
to access and was less formal than a GP practice. 
"We have the key position of being the most approachable part of the 
health service. II (P02jFG1) 
Four pharmacists had mixed views on whether the community pharmacy 
was the best setting and could see advantages and disadvantages for 
conducting them here. The advantages of having the service placed in 
the community pharmacy, was easier access for the patient and it 
offered the patient a choice. The disadvantage was that it was more 
difficult to build an effective relationship with the doctor and be included 
as part of the primary health care team when the pharmacist was 
providing a clinical service outside the GP practice. 
"If we were in the surgeries offering this service, then we would be seen 
as being one of the doctor's team and therefore the strengths that 19 's 
pointed out perhaps would not apply. Another reason for it happening in 
the community is that our access - the access that pharmacists have, as 
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far as patients are concerned is much better than if we were in a 
surgery. So that's another advantage. The disadvantage maybe of 
being in the community is that we don't have this - we don't have a 
relationship with the doctor, the trust of the doctor perhaps, that we 
could build on effectively within the surgery. And I think that's one 
advantage that the surgery may well have over the community. Which 
is better, the better model, I really don't know. 1/ (P16/FG4) 
Two pharmacists saw the service being conducted in a community 
pharmacy as a disadvantage as they believed it was unrealistic that they 
would be able to give patients an adequate amount of time when they 
came into the pharmacy on subsequent occasions. They believed this 
would send mixed messages to patients. 
"But I know that being based at a surgery is always going to be an 
advantage than working in a shop, it is so difficult because you don't 
have the time. I know people can come in and you are accessible but 
when you are doing over 500 items a day; it's difficult to give people 5 
minutes of time, let alone 10-20 minutes. 1/ (P03/FG1) 
Three pharmacists thought that it would be easier for practice 
pharmacists in the GP practice to conduct this type of service, although 
they acknowledged there was no reason why community pharmacists 
could not do medication reviews. 
The responses given suggest that many pharmacists did not view the 
community pharmacy as the most appropriate setting for a MMS. 
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6.9 Identified barriers to community pharmacist's 
involvement in a MMS 
After providing an initial assessment of their experiences undertaking a 
MMS, pharmacists were then asked to identify difficulties or barriers 
they had so far encountered. 
6.9.1 Lack ofGP engagement 
The most significant, negative aspect of the MMS reported by the 
pharmacists was thought to be the lack of GP engagement with it. 
Pharmacists reported a lack of communication from some of the 
participating GPs concerning their clinical recommendations and whether 
these had been implemented. GPs' lack of interest in the MMS had been 
a problem encountered by seven pharmacists interviewed, this was 
particularly evident in one pilot site. The delay in responding to 
pharmacists' recommendations had caused problems for the 
pharmacists and they believed in several cases this had resulted in 
patients losing faith in them. The following quotes illustrate this. 
"Yes, I mean I feel pretty strongly that GPs are basically just paying lip 
service to the project and I've had I think four intervention forms back, 
one where everything has just been ignored; others where the GP has 
said yes, he agrees with this, yes, he will action this and subsequently 
absolutely nothing has happened." (P15/FG4) 
"I think I've had one alteration. I've had about eight or nine brought 
back. And others have said yes, you know. Nothing's been actioned. 
There's one intervention that they have actioned." (P18/FG4) 
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As a consequence, four pharmacists stated that communicating 
information to patients was difficult because they did not know if GPs 
would follow their advice. 
"I think the main problem is if you are going to make an intervention, 
it's how to communicate that to the patient without saying 'This will 
happen!' because you don't want to tell them in case the GP decides 
that it won't! I think that's the bit where you feel a bit ineffective really." 
(P02/FG1) 
Pharmacists in one pilot area reported that they had been suggesting 
interventions which had been ignored by the participating GPs. In one 
particular case, the patient had died and this raised an issue of liability 
for the pharmacist if their advice was ignored. The following quote 
illustrates this. 
"And one particular case, the patient has died and I made 
recommendations because the guy had a systolic of over 180 and 
cholesterol of 6.4. I made recommendations to introduce a statin and to 
introduce amlodipine and the GP agreed but did nothing about it. A few 
weeks later the guy had a stroke the GP subsequently introduced 
amlodipine but not a statin, and I think about three weeks ago the 
patient died. And I just don't think GPs have, you know, taken it on 
board." (P15/FG4) 
As a consequence, pharmacists in this particular pilot site were very 
concerned at making clinical recommendations when they had no 
influence in their enforcement. 
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Two pharmacists also reported that practice nurses had been allocated 
the task of dealing with the interventions, making it even harder to 
communicate with the GPs. This lack of engagement had caused the 
pharmacists to feel disheartened about the MMS and the role they could 
play in medication reviews. 
"Yes, I just feel that, you know, I just feel as if it's - the impetus was 
just lost once the intervention form goes out." (P18/FG4) 
Pharmacists thought the lack of engagement may have been due to GPs 
expecting their workload to be reduced and this had not been the case 
as they had received a lot of paperwork from the pharmacist. 
"But I do wonder whether the GPs saw this as being a way of actually 
reducing their work load. And when it's come down to it, because of the 
selection of patients and all the paperwork they've had to do, it's 
actually been a lot more on them than they expected so it hasn't 
actually given them what they were expecting either." (P19/FG4) 
Pharmacists believed GPs needed to commit time for meetings so 
recommendations could be discussed. However, it was acknowledged 
that this would be unlikely to happen because GPs saw themselves as 
already overworked and this would be an ongoing concern if the project 
was rolled out nationally. 
"It's so difficult. I mean it's difficult enough to get to talk to them on the 
phone about somebody, to actually get a face to face meeting." 
(P23/FGS) 
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At this early stage of the MMS, many community pharmacists had 
concerns around the lack of GP involvement in the MMS and response to 
their clinical recommendations. Pharmacists acknowledged that greater 
face-to-face communication was needed to discuss their 
recommendations but seemed resigned to the fact that this would not 
occur due to time pressures on the GP. 
6.9.2 The extended role of the practice nurse 
It became evident throughout the focus group that whilst pharmacists 
thought that GP were not supporting them to undertake a MMS they 
believed that nurses had been able to extend their role within the 
primary care setting. Their frustration centered on the fact that GPs had 
supported practice nurses to undertake new roles but they seemed 
reluctant to allow community pharmacists to do the same. The following 
quotes demonstrate this. 
"But what annoys me is that nurses can prescribe and do this and that, 
and that really annoys me." (P32/FG8) 
"1 think what 1 find difficult to understand is that GPs seem very happy 
to off load as much work as they possibly can to the nurses but when it 
comes to the pharmacists .... maybe it is this shopkeeper thing." 
(P15/FG4) 
Pharmacists believed the lack of support towards their role extension 
might have been due to them being outside of the GP's control. It was 
acknowledged that practice nurses based within the GP practice, usually 
worked to a protocol and were supervised by GPs to a much greater 
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degree than a community pharmacist. This observation is supported by 
literature which has explored the nurse/GP relationship in the primary 
care setting (Wiles, 1994; Willis et ai, 1999; Charles-Jones et ai, 2003). 
They concluded whilst there was often a constructive relationship 
between nurses and GPs, GPs delegated work to nurses that they did 
not want to undertake, for example, nurses could manage patients with 
'minor ailments'. This allowed GPs to maintain their dominant position 
within the primary care team. The following quote illustrates this theme. 
"We're outside of their control but the nurses are very firmly under their 
supervision aren't they? We're not; we're a bit of a loose cannon and we 
have a personal judgement and our slant is slightly different to the 
nurses." (P19/FG4) 
Consequently, this group of community pharmacists thought GPs 
perceived them to be more of a threat than nurses when undertaking 
new roles. Community pharmacists recognised that GPs might be 
threatened by them questioning their clinical deCisions regarding 
patients' medication, and rather than viewing it as 'collaborative team 
work' they would see it as being 'checked-up on'. The following quotes 
illustrate this. 
"1 think it's because they feel threatened (refers to GPs); its human 
nature isn't it? You are impinging on their territory and if you make a 
change and it's for the better the patient is going to say but the 
pharmacist said and it was changed and that makes him feel ... it's 
tricky." (P34/Tl1) 
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"They might feel their opinion is being challenged, that they are being 
checked upon, or whatever, because] suppose they are not used to it. 
It is a new thing for them really to have someone who is looking at the 
notes they have done themselves." (P09/FG2) 
However, three pharmacists did not think GPs would be threatened by 
community pharmacists undertaking a medicines management role, as 
the pharmacist was only making a clinical suggestion and the GP still 
had the ultimate decision regarding a patient's treatment. These 
pharmacists concluded this was not an adequate explanation as to why 
they would not support them. It was acknowledged by two pharmacists 
that there would be a mixed response from GPs regarding community 
pharmacists undertaking a medicines management role, with some GPs 
simply refusing to accept community pharmacists undertaking an 
extended role. 
"There are those GP's who accept this quickly and others who won't." 
(P28/FG7) 
Four pharmacists feared that as nurses and community pharmacists 
started to extend their role then they would be in competition with each 
other. A particular fear was practice nurses were cheaper to employ 
than community pharmacists. However, two pharmacists disagreed with 
this and stated they believed pharmacists had a more extensive 
knowledge base so they could offer a broader range of skills than a 
specialist nurse. 
"] actually think we have a lot to offer because if you have got a 
specialist, a nurse specialist, they are very good, very well trained but 
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are you going to employ a nurse specialist for every area? Or are you 
going to work with someone like a pharmacist who has a broad base and 
the ability across the board. So I think we have a lot to offer. " 
(P02jFG1) 
One pharmacist also believed that community pharmacists should be 
focusing on a different patient population to the ones specialist nurses 
were reviewing, primarily on patients that did not need to be seen in the 
GP practice. 
These data suggest that many community pharmacists thought they 
were in competition with nurses and were anxious that nurses had taken 
roles they could potentially undertake. This fear was further fuelled as 
pharmacists believed that GPs were more willing to support nurse role 
extension. These pharmacists postulated this was because nurses posed 
less of a threat to GPs' autonomy. 
6.9.3 Patient selection 
There were a number of concerns stated by the pharmacists regarding 
the patients selected to be involved in the MMS. The first problem 
identified, was the patients seen were often very motivated, well and 
required little pharmaceutical input. As a consequence, pharmacists 
reported they had made few clinical and lifestyle interventions and had 
just reinforced information. There were also few examples of the 
pharmacist having an impact on a patient's compliance as most 
pharmacists reported that the majority of patients they reviewed were 
compliant with their medication. 
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"As I have said so far all the ones I've seen are already on you know like 
the health centre I work with is implementing the NSF recommendations 
for coronary heart disease so all of them were already on a statin, 
aspirin, beta-blocker what have you." (P27/FG6) 
This problem was further precipitated as pharmacists stated that only 
motivated GP practices had taken part in this project and these practices 
were likely to have implemented NSF guidelines for CHD. It was also 
recognised that if a specialist cardiologist was treating a patient then 
GPs were usually reluctant to alter medication, again making it difficult 
for the pharmacist to have any clinical input. 
Although pharmacists thought that consultations had probably been 
beneficial to these patients, there was a general belief that the review 
process would have been more beneficial for patients who were known 
to have significant medication and lifestyle issues in need of addressing. 
Pharmacists therefore believed more scrutiny should have gone into the 
patient selection. The following quotes illustrate this. 
"If I was asking to select patients to come in and have a half hour chat, 
they didn't match the group that volunteered to come in and have the 
half hour chat." (P31/FG8) 
"The only concern, was that a lot of the patients because they've been 
chosen at random, they wouldn't necessarily have been the patients 
that you would see if a doctor had referred them to you. So a lot of the 
time you're seeing the patients, you will discuss all their medication and 
there might not be anything to refer. And I wonder how beneficial that is 
really. (P12/FG3) 
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Pharmacists believed if their local knowledge had been utilised in 
selecting appropriate patients, then this would have helped improve the 
patient's response rate, which was exceptionally low in several of the 
pilot sites. 
"I think if the community pharmacist's local knowledge of the area had 
been utilised too, you know for recruitment then it might have produced 
a higher response rate. So that we virtually told which patients they 
were. So when they came in we could have said it's only going to be a 
study we are going to look at you and help look after you." (P34/TIl) 
One pharmacist also suggested that the CHD nurses and GPs could have 
been more proactive in selecting patients, by speaking with patients who 
had medication issues and recommending that they went to see the 
community pharmacist for a discussion. They believed if they had 
endorsed the project more, patients would have been more willing to 
participate. 
Three pharmacists believed that patients had agreed to take part in the 
project without fully understanding the implications. This had resulted in 
patients cancelling appointments at the last minute, which in turn had 
caused problems if the pharmacist had arranged locum cover. This again 
suggests that the pharmacist and patient relationship is quite different 
to that of the physician/patient relationship, notably the patients having 
less respect for the community pharmacist. 
"Like one lady said to me 'I don't know if I want to see you today!" 
(P32/FG8) 
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These responses suggest that community pharmacists were frustrated 
that they had been unable to review patients that had a genuine need 
for a medication review. If they had been able to have had a greater 
input into patient selection, or if GPs and nurses had encouraged 
patients with medication issues to see the pharmacist this may have 
helped to address this issue. 
Three pharmacists in one pilot site stated that they believed GP 
practices had examined and reviewed patient's medication as the project 
was commencing. By the time the pharmacist had reviewed the patient's 
treatment, their treatment complied with NSF standards, resulting in the 
pharmacist having little input into a patient's medication regimen. 
"We're starting to see at the main phase now that, you know, sort of 
patients' notes coming through and things have been actioned to sort of 
fall in with the sort of national service framework so where someone has 
a sort of raised cholesterol they've been suddenly started on a statin." 
(P15/FG4) 
"I've had a couple of people started on statins before we'd got to them. 
And they were crying out for a statin but they'd been without one for 
goodness knows how long. " (P18/FG4) 
These data perhaps suggest that some GPs were threatened by the 
prospect of community pharmacists reviewing their patient prescribing 
and therefore took measures to prevent the pharmacist from identifying 
any issues with their CHD patients. 
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Pharmacists also reported that if the GP practice employed a practice 
pharmacist or a CHD nurse they had usually gone through the CHD 
registers. 
"You see I think that will make a vast difference if they are from a 
practice where they already get pharmaceutical input. Where they have 
already gone through the registers, you are going to have a different 
base to it." (P02/FG1) 
Consequently, participating community pharmacists only made minor 
interventions as the CHD patients were already appropriately managed. 
6.9.4 Lack of access to patients' medical records 
As reported in Chapter 3, participating pharmacists received a set of 
medical information about the patients that were to receive a medication 
review. Pharmacists were therefore asked to provide feedback on the 
audit forms they received, which provided pharmacists with the clinical 
data on the patient. The general consensus was that there was 
insufficient information on the audit forms and this made it difficult (at 
times) to carry out a full medication review. Information such as urea 
and electrolytes, creatinine, liver function tests, past drug history and 
other diagnosed illnesses of the patient in some cases were necessary 
and were sometimes imperative to know, in order to make an 
appropriate assessment. 
"You do need a bit more info because otherwise you come across as 
stupid. " (P10/FG3) 
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Five pharmacists reported that the lack of information and access to 
patients' medical notes had been a particular problem and the 
medication review had been much more difficult as a result. There were 
also individual cases of inaccurate or out of date data given to seven 
pharmacists. The following quotes illustrate this theme. 
"[ can't remember the details now but [had one chap he told me he'd 
had an angioplasty and a bypass graph and neither of them were down [ 
don't think on the form. I've had one or two where the actual diagnoses 
were not all that accurate." (P2S/FGS) 
"I've had several occasions where tablets are being taken actually in the 
cardiovascular heart disease area and they've not been down, so [ lost a 
bit of confidence with the data." (P21/FG5) 
Two pharmacists thought that for an effective medicines management 
consultation to be carried out then shared computerised medical records 
needed to be in operation, so that clinical information could be accessed 
between the GP practice and the community pharmacy. Eight 
pharmacists argued that carrying out effective medication reviews would 
have been facilitated by them obtaining clinical data from the medical 
notes. 
"I suppose you could argue that it should be us getting the data in a 
way. Alright I'm not talking like I want to take on loads and loads more 
work, [ just mean if you're going to do it, if you were looking at the data 
and extracting it you would know what you were looking for and what 
you wanted to know, whereas now you're looking at data that somebody 
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else has extracted and hoping that it's what you want and that its 
complete." (P25/FG5) 
Four pharmacists currently reported that they were using patients' 
medical notes in addition to the audit forms9 • One pharmacist went to 
the GP practice to obtain relevant additional information, whilst the 
three other pharmacists had contacted the practice pharmacist to obtain 
more clinical information on their behalf. 
"I organised to go into the GP surgery and look up the notes and stuff 
like that on the same day. So, like, in the morning I went in, had a look 
at everything (refers to the medical notes), I already had their 
permission I would do that, start the interviews lunchtime, went in again 
to look at the rest and then when the interviews finished, finished off the 
paperwork and looked up anything else." (P34/TIl) 
However, two pharmacists stated that being located outside of the GP 
practice and lack of time were currently barriers for community 
pharmacists to have access to patient medical records. 
"Yes, access is probably a problem. I can see if I had access to the GP's 
copy then I could see if like they had all their tests done then, but to do 
that is very difficult being an outside business person. To walk into a 
GP's surgery and have full access to full confidential things. So I think 
there is a huge barrier there and I think that can only be overcome if 
you are part of the GP surgery basically. Unless they give you 'titbits' of 
9 The project protocol permitted community pharmacists to access patients' medical 
records if they required further clinical information for a patient. 
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results and things, just when you ask for them so it's much better to 
have it in front of you than to ask for it at a later date." (P03/FG1) 
The data suggests that not having access to patients' full medical 
records had been a barrier for some pharmacists to conduct a full 
medication review with patients. However, despite recognising this as a 
barrier only four pharmacists had attempted to obtain the extra clinical 
data that they required from patients' medical records. 
6.9.5 Organisational problems 
A further problem identified by pharmacists was organising a time to 
conduct patient medication reviews. The first issue had centred on trying 
to organise patient interviews to either coincide with locums, or when 
there were two pharmacists in the pharmacy. This had proved too 
difficult for six pharmacists and had therefore resulted in them carrying 
out patient interviews on their days off. 
"Because it's so difficult to coincide what the patient can do with what 
the locum can do. I mean you can book a locum and then get in touch 
with the patient and they can't come, and vice versa. So it just you 
know, it made it easier ... it just makes it easier to do on my day off, you 
know." (P18/FG4) 
Another problem identified was finding enough time in the pharmacist's 
workday to fit in patient interviews. Eight pharmacists reported that they 
were either conducting patient consultations on their days off or in their 
lunch hour, as this was the most convenient time to carry them out. One 
pharmacist reported that whilst they conducted patient consultations 
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during working hours all preparation and writing up was carried out at 
home as they did not have time to do it during the day. 
"Yes time is the main thing, trying to fit it all in with your normal routine 
really when you have got so many other things to do." (P08/FG2) 
Three pharmacists from one pilot site also commented that attending 
training sessions had been difficult due to childcare issues or getting 
locum cover. This had resulted in two of their colleagues withdrawing 
from the project because they were unable to attend training sessions. 
Again, it was stressed that if this project was to roll out nationally this 
issue would need to be addressed so that training courses were run 
more frequently, and in more locations so pharmacists had the 
opportunity to attend them. 
6.9.61nadequate consultation areas 
Community pharmacists were only able to participate in the MMS, if 
their pharmacies had a designated confidential area to conduct 
medication reviews with patients. However, four pharmacists 
commented that they had inappropriate consultation areas to conduct 
patient medication reviews. Two pharmacists had used their office as a 
consultation area. This had proved both difficult and time consuming to 
get older patients up to this area, especially if they were required to 
climb stairs. 
"The only problem that I've had is that we use a room upstairs, so I'm 
constantly having to check that people can actually climb a flight of 
stairs." (P17/FG4) 
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One pharmacist reported they did not have a consultation area and had 
therefore conducted their consultations during their lunch hour when the 
premises were closed, in order to ensure privacy for the patient. The 
fourth pharmacist reported that they had conducted their patient 
consultations in the staff tearoom, which had been less than ideal. 
"Yes, I think the pharmacies should be prepared to have such patients, 
in other words they should be really a place set a side for that because 
you'd find sometimes you would have to go into a tearoom. The people 
are really nice they tried not to interfere as much as possible. " 
(P35fTl2) 
It was acknowledged that for many pharmacy premises, not having a 
designated consultation area would be a barrier against community 
pharmacists conducting medication reviews. Pharmacists stated that 
unless a community pharmacist knew that conducting medication 
reviews would generate an income they were unlikely to spend money 
to ensure they had an adequate consultation area. 
"I think pharmacies in general. I think premises would be one, the style 
and design, if you are looking at pharmacy in general because we all 
needed somewhere to do a consultation. Again I think you're back to 
whether the pharmacist would be prepared to do the consultation area 
without knowing it was going to generate enough income. I think from a 
financial point of view that's why people don't have them. I'm sure they 
would do them if they knew it was worthwhile, I think it is one of the 
major drawbacks." (P02/FG1) 
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Again, this highlights the fact some pharmacists are unwilling to engage 
in service development unless they are guaranteed to make a profit 
from doing it. Without having an appropriate and confidential area in a 
pharmacy then community pharmacists are unable to conduct patient 
medication reviews 
6.10 Future development of a MMS 
Finally, participants were asked to provide their views on whether a 
MMS was a sustainable and realistic service within the current 
organisational structure of community pharmacy. There was a general 
agreement amongst the pharmaCists interviewed that whilst they would 
like to continue providing a MMS, with the current payment contract and 
working structure of community pharmacy then it would be extremely 
difficult to carry out this service. In particular, it was acknowledged that 
pharmacies would either need to have two pharmacists or dispensing 
technicians in place to allow a pharmacist enough free time to carry out 
a MMS. The following quotes illustrate this. 
"I would love to do it but I think you need to have a retail pharmacy 
structured slightly differently. To take it on is a big issue; you really 
need to have a second pharmaciSt." (P02/FG1) 
"I mean one thing, which has become absolutely crystal clear that to 
provide medicines management services at this level it is absolutely 
impossible for one pharmacist, running a pharmacy, to do it in normal 
working hours." (P28/FG7) 
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Pharmacists stated that to carry out a MMS on a long-term basis then it 
would have to be more organised, with designated times and days for 
this service to be carried out rather than trying to fit patient 
consultations into their current day-to-day workload. Pharmacists also 
believed if this service were to continue then there needed to be 
adequate remuneration for the pharmacist to carry out medication 
reviews to compensate for the time taken away from dispensing 
medication, their current source of remuneration. 
"[ think the way pharmacists are paid generally will have to change. I 
think with the current contract where we're paid piece work, [don't 
think it could work." (P16/FG4) 
Pharmacists also described how they hoped a future MMS would work. 
Pharmacists hoped as they tried to develop their clinical role then 
adequate remuneration would be put in place which would allow 
pharmacies to close for dispensing for deSignated times to allow a MMS 
to be undertaken instead. It was also recognised that different 
pharmacies could take on different roles. For example, some pharmacies 
could continue dispensing medication whilst others could develop a 
MMS. 
"[ just feel, as we develop more of a clinical role, then there should be 
more encouragement for pharmacy. Maybe to be able to close for 
dispensing and selling medicines for Y2 day or a couple of hours away a 
day and it's something you train your customers in to. People will, if you 
are the sole pharmacy in the area, then people will fit in around you. If 
you are one of a number of pharmacies within the area then there is no 
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problem providing you are properly remunerated for doing what you're 
doing then ok. You just lose a few prescriptions." (POS/FG4) 
However, pharmacists stated until communication improved between 
themselves and the GPs, and GP practices saw it as a beneficial service 
then a MMS would be hard to undertake. 
"It would be great if you could really liaise with your local surgery, with 
your local one or two surgeries. And I'm quite happy to see patients that 
don't come to our pharmacy as well, but just to have a really good 
rapport with the local practice, the doctors and the nurses, and if they 
generally felt there was a benefit as well, rather than it being a chore 
because they've had to get all the forms out and then they've had to 
respond to forms. I think if it became a much more naturalistic process; 
I'm sure there really is a future in it." (P31/FG8) 
Two pharmacists however, stated just because they had faced problems 
in trying to conduct this service they should not dismiss the opportunity 
to undertake this extended role. 
"I wouldn't kick it in to touch because I think its something we've got to 
address ourselves and find a solution to. I wouldn't say that because of 
the problems we can't do it, forget it." (P28/FG7) 
6.11 summary 
All pharmacists were positive in terms of the concept of being involved 
in a MMS. However, the general consensus held by pharmacists at the 
beginning of the twelve-month intervention period, was that a MMS was 
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not a sustainable and realistic service within the current working 
structure of community pharmacy. A number of attitudinal and 
organisational barriers to conducting a MMS were identified. 
Despite nearly all pharmacists stating they had a good working 
relationship with their local GPs prior to the MMS commencing, some 
pharmacists expressed concerns about having to discuss medication 
issues with their local GPs face-to-face. Whilst some pharmacists 
believed GPs viewed them as professionals, some pharmacists believed 
GPs saw them as shopkeepers rather than health professionals, which 
resulted in GPs not viewing them as having a similar professional status. 
This identified hierarchy theme is supported by Hughes and McCann's 
work (2003). Pharmacists also believed GPs had little understanding of 
their current role, particularly surrounding patient confidentiality. 
Pharmacists were also concerned at the lack of GP engagement with the 
project. Pharmacists acknowledged that by undertaking a MMS they had 
to question a GP's clinical judgment and this might result in the GP 
feeling threatened and they could view this new role as boundary 
encroachment and loss of control over their patients. All these attitude 
barriers may have accounted for the GPs lack of engagement with the 
project. 
Pharmacists also identified a number of organisational barriers which 
could prevent them undertaking this extended role. These included, time 
restraints, access to patient's medical records, inappropriate patient 
selection and lack of remuneration. The absence of financial incentives, 
inadequate consultation areas, time restraints and obtaining clinical 
information have all been identified in the literature as restraints 
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impacting on pharmaceutical care implementation (Miller and Orteimer, 
1995; Trinca, 1995; Bell et ai, 1998a; Chen et ai, 1999a; Rutter et ai, 
2000; Rushton, 2001; Rossing et ai, 2001). Whilst the pharmacists in 
this project identified similar organisational barriers, some pharmacists 
had found ways to overcome some of these barriers. This suggests that 
the individual aspirations and motivation of a community pharmacist 
may also contribute as a major factor towards successful role extension 
for the community pharmacist. 
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7. GPS' VIEWS AND EXPERIENCES OF 
COLLABORATIVE WORK WITH COMMUNITY 
PHARMACISTS 
7.1 Introduction 
This chapter describes the main findings from a series of qualitative, 
individual telephone interviews conducted with twenty-one GPs (eleven 
male and ten female). Interviews were carried out during July 2003 to 
February 2004. This was approximately six to twelve months after the GP 
had become involved with the MMS, in order to allow them time to gain 
experience of collaborating and receiving clinical recommendations from 
community pharmacists. The aims of the interviews were to explore the 
relationship between the GPs and community pharmacists, prior to and 
during the evaluation of the MMS, and to establish their views and 
experiences of working with community pharmacists conducting a MMS. 
GPs were also asked to discuss any potential or actual barriers that could 
limit community pharmacists from undertaking this extended role. 
Interviews lasted approximately twenty minutes and were conducted with 
GPs in all nine pilot sites. 
The first part of this chapter focuses on the data obtained from GPs 
regarding their relationships and perceptions of community pharmacists. 
The second half of the chapter concentrates on GPs' experiences of being 
involved with the MMS. Throughout this chapter I have used numbers to 
help quantify and support the pOints that I report. This should allow the 
reader to gain a sense of perspective of the data as a whole. However, it 
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should be noted that when reporting the range of key themes, sometimes 
not all GPs are represented. This was largely due to some GPs being very 
ambiguous in their responses and despite further questioning their views 
could not always be clarified. This problem was further precipitated, as I 
only had around twenty minutes to conduct an interview with each GP. The 
key themes are reported in the following sections. 
7.2 GPs' current working relationships with community 
pharmacists 
At the start of the interviews, all GPs were asked to comment on their 
working relationship with community pharmacists in their area, prior to the 
MMS commencing. Nineteen GPs stated that they had a good working 
relationship with the community pharmacists in their area, describing their 
relationships as open and productive. GPs also reported that they found 
community pharmacists helpful and obliging. However, the relationship was 
often reactive in nature, with the community pharmacist contacting them 
only if they had made mistakes with their prescribing. Likewise, the GP 
would only phone them if they required advice and information concerning 
medication issues. 
"1 mean normally it's fine, we ring them up for information and they ring 
us up if they have spotted mistakes we've made and things and it's actually 
a very useful productive relationship." (GP03) 
Two GPs stated they had a poor relationship with particular pharmacists 
within their area, although they pOinted out that they got on well with the 
majority of the pharmacists in the project. One GP would not state the 
reason for this poor relationship however; the other GP stated that it was 
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due to the previous community pharmacist retiring and a lack of 
communication with the new pharmacist. 
However, it was apparent that relationships were particularly productive 
with community pharmacists when community pharmacists were located in 
or near their practice, or where the community pharmacist had been in 
post for some time. GPs stated in these instances they had a more 
established and trusting relationships with these pharmacists. Five GPs 
explicitly stated that they trusted and valued the community pharmacist's 
advice, and viewed them as the experts when pharmacological and 
pharmaceutical advice was required. One of these GPs stated that GPs 
should be listening to pharmacists' advice as they were the 'experts' 
regarding pharmacy issues. Two of these GPs also made reference to the 
fact that they viewed pharmacists as professional equals. The following 
quotes illustrate this. 
"Us personally get on with pharmacists really well and they are equals to 
us, thank you very much, and they are incredibly helpful with what they do 
know because they are experts just in pharmacology." (GP12) 
"1 do ring the pharmacist all the time so 1 would very much see them as an 
equal professional who knows more about drugs than 1 do." (GP09) 
Three GPs stated that if they did not have an established relationship with 
their community pharmacist then it was hard to have trust and confidence 
in them. In several instances, where there had been a succession of locums 
in a shop the GP stated that their level of trust and confidence in the 
community pharmacist was not too good. One GP also stated that it was 
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difficult for a GP to follow advice from a community pharmacist unless they 
believed their advice was correct. 
"That was the other thing 1 was going to say, if you don 't actually feel that 
your local pharmacist was particularly good then obviously you would think 
1 am now getting someone else telling me what to do and also how do 1 
know that 1 am following the right information?" (GP09) 
Six GPs stated they believed that it was important that there was a good 
relationship between the GP and the community pharmacist to undertake a 
MMS. They believed that the personality and attributes of the GP and 
community pharmacist involved would determine the success of the 
collaboration between the two professions. They thought it was imperative 
that a community pharmacist had the confidence to interact with their GP. 
Similarly, the GP would have to be willing to receive information concerning 
prescribing errors and accept and action medication advice regarding their 
patients. If this relationship were not in place, it was acknowledged that 
this type of service would be unlikely to work. 
"1 think it depends on the quality of your pharmacist and how they are 
going to interact. Our pharmacist is quite happy to pick up the phone and 
say: "Did you realise you have given this patient five million tablets?" 
(laughs). We can have a laugh and they say did you know this product is 
no longer prescribable? 1 mean they are quite happy to do that and we are 
quite happy to sit there and say "Oh dear!". They also are quite happy to 
say do that. ......... so 1 think if you are gOing to work with it you have to have 
good relationships with the pharmacist." (GP06) 
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These data suggest that before the commencement of the MMS, GPs had a 
positive relationship with the majority of community pharmacists within 
their area, although the relationship was reactive in nature and 
communication was generally conducted via the telephone. 
7.3 Working relationship with community pharmacists during 
the MMS 
One objective of the evaluation was to explore how the MMS had altered 
relationships between the two professions, therefore GPs were asked to 
comment whether the MMS had changed their relationship with the 
participating pharmacists. Five GPs thought their relationship had been 
strengthened as a result of taking part in the project, as it had given them 
the opportunity to communicate more with the community pharmacists. 
For one GP, it had given them the chance to mix with the community 
pharmacists and build relationships in a more social environment, which 
they stated did not happen in their normal working day. 
"Oh I do and I think that the evening meetings that we had were good 
because I mean obviously there was the contexts of what the meeting was 
but it was also a social situation to sort of meet people who you do see but 
you never get a chance to have a coffee with or something like that, so I 
think on that score it was beneficial as well." (GPll) 
Three GPs stated they thought the project had not altered their relationship 
with the community pharmacist, and one GP thought the relationship with 
one of the participating pharmacists had deteriorated as a result of the 
correspondence they had received from them. When questioned further, 
194 
this GP stated they had found the pharmacist patronising in the way they 
had conveyed clinical recommendations. Despite asking GPs to comment 
on how the MMS had altered their existing relationship with the 
participating pharmacists, the rest of the interviewed GPs were non-
committal in their answers and therefore could not be represented. In 
many instances these GPs reiterated that they generally had a good 
relationship with their local community pharmacists. This perhaps suggests 
that these GPs had not had much contact with the community pharmacists 
during the MMS and were unable to comment whether the MMS had altered 
relationships. 
7.4 GPs' perspectives on the differences between practice 
and community pharmacists 
The literature suggests that GPs view the clinical capabilities of practice 
pharmacists differently to those of community pharmacists (Adamcik et ai, 
1986; Hughes and McCann, 2003), with GPs seeing the practice 
pharmacist's clinical knowledge as something unique to a practice 
pharmacist, rather than pharmacists in general. As many GP practices 
routinely have a practice pharmacist attend their practice to help 
rationalise their prescribing, GPs were asked if they currently had a 
practice pharmacist working with their practice, and how they thought 
practice pharmaCists differed from community pharmacists. 
Although a third of GPs stated they had a practice pharmacist working with 
them, these GPs were generally unsure about how a community 
pharmacist differed from a practice pharmaCist. Most GPs acknowledged 
that practice pharmaCists had access to medical records, with two GPs 
specifically stating that they only allowed practice pharmaCists to look at 
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medical records and this activity was not granted to community 
pharmacists. 
"Well the practice pharmacist looks at our record; well we don't let the 
community pharmacist come and look at our computers." (GP18) 
GPs also thought practice pharmacists had a greater understanding about 
how a GP practice operated. Three GPs believed that this familiarity with 
the GP practice allowed GPs to build relationships with practice 
pharmacists, putting them in a better position to carry out medication 
reviews. However, it was acknowledged that a community pharmacist could 
gain familiarity with the way a GP practice worked and also that they had a 
greater knowledge regarding the practicalities of patients taking tablets 
than the practice pharmacist. 
"That's a difficult one to answer really, I suppose because we can build up 
a relationship with them, but I don't know otherwise. I instinctively feel 
that practice pharmacists have got a bit more understanding about general 
practice that community pharmacists don't have." (GP03) 
GPs stated they valued their practice pharmacists and they currently relied 
on them to undertake a number of clinical roles within their practice. Roles 
included conducting medication reviews, providing evidence-based 
literature, giving information regarding drug interactions and liaising with 
health professionals in secondary care over patient's discharge medication. 
In one particular GP practice, the practice pharmacist was undertaking 
more clinical roles such as taking blood pressure readings and carrying out 
basic urine tests. This GP then went on to explain that they had been so 
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impressed by this practice pharmacist they now independently employed 
them on a sessional basis for their practice. 
Although GPs were generally unable to explain how practice and 
community pharmacists differed, they were able to explain differences by 
using task differentiation. In these instances, GPs were happy for the 
practice pharmacists to undertake a variety of clinical roles and have 
access to patients' medical records. These data suggest that the 
participating GPs viewed practice pharmacists differently to community 
pharmacists, perhaps viewing their clinical capabilities as being greater 
than that of a community pharmacist. 
7.5 Expertise of the community pharmacist to undertake 
medication reviews 
Ellis et al (1992) found when assessing GPs' views about pharmacists 
extending their role, 44% of GPs questioned did not think pharmacists' 
training was adequate to undertake an extended clinical role, and only 19% 
of GPs questioned indicated they had investigated the extent of a 
pharmacist's training. Interviewed GPs were asked to comment about their 
knowledge of a community pharmacist's training and why they thought 
community pharmacists were trying to undertake new roles. Finally, they 
were asked to comment whether they perceived community pharmacists as 
having the necessary expertise to undertake medication reviews. 
Eighteen GPs stated that they had very little knowledge about a community 
pharmacist's training, although three GPs stated that they knew what a 
community pharmacist's training entailed, because they knew friends or 
had relatives that were community pharmacists. Two GPs specifically 
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stated they were aware of the changing contract occurring for community 
pharmacists and thought this was the reason they were trying to redefine 
their role. Another GP thought that community pharmacists were likely to 
feel underused and frustrated with their current role and that this was the 
driving force for them trying out new roles. 
"1 would assume that the pharmacists are well trained, they must be bored 
to tears with handing out twenty eight pills every month and stuff. They 
probably feel underused as a service, their abilities are underused and I 
think getting in to patient advice and management, it just seems natural to 
me." (GP04) 
These data suggest that the majority of GPs had a poor knowledge of a 
community pharmacist's training and little understanding around why 
community pharmacists were being encouraged to develop their role into 
more clinical domains. 
GPs were then asked to comment on whether they believed community 
pharmacists had the necessary expertise to carry out medication reviews 
on patients. Overall, seven GPs thought community pharmacists had the 
necessary expertise, providing they received training and had supervision. 
It was acknowledged by GPs that pharmacists generally had good 
interpersonal skills and a thorough knowledge of medicines which was 
often greater than the doctors, although several GPs had some concerns 
that they did not know patients as well as the GPs. 
GPs believed that community pharmacists would require training, 
particularly in areas such as choosing appropriate blood tests, as this was 
not a routine role for the community pharmacist. However, they believed 
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with mentoring and support from GPs, a community pharmacist could 
easily learn these skills. It was acknowledged that the level of help 
required by a pharmacist would be dependent on their experience. One GP 
thought that older pharmacists may be more hesitant about undertaking a 
MMS than younger pharmacists, but would be able to do it once they 
received training and support from GPs. 
"I think they are bright individuals they have all got degrees for starters 
and many of them have good interpersonal skills and I think that with a bit 
of training, and particularly with supervision and mentoring, they have got 
to have a set up of people I think to supervise them and mentor them so 
that they have got a professional tree to work to. Then I would be 
suggesting, yes, I think that they have got the skills. I mean we all need 
training. If we are going to do something different then we need training. " 
(GP06) 
One GP acknowledged that nurses now tended to have a more prominent 
role with patients within the primary care setting and this had occurred 
with support from medical colleagues. Therefore, they believed providing 
there was support from the medical profession, there was no reason why 
community pharmacists could not extend their role. 
"We are putting so much emphasis now on chronic disease management, 
chroniC disease management clinics in the primary care setting are now 
increasingly being run by our nurses, now these nurses have no formal 
medical training but over a period of time with practice and support from 
their medical colleagues they have been able to take on this mantle and 
there is no reason why the community pharmacist cannot do that with 
adequate support." (GP01) 
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Eight GPs were unsure if community pharmacists had the necessary 
expertise to carry out this extended role. Four of the GPs clarified their 
views further. Two GPs thought community pharmacists' ability would be 
quite varied and it depended on how much postgraduate training they had 
undertaken. The other two GPs thought that community pharmacists would 
find it difficult to undertake a MMS due to them not having full access to 
medical records, rather than a lack of expertise. They acknowledged that 
community pharmacists would be unable to conduct a medication review 
for a patient without access to the patient's medical records. 
"I think they certainly have the expertise, I think that without the clinical 
knowledge background, that's not saying they don't know their stuff, it's 
saying they don't have the information about the patients, I think that they 
were inevitably limited. If I had to ·do the same job without access to the 
patients' records I would be limited in exactly the same way so it's that 
that limits it, not their training or expertise." (GP02) 
Again, despite asking GPs to comment on this topic the remaining GPs 
were non-committal in their answers and therefore could not be 
represented. However, what these data suggest is when GPs did provide 
their views, they believed community pharmacists could extend their role if 
they received training and support from their local GPs. 
7.6 GPs' perspectives on collaboration with community 
pharmacists 
In order to assess how the general GP population would react to a closer 
working relationship with community pharmacists, participating GPs were 
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asked to provide their views. Five of the interviewees thought the GP 
population would generally welcome having a greater degree of 
collaboration with community pharmacists, probably viewing it as helpful in 
reducing GPs' workload and creating a closer working relationship between 
GPs and community pharmacists. 
"I think they will find it very helpful, especially if pharmacists do sort of 
really review medication, especially if you look in the over 75 NSF with the 
patient review, patient self-medication. If they are on more than four 
(medications), then it is every six months, then that is quite an 
undertaking. So if pharmacists would take that off our hands, then I don't 
think any GP is going to complain." (GP16) 
Seven GPs thought that there would be a mixture of reactions from the GP 
population regarding a closer working relationship with community 
pharmacists. Participating GPs believed that greater collaboration with 
community pharmacists would be appreciated by GPs used to working in a 
team environment. However, it was acknowledged that some GPs would 
not welcome this because they would not accept advice from a community 
pharmacist. It was stated that some GPs would not follow guidelines and 
prescribed medications how they saw fit, and therefore would not be willing 
to change their prescribing habits. It was also thought that there would be 
a third group of GPs, who would initially be suspicious and hesitant about 
working with community pharmacists, but would be willing to attempt 
greater collaboration with them. Three GPs increasingly thought that more 
and more of their GP colleagues would be happy to work co-operatively 
with pharmacists. 
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The following quote from one GP illustrates how they believed the general 
GP population would react to collaborating with community pharmacists. 
"Well I think you will get three different responses; one will be GPs who 
already work in teams and work with other professionals, who will think 
this is great. Then you'll get another response which is GPs who feel they 
are the dominant, deciding force in medicine and other professionals 
should pay heed to them and they won't be interested. And then you'll 
have a group of GPs in the middle, who will think"Is it going to increase my 
workload or not?" Once they have been reassured by the pilot schemes it's 
not and they can see that it's going to help, I think they will probably go 
for it, so I think there is those three groups." (GP04) 
However, three GPs thought that the GP population would generally be 
against having a greater collaboration with community pharmacists. The 
main reason for this was that GPs would see it as causing an increase in 
their work load, as they would need to set aside time to discuss issues with 
the community pharmacist. They also thought GPs would see the 
community pharmacist as 'an interference' and would generally be 
threatened by them, which, in turn, would make them unwelcoming to this 
type of service. One GP thought that if GPs had the opportunity to work 
with community pharmacists this could change their attitude towards them 
as they would see benefits. 
"A lot of GPs seem threatened by it I suspect, but us personally don't, but 
if you have worked with them an awful lot and got the benefit from them 
you love them to bits." (GP12) 
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As before, the remaining GPs were ambiguous in their responses and 
therefore could not be represented. 
Participating GPs were then asked to give their views on why GPs would 
not welcome collaboration with community pharmacists. A variety of very 
pertinent themes were suggested. Eight GPs believed this could be due to 
the personality of the GP, where doctors did not like their judgment being 
questioned, or were not a team player. 
"Basically because doctors are arrogant bastards!" (GP14) 
GPs then expanded this theme by stating that there were also hierarchy 
issues, whereby doctors believed they were professionally higher than 
pharmacists. They therefore believed they had greater knowledge than a 
community pharmacist and were not willing to accept another 
profeSSional's advice. They were also threatened when another professional 
appeared to know more than them. The following quotes illustrate this 
theme. 
"Professional boundaries, old style doctors know best kind of things. " 
(GP02) 
"1 think doctors do feel threatened if another professional appears to know 
more than them about something especially when the, 1 suspect the 
psychology behind'it is I am a doctor, I am better than you, you're just a 
pharmaCist, I think." (GP12) 
However, it was acknowledged by GPs that this mentality was changing as 
doctors, particularly younger doctors were more used to working as part of 
203 
a multidisciplinary team, and therefore realised they were not the only 
health care professional that could have a role in managing patients. As a 
consequence, doctors were happier to delegate tasks that had previously 
been seen to be physician's roles, such as medication review to the 
pharmacist. 
"1 think medical people are changing and 1 think your younger doctors are 
probably not so threatened because they are used to working in 
partnership with professionals on the same level, but your older style 
doctor, or the ones that maybe are younger but still have that mentality, 
have problems with it." (GP12) 
Three GPs thought that some GPs were very threatened by community 
pharmacists pointing out potential problems with how they managed their 
patients. These GPs saw delegating work as loss of control over their 
patients. 
"Threatening, I think it's threatening ...... Challenging management and 
criticism, someone else saying you're not doing what you should." (GP07) 
One GP thought that GPs would not want collaboration with pharmacists 
because it would potentially lead to conflict between the two professions 
and could send out mixed messages to patients regarding who was 
responsible for them. When questioned further, this GP stated that they 
thought it was outside the role of the community pharmacist to have a 
greater input into patient care. 
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"1 would ... 1 wouldn't see it as the traditional role of a pharmacist, whether 
it is the role, or the developing role, of the pharmacist is for other people 
better than me to tell me. " (GP15) 
However, one GP stated that they found it difficult to understand why GPs 
were not willing to undertake collaborative projects when they had the 
opportunity to off load work. Similarly, two GPs stated that just because 
GPs were often negative about undertaking projects with community 
pharmacists, collaborative work should still be pursued because it would 
take time to change and convince GPs that collaborative work with 
community pharmacists could be beneficial. 
"1 said that basically they will have to continue to knock on GPs doors and 
not be put off by any perceived negativism, partly because GPs are slaves 
of their habit. It is true and 1 can say this as a GP myself, GPs are slaves of 
their habit and it's a sort of a habit that has been founded over so many 
years and they look upon pharmacists or rather we look upon pharmacists 
as outsiders, so there is this artificial barrier and this barrier has to be 
broken down. n (GP01) 
These data has indicated that GPs believe that there would be a mixed 
response from the general population of GPs about having a closer working 
relationship with community pharmacists. GPs stated the advantages of 
increased collaboration included reduced workload, whilst reasons put 
forward against collaboration included professional hierarchy, 
fragmentation of patient care and anxieties around boundary 
encroachment. 
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7.7 General assessment of the MMS 
In the second half of this chapter, the attitudes of GPs towards the actual 
role of community pharmacists in a MMS are reported. In each of the 
interviews, GPs were asked to provide a general assessment of how they 
had experienced the MMS. GPs were also asked to comment on why they 
had participated in the project, along with the advantages and 
disadvantages of being involved in a collaborative MMS. 
A variety of perspectives were encountered. Six GPs expressed a positive 
overall view about the MMS, with strong pockets of support in one of the 
pilot areas. Those GPs reported that the project was going well; it was 
encouraging collaboration with the local community pharmacists, enabling 
them to build a rapport and utilise the pharmacist's knowledge. However, 
eight GPs expressed more ambivalent views about the MMS, stating that 
the concept of the project was good, but practical issues such as poor 
patient recruitment and the lack of shared computerised medical records 
had impinged on the success of the project. The remaining seven GPs 
were more negative in their assessment of the service. This was due to a 
number of factors, including the belief that it had made little impact on the 
management of their CHD patients and it was often duplicating work that 
had already been carried out within the practice. An increase in workload 
and paperwork associated with the project, particularly in the initial stages 
were also seen to be negative aspects. The following quotes illustrate the 
range of views given by the GPs about their actual experience of being 
involved in the MMS. 
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"I thought it was a good way forward, I thought it was a good first step for 
us to be working together as a team." (GPOl) 
"It's generally working reasonably well. I like the involvement of the 
community pharmacist. However, I think one of the major drawbacks, 
because they're not operating and using the same record system, they're 
not aware of what ~ e e are doing always and therefore that limits it." (GP02) 
"I don't think it has made a blind bit of difference." (GP18) 
These data suggest that more GPs were ambivalent or negative about the 
MMS than those that were positive. 
7.8 Motivation to participate in the MMS 
A variety of factors were identified by the GPs, which had motivated them 
to participate in this project. Four GPs stated they had seen this type of 
service as a chance to improve collaboration with the local community 
pharmacists, which they perceived to be good. Two GPs stated they had 
participated because it was an adjunct to other work carried out within the 
practice. Three GPs stated their practices had participated in the project as 
they hoped it would help improve services for their patients. They believed 
that having community pharmacists' input into reviewing patients' 
medication could potentially improve patient compliance, rationalise 
medicines, and be more convenient to the patient, as they could have their 
medication reviewed at the pharmacy rather than the GP practice. This 
could be particularly beneficial if the patient had a good relationship with 
their local community pharmacist, as it was an ideal opportunity for the 
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community pharmacist to become more involved in reviewing their 
medication . 
., .... They are often ... the patients are quite attached to a local pharmacy 
business. Things like Boots, where there is different pharmacists in, and its 
not their own business, that's a bit different, but local little pharmacists 
running their own shops are sort of little pillars of the community and that 
area of the community are quite attached to that person and trust them. 
So we thought that would be a way forward since we were using 
pharmacists a lot anyway in our surgery we thought well ok it seems a 
good idea to use them out in the community as well if they are willing to do 
it." (GP12) 
Just over a third, of GPs stated they had got involved in the project after 
being approached by the peT to take part, or because partners in their 
practice had shown an interest. However, three GPs stated that they felt 
obliged to take part in this project even though they believed the project 
would not be beneficial to their practice, or the project held little interest to 
them. 
"Because we were part of the primary care collaborative project and we 
didn't have much choice in the matter. I think at the beginning we felt we 
didn't need it for our practice." (GP03) 
Nearly all the GPs interviewed stated they had had little input in to the 
project and had only ever attended the launch meeting, with several GPs 
stating they had attended no meetings10 • This suggests that despite GPs 
10 community pharmacists and GPs were initially invited to attend a launch meeting which 
aimed to give an overview of the CPMMP. Subsequent meetings were held during the course 
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citing a variety of reasons why they had become involved in the project, 
the majority of the participating GPs did not become actively involved in it, 
perhaps suggesting they did not view this project as a high priority. 
7.9 Clinical recommendations 
To assess whether the clinical recommendations GPs had received from the 
participating community pharmacists had been appropriate and beneficial, 
all the GPs were asked to provide feedback. Nine GPs thought they had 
received recommendations which had been appropriate. Within this 
feedback, one GP stated they were surprised that the majority of the 
recommendations were not concerning CHD medication, and although 
appropriate they had not set enough time aside to review other medication 
issues. One GP thought the recommendations they had received from the 
community pharmacists had been adequate in the CHD area, but they had 
concerns regarding their knowledge in other clinical areas as they thought 
the recommendations were not as evidence based. Two GPs stated that the 
CHD recommendations although appropriate were just duplication of work 
that had already been carried out within their practice but acknowledged 
they had found recommendations in non-CHD areas useful. 
Four GPs stated they had received a mixture of appropriate and non-
appropriate recommendations from the community pharmacists. One GP 
acknowledged that the lack of medical notes might have caused this to 
occur. 
of the CPMMP to provide participants with an update of the progress of the project but 
participation was voluntary. 
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"They have generally been appropriate except where things have been 
thought about before. So for instance, they might say: "Why is a patient on 
this drug?" When there are indications that we have in our records that say 
why this decision was taken." (GP02) 
One GP stated that the majority of recommendations they had received 
had not been helpful, as the recommendations had been things that they 
were already aware of or knew. 
"There has been lots of lengthy comments about side effects and things, 
which we know already. Like .... "Did you know ibuprofen causes stomach 
upsets?" Not much of the stuff I have seen has been helpful." (GP03) 
Five GPs stated they could not comment on the appropriateness of the 
community pharmacists' recommendations. This was due to one GP not 
knowing whether the recommendations had come from the practice or 
community pharmacist, three GPs not receiving any recommendations from 
community pharmacists and one GP stating that their practice pharmacists 
had generally dealt with the recommendations. 
"It's very, very difficult. .. the doctors haven't really done it because it's gone 
through to our pharmacists." (GP12) 
Fifteen GPs interviewed thought the majority of their patients were already 
on the recommended regimen of drugs for CHD (the remaining GPs never 
clarified this). However, two of these GPs acknowledged that it was still 
useful to have another professional review the management of their 
patients, because until a mistake was highlighted then they tended to think 
their patients were on the correct regimen of medication. 
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"The trouble is you always think your patients are on the correct treatment 
and I think its only when somebody points out has this person had their 
cholesterol done that you think oh, right ok and that's why I think it's quite 
useful with another professional looking at your management because you 
tend to think that you do things ok." (GPll) 
These data suggests that the majority of GPs thought that their CHD 
patients were already on the correct regimen of medication and were 
ambivalent about the recommendations they received from community 
pharmacists. Once again, the data suggests that some GPs perhaps did not 
view this project as a priority as they had left the practice pharmacist to 
deal with community pharmacists' recommendations. 
1.10 Perceived advantages of community pharmacists 
carrying out a MMS 
GPs were asked to comment on the perceived benefits of community 
pharmacists carrying out a MMS. Nineteen of the GPs thought the MMS had 
a positive affect on patients, in that it allowed patients another point of 
contact, especially for patients that were fearful to see the GP. They also 
believed it had helped patients to understand their medicines more. One 
GP thought patients were sometimes uncomfortable discussing problems 
about their medication because they did not want the GP to be displeased 
with them and, as a result, they did not talk about medication issues with 
their GP. This particular problem could potentially be avoided if the patient 
had the opportunity to discuss their medication with community 
pharmacists. The following quote illustrates this pOint. 
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"The patient also feels that sometimes it's difficult to bring a little thing 
back, like she doesn't like a tablet or he doesn't like a tablet, I had better 
not tell the doctor because there's a socially desirable situation going on as 
well. So the patient coming in has to work out whether they think we will 
approve or disapprove and if they think we will disapprove they won't tell 
us, but if they think we are ok we might approve they will tell us, but there 
is a lot of people out there who actually feel that it's not appropriate to be 
talking about that with the GP." (GP06) 
Twelve GPs reported that they had received feedback from their patients 
regarding this project. In all but two of the cases, the GPs stated that the 
feedback received had generally been positive. This was mainly because 
patients had appreCiated and enjoyed someone taking an additional 
interest in them. Two GPs stated they had received feedback from patients 
that it had been a waste of time. 
"Certainly the patients that came in to us, their only comments was that 
we were wasting their time and they felt it was built up to be something 
really wonderful and when they got it, it wasn't really anything at all." 
(GP18) 
Other perceived advantages for community pharmacists providing a MMS 
were thought to be the potential to reduce the GP's workload. Three GPs 
hoped that community pharmacists having a larger role in reviewing 
patient's medication would free up time for them. It was also 
acknowledged that this was a role that they currently did not have time to 
do and consequently, they were only getting 'snap shots' of the potential 
problems patients were experiencing with their medication. 
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Five GPs believed that community pharmacists had the advantage of 
knowing whether patients were collecting their prescriptions, and were 
therefore often more likely to know than the GP whether patients were 
taking prescribed medication on a regular basis. GPs acknowledged that 
once they had written a patient a prescription, they often had little idea 
whether patients actually took this medication. Community pharmacists 
having this greater 'ground knowledge' could aid a patient's compliance, as 
the pharmacists could alert GPs when patients were not collecting 
prescribed medicines. Three GPs also believed that in providing a MMS, 
community pharmacists would provide a double check on patient's 
medication, and could have a role in providing lifestyle advice, alerting the 
GP if problems arose. 
"Well there will be sort of more consistent advice because they tend to go 
to a pharmacist not just for their medication but for other things. I think 
you tend to find the pharmacist tend to have in general more sort of 
ground intelligence, which GP's don't always have. So I think from the 
point of view of actually managing their life style as well, pharmacists can 
have quite a great impact," (GP16) 
Three GPs saw no real advantages to community pharmacists providing a 
MMS, other than highlighting a few patients that they needed to follow-up. 
One of these GPs acknowledged that community pharmacists providing a 
MMS in a non-computerised practice probably would have been useful. 
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7.11 Concerns and barriers to community pharmacists 
undertaking a MMS 
Participating GPs were then asked to identify any key difficulties they had 
encountered whilst undertaking this project. GPs were then asked to 
identify any barriers or further concerns they had over community 
pharmacists undertaking a MMS. Despite GPs hoping that a MMS led by 
community pharmacists would reduce their workload, the most common 
difficulty encountered by half of the GPs had been the workload impact. 
GPs commented on the amount of administrative work that either they or 
their staff had to undertake at the beginning of the project, which had been 
both timely and laborious to complete. Other GPs commented on the 
amount of paperwork they received as a result of the pharmacist 
recommendations. Their main comment was that they had not been 
expecting to receive so much paperwork and as a result it had taken them 
longer than anticipated to go through the recommendations and act on 
them. This perhaps indicated the GPs' main interest in being involved in 
this project had centered on how the MMS could have helped reduce their 
workload. MacRae et al (2003) concluded that whilst the majority of GPs 
considered a PLMR as a useful service, views were divided between GPs 
who perceived the PMLR had increased their workload and those who 
believed it reduced workload overall. To some GPs, the time to deal with 
the extra workload appeared more of an issue than the perceived 
importance of the PLMR service. 
"On the basis of what has come out of this last project it has just actually 
made my life busier and been an increased workload and I don't think it 
has taken anything off my workload. " (GP15) 
214 
A second concern held by over a third of GPs, was that the work 
undertaken by the community pharmacist in this MMS had already been 
carried out within the practice, therefore it was merely duplicating work. 
This further precipitated the workload issue as GPs were spending time on 
patient issues that had often had been covered. In some instances, GPs 
were frustrated that community pharmacists were making clinical 
recommendations that they had already considered, as demonstrated by 
the following quote. 
"Again 1 suppose we felt just because of the area that it was just 
duplication, again you know if they're not on aspirin, there is obviously a 
good reason why they are not on aspirin." (GP09) 
Two GPs acknowledged that duplication had occurred because often the 
participating community pharmacists were not aware what had already 
been done for the patient. For example, whether a particular medication 
had been tried because they did not have access to the patient's medical 
records. 
"1 think one of the problems could have been that what the pharmacist was 
doing he didn't really have access to our medical records so they seemed 
to be going over a lot of old things that we had covered anyway." (GP08) 
Three GPs believed that access to shared records would be imperative to 
operate this type of service effectively, and to reduce the confusion that 
could occur if a community pharmacist was having a greater role in 
reviewing patients' medication. 
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7.ll.l Commercial interests of a community pharmacist 
The literature suggests that many GPs see community pharmacists 
primarily as business people, shopkeepers or special retailers (Adamacik et 
ai, 1986; Spencer and Edwards, 1992; Ellis et ai, 1992; Hughes and 
McCann, 2003), and this represents a conflict of interest when community 
pharmacists undertake health care roles. For example, in both Ellis et al 
(1992) and Spencer and Edwards (1992) study, approximately a third of 
GPs questioned thought commercial pressures biased the pharmacist's 
advice. In this project, two GPs stated this was a concern held by them, 
and two GPs implied that this was a concern, although on further 
questioning they would not clarify whether this was a concern. These GPs 
believed that the advice community pharmacists provided to patients could 
be affected by a commercial interest. The following quotes illustrate these 
concerns. 
"The difficulty I have really is trying to be certain that their advice is not 
commercially related." (GP19) 
"So I think the money making thing, about selling the product that either 
they make the most money from or they want to get off their shelves I 
don't know which it is, I have no idea." (GP18) 
As a consequence, these GPs were often suspicious of the advice they 
received from community pharmacists as they believed products were 
recommended to make a financial gain. Two GPs gave examples of how 
they believed community pharmacists had tried to make a financial gain 
when providing them with prescribing advice. The descriptions also 
suggested that these GPs believed community pharmacists gave either 
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inappropriate or dishonest advice so they could make a financial gain. The 
first quote describes how the GP believed the community pharmacist had 
given inappropriate advice in order to sell a more expensive product to 
them. 
"I'm not sure. Obviously the audit commission survey was showing people 
getting inappropriate advice. Certainly when I have gone to pharmacies for 
my children I have been persuaded to buy things, which you know like 
MedisecJ® for example, which I don't believe in they're telling me it is better 
than CalpoJ® and things like that. And patients tell me that's what 
pharmacists tell them." (GP18) 
The second quote describes a situation whereby the GP believed the 
community pharmacist has not been totally honest about a supply problem 
with a particular medicinal product. As a consequence, the GP believed the 
pharmacist had made a financial gain through their advice. 
"Well yeah, it's a little bit difficult because if I get contacted and say so and 
50 is no longer available, I suggest you prescribe X and you find X is a lot 
more expensive than what has just been discontinued, then you find it was 
a temporary supply problem and you think now hang on a minute, this 
repeat prescription has now been changed, it is going to be difficult to 
change it back again and a commercial gain has been made as a result of 
that advice. I'm thinking "Well hang on a minute!" Did the pharmacist 
know that it was a temporary problem? (GP19) 
Hughes and McCann (2003) concluded that the commercial aspect of 
community pharmacy could create perverse incentives for community 
pharmacists to sell more medication. They also argued that the commercial 
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aspect influenced GPs' views on pharmacist prescribing because they 
believed community pharmacists would prescribe more medication. One GP 
in this project stated that unless the commercial element was excluded 
from a community pharmacy, it would represent a conflict of interest and 
present a barrier for community pharmacists to undertake a medicines 
management role. The following quote is from a GP who describes a 
project in a neighbouring town where community pharmacists were issuing 
OTe medication free of charge. The GP believed that this project was more 
credible, as the financial gain had been removed. 
"Well yes it does because the commercial side keeps rearing its head. 
Where the commercial side of things has been cut out completely is at a 
neighbouring town to here is XXXX. They have got a project going whereby 
the pharmacist can actually issue OTe medication free of charge, so there 
is no commercial difference." (GP19) 
Although only a small number of GPs stated that the commercial aspect of 
community pharmacy was a concern, these data have demonstrated that 
for some GPs this concern affects how they view community pharmacist's 
clinical advice or recommendations. 
7.11.2 Access to medical records 
Participating GPs were asked if they would be willing to allow community 
pharmacists access to medical records. This was pertinent, as GPs had 
previOusly acknowledged that community pharmacists not having access to 
medical records would limit their ability to undertake a MMS and 
duplication of work had occurred as a consequence. Eight GPs stated they 
would be willing for community pharmacists to have access to patients' 
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notes providing they had the patient's consent and the pharmacist could 
uphold patient confidentiality. It was acknowledged by three GPs that they 
already had practice pharmacists looking at medical notes. There were 
some practical concerns over how the community pharmacist would access 
the notes, and there was a general agreement that the practice would have 
to know the pharmacist. GPs also believed it would be unacceptable to 
have locum pharmacists looking at the notes. Whilst one GP did not object 
to community pharmacists having access to medical records they had 
concerns regarding a community pharmacist's capability to understand 
them, as illustrated in the following quote. 
"I would think pharmacists would have a bigger problem in trying to 
understand them! I mean I don't, again whether the training would let 
them cope with the medical records but I don't have a sort of emotional 
problem with it." (GP17) 
Six GPs stated they were unsure whether community pharmacists should 
have access to patient medical records, while two GPs stated they were 
against this idea. Their concerns all centered around patient confidentiality, 
as pharmacists would have access to information outside medication 
issues. GPs stated they guarded their patients' privacy very carefully and 
believed it would be difficult to 'police' the information that the community 
pharmacist was obtaining about a patient. The following quote illustrates 
one GP's concerns about community pharmacists having access to patient 
medical records. 
"Yes and no. I think the whole area then that opens up is all the areas of 
confidentiality and people who are not actually part of the GP primary care 
team, who have access to confidential medical records, which may include 
50 and 50 is having an affair with 50 and 50, who might happen to be the 
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pharmacists neighbour, you know. It may not. .. it's a most unlikely scenario 
but our duty first and foremost to all o,-!r patients is confidentiality." (GPls) 
Several pertinent themes can be identified from this quote. Firstly, this GP 
did not consider the community pharmacist as a member of the primary 
care team. This was mainly due to the community pharmacist not being 
located within the GP practice and perhaps (although this was not 
substantiated) because they were not under the direct supervision of the 
GP. However, only this particular GP made this reference therefore it is 
difficult to discuss this theme further as it appears as an isolated case. 
Secondly, there was no consideration by this GP that a community 
pharmacist had their own code of professional ethics, which state they 
should respect and protect patient confidentiality (Royal Pharmaceutical 
Society of Great Britain, 2005). During the course of the interviews it 
became apparent that GPs had little knowledge regarding a community 
pharmacist's professional responsibilities regarding confidentiality issues. 
Only two GPs made reference to the fact that community pharmacists were 
also professionals and would be bound by a confidentiality code. 
"Again the pharmacists are professionals they're not just anybody looking 
at records and are bound by the codes of confidentiality in any case. " 
(GPll) 
However, it should be noted that even though one of the GPs 
acknowledged that a community pharmacist was bound by a code of ethics 
to uphold patient confidentiality, they stated that they were against 
community pharmacists having access to a patient's medical records. The 
following quote demonstrates this. 
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"Obviously the pharmacist is another professional working with that patient 
but I feel looking through the medical records I don't know just because 
obviously it's going to contain information that has got nothing to do with 
the medication." (GP09) 
These data suggest that the majority of GPs had varying degrees of 
concern about community pharmacists having access to patients' medical 
records, due to issues surrounding patient confidentiality. This concern held 
by GPs could potentially be a major barrier for community pharmacists to 
conduct medication reviews fully. 
7.11.3 Communication of clinical information between community 
pharmacists and GPs 
Participating GPs were asked to comment on how they had received the 
clinical recommendations from the community pharmacists during the 
project. They were then asked to comment whether they found this form of 
communication acceptable. Seven GPs received all the clinical 
recommendations via post and had no face-to-face contact with the 
participating pharmacists during the project. The majority of these GPs 
claimed they were happy to receive recommendations via post as often it 
was more reliable than receiving a verbal recommendation because they 
had evidence of the recommendations. It also gave GPs the opportunity to 
respond the interventions at a time convenient to them. One GP, although 
happy receiving written recommendations, stated that after the pharmacist 
had received their comments then a telephone call may have been useful 
to confirm and discuss the comments. 
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Two GPs stated that they would have liked some face-to-face contact with 
the participating pharmacists. One GP stated that there had been some bad 
feeling between a particular pharmacist and their practice and believed a 
face-to-face meeting may have helped eased the tensions, as both parties 
would have had the opportunity to discuss their needs and requirements 
from the project. The other GP worried that the community pharmacists 
may have thought their comments were abrupt, particularly if their 
suggestions were being declined. They believed that a face-to-face meeting 
would have given them a chance to explain the reasons behind them not 
following recommendations. 
"Well I wonder whether they'd like that, because sometimes I feel you 
know we actually putting messages on the forms and sometimes I think 
well perhaps they are a bit abrupt if you say no this patients being seen at 
hospital and were under review, and that sort of business, when actually 
their points are very valid." (GP06) 
Three GPs stated that they had face-to-face meetings to discuss the 
pharmacist's recommendations and all were happy with this method of 
communication, although one GP stated they also would have liked written 
confirmation of the recommendations to supplement the meeting. The GPs 
stated that they found this method of communicating recommendations 
satisfactory, as it allowed them the opportunity to explain more difficult 
cases. For example, why certain medications were not being used in 
individual patients. 
Three GPs stated that they had received recommendations by post and 
face-to-face. One GP stated they liked having face-to-face meetings but 
acknowledged that the time involved could be an issue. The other two GPs 
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stated that they currently communicated a lot with their community 
pharmacist, so they were used to the community pharmacist phoning them 
up about patients. 
"I quite like the direct contact really, but that's a time issue for both the 
pharmacist and myself, as I say it's quite nice to be given something. It 
takes quite a lot of the pharmacist's time and I think it's quite nice for 
them to realise that we do appreciate what they have been doing." (GPll) 
The remaining GPs had either not received any recommendations, or were 
ambiguous in their comments and therefore could not be represented. 
However, from the feedback obtained the data suggests that some GPs 
would have welcomed more face-to-face communication with the 
community pharmacist. 
Despite the majority of GPs being satisfied with how the recommendations 
had been communicated, four GPs still held concerns over how clinical 
information potentially would be communicated between the GP and the 
community pharmacist, if the community pharmacist had a larger role in 
reviewing medication. These concerns centred on the patient having to 
pass information between the two parties. This, they feared, could lead to 
confusion about what the patient was actually taking and what the patient 
perceived they were taking because there had been inadequate 
communication between the GP and community pharmacist. 
" Yes there is communication issues and there is what patients perceive 
they're being told, and then you mixed messages and the GP said one 
thing and the pharmacist said something else and maybe they didn't, it's 
just misconceptions and again it all boils down to communication." (GP12) 
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In addition, three GPs also reported that although some of the 
recommendations they received throughout the project were appropriate, 
they had put the GP in a difficult position due to the manner in which they 
were communicated to the patient. This had usually been because patients 
were expecting medication changes to occur as a result of seeing the 
community pharmacist. In some instances, GPs reported that patients were 
expecting changes to medication despite having already discussed these 
changes with their GP. As a consequence, the GP was then required to 
reiterate this information to the patient which was both frustrating and 
time consuming for the GP. 
"Because I think part of the difficulty was this wasn't a case of the 
pharmacist interviewed the patient and then sent me the 
recommendations. These recommendations were discussed with the 
patient. The patients came to me expecting me to make those changes in 
their medications, which put me in a very difficult position in a lot of 
instances." (GP19) 
These data suggest that a small number of GPs were concerned about the 
potential for the MMS to cause either confusion for the patient or 
undermine the patient/GP relationship. 
7.11.4 The role of community pharmacists in medication reviews 
During the interviews, four GPs raised concerns over the appropriateness 
of community pharmacists conducting a medication review. On further 
questioning, two of these GPs stated outright they did not believe 
conducting a medication review was the role of the community pharmacist. 
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Their concerns centred on the pharmacist having the responsibility of 
changing a patient's medication. They acknowledged community 
pharmacists could have a role in some aspects of reviewing a patient's 
medication, for example, checking a patient's compliance but they believed 
they should not have the responsibility for changing medication. The 
following quote illustrates this. 
n ... Now I'm not sure the pharmacist is the best person to do that, they can 
actually check the drugs they're taking, that they're complying but I'm not 
sure they are the person to have the responsibility for changing 
medication." (GP1S) 
It should be noted that community pharmacists in this MMS were only 
recommending changes to a patient's medication regimen, the GP still had 
the overall responsibility and decision regarding whether clinical 
recommendations were implemented. This suggests that some of the GPs 
had a poor understanding, or had misunderstood the role of the community 
pharmacist in this MMS. The interviewed GPs were not specifically asked to 
comment about their views on community pharmacists having the 
responsibility of changing medication or prescribing medication, these 
concerns were voiced independently by some GPs. 
The data suggests that GPs had further concerns about community 
pharmacists providing medication reviews. GPs had concerns that 
community pharmacists often did not know patients well enough to make 
decisions over their medication and therefore, should not have this 
responsibility. Two GPs believed that community pharmacists could follow 
straightforward clinical guidelines regarding medication but stated patients 
were more complex than guidelines. One GP also believed community 
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pharmacists should not need to undertake a MMS role if the GP was 
carrying out their job correctly. The following quotes illustrate the views of 
GPs about the complexity of patients and medication. 
"As I say they're following fairly clear and straight forward guidelines, 
patients are often more complicated than guidelines and patients often 
have a long history so when they see a patient for however long they see 
a patient I am not sure how long it is, they're not aware necessarily of a lot 
of time and work that's gone in before over some years." (GP02) 
"I mean I think getting medication right is quite complicated and it 
depends on quite a lot of medical historical information and unless they 
have got the whole set of notes and they are sitting down with the patient 
and got to know them over a period of time they can't do that." (GP15) 
One GP had concerns because community pharmacists were not based 
within the GP practice. This meant that GPs had no control over what work 
they carried out regarding medication reViews, nor did they know exactly 
what they were doing. They compared it to having district and practice 
nurses and stated they found it easier to work with practice nurses because 
they were based within the GP practice and could oversee their work. 
"I want to know what's happening and it is always ... it is just like asking a 
district nurse to do something rather than asking a practice nurse to do 
them. There is an enormous difference because the practice nurse is based 
within the practice and basically we are responsible for the quality of her 
work you know what you get done. While with a district nurse if you ask a 
district nurse to do something it is very different. You are not responsible 
for what they do, you can't control the quality of what they do and 
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sometimes it gets done and sometimes it doesn't and sometimes it's done 
well and sometimes it isn't, which is not the case for practice nurses 
because you know what you get." (GP18) 
This particular GP also had concerns regarding the cost involvement of 
pharmacists undertaking medication reviews, and believed other members 
of the primary care team could undertake this role more cheaply. They 
suggested either a nurse or healthcare assistant as a cheaper and 
therefore more appropriate person to be undertaking a MMS. 
GPs were also concerned that if community pharmacists had a larger role in 
reviewing patient medication, this could cause a fragmentation of 
responsibility and care in terms of who was prescribing and who was 
responsible for those prescriptions. Three GPs specifically stated they had 
concerns about community pharmacists having a role in prescribing, 
arguing that it would be difficult to manage their patients if more than one 
person was prescribing for them. They feared it could potentially lead to 
confusion over what a patient should be taking. They therefore believed 
there should be one person responsible for issuing and adjusting 
medication. There were also concerns that it could cause conflict between 
the two professions if they both had a role in reviewing medication. One of 
these GPs also believed that legally doctors and pharmacists should not 
work too closely together in case they were deemed to be conspiring with 
each other. 
"I mean to a certain extent you know we have always had this divide that 
legally implies that you know you shouldn't be too close to the pharmacist 
in case it was felt that we were colluding." (GP17) 
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These data suggest that GPs had a variety of concerns about community 
pharmacists conducting medication reviews. These included lack of 
knowledge about patients' clinical history, fragmentation of responsibility 
for patient care, and anxieties over not being able to oversee the work of 
community pharmacists. 
7.12 Future roles for community pharmacists 
During the course of the interviews, GPs often stated the roles that they 
believed community pharmacists could undertake that would be more 
beneficial to help reduce GP workload and benefit patient care. Four GPs 
believed that community pharmacists could have a much larger role in 
managing patients' repeat medication. GPs stated this was an area that 
was often poorly managed within their practice and was a considerable 
workload for them. It was proposed that community pharmacists could 
help make sure patients ordered their medicines at the correct time and 
have a system where they collected tablets from a community pharmacist 
over a set period of time, with the community pharmacist referring them to 
the GP if problems arose. The following quotes illustrate this. 
"Again you can take quite a bit of the workload off the doctor because I 
know in quite a lot of countries where patients have to come for 
prescriptions every four weeks and meaning they take a prescription for 
maybe six months to the pharmacist and collect their tablets every one or 
two months." (GP20) 
"I wouldn't like to see them necessarily changing medication but I think 
they can go a long way helping to rationalise their medication, especially in 
things like if they are on a monthly prescription but each drug is ordered at 
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a different time, you know trying to tie it all up together and 1 would be 
happy to have a system where we didn't have to necessarily sign a 
prescription every month." (GP10) 
One GP thought that community pharmacists could have a role in patients' 
medication post hospital discharge, as they believed this was often a time 
when patients required help and education on their medication due to 
changes made during their inpatient stay. Another GP suggested a system 
whereby GPs referred patients, particularly the elderly, on poly-pharmacy 
to the community pharmacist for their input. One GP stated their practice 
pharmacist was already reviewing all the medication for the over '65's' on 
more than four medicines and this was proving to be very effective. This 
particular GP acknowledged that doctors should attempt to find out what 
pharmacists could do so they could utilise their help. This is shown in the 
following quote. 
"I think there should be closer co-operation; it would be 1 think we as 
doctors should get to know what pharmacists should be able to do and 
actually we ought to be, I would like to see a situation where we are 
sending people to the pharmacist for their input." (GP06) 
These data shows that GPs were often suggesting roles for the community 
pharmacist to undertake that had little autonomy. Once again, GPs made 
reference to the fact that they would not like to see community 
pharmacists having a role in prescribing. 
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7.13 The suitability of the community pharmacy premises 
GPs were asked if they thought a community pharmacy was an appropriate 
setting to be conducting a MMS. Over half of the GPs thought that a 
community pharmacy was adequate providing there was a private 
consultation room to carry out the review. However, four of these GPs 
commented that currently many pharmacy shops would find it difficult to 
provide a confidential area because they did not have the space. This 
would be an issue that needed addressing if a MMS were to be conducted 
from a community pharmacy, as having a confidential area was imperative 
to undertake this type of role. 
However, two GPs believed that the consultations should be carried out 
within the GP practice. They believed it would make it a more efficient 
process due to the patient information being held at the GP practice. 
Furthermore, discussions with the patient could be recorded on the GP 
computer system, which would help reduce duplication of work. 
"1 think it has to be the most efficient. 1 can't see the prescription review 
outside the surgery could possibly be more efficient than one within the 
surgery because it just puts an extra wing on it. Which I think when it is 
done within the surgery you know the prescriptions, you know the 
information is on the computer system, which if obviously someone outside 
has done it then that information has then got to be put on our computer 
system, otherwise we are not going to know it is done and we are going to 
repeat it and I think that is a problem." (GP18) 
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7.14 Attitudes towards the future development of a MMS 
GPs were asked to give their views about whether they would support a 
MMS being rolled out nationally. Mixed views were obtained, with six GPs 
stating they would support a MMS being rolled out as they believed 
community pharmaCists could have a larger role in reviewing patient 
medication. They believed this would benefit patients and improve working 
relationships between GPs and community pharmacists. As a result of this 
project, one pilot site was currently undertaking a second medicines 
management project within their area. Seven GPs had mixed views as to 
whether the MMS should be rolled out for a variety of reasons. Two of 
these GPs believed that there were other projects that would be more 
beneficial to conduct nationwide, for example increasing the availability of 
the emergency hormonal contraceptive pill. The other GPs had concerns 
about the current model not working, particularly around access and 
communicating clinical information. Three GPs stated that they would not 
support a national roll-out of the MMS because they were not convinced 
this type of service was required in practices, it was not deemed to be a 
priority and this model did not encourage medicines management to be 
undertaken as a team. The following quotes show a range of views 
obtained from GPs about the future development of a MMS 
"l can't see how it would damage the relationship between us I think it 
would actually bring us closer together and I think it would be beneficial to 
the patients." (GP08) 
"l see we have to improve medicines management as a team and I think 
having some separate project makes it worse not better, it is yet more 
paper, yet more bits, and you think. .. and actually it distracts you from 
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looking at the process as to how you manage medicines. How do you 
decide who gets managed by the pharmacist and who gets managed by the 
doctor?" (GP18) 
Over half of the GPs believed that if a MMS service was rolled out nationally 
and became a long-term service then it should be the PCT's responsibility 
to fund this type of service rather than the GP practice. 
"Oh right, no peT! We have difficulty enough extracting money for us 
without sharing it with anybody else!" (GP19) 
The majority of these GPs deemed a community pharmacist-led MMS to be 
a low priority for their practice if they had to fund the service. A variety of 
reasons were given including too many other things within their GP practice 
that needed addressing first, a practice pharmacist was already in place to 
do this type of service, not needing a pharmacist in the practice to review 
medicines because they were under-spent, and rating other members of 
the GP practice as more important than employing a pharmacist. The 
following quotes illustrates how a GP believed funding a receptionist for 
their practice was a higher priority than having a community pharmacist 
conduct a MMS. 
"But I mean in terms of getting this pot of money we are going to get in 
the future to run our practice I think the priorities for funding a pharmacist 
would be less than having a receptionist on the desk to see a patient. " 
(GP17) 
Although the majority of GPs were not opposed to the concept of a MMS 
being rolled out nationally, these data suggest that the GPs did not view a 
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MMS as high priority or a necessity within their practice if they had to fund 
the service. 
7.15 Summary 
Almost all the GPs stated they currently had a good relationship with the 
community pharmacists in their areas. However, the data suggested that 
when GPs had a particularly established working relationship, the GPs were 
more likely to be positive about community pharmacists' roles in medicine 
management. 
Whilst no GPs completely rejected the idea of a community pharmacist led 
MMS, they identified a number of attitude and organisational barriers that 
could prevent them from undertaking this role. These barriers included 
beliefs about the expertise of the pharmacist, their commercial interests 
and how this affected their clinical advice, potential communication of 
clinical recommendations and concerns over fragmentation and 
responsibility of patient care. There were also considerable barriers held by 
GPs towards community pharmacists having access to patient's medical 
records. 
A third of the interviewed GPs stated they currently had a practice 
pharmacist attending their practice. Although GPs were generally unable to 
explain how practice and community pharmacists differed, they were able 
to give an explanation by using task differentiation. These results 
demonstrated that the GPs interviewed had built a good working 
relationship with their practice pharmacist and as a consequence, practice 
pharmacists currently undertook a variety of clinical roles within the 
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practice. GPs were also more willing to let practice pharmacists have 
access to patients' medical records. These data suggested that 
participating GPs viewed the practice pharmacist's clinical abilities as 
different to that of a community pharmacist and perhaps as something 
unique to them. This finding supported Adamcik et al (1986) theory of 
clinical pharmacists being perceived by GPs as 'deviant' pharmacists. 
These data also suggested that this project had a minimal effect at 
improving relationships between the participating GPs and community 
pharmacists and in many instances GPs' perceptions of community 
pharmacists remained unaltered. This may have been due to the identified 
issues surrounding communication between the two professions and the 
minimal input that some GPs had in the project, which was confirmed by 
the lack of attendance to meetings and letting the practice pharmacist deal 
with recommendations sent by the community pharmacist. 
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8. COMMUNITY PHARMACISTS' OVERALL 
EXPERIENCES OF UNDERTAKING 
COLLABORATIVE WORK WITH GPS 
8.1 Introduction 
This chapter presents data from twenty-eight telephone interviews with 
community pharmacists, conducted at the end of the twelve-month 
intervention period. The interviews were carried out between January and 
February 2004. All the pharmacists interviewed had completed patient 
consultations, although the number of consultations conducted ranged 
from two to forty. This allowed all the interviewed pharmacists the 
opportunity to report their experiences. 
The first part of the chapter reports the data that focused on how the MMS 
had affected the relationships between the participating pharmacists and 
GPs. Pharmacists were also asked to comment whether they believed the 
project had altered GPs' perceptions of community pharmacists, and 
whether having a prior established relationship with the GP had impacted 
on the success of the project. The interviews also explored pharmacists' 
general assessments of the MMS, as well as their achievements from taking 
part in the MMS and the follow-up undertaken of patients over the twelve-
month intervention period. Finally, the barriers and difficulties encountered 
throughout the project were investigated. These data have been reported 
in the second part of the chapter. 
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Finally, in the last part of this chapter, pharmacists were asked to share 
their views about whether the medicines management model was 
sustainable in clinical practice on a long-term basis. As with the previous 
two results chapters, I have used numbers to help quantify and support the 
points that I have reported. The key themes are reported in the following 
sections. 
8.2 Community pharmacists' relationships with GPs 
Pharmacists were initially asked to comment whether they thought being 
involved in the MMS had affected their relationship with the local 
participating GPs, and whether they thought the project had enhanced 
their status as a health professional to the GPs. Finally, they were asked to 
comment whether they believed having an established relationship with 
their local GPs impacted on the success of a MMS. 
As reported in the earlier pharmacists results chapter (refer to chapter 6), 
twenty two pharmacists reported they had a good, or satisfactory working 
relationship with their local GPs prior to the MMS commencing. The 
remaining pharmacists stated they had dealt with GPs in the project that 
they had no prior relationship with. Sixteen pharmacists thought that as a 
result of being involved in the MMS, their relationships with some of the 
participating GPs had been enhanced to some extent. In these Instances, 
the majority of these pharmacists stated that relationships had often only 
improved slightly, and had usually only improved with one or two GPs in a 
practice. This was usually due to the fact that these GPs had been 
designated to deal with the MMS intervention forms, and therefore were 
the only GPs that they had had contact with. Three pharmacists thought 
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that relationships had particularly improved with GPs that they had 
previously not known very well prior to the project commencing. 
"I'd got a fairly good relationship with them but, yes, 1 would say probably 
with the ones that I wasn't quite so familiar with, yes." (P02) 
Four pharmacists stated that as the project had allowed them to meet in a 
semi-social environment, it had encouraged communication between the 
two parties and this had resulted in their relationship with their usual GPs 
improving. 
"1 think it has. I mean we have had two or three main meetings with the 
GPs that were on board so we have seen them more in a social, semi-social 
atmosphere and then just through the post-consultation referral process, 
again you feel you have got to know them more. Yeah certainly, I mean 
quite definitely know the ones that were on board better than 1 knew them 
before." (P21) 
Some pharmacists believed that as a result of their relationship improving 
with their local GPs, it was now easier to contact and convey information to 
them. Three pharmacists also believed that due to GPs gaining experience 
of receiving recommendations from community pharmacists, it had had a 
positive effect when they made clinical recommendations on patients not 
involved in the project. Muijrers et al (2003) concluded that improving the 
relationship between GPs and pharmacists would have a significant, 
positive effect on the attitude of GPs towards the pharmacist's care-
providing function. The following quote illustrates this pOint. 
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"1 just feel that 1 can pass on information to them more easily. You know 
it's easier to get hold of them, contact them and through this experience, 
knowing the kind of training 1 have now had and 1've had in this particular 
clinical area, they are willing to accept any comments or recommendations 
that 1 have for other patients outside of the project." (P04) 
However, eight pharmacists thought the MMS had little impact on altering 
their relationship with their local GPs, largely because they had very little 
contact with them during the project. This resulted in their relationship 
remaining the same, which in some cases was stated to be good. The 
following quotes illustrate these thoughts. 
"1 wouldn't say it's made much difference." (P10) 
"1've not got a bad relationship with them, far from it. 1 just didn't have 
any contact with the GPs. 1 mean ok 1 was filling the forms in but 1 actually 
got the impression the GPs were very sorry they had ever got involved in 
it. " (P38) 
On the other hand, two pharmacists thought the MMS had a negative 
impact on relationships between pharmacists and GPs. This was mainly due 
to the poor organisation and time delays associated with the project having 
an adverse effect on the participants. 
"I think it could have easily been handled a lot better and basically the 
relationships between pharmacists and GPs weren't improved, and in many 
aspects it had an adverse effect. " (P34) 
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Two pharmacists thought their relationship had improved with the 
participating practice's staff rather than the GP, as they had mainly dealt 
with these members of the practice and not the GP during the project. 
Likewise, three pharmacists stated that they had generally dealt with the 
practice pharmacist throughout the project, and as a result their 
relationship with the practice pharmacist had improved. 
"I wouldn't say the relationship between the GPs and myself had improved 
that much but possibly between myself and the surgeries if I can make 
that distinction ... 8ut also the practice pharmacists - we were dealing with 
them as well, so it did develop the relationship with the practice pharmacist 
and myself, maybe not necessarily the GPs. " (P06) 
The data suggests that just over half of the interviewed pharmacists 
believed that relationships with some of the participating GPs had improved 
to some extent, whilst the rest believed it had made no impact or had an 
adverse effect on their relationship. In many instances, increased 
communication was the reason stated as to why relationships had 
improved. 
With regard to the MMS raising the pharmacist's professional profile 
relative to the GP, seven pharmacists believed this had occurred to some 
degree. These pharmacists believed because they had had the opportunity 
to liaise with GPs and make clinical recommendations, this had 
demonstrated to the GP that they had appropriate clinical training and 
knowledge to undertake patient consultations. In one instance, a 
pharmacist reported that their local GP practice had approached them to 
undertake peT work. 
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"1 mean its been a way of introducing myself not just as the community 
pharmacist that works alongside them next door but its somebody who can 
get involved with, in helping them through certain reviews and stuff like 
that which they've obviously picked up on, and they want me to be their 
regular PCT pharmacist now." (P4l) 
In contrast to this, three pharmacists stated they already had a lot of 
contact with their local GPs and thought their local GPs already perceived 
them as a health professional. Therefore the MMS had had no impact on 
altering this perception. The remaining pharmacists however, believed the 
MMS had made little or no impact on how GPs perceived them. This was 
largely because they had either encountered uncooperative GPs, or there 
had been a lack of opportunity to make clinical recommendations from the 
patient consultations. The following quotes illustrate this. 
"To be honest 1 don't think GPs view me any differently unfortunately. You 
know it would be nice to think that they perhaps thought a bit more of 
pharmacists but I don't feel I've progressed in that quarter at all." (P40) 
"Very slightly, very slightly. 1 think the issue that we just had of raising 
their awareness of what we could do, that's good but like I say the actual 
communication from the GP was not brilliant in most cases. So my 
particular experience is yes it has raised my profile slightly." (P39) 
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The data suggests that if the pharmacist had the opportunity to increase 
their contact with GPs, or had the chance to demonstrate they could make 
clinical recommendations then this raised their profile to the GP. Again, this 
demonstrates the importance of increasing the contact between community 
pharmacists and GPs. 
Twenty three pharmacists thought having an established relationship 
impacted on the success of a MMS. Pharmacists believed that if the GPs 
already knew the pharmacist, they would be more likely to trust them and 
respond to their recommendations. Contacting GPs was also thought to be 
easier if the GP already knew the pharmacist, therefore making it easier to 
discuss patient issues. Likewise, pharmacists thought GPs were more likely 
to share information about patients if they knew the community 
pharmacist. Pharmacists also commented that they found it less 
threatening to make suggestions if they knew the GP because they knew 
how the GP would react to their suggestion. The following quotes Illustrate 
this. 
"/ just feel if they have got trust in the pharmacist, they are much more 
likely to take these things on board and share various factors, you know, 
across the telephone or face-to-face." (P21) 
On the other hand, four pharmacists were unsure whether an established 
relationship did impact on the success of a MMS. Pharmacists reported they 
had not needed to speak with their GPs during the MMS (so their 
relationship with them had not altered) and their clinical recommendations 
had been followed. However, they acknowledged GPs might be more 
receptive to pharmacists' recommendations if they knew the pharmacist 
involved. 
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"I wouldn't think it would be essential to have a good relationship but if 
you did it would help because at least they might take a bit more notice of 
forms that you send to them or if you had to speak to them. But I didn't 
actually have to speak to them about anything. But I think actually GPs can 
be quite shirty with pharmacists, they phone them up about things, so I 
think if you've got a good relationship in the first place then at least you're 
not going to have that barrier to overcome." (P38) 
only one pharmacist thought that having an established relationship had 
no impact on the success of a MMS, as they believed relationships could be 
built. Again, it was acknowledged by this pharmacist that it might be easier 
to carry out this type of service if there was an established relationship 
already in place between the pharmacist and GP. 
"No, I think you can build them. I think it makes it easier if you're got a 
good relationship because the contact's eaSier, you're more comfortable 
with it and they already know you and whether or not they trust you, your 
opinion. I think you can build that with somebody else so no, I don't think 
so." (P02) 
These data indicate that the majority of pharmacists believed that having 
an established relationship with the GP increased the success of a MMS. 
This suggests that it is imperative for community pharmacists and GPs to 
communicate more and develop relationships if community pharmacists are 
to undertake a medicines management role. 
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8.3 General assessment of the MMS 
In each of the interviews, pharmacists were asked to give their overall 
impression of the MMS and to summarise their experiences of participating 
in it. Eighteen pharmacists had a positive overall impression of the MMS, 
and there were strong pockets of support for the MMS in three of the nine 
pilot sites. 
"It has been extremely interesting; it has been a great learning process for 
my colleagues and I to have time to speak with the patients because we 
work in a very busy dispensing store, well two stores in my case. We have 
very little time to actually sit and spend with patients and it has been 
really, really good to do that. " (P39) 
Although there were indications that pharmacists had encountered some 
practical difficulties with the MMS, pharmacists generally thought the MMS 
had been interesting, rewarding and a good opportunity to improve their 
clinical knowledge. It had also allowed them the time to speak to patients 
in-depth, which often did not occur in their usual working day. 
Eight pharmacists had a mixed impression about the MMS, stating the 
concept of the service was good but practical issues such as lack of GP 
support, conducting few patient consultations and insufficient patient 
clinical information had impinged on the success of the service. 
"I thought in theory, it was really, really good but in practice 1 found that it 
didn't really work for me." (P26) 
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Two pharmacists had a negative overall impression of the service as they 
had found the organisation of the project had had an adverse effect on the 
participants involved, and it had not improved relationships between 
pharmacists and GPs. 
"I think it waned as it developed!" (P36) 
Likewise, almost all the pharmacists saw their involvement in a MMS as a 
positive experience, even though some had experienced practical 
difficulties such as time delays, lack of patient consultations and 
uncooperative GPs. The following quote illustrates this. 
"Well it's been positive in that I've been able to work with the GPs and 
nurses and also I've been able to get involved in other things because of 
the medicines management project, in different schemes that are running 
in the area, just because I felt I'd built up the confidence, built up 
confidence in this part of my work which means I can just get involved in 
other things." (P04) . 
One pharmacist however, stated they saw their involvement in the MMS as 
both a positive and negative experience. The positive aspects had been 
interviewing the patients and receiving GP's feedback, but the time delays 
experienced and the intervention forms being badly designed were seen to 
be negative aspects. 
The data suggests that the majority of pharmacists were positive about 
being involved in the MMS and saw the opportunity to participate in it as a 
positive experience 
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8.4 Motivation and achievements gained from undertaking a 
MMS 
As reported in the previous pharmacist results chapter (refer to chapter 6), 
the main motivational factor to become involved in this MMS was the 
opportunity to extend and develop the community pharmacist's role. 
Pharmacists hoped by participating in the MMS they would have an 
opportunity to have a greater clinical role and build relationships with 
patients and their local GP practices. 
Pharmacists were therefore asked to comment on what they had achieved 
by taking part in the MMS and whether they had achieved all of their 
objectives. Seven pharmacists thought they had learnt new skills and as a 
result their clinical knowledge on CHD had improved. For one pharmacist it 
had given them more insight into the problems patients faced with their 
medication, and one pharmacist thought they were now a bigger part of 
the primary health care team as a result of participating in the MMS. Five 
pharmacists thought they had achieved more confidence and job 
satisfaction, particularly when having to converse with patients and GPs. 
One pharmacist in particular believed that patients' confidence had 
increased in them as a result of participating in the MMS, as illustrated by 
the following quote. 
"Also has increased my confidence you know and also it has increased the 
confidence the patients have in me. " (P27) 
When pharmacists were asked if they had achieved their objectives, ten 
pharmacists stated they had not achieved them. A variety of reasons were 
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given, including the pharmacist not having the opportunity to conduct 
many patient consultations, not having the opportunity to have much 
clinical input into patients' medication regimens (as they were already on 
an appropriate regimen of drugs and following lifestyle advice), having 
uncooperative or uninterested GPs and personal circumstances, such as 
having to leave the project early. The following quotes illustrate this. 
"Well no because we didn't see enough patients for that." (P19) 
"l think that as I say the one thing that I would have liked to have come 
out of it would be that a little more I suppose respect ;s the word, from 
GPs. " (P40) 
Pharmacists were then asked to comment whether they believed that there 
was a need for MMS, as their feedback had indicated that they had not 
seen many patients, or made many clinical recommendations. Despite this, 
over half of the pharmacists thought that community pharmacists should 
be providing a MMS, as they believed there was a need for medicines 
management and their clinical training was under utilised in their current 
role. The following quote is from one pharmacist who despite not seeing 
many patients in the MMS, states that there that is still a need for the 
service. 
"l think there is a definite need for medicines management. I think it has 
been there for far too long and as pharmacists in general we have been 
meek to show our capabilities." (POS) 
However, two pharmacists stated that it should be the choice of the 
individual pharmacist whether or not to undertake a MMS. They 
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acknowledged that there would be a time commitment to undertake this 
role and it could prevent the community pharmacist from conducting other 
roles, which a pharmacist might consider to be more beneficial to the 
patient. Likewise, there would be some community pharmacists that would 
not wish to undertake this role. 
"1 think it depends on the community pharmacists themselves because I 
mean there would be some people who would be happy to do it and some 
people who probably wouldn't. /I (P43) 
Despite some pharmaCists not achieving personal objectives whilst 
undertaking the MMS, pharmaCists were still positive about the concept of 
a MMS. 
8.5 Community pharmacists' relationships with patients 
At the beginning of the MMS, pharmaCists cited the most significant benefit 
to providing a medicines management role was the opportunity to have a 
greater input into patient's care (refer to chapter 6). PharmaCists were 
therefore asked to comment how the MMS had impacted on their 
relationship with patients over the twelve-month intervention period, and 
whether their status as a health profeSSional to patients had increased. 
Nineteen pharmaCists stated new patient relationships had been 
established and their relationships with existing patients had improved as a 
result of participating in the MMS. Seven pharmaCists commented that 
patients involved in the project were now returning to their pharmacies to 
ask them more clinical questions. 
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"Oh it has with them particularly yes, 1 mean they come in now and we talk 
to them specifically, you know, because they come and ask you know more 
things so yes, it's good built up the relationship." (P10) 
One pharmacist had seen patients they had previously not known, as these 
patients did not normally use their pharmacyll. They believed the 
relationship that could be built between a community pharmacist and a 
patient was easier and more beneficial, if the pharmacist knew the patient, 
as it would support a relationship to develop over time. Two pharmacists 
did not think the MMS had impacted on their relationship with their patients 
because the consultations had been a one off event. 
"1 don't think it has made a deal of difference, 1 think the reason for that is 
because this is a bit of a one off thing." (P25) 
Nineteen pharmacists also thought this service had enhanced their status 
as health professionals in patients' eyes because it had given patients the 
opportunity to see the pharmacist having a more clinical role. Even though 
pharmacists thought they had a good relationship with their patients, they 
thought some patients perceived them as shopkeepers or dispensers and 
believed patients did not realise that a community pharmacist could 
undertake medication reviews. The following quotes demonstrate this. 
"1 think they were quite surprised that we have the knowledge and we 
were even engaging in sort of cooperation with the GPs on this. So yeah, 1 
think there was generally the view was that 'oh I didn't realise you would 
be able to do this!'" (P21) 
11 Some patients had a medication review conducted at a pharmacy they did not generally 
attend, due to their usual pharmacy either not being involved in the project or being 
oversubscribed. 
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"Well I already had quite a good relationship but I think its helped in terms 
of them seeing me as a professional person rather than a shopkeeper if 
you like. " (P44) 
Three pharmacists did not think this service had enhanced their status as a 
health professional to patients. One pharmacist had seen so few patients 
and another thought the service had had little impact. Both these 
pharmacists acknowledged if they had seen more patients or if the service 
had been ongoing that might have changed. The third pharmacist believed 
their patients already saw them as a health professional. 
"To be honest where I am personally concerned I don't think it has done an 
awful lot in that respect purely and simply because I think, I'm not trying 
to sound big headed, but I think the patients here, it is a vii/age 
environment and I think the patients basically treat me with professional 
respect anyhow." (P28) 
The data suggests that the MMS had a positive effect in helping to build 
and strengthen the pharmacist/patient relationship. It also had a positive 
impact in raising community pharmacists' professional profile, in that 
patients had the opportunity to see a community pharmacist undertaking a 
medication review. This perhaps suggests that because community 
pharmacists primarily spend their time dispensing medication, patients 
have no perception that they have the capability to undertake a more 
clinical role. 
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8.6 Patient medication reviews 
Pharmacists were then asked to provide their views about whether they 
believed their medication reviews had impacted on patients' knowledge 
about their medication and disease states. Over half the pharmacists 
thought their consultations had a limited impact on a patient's 
understanding of health promotion messages and their disease state. They 
believed this was due to the majority of patients seen to be well educated 
and motivated in these areas; therefore pharmacists believed they were 
often just reinforcing the information. This finding was reflected in the 
earlier pharmacists' data chapter (refer to chapter 6), whereby pharmacists 
stated that they had only reviewed motivated patients who required little 
pharmaceutical input. 
"Well some of them were very aware of them so you know it was a bit like 
teaching your granny to suck eggs." (P02) 
Likewise, pharmacists thought many of the patients seen were already very 
compliant with their prescribed medication so often they could have little 
impact in this area too. Although it was acknowledged that patients were 
generally compliant with their medications, pharmacists still believed it was 
worthwhile checking compliance as patients sometimes took medication 
incorrectly. This was reported to be usually due to a poor understanding as 
to why a patient needed to take a particular medication and the long-term 
benefits of complying with it. The pharmacists also believed the patients 
had enjoyed the opportunity to talk to another health professional and their 
understanding of their medicines had probably improved, which could in 
turn help patients make an informed choice about taking their medication. 
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"1 think that information allows a patient to make an informed choice and 
also to be able to say if you're not happy with the medication you're on 
then you should go back and have a word with your doctor or lets talk 
about it now. H (P29) 
Pharmacists believed that patients perceived their consultations differently 
to a GP's consultation, notably as having less power and more time than a 
GP (as reported in Chapter 6). There was a general agreement that 
patients were often more likely to speak to them about issues they would 
not talk to their doctor about. Pharmacists thought this was probably due 
to the patient finding them more approachable and less intimidating than 
the GP, and patients did not worry about 'pleasing' a pharmacist regarding 
their medication. However, one pharmacist also thought patients would not 
be truthful with the pharmacist regarding whether they took medication 
because the consultations were formal. 
"1 think even, because it's still formal sitting down with you know me doing 
it, they still wouldn't admit you know to a lot you know." (P10) 
One pharmacist stated they had concerns that if they tried to make their 
patient consultations too formal then patients would start to feel intimated 
and would not discuss issues with the pharmacist. 
"1 worry that if we formalise things too much then we lose the possibilities 
of keeping that intimate trust certainly that I have managed to build up 
with those patients. If we started to edge towards a GP style, come into a 
separate room with the door closed, tell me all about it, it gets a bit scary 
and I think they won't open up as much". (POS) 
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Pharmacists were also asked to comment whether they thought a thirty-
minute patient consultation could have an impact on a patient's health. 
Five pharmacists thought that a thirty-minute consultation could have an 
impact, providing the pharmacist had adequately prepared beforehand. 
However, it was acknowledged that patients would get more out of the 
consultation If there was a prior relationship between the pharmacist and 
patient, so the pharmacist did not have to spend time introducing 
themselves and explaining their role. 
"But as I say if the pharmacist has prepared adequately beforehand then I 
think you can achieve a lot in thirty minutes. I think to prolong it 
unnecessarily is actually going to be counter-productive because we are 
asking the patient to give up their time and if you end up keep getting 
them back and going round in circles or whatever, then they are going to 
lose confidence." (P28) 
On the other hand, some pharmacists thought that in order for it to have 
an impact, then it needed to be an ongoing process where patients were 
followed up at regular intervals. Pharmacists gave different time intervals 
that they believed were adequate time frames to have an impact. These 
ranged from seeing the patient four times after their initial consultation, to 
an annual, thirty-minute interview, to it being an on-going process. 
"My view is medicines management is an ongoing thing and can be 
practiced anytime the patient comes in. Again an informal chat with 
somebody as their repeat medication goes out could then turn into 'Look 
we need to talk about this a little more. Come back at a quieter time and 
we'll sit down and go through something'. " (POS) 
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The data suggests that pharmacists believed their medication reviews could 
have an impact on a patient's health, although there were mixed opinions 
regarding how often medication reviews should be conducted. However, if 
pharmacists are to undertake medication reviews as an ongoing service 
then they need to be able to commit and allocate time to undertaking this 
role. 
8.7 Clinical follow-up with patients over the twelve-month 
intervention period 
As reported in chapter 3, it was left up to the discretion of the pharmacist 
to follow up the progress of the patient over the twelve-month intervention 
period, determining the number of subsequent consultations based on the 
need of the patient. Pharmacists were therefore asked to provide feedback 
on whether they had followed up patients with subsequent, patient 
consultations. Four pharmaCists reported that they had arranged formal, 
subsequent meetings with some of their patients to follow up their 
progress. Two pharmaCists reported that they had followed up their 
patient's progress by telephone rather than a face-to-face meeting. 
"Well what I've tended to do is give them a phone call just to chat about, 
well that's what I'm doing for them now actually, but about a year on or 
sort of ten months on, just to check what's going on. But I mean I've 
followed them up from the initial if there's any action to change. I've 
followed them up then and told them what the doctors agreed to, and then 
I've left it to follow up about a year on." (POg) 
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Fifteen pharmacists reported that they had followed patients' progress 
opportunistically when patients had come into the pharmacy to pick up 
their repeat medicines. 
"1 mean I've spoken to them obviously because they're in and out of the 
pharmacy anyway and we have spoken about the day that we came and 
sat and told you about our tablets." (P44) 
Pharmacists also stated they had not followed some of their patients up 
during the intervention period. Six pharmacists reported that they had not 
had time to do formal patient consultations, particularly if they did not 
have a second pharmacist in place or had not received allocated cover. 
Seven pharmacists stated that they did not see the need to follow up their 
patients with a formal consultation, because with some of the patients they 
had not made many recommendations in the original consultation. 
"1 don't know that there was a definite need with a lot of the ones that 1 
had to do. So 1 mean there were some of them that 1 didn't actually make 
any recommendations on because 1 felt that what they were on probably 
was what they should have been on anyway." (P43) 
Eight pharmacists stated that they had not received recommendations 
forms back from the GPs. This therefore it made it difficult to follow up 
patients. 
"It was quite difficult really because if you hadn't had an intervention form 
back you know and quite a lot of them nothing happened anyway to what 
they were already on." (P18) 
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Three pharmacists stated they did not realise that they were supposed to 
be formally following up patients over the twelve-month intervention 
period. Four pharmacists also thought if formal, follow-up consultations had 
been required with every patient, then the payment they received during 
the project might not have been adequate. It was acknowledged that 
following up patients formally was potentially very time consuming. The 
following quotes illustrate this point. 
"1 mean 1 suppose the payment, if you had to do another hour and you 
know, another formal interview with every patient it would start being less 
attractive but with the phone follow up and the GP follow up plan and what 
have you, it's about right. /I (P09) 
On the other hand, one pharmacist thought pharmacists should not receive 
a payment for providing a MMS. They believed community pharmacists 
should have been providing this type of service anyway as part of their 
day-to-day role. 
"1 think that's part of the job I really do and it should just come under the 
globalism and to get additional fees it's wrong. /I (POS) 
The data suggests that few pharmacists had followed up patients over the 
twelve-month intervention period with formal interviews. Whilst there were 
legitimate reasons such as, patients not requiring them there was also 
indications that they were not conducted due to time issues and inadequate 
remuneration. This again questions how committed some pharmacists were 
to undertaking this role. 
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8.8 Difficulties encountered with the MMS 
After providing an initial assessment of the MMS, participating pharmacists 
were asked to identify any difficulties they had encountered throughout the 
twelve months of conducting the MMS. The difficulties identified were 
similar to those reported at the beginning of the project (refer to chapter 
6), in particular lack of access to patients' medical records and lack of GP 
engagement. These factors continued to be troublesome throughout the 
twelve-month intervention period. 
8.8.1 Access to medical notes 
Twelve pharmacists reported that lack of access to patient's medical 
records was the biggest barrier they had encountered whilst undertaking 
the MMS. As previously reported, the lack of clinical information and 
sometimes inaccurate information received, had occasionally limited the 
pharmacist's ability to carry out an effective medication review. Two 
pharmacists reported that as their pharmacy was situated near to the GP 
practice they were able to go in to the practice and get the extra clinical 
information they sometimes required. 
"What they did at the surgery next to where the majority of my patients 
come from, they had a receptionist there designated to the medicines 
management project to help me out so I could pop in at any time and 
actually get the medical information that I needed. " (P04) 
However, four pharmacists thought the only solution to this problem would 
be electronic links to the GP practice to obtain the clinical data, as their 
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pharmacies were not situated close enough to the practices for them to 
regularly visit and look at patients' medical records. 
Lack of clinical information and access to patients' medical records 
continued to be a barrier for some pharmacists to conduct a full medication 
review. However, once more the data suggests few pharmacists had taken 
the opportunity to go into GP practices and access the clinical information 
they required. 
8.8.2 Reflections on GPs'involvement with the project 
Seven pharmacists thought the lack of support from the participating GPs 
had been the key difficulty they had encountered whilst undertaking the 
MMS. Pharmacists believed that the GPs had not taken the project seriously 
and were frustrated and disappointed by their lack of support. The 
following quotes demonstrate the views held by the pharmacists. 
"[ think it's frustrating that you know they perhaps didn't take the thing 
seriously from the word go." (P40) 
"But as time went on [ became more and more disappointed with the lack 
of response from the GPs." (POS) 
One pharmacist thought if the participating pharmacists and GPs had met 
before the MMS commenced and established their objectives together then 
this might have helped reduced the problems experienced. The work of 
Chen et al (1999a, 1999b) has highlighted the importance of allowing GPs 
and community pharmacists the time to meet in a semi-social 
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environment, to help try and build relationships before commencing 
collaborative work together. 
"1 think the health service, the system as it is GPs, peTs all across the 
board don't respect and know what community pharmacists can do. They 
do see on a weekly basis maybe a practice pharmacist come in and do a 
particular job but that's their only real exposure to a pharmacist, other 
than a pharmacist phoning up and complaining they have made an error on 
a prescription. So I feel more should have been done before hand to bring 
maybe the GPs and the pharmacists together to plan what should have 
gone on. " (POS) 
It was also acknowledged by three pharmacists that unless they had the 
cooperation of the GPs, this type of service would not work as it was 
important to be giving the patient a consistent message. 
"You need the cooperation. There's no point the pharmacist being in 
disharmony with the local doctors, to have credibility you've got to be 
singing the same tune to the patient." (P10) 
Despite repeatedly chasing up the recommendation forms, pharmacists 
reported that it often took a long time to receive feedback from the GPs 
and there were occasions when they did not receive any feedback. In some 
instances they never received the recommendation forms back as they had 
gone missing. 
"We'd passed it along to a GP but we got very little feedback from that, 
from them you know. Papers would be lost, requests when we tried to 
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follow it up, it was difficult to get appointments with the GPs to be perfectly 
honest. " (P36) 
"I got one back (recommendation form) with this sort of ridiculous 
comment on it and then all the rest just disappeared in to oblivion despite 
chasing. " (P40) 
One pharmacist reported that they had received out of date clinical data, 
such as blood pressure and cholesterol readings. When they had contacted 
the practice to obtain the up-to-date clinical laboratory values, the practice 
nurse had refused to give them to the pharmacist as it was duplicating 
their work. As a consequence they were unable to make any clinical 
recommendations because they were unable to obtain up-to-date values. 
"And 1 phoned up to speak to the practice nurse and I was told it was 
duplication of her work and she wasn't willing to give me the values." (P26) 
Pharmacists were then asked to comment whether GPs had followed their 
clinical recommendations. Eight pharmacists reported that they had often 
not received the recommendation forms back from the GP practices, so 
they were unable to comment whether their recommendations had been 
followed. Five pharmacists thought all their recommendations had been 
followed. Fifteen pharmacists reported that the majority of their 
recommendations had been followed, with reasons given by the GP if the 
recommendations were not acted upon. 
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"I'd say the vast majority were followed up and the pOints were addressed 
and, as you say, if there were reasons why the GP had another idea, 
whatever it was that it was documented and 1 was told. " (P04) 
In addition, it was acknowledged by three pharmacists that they had 
received intervention forms back more quickly when they knew the GPs 
involved. 
"Most of the interventions were actioned and because we were sitting down 
with a doctor next to me and went through it obviously got immediate 
feedback which again I think helps. It is probably the best way of getting 
the feedback. I mean interestingly with the GPs from different surgeries 
that I didn't sit down with, they took a lot more chasing up. It was 
interesting, but where there was already a relationship there, it was you 
know, ten times easier than if there wasn't you know." (P09) 
One pharmacist stated they had received unhelpful feedback from the GPs 
"Just having little replies like 'we know this already' exclamation mark, it 
was like if you know this already why haven't you acted on it?" (POS) 
Two pharmacists stated some clinical recommendations were not followed 
because they were inappropriate for the patient. Pharmacists 
acknowledged that their recommendations had been inappropriate but 
stated they had made the recommendations because they were unaware of 
some imperative clinical information about the patient. The following quote 
illustrates this point. 
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"Yes for instance there was one I asked if they could be placed on an ACE 
inhibitor and the feedback came that because she had some kidney 
problems in addition, and that wasn't in the notes that I saw you see, so 
they told me why they wouldn't, you know want to do that." (P27) 
Despite reports that GPs did not reply to pharmacists' clinical 
recommendations, the data suggests that good levels of communication 
between the community pharmacist and the GP, correlated to the most 
satisfactory reports from pharmacists surrounding the feedback of 
intervention forms. Likewise, it was acknowledged by some pharmacists 
that to help try to increase GP engagement then better communication 
with them could have helped. However, there is no indication from the data 
that community pharmacists had taken the initiative to try and increase 
communication with GPs. 
8.8.3 Time constraints 
Seven pharmacists stated that time constraints had been a difficulty they 
had encountered. This was particularly pertinent after the initial patient 
consultations had been conducted, as they had to set aside time to chase 
GPs and follow-up patients. In many instances they had not received 
allocated cover to undertake these tasks. 
"sort of allocating the time and having a busy shop to run as well, to chase 
up the doctors and follow up the patients. I found it ok to get the initial 
interviews all done; I didn't find any problems there because I had 
allocated cover. But the actual phone calls and chasing up and trying to 
find out if interventions had been done, I didn't find that I had the time to 
do at the moment." (P26) 
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Likewise, four pharmacists had found that not having a second pharmacist 
had made conducting a MMS difficult because they were unable to follow 
up patients opportunistically. 
Time constraints and having a second pharmacist were once again seen as 
a barrier to undertaking a MMS (refer to chapter 6), this suggests that until 
these organisational constraints are addressed some pharmacists would be 
unable to undertake a MMS fully. 
8.8.4 Practice Pharmacist in situ 
Pharmacists stated when GPs employed a practice pharmacist they had 
found little opportunity to recommend anything for patients and were often 
just duplicating work already carried out by the practice. 
"The other issue we had was that a lot of the surgeries already had a 
practice pharmacist in them, which meant things like everyone was on 
aspirin was already done and [ found that if you were going to go in to 
certain surgeries in my area I'm sure there are a lot more things we could 
have picked up on, but because we were working for surgeries who are far 
thinking, who have got practice pharmacists in, they basically done the job 
we were trained to do and that's what [ found a little disappointing. /I (P06) 
When pharmacists identified that the local GPs participating in the project 
had a practice pharmacist they were asked to comment whether they 
thought there was a need for a community pharmacist to conduct a MMS. 
Five pharmacists believed there was still a need for a community 
pharmacist to conduct a MMS because practice pharmacists often had 
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limited patient contact and the community pharmacists believed the 
patients had benefited from the interview. 
"It depends what the practice pharmacist is doing 1 think. I think that if it's 
capable of doing it as we are but I think we're more easily accessible 
sometimes and depending on the background, the aTe to take into 
account. So if some practice pharmacists only do well, audit work or, you 
know, prescribing work they don't always do the interviews with the 
patients. So I think that's different." (P02) 
However, it was acknowledged if there was a practice pharmacist in place 
then community pharmaCists might want to focus on particular aspects 
during a patient review to prevent duplication. 
"Yes but you might not want to do the whole thing. You might actually just 
want to interview the patient and work on compliance and how well they're 
getting on with their medicines." (P31) 
Two pharmaCists stated if the local GPs had a practice pharmacist in place 
then it was difficult for a community pharmacist to conduct a MMS because 
it was duplicating work already carried out within the practice. 
"I think you're dotting the 'Is' and crOSSing the 'Ts'. I don't think there's a 
lot of scope there." (P36) 
There was mixed opinions from community pharmaCists whether there was 
a need for them to undertake a MMS if there was a practice pharmacist in 
their local GP practice. 
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8.8.5 Other Identified barriers to undertaking a MMS 
There were a number of other barriers to undertaking a MMS identified by 
the participating pharmacists during the course of the interviews. One 
pharmacist thought the biggest difficulty had been their lack of clinical 
knowledge and this would be a barrier for community pharmacists 
undertaking this extended role unless training was received. 
"I think the only thing is the clinical knowledge barrier, you know. It 
obviously needs to be well learned. "(P21) 
Three pharmacists commented the lack of space had been a difficulty 
encountered, as patient consultations often had to be held in upstairs 
offices which was often difficult for older or CHD patients to reach. 
"It wasn't ideal in the fact that the only room that we had available is 
upstairs and at the opposite end so you had to go up a flight of stairs and 
walk the full length of the store to the front of the shop again, so it's quite 
a considerable walk for somebody who has got angina." (P43) 
Three pharmacists thought they had received a lack of company support 
throughout the MMS, particularly surrounding pharmacist cover to carry 
out patient consultations. Continuity was also stated to be a problem if 
phar:macists either worked part-time or in more than one premises. This 
was illustrated by one pharmacist who had moved stores during the 
project, resulting in difficulties for the pharmacist to follow patients up as 
they now only worked at the participating premises two days a week. This 
was also a difficulty encountered by four other pharmacists that worked 
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part-time and for one pharmacist that was undertaking the MMS as a 
locum. 
"My particular problem that I can see is to do with continuity, in that 
myself and another colleague of mine who operated in ****** area are 
part-time and so we haven't been able to see these people when they 
come in for their monthly supplies." (P39) 
This demonstrates that if community pharmacists are going to undertake a 
MMS on a long term basis and are employed by a company, then it is 
imperative that the company also engages with the MMS. 
8.9 The MMS model in clinical practice 
Finally, pharmacists were asked to comment whether they thought this 
model of medicines management had worked within the current 
organisational structure of a community pharmacy. Almost all pharmacists 
thought the model worked within reason but Identified a variety of factors 
(as reported in the earlier part of this chapter) that could be potential 
barriers against a MMS being conducted. For example, four pharmacists 
thought that the model would have worked better if they had had access to 
the patient's medical records, preferably electronically. 
"1 would think the ideal would be for the pharmacist to actually, eventually 
be online but to have access to the patient records and actually make their 
own records." (P28) 
Three pharmacists stated they thought the model would have worked 
better if there had been a second pharmacist present, as it would have 
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allowed the service to be organised more effectively. Currently some 
pharmacists were conducting the interviews on their days off, which they 
acknowledge could not be a long-term commitment. 
"Yes, with some reservations. I think you need a second pharmacist to 
allow you the time. I don't think you can just fit it in and to do it any other 
way you'd sort of have to give up your free time." (P02) 
Three pharmacists believed that a MMS was most ideal when pharmacists 
were seeing patients already known to them, as it allowed the opportunity 
to follow up patients on a regular basis when they came into the pharmacy. 
"Well I think they need to be people that you deal with on a daily, weekly, 
monthly basis, not patients that you have never seen before! I don't think 
you can offer the services easily, you can still do a passable job hopefully 
but you can't really keep it going." (P25) 
Two pharmacists believed the service would have worked better if the 
patients had been referred by the GPs, as they would have seen patients 
with identified problems and the GPs may have been more motivated to 
respond to the pharmacist. 
"But the model works well, it would be better if the GP actually felt there 
was a problem and they were ferrying people in to pharmacies for a block 
booking, because there would be motivation on their part to improve 
compliance as well." (P31) 
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One pharmacist thought they should be seeing CHD patients shortly after 
they were discharged from hospital with a cardiac event, as they believed 
this was a critical time to educate patients about their cardiac medication. 
One pharmacist thought that inadequate space within the pharmacy would 
be a problem for many pharmacy premises. Three pharmacists believed 
that the model would have been more effective if conducted in the GP 
practice because they believed it was easier to address clinical problems 
and the patient's notes would be there. Another pharmacist believed that 
all medical services should be conducted in the same locality. 
"I personally think the surgery is probably a better setting ....... I really think 
all medical services should be available under one roof. I mean I think 
that's the way it should go and pharmacists sitting out on a limb out with 
the health service, I'm not entirely sure that's tenable in the very long 
term." (P44) 
However, while one pharmacist thought the model of the MMS had worked 
in the community pharmacy setting, they could see no advantages for 
community pharmacists to do this type of service if the GPs had time to do 
it. 
"I can't see an advantage of a pharmacist doing it necessarily. If GPs could 
give patients half an hour, a lot of these things wouldn't occur in the first 
place if you see what I mean. " (P19) 
When questioned about whether the service represented value for money 
for the Government, half the participants thought it had. Two pharmacists 
believed it would have been better value for money if they had had closer 
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collaboration with other members of the primary health care team so they 
were not spending time on areas already covered by other members of the 
primary healthcare team. 
"Yes, though I wonder if it would be better enhanced if we were much 
more aware of the total team effort in terms of diet and nursing standards, 
and it was quite difficult to get information about some patients seemed to 
have already had intervention from stroke clinics and rehabilitation clinics 
and we were reinforcing messages. II (P31) 
Seven pharmacists were unsure whether this service had represented value 
for money, as they had often made few clinical recommendations on 
patients but had still needed to pay for locum cover. One pharmacist was 
unsure whether it represented value for money as the majority of their 
clinical recommendations had requested the addition of medication, so 
patients were complying with the NSF guidelines. Three pharmacists stated 
that they did not believe this service had been value for money as they had 
conducted few patient consultations and made few clinical 
recommendations. One pharmacist stated although they did not think the 
service had represented value for money with the patients they had seen in 
this project; they could identify patients where a MMS would have been 
cost effective. 
"With the patients I had on the study not so much, but I can think of 
hundreds of people that I'm dealing with regularly that I could make a 
huge impact on, which obviously then would." (P40) 
Pharmacists were finally asked to comment on whether they would be 
interested to participate in other community pharmacy projects that were 
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focusing on service development. All the pharmacists interviewed said they 
would be interested in taking part in future projects providing they had 
company support and time to complete the project. 
8.10 Summary 
Community pharmacists identified the key barriers to undertaking a MMS 
as lack of GP engagement, lack of access to patients' medical records and 
organisational barriers, such as lack of consultation space, time and 
financial constraints, not being situated near the GP practice and requiring 
a second pharmacist to effectively conduct a MMS. These were Identified as 
barriers throughout the course of the project. 
Lack of GP engagement often had practical consequences for the 
pharmacist. Lack of feedback from the GP made it difficult for the 
pharmacist to follow up patients, which sometimes had an adverse effect 
on the patient's confidence in the pharmacist. It also caused considerable 
frustration and disappointment for the pharmacist. Bradshaw and Doucette 
(1998) argued that the reactions and attitudes of GPs could either hinder 
or facilitate the expansion of the pharmacist's role. Likewise, Mrtek and 
Catizone (1989) argued that community pharmacists would only embrace 
more clinical roles when other health professionals were at hand, with 
whom they could interact as respected peers. 
Lack of GP engagement, along with geographic isolation often resulted in 
minimal contact between the two professions and this may have explained 
the limited impact the project had in improving relationships significantly 
and attitudinal perceptions between community pharmacists and GPs. Work 
in Australia (Chen et ai, 1999a, 1999b), has highlighted the importance of 
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breaking down professional barriers prior to community pharmacists and 
GPs undertaking collaborative services. likewise, Bradshaw and Doucette 
(1998) argued that lack of face-to-face contact with the rest of the primary 
healthcare team was a considerable barrier to pharmacists taking on new 
roles. 
The importance of having a good relationship with the GP in the MMS was 
reflected by almost all pharmacists stating that having an established 
relationship with the GP impacted on the success of a MMS. Pharmacists 
stated that by either having an established relationship, or improving 
relationships with GPs had had a positive effect on the GP's attitude 
towards the community pharmacist's clinical capability. Likewise, 
pharmacists acknowledged that when they did have the opportunity to 
meet with their local GPs this allowed them to build relationships with them 
and made contacting and conveying information to the GPs much easier. 
This finding is supported by the literature, which suggests that improving 
the relationship between GPs and pharmacists could have a positive effect 
on GPs' attitudes towards the pharmacist's clinical role (Chen, 2001b; 
Muijrers et ai, 2003). However, whilst pharmacists acknowledged the 
importance of establishing relationships with GPs, the data suggests that 
few pharmacists had taken any measures to try and increase contact and 
communication with their local GPs. 
Whilst it can be concluded that it was important that community 
pharmacists received support from the GPs to successfully undertake a 
MMS, the self-motivation of the individual pharmacist was also an essential 
factor. Despite pharmacists being positive regarding their involvement in 
the MMS and stating the main motivational factor to become involved with 
the project was the opportunity to extend and develop the community 
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pharmacist's role, only four pharmacists stated they had followed-up some 
of their patients with formal meetings during the twelve-month 
intervention period, with several pharmacists stating that they would not 
follow patients up due to inadequate remuneration. 
All the interviewed pharmacists identified similar barriers to providing a 
MMS, but despite this some pharmacists still managed to undertake a full 
MMS service. This mirrors the history of service innovation in community 
pharmacy practice in the UK, whereby individual or small groups of 
community pharmacists have been responsible for developing innovative 
roles for their profession (Tan et ai, 1996; Bell et ai, 1998b; Rushton, 
2001). 
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9. DISCUSSION 
9.1 Introduction 
This chapter is divided into three sections. The first section discusses the 
limitations of the project, which includes the methodological problems 
associated with being part of a large multi-centre study. I also discuss my 
reflections on the analysis and generalisibility of the data, along with some 
considerations on my role as a clinical pharmacist conducting HSR. 
In the second section of the chapter, I discuss the GPs' perceptions and 
attitudes towards the community pharmacist, along with some reflections 
on how community pharmacists believed GPs perceived them. The working 
relationships between the two professions (both pre and post MMS) will be 
discussed. I argue that having an established relationship between the 
community pharmacist and GP increased the success of a pharmacist lead 
MMS, due to the GP having a more positive attitude towards the 
community pharmacist and the community pharmacist being more 
confident to interact with the GP. I draw an analogy with how GPs are more 
accepting of practice pharmacists and the nursing profession extending 
their roles within the primary care setting, as generally they have closer 
working relationships. 
In the final part of this section I look at the responses of the participating 
GPs to community pharmacists' attempts to extend their roles. I argue that 
some GPs in the project exhibited negative attitudes towards community 
pharmacists extending their role, particularly into areas such as prescribing 
and modifying patient's drug therapy regimens. I argue that the majority 
272 
of GPs saw the actions of the pharmacist as boundary encroachment and 
consequently were more supportive of the community pharmacist 
extending their role into areas which they exercised little autonomy. I 
discuss the arguments put forward by the GPs supporting this claim and 
look at the existing literature which has explored the responses of 
physicians to the expanding role of the pharmacist. 
In turn, the third section of the discussion chapter focuses on community 
pharmacists' responses to having the opportunity to expand their role. The 
motivation and aspirations of the participating pharmacists will be 
discussed, along with the difficulties identified by the pharmacists to 
undertake and follow-up patients in a MMS. I argue that the participating 
pharmacists in this project had neither the organisational means, nor the 
motivation to encroach into the GP's territory. I end this section by looking 
at how community pharmacists viewed nurses within the primary care 
setting. Whilst I have argued pharmacists did not view their actions in this 
project as encroachment, pharmacists did view nurses within the primary 
care setting as potentially encroaching on roles they could undertake. 
Finally, a conclusion to this piece of research is provided. 
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9.2 SECTION ONE 
9.2.1 Limitations of the study: methodological issues 
The data collected for this thesis formed part of a larger body of data being 
collected by a collaborative research team (consisting of the Universities of 
Aberdeen, Keele and Nottingham and the College of Pharmacy Practice), 
who were responsible for independently evaluating the Department of 
Health funded Community Pharmacy Medicines Management Project. A 
concern I had throughout my thesis was I was collecting data from two 
varying perspectives. I was employed as a research fellow to collect 
qualitative data from community pharmacists, GPs and patients 
participating in this project (to determine their views about community 
pharmacists undertaking a MMS) and I was also using these subjects to 
obtain data to undertake a part-time PhD. My concerns centred around two 
areas; firstly, I had no involvement in the design of the protocol for the 
project, having been employed subsequent to this. Secondly, my PhD data 
collection would be secondary to much larger objectives set out in the 
project protocol that I had to achieve as a research fellow. I often found 
my data collection for the thesis had to follow the time and financial 
constraints imposed on the project. I do not know whether this impacted 
on the quality of the data I collected. 
The project was conducted in nine pilot sites throughout England. Whilst 
these sites were chosen by purposive sampling to incorporate a range of 
demographic factors, it imposed restrictions on which qualitative methods I 
could use to collect my data. I also could not carry out any quantitative 
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work to triangulate with the qualitative work I was conducting, as another 
research fellow had been employed in the trial to undertake this research. I 
have therefore, in some instances referred to this quantitative work to 
consolidate my qualitative findings. 
As discussed in the methodology chapter (refer to Chapter 5), focus groups 
were chosen in order to obtain data on the views and experiences of 
pharmacists participating In the project since they facilitated the collection 
of views from a large number of the participating pharmaCists reasonably 
quickly, and without incurring repeated costs in having to travel to the pilot 
sites. On reflection, I found that focus groups were difficult to organise, 
particularly when I had no local knowledge about the pilot area and 
community pharmacists. LRCs were employed at each pilot site and they 
potentially could have helped in this process but in reality I found they 
offered little practical advice. Furthermore, it was difficult to build a rapport 
with the community pharmaCists over the telephone and ensure that they 
attended an evening focus group. This was partly caused by practical 
issues such as being able to find a convenient time for all the pharmacists 
to attend. These problems were accentuated because pharmaCists had 
been asked to attend a number of other meetings concerning the project, 
and were therefore often reluctant to attend. Other than providing food and 
refreshments for the pharmaCists, financial restrictions and ethical approval 
ruled out offering cash as an incentive to persuade pharmaCists to 
participate. This problem was further compounded because pharmaCists 
had received payments to attend other meetings12 • All these factors seem 
likely to have influenced the attendance rate by the pharmaCists at the 
focuS groups (refer to Table 6.). 
12 PharmaCists received a payment for attending training events and feedback meetings 
organised by the PSNC. 
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Time restraints also meant that I had to conduct focus groups when some 
community pharmacists had yet to carry out medication reviews with 
patients, so they were unable to share their views and experiences. This 
was at times frustrating and probably an inefficient way of collecting data, 
and may have affected the quality of the data. However, there was often 
no way around the problem given that other objectives had been stipulated 
within the project, and time and financial constraints had to be met. Also, 
as a funded research project there was an explicit set of research questions 
that needed to be addressed. The facilitator often had to intervene in the 
focus group discussion to make sure that other research objectives were 
achieved, rather than focusing on the issues of relevance to this thesis. 
Again, I do not know whether this impacted on the quality of the data I 
collected. 
A further problem, not unusual in focus groups, was that not all 
participants expressed views about the MMS, despite encouragement from 
the facilitators. This has made it difficult at times to report the overall 
views of the pharmacists because some pharmacists failed to express their 
views fully. 
Due to the poor attendance rates I experienced in the initial focus groups, 
it was decided (in conjunction with the project team) to conduct telephone 
interviews for the follow-up work with pharmacists and GPs. I also had a 
mixed response to this method of data collection. The major limitation was 
the low response rate by GPs in nearly all of the pilot sites (refer to Table 
8.). Despite repeated telephone calls (up to six times) to the practice 
manager it proved difficult to either identify a GP willing to take part in an 
interview, or there were difficulties contacting those GPs who agreed to be 
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interviewed. For example, two GPs agreed to be interviewed, an interview 
was arranged with them personally, but on the day of the interview one GP 
was on annual leave and another was not in the GP practice. To circumvent 
these difficulties two members of the Steering Group (both academic GPs) 
contacted lead GPs personally and by fax to try to arrange interview times. 
In some instances this proved successful. 
On the other hand, using telephone interviews to gain subsequent data 
from pharmacists proved more successful and a high response rate was 
achieved. Pharmacists may have been more willing to be interviewed given 
that I had already met many of them at focus groups and they may also 
have wanted to discuss their experiences of the project, given its impact on 
their day-to-day roles. 
I think it is also important to acknowledge that I had no active involvement 
in the recruitment of GPs and community pharmacists on to the project. 
Participation in this project was voluntary, with community pharmacists 
and GP practices in each pilot site being invited to participate. Both parties 
received a payment for attending the launch meeting set up by the PSNC 
and then subsequent payments for taking part (GPs received a payment for 
recruiting patients on to the project and community pharmacists received a 
payment for undertaking the consultations with patients). Although 
pharmacists and GPs received a payment for participating in this project, 
they were under no obligation to attend focus groups or be interviewed. 
Any participant that agreed to provide feedback (either at a focus group or 
by telephone interview) did so on a voluntary basis and if they refused to 
do so there was little I could do about it. It was particularly difficult to 
recruit GPs for interview. As such, this was an opportunistic sample 
(because I could only interview partiCipants willing to be interviewed rather 
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than selecting participants to be interviewed) and thus this work did not 
adhere to the broad principles of theoretical sampling. The views obtained 
may not represent those of all pharmacists and GPs in the project and it 
was not possible to keep interviewing until saturation occurred. It is 
impossible to know if those who did not agree to be interviewed would 
have held different views. However, the GPs and pharmacists whom I 
interviewed provided a wide range of responses and there is nothing to 
suggest that these views obtained from these GPs and pharmacists would 
be different from GPs and pharmacists not interviewed. 
9.2.2 Reflections on the analysis of data 
There are various techniques and programmes which can be used to assist 
with the analysis of qualitative data in order to help make it more rigorous. 
For example, reporting deviant cases, using computer programs such as 
NVivo to help with coding and analysis, and using additional qualitative 
researchers to assess transcripts (Mays and Pope, 1995; Seale, 1999; 
Silverman, 2000). However, as with all qualitative (and quantitative) 
research, the themes that I have produced and reported are dependent on 
my judgment and skill as a qualitative researcher. I therefore wish to 
reflect on the analysis of the data that has been produced in this thesis. 
As indicated in the methodology chapter, I used the Grounded Theory 
(Glaser and Strauss, 1967) approach in its broad outline to guide my 
research and analysis of data. By this I mean that I generated themes from 
an initial overview of the data, and then used the technique of constant 
comparison when re-analysing the data to and examining each case in 
relation to the theme. Part of this process involved repeatedly reading the 
transcripts and considering the interpretations that I was beginning to 
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bring to bear in relation to my data. To improve the consistency and 
reliability of the data, the transcripts were read separately by my two 
supervisors and myself and to some extent represent a collaborative set of 
analytical decisions. 
Due to time constraints, it was often difficult to begin analysiS of the data 
whilst also collecting data, as data often had to be collected very quickly. 
However, the constant comparison technique was helpful in terms of 
identifying key themes, for example, around established relationships and 
willingness of the GPs to accept community pharmacists undertaking a 
MMS. There were also clear instances of deviant cases. For example, 
despite one GP having an established relationship with their local 
pharmacist they expressed negative views regarding pharmacists 
undertaking a MMS. By examining the interview data in greater depth, it 
became apparent that this GP held different beliefs about which roles were 
appropriate for community pharmacists to undertake to other GPs that had 
good relationships with their local community pharmacists. This particular 
GP's view was independent of their relationship with the community 
pharmacist. Whilst I am unable to account for this GP's view it is 
interesting to look at and acknowledge deviant cases. 
I used the computer program NVivo to assist in the analysis of the 
pharmacist focus group data, due to the large quantity of data that was 
generated. Although it took some time to use this computer package, I 
believe it enabled me to look at this data much more quickly and efficiently 
than if I had done it manually. I decided not to use the programme when 
analysing the telephone interview transcripts, as there was considerably 
less data to analyse. 
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Seale (1999) and Silverman (2000) both advocate that qualitative 
researchers should support generalisations by the simple counting of 
categories ('quasi-statistics'). They argue that quantification may be useful 
as it allows the reader a chance to gain a sense of a perspective regarding 
the data as a whole. I decided to use this technique when reporting my key 
themes, because I had a large corpus of data to report and therefore 
believed this technique would help the reader gain some perspective of the 
data. However, I acknowledge that there is a danger when quoting 
'numbers' in qualitative research, in that the range and strengths of views 
expressed may be overlooked as a consequence of using a numerical 
approach to data analysiS. 
9.2.3 Reflections on my role as a pharmacist undertaking 
Pharmacy Practice/Health Services Research 
It has been suggested that all researchers need to reflect on the effects of 
their personal characteristics such as age, gender, social class and 
professional status, as well as the interview setting or the context in which 
the research was conducted. All these characteristics have the potential to 
influence each other reciprocally (Britten, 1995; Mays and Pope, 2000). 
With regard to my own research, the above were necessary considerations, 
because at the time of data collection I was also occasionally practicing as 
a clinical, hospital pharmacist. On reflection, I believe that my professional 
background had the greatest potential to impact on my data collection. 
This was due to my personnel preconceptions and assumptions (prior to 
and during the project) towards the pharmacist and physician relationship 
and attitudes towards each other, based both on the literature and my 
experiences as a hospital pharmacist. I acknowledge that there are both 
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advantages and disadvantages to having a similar professional identity to 
the group being researched. It is possible to understand a groups 
experiences, given a shared sense of professional identity, thus enabling 
the interviewer to have a degree of empathy regarding the difficulties or 
pressures that the interviewee may face. However, this closeness to the 
subject may also stop the researcher from identifying issues which seem 
unusual about the research, because they may share similar experiences to 
that of the interviewee. It may also be that when a researcher shares the 
professional background of the group being studied, certain issues of 
findings may be 'taken for granted' and not viewed in the same light if a 
researcher with a different professional background. 
There is little published literature that has considered the effect or impact 
on the quality of data obtained by interviewers with clinical backgrounds, 
when their professional background is disclosed to the interviewee. This 
topic is rarely discussed in the medical and health services literature, 
usually due to the word restrictions placed by medical journals on the 
length of articles (Hoddinott and Pill, 1997b). The literature that is 
available has mainly focused on the impact of the professional identity 
(usually a GP) on patients (Hoddinott and Pill, 1997b; Hamberg and 
Johansson, 1999; Richards and Emslie, 2000; Con neeley, 2002). 
Occasionally it has focused on the impact on fellow health professionals 
(Chew-Graham et ai, 2002; Conneeley, 2002). These studies suggested 
that the professional identity of the interviewer did produce notable 
differences in the interviewees' responses. For example, Hoddinott (1997b) 
a GP, found she obtained richer data from patients when her GP 
background was disclosed. They concluded that they would make their 
professional background clear when they conducted their qualitative 
research. Con neeley's (2002) professional background was also disclosed 
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to both patients and fellow practitioners. She concluded that whilst patients 
were not inhibited by her professional status, fellow professional staff 
appeared anxious and gave information in a descriptive way. This may 
have been due to the fact they felt the interviewer (Conneeley) was being 
critical of their work. 
Chew-Graham et al (2002) reported similar findings and concluded when 
the GP's status was not known to GP interviewees, the interview was 
narrower in focus, with less discussion and diversion, and much less 
emotionally charged. Responses tended to be more explanatory and 
respondents could sometimes be resistant to questions about their 
attitudes towards clinical practice. Where respondents recognised the 
researcher as a clinician, access to the GP was easier; interviews were 
broader in scope and provided more personal accounts of their attitudes 
and behaviour in clinical practice. The authors also concluded that at times 
the GP interviewer was identified as an expert and/or judge in clinical 
decision-making issues. Occasionally, interviewees believed the GP 
interviewer was making moral judgments over how they had acted in their 
patient consultations. If this occurred then respondents were likely to be 
cautious in their conversation. Richards and Emslie (2000) concluded that if 
a researcher decided to declare their professional background and states 
that they are medically qualified, they should be aware of the interviewee's 
possible preconceptions and should take the time to explain their role as a 
researcher. 
Whilst the literature suggested that it may be possible to obtain richer 
qualitative data by disclosing ones professional background, I had concerns 
about doing so. I feared that this could have a detrimental effect on my 
interviews because my clinical background was not exactly the same as 
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that of the respondents (the literature had only looked at interviewing 
fellow peers). I therefore decided that in this project, I would not disclose 
my professional background unless asked by the interviewee. I had 
concerns when I interviewed GPs that they may not have been so candid 
about their attitudes towards community pharmacists extending their role, 
if they knew I was also a pharmacist. Like Chew-Graham et al (2002), I 
found because GPs assumed that I had a non-clinical background, there 
were times when the GPs were reluctant to discuss their attitudes about 
community pharmacists. Instead they would often talk about attitudes held 
by the GP population, rather than their own personal attitudes. Their 
reluctance to discuss their personal views might also be attributed to the 
short time I had available to interview the GPs and the fact that a 
telephone interview creates a 'distance' between the interviewer and 
interviewee. On reflection, I still would not disclose my professional 
background but I believe this research has demonstrated that the 
interviewer's professional background potentially can playa major part in 
how respondents interact. Although outside the scope of this thesis, it 
would have been interesting to have had an academic GP conduct some of 
the GP interviews. This would have allowed some comparison to be made 
as to whether GPs would have been more willing to disclose their attitudes 
if they had known a fellow peer was interviewing them as opposed to a 
'researcher', and in turn how this would have impacted on the data 
obtained. 
I also decided not to disclose my professional background to the 
community pharmacists, again because my professional background was 
not equivalent. I am a hospital pharmacist and have very little experience 
of working as a pharmacist in the community setting. I also believe there is 
a tendency for hospital pharmacists to conSider themselves as possessing 
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'superior' clinical knowledge to community pharmacists, and that this can 
create a divide amongst hospital and community pharmacists. On 
reflection, I believe that not disclosing my professional background was the 
right decision, as the community pharmacists sometimes referred to 
hospital pharmacists being more experienced in undertaking medication 
reviews and liaising with doctors. I believe if I had disclosed my 
professional background, pharmacists might have felt that I was judging 
them, particularly when I asked them to talk about clinical interventions 
that they made and how they had followed these up with the GP. I found 
the pharmacists very forthcoming in discussing their views and experiences 
about their relationships with their local GPs. This may have been due to 
the fact that the initial data collection was achieved by holding a focus 
group, so this data collection method may have been less intimidating for 
pharmacists than a one-to-one interview. When I came to undertake the 
telephone interviews, having previously met the majority of the 
interviewees at the focus groups, this allowed some level of rapport 
between the pharmacist and myself to be established. 
I also believe it is important to acknowledge the background of my 
supervisors and fellow members of the research team who were also 
involved in my data collection. Barry et al (1999) argued whilst reflexivity 
was often described as an individual activity, using reflexivity as a team 
activity, through activities such as group discussions could improve the 
rigor and quality of research. Pope et al (2000) also stated that there may 
be merit in using more than one analyst in situations where researcher bias 
could be a problem. When designing the semi-structure interview schedule 
and when analysing the data my supervisors (a medical SOCiologist and an 
academic pharmacist) and a member of the Steering Group (an academic 
GP) also reflected on the data. I believe their involvement in this process 
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enabled me to question my own preconceptions and reduced interviewer 
bias. Likewise, having two facilitators (one facilitator did not have a clinical 
background) conducting the pharmacist focus groups, may have helped 
reduce the influence of my professional background on the interview 
process and preconceptions about community pharmacists. 
9.2.4 Generalisability of the data and implications for further 
research 
Qualitative research has been criticised for 'lacking generalisability', in the 
sense that some quantitative data sets can be generalized to a population. 
It has often been reported that an indicator of the quality of qualitative 
research, concerns the extent to which findings can be generalised beyond 
the setting in which they are generated (Mays & Pope, 1995). I believe that 
many of the themes identified in this project are likely to be reproduced in 
research exploring interprofessional collaboration in other settings, on the 
grounds that the themes I have identified have been acknowledged in 
other research studies. Likewise, the respondents interviewed were 
recruited from a range of pilot sites and the themes identified were 
replicated in all these sites. It is unlikely that the identified themes would 
be 'unique' to these pilot sites, since the sites were chosen to incorporate a 
range of different demographic factors. 
As I stated before, the themes identified in this project have also been 
identified in a number of other studies which have explored 
interprofessional barriers between GPs and community pharmacists 
(Adamcik, 1986; Hughes and McCann, 2003) or physicians' responses to 
the extension of the community pharmacist's role (Spencer and Edwards, 
1992; Ellis et ai, 1992; Bleiker and Lewis, 1998; Ewen and Triska, 2001; 
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Howard et ai, 2003). The majority of these studies studied GPs' and 
pharmacists' views about role extension for community pharmacists from a 
hypothetical perspective, and they were currently not undertaking 
collaborative work with each other. This project has demonstrated that 
similar concerns and perceived barriers have been identified even when the 
community pharmacists and GPs were working together. Sadly, this project 
had a limited impact on altering views held by the two professions. 
Prior to, and during the project I believe insufficient emphasis was placed 
on encouraging the participating GPs and community pharmacists to 
regularly meet up and to address any attitudinal barriers to effective 
collaboration. I was disappointed that greater emphasis was not given to 
this issue and incorporated into the CPMMP protocol, particularly as this 
was an issue that should have been identified, and subsequently addressed 
by a review of the literature. As I stated before, I had no involvement in 
the trial protocol due to being employed subsequent to this, therefore it 
was simply an issue that I could not address. However, it became apparent 
quite early on in the data collection that it should have been an integral 
part of the protocol. 
overall, I believe this project has highlighted that there are both attitudinal 
and organisational barriers that need to be addressed in order for 
collaborative work between the two professions to flourish. Furthermore, I 
believe this project has demonstrated the importance of developing better 
relationships between GPs and community pharmaCists before undertaking 
collaborative work, and the consequences on a collaborative project if they 
are not addressed. An overview on the literature that has looked at the 
processes and strategies towards building collaborative relationships will be 
given in chapter 10. 
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9.3 SECTION TWO 
9.3.1 Introduction 
In this section of the chapter, I discuss the GPs' perceptions of and 
attitudes towards community pharmacists, alongside some reflections on 
how community pharmacists believed GPs perceived them. Aspects of the 
working relationships between the two professionals (both pre and post 
MMS) will then be explored. From the data collected I discuss the factors 
that may have contributed to relationships not improving during the 
project, and argue that having an established relationship between the 
community pharmacist and GP increased the success of a pharmacist lead 
MMS. This was due to the GP having a more positive attitude towards the 
community pharmacist and the community pharmacist finding it easier to 
interact with the GP. I draw an analogy with how GPs are more accepting 
of practice pharmacists and the nursing profession extending their roles 
within the primary care setting, as generally they have closer working 
relationships. 
Finally, GPs' views and attitudes towards community pharmacists 
attempting to extend their traditional roles will be explored and discussed. 
I aim to focus on the extent to which GPs in this project saw role extension 
by community pharmacists as boundary encroachment, and by illustrating 
this argument through a discussion of some of the existing literature on the 
sociology of the professions. 
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9.3.2 Perceived attitudinal barriers between community 
pharmacists and GPs 
A number of attitudinal barriers were identified from the qualitative data. 
Whilst some pharmacists thought GPs viewed them as fellow clinical 
professionals, it was apparent that some community pharmacists believed 
GPs perceived them to be 'shopkeepers' rather than health professionals. 
Likewise, some GPs expressed a concern that commercial interests could 
affect a community pharmacist's clinical advice. The perception of 
pharmacists as a 'shopkeeper' is supported by a number of other studies 
looking at physicians' responses to role extension by pharmacists (Adamcik 
et ai, 1986; Spencer and Edwards, 1992; Ellis et ai, 1992; Hughes and 
McGann, 2003). In several of these studies, up to a third of GPs 
interviewed believed that the pharmacist's advice could be biased by 
commercial pressures and their primary motive when giving clinical advice 
was to make a profit. Hughes and McGann (2003) argued that if a GP 
perceived a community pharmacist as a business person or shopkeeper, 
then it created a conflict of interest in health care, and this might have 
accounted for GPs' concerns over pharmacists prescribing and extending 
their clinical role. Although not specifically questioned, no GPs interviewed 
in this project volunteered any reference to the commercial element 
associated with general practice. In the study conducted by Hughes and 
McGann (2003), several GPs stated that there was a commercial element 
to general practice but believed it was not as blatant as community 
pharmacy. 
As a consequence, some pharmacists believed that some GPs did not view 
them as not having an equivalent or similar professional status to them. 
The GPs interviewed in this project openly admitted that some of the GP 
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population did believe they were professionally superior to a community 
pharmacist. However, it is more difficult to determine whether they 
themselves also held this attitude. Some GPs in this project were positive 
about community pharmacists' professional standing, stating they were the 
'experts' in medication and pharmacological issues, and clearly welcomed a 
greater degree of collaborative working. Hughes and McGann (2003) state 
that professional hierarchy represents a boundary to the role extension of 
community pharmacists, with community pharmacists commenting that 
GPs considered them subordinate in professional terms and on the 
periphery of the primary healthcare team. 
Similar to Hughes and McGann (2003), the pharmacist qualitative data 
Suggests that some community pharmaCists believed that GPs did not view 
them as a member of the primary care team. This perception is supported 
to some degree by the qualitative GP data. A small number of GPs reported 
that community pharmaCists were not members of the primary health care 
team, and held concerns about them having a greater clinical involvement 
in patient care as it was considered outside their remit. The GP qualitative 
data also suggested that some GPs interviewed had a strong opposition to 
community pharmacists having a role in prescribing. Hughes and McGann 
(2003) also found GPs expressed concerns about pharmaCists assuming 
roles they considered to be general practice activities and were 
unenthusiastic about them having a role in prescribing. 
Community pharmaCists in this project also believed (and were frustrated 
about the fact) that GPs did not have a clear understanding of their current 
role, particularly with regard to patient confidentiality. Whilst several GPs 
stated that they had a good awareness of a community pharmaCists 
training and day-to-day role (this was usually due to them having relatives 
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or friends that were pharmacists), the majority of GPs interviewed openly 
admitted they had a poor knowledge about the training a pharmacist 
received and their current role. This lack of awareness was highlighted by 
the concern held by over a third of GPs, about community pharmacists 
having access to patients' medical records. GPs feared that patient 
confidentiality might not be upheld if community pharmacists had access to 
these records. Only two GPs made reference to the fact that a community 
pharmacist was bound by a code of confidentiality. 
Several other studies have highlighted the physician's lack of awareness 
over a pharmacist's training and role in health care (Smith et ai, 2002; 
Hughes and McGann, 2003). For example, Smith et al (2002) argued that 
as few physicians had an understanding of the training a person undergoes 
to become a pharmacist, then this could mean they had 'no expectations' 
of the clinical work a pharmacist could undertake. This situation has also 
been discussed within an article (Anon., 2004). Anon. (2004) looked at 
how newly qualified hospital pharmacists integrated into the healthcare 
team. They argued other health care professions' perceptions and poor 
understanding of what a pharmacist's job entailed caused problems for the 
junior pharmacists, as other health care professionals did not know what to 
expect from them. This problem was further exacerbated as pharmacists 
usually worked alone, rather in hierarchical teams like physicians and 
nurses. The absence of a hierarchical title13 to indicate the pharmacist's 
level of experience may also have led to other health care professionals 
having unrealistically high expectations of junior pharmacists. This was a 
factor that caused junior pharmacists not to participate fully in the care of 
the patients for whom they had responsibility. These studies conclude that 
13 For example, hospital physicians have the titles, Junior House Officer Senior House Officer 
Registrar and Consultant to indicate their level of expertise.' , 
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physicians lack of awareness ultimately leads pharmacists to have a sense 
of frustration and feel undervalued in their work (Hughes and McGann, 
2003), and physicians to have no, or inappropriate expectations of 
pharmacists (Smith et ai, 2002; Anon, 2004). 
A further interpretation from these data is the suggestion that some GPs 
viewed practice pharmacists differently to community pharmacists. When 
GPs were questioned about how they believed a community and practice 
pharmacist differed, many GPs stated that the practice pharmacist knew 
how their practice ran, had access to patients' medical records (which GPs 
did not object to) and were able to undertake more clinical activities, such 
as checking patients were on appropriate medication and monitoring 
clinical parameters such as blood sugars. These data suggest that GPs 
believed practice pharmacists' clinical abilities were greater than that of 
their community colleagues. From their study conducted in the USA, 
Adamcik et al (1986) noted that physicians who had contact with clinical 
pharmacists may have attributed those pharmacists' skills and expertise as 
something unique to them, and by acknowledging the excellence of these 
so-called 'deviant clinical pharmacists' they confirmed the stereotype of the 
community pharmacist. Hughes and McGann (2003) argued that many GPs 
saw a practice pharmacist as the preferred model in terms of 
interprofessional working and prescribing support, as they were located 
within the practice and worked directly with GPs. This helped erase the 
shopkeeper image which they typically associated with community 
pharmacists and brought them into the primary care team. 
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9.3.3 Working relationships between community pharmacists 
and GPs 
Despite a number of attitudinal barriers identified in this project between 
the pharmacists and GPs, almost all the participating pharmacists and GPs 
stated they had a good working relationship with each other prior to the 
MMS commencing. GPs reported that they found the community 
pharmacists helpful and obliging, and reported that they often phoned 
them for advice and information concerning pharmaceutical issues. 
Approximately a quarter of the GPs interviewed also stated they trusted 
and valued the community pharmacist's advice. The majority of 
pharmacists however, hoped the MMS would enhance relationships 
between themselves and the GPs. 
The community pharmacist relationship with the GPs was often more 
reactive in nature, with them generally only contacting GPs if they had 
identified mistakes with their prescribing. This may provide an explanation 
why community pharmacists hoped that participating in the MMS would 
further improve relationships with GPs, as the service gave them the 
opportunity to have a more proactive relationship with their local GPs. For 
example, they could suggest modifications in drug management rather 
than just highlight medication errors to the GPs. 
However, both professions stated their communication pre-MMS was 
generally restricted to telephone conversations and there was often little 
face-to-face contact. From their study conducted in Australia, Chen et al 
(2001b) concluded that this was not an unusual finding and the most 
common medium for communication between GPs and community 
pharmacists was via the telephone. This was due to most GP practices and 
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community pharmacies being geographically isolated from each other, 
precluding regular face-to-face contact during business hours. They 
concluded when telephone communication occurred, calls were generally 
short in duration, usually concerned one 'simple' issue to discuss and were 
initiated more often by pharmacists than GPs. 
At the end of this project, both pharmacists and GPs reported that the MMS 
had a limited impact on improving their existing working relationship. In 
one instance, a GP reported that it had a detrimental effect on their 
working relationship as a result of the correspondence they had received 
from the community pharmacist. Likewise, several pharmacists stated they 
believed the project had had an adverse effect on relationships between 
GPs and themselves. Pharmacists more commonly reported the MMS had 
impacted (to some extent) on their existing working relationships with GPs, 
as it had encouraged communication between the two professions. Seven 
pharmacists also believed their professional profile had been enhanced with 
the GPs as a result of taking part in the MMS. This was due to them having 
the opportunity to demonstrate to the GPs their potential clinical input into 
a patient's care. 
McDonough and Doucette (2001) argued it was paramount to understand 
how a collaborative relationship between a physician and pharmacist 
developed, as pharmacists could often impact patient outcomes through a 
cooperative relationship with physicians. They stated few studies had 
examined which types of characteristics were most important for fostering 
the growth and development of a collaborative relationship. As a result, 
they developed a theoretical framework for the physician/pharmacist 
collaborative working relationship (CWR), which was based on models of 
business relationships and physician-nurse relationships. 
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The CWR model postulated pharmacists and physicians progressed through 
five stages14 of increased collaboration, characterised by greater trust, 
shared decision making and interdependence. Relationships were 
developed and driven by three groups of characteristics termed participant, 
context and exchange. Participant characteristics reflected personal 
characteristics, such as level of education, training experience and age. 
context characteristics were features related to the participants' practice 
environment for patient care activities, such as personnel, facilities, or 
organisational structures, and exchange characteristics, encompassed the 
nature of social exchanges between both parties. Each of the 
characteristics had the potential to playa role in the development of a 
collaborative relationship by positively or negatively influencing the stage 
of development. 
Brock and Doucette (2004) aimed to evaluate the CWR model by 
determining the degree of collaboration present in a small number of 
pharmacist-physician professional relationships. They also aimed to identify 
the variable factors that were important in establishing collaboration 
between the two professions. Likewise, Zillich et al (2004 & 2005) aimed to 
14 Stage 0: Professional Awareness (exchange is minimal and interactions are discrete 
between pharmacists and physicians). 
Stage 1: Professional Recognition (Pharmacists begin to proactively promote exchanges with 
a physician). 
Stage 2: Exploration and Trial (Practitioners can gauge and test their goal compatibility, 
expectations, trustworthiness, and commitment to the relationship). 
Stage 3: Professional Relationship Expansion (Communication becomes more bilateral and 
interdependence increases). 
stage 4: Commitment to Collaborative Working Relationship (Collaboration occurs when 
physicians believe that the amount of risk to their practice generated through increased 
exchanges with a pharmacist is less than the value added to their practice). 
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test the CWR model and determine which relationship characteristics drove 
physician/pharmacist collaboration from a physician's perspective. 
Both studies found that although participant and context factors influenced 
physician/pharmacist collaborative relationships, exchange characteristics 
were the most influential relationship drivers. Role specification, 
trustworthiness, and relationship initiation were positively associated with 
increased physician/pharmacist collaborative practice. The CWR model 
demonstrated that pharmacists were often responsible for initiating 
communication with physicians. The authors recommended that in the 
early stages of the CWR, pharmacists should strive to learn more about the 
physician's practice and how they could positively affect patient care. 
Pharmacists who showed Interest in the physician's practice and developed 
services that improved the physician's care of patients were more likely to 
have better success in developing a CWR. 
Trustworthiness was another critical factor in collaborative relationships, as 
pharmacists who had worked with physicians over a period of time had 
more opportunities to demonstrate their knowledge and clinical expertise. 
As physicians became more familiar with pharmacists they gained 
confidence in their abilities, and trust and commitment to the relationship 
began to develop. In some instances, physicians were more willing to 
initiate the interaction by seeking the pharmacist's advice regarding clinical 
considerations once trust has developed. The authors concluded that as the 
practitioners interacted, more role specification took place, and roles and 
responsibilities evolved to define the CWR. This was also demonstrated by 
Naccarell and Sims (2003) who concluded that GPs would often interact 
with other health care professionals whom they already trusted. 
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This was reflected in this project, by GPs stating that if they did not trust a 
community pharmacist then it was difficult for them to have faith in the 
pharmaceutical advice given to them. Similarly, pharmacists stated that if 
GPs trusted them then it was much easier to convey information to them 
and GPs were more likely to listen to their advice. 
Ambler (2003) stated that often community pharmacists and GPs had not 
developed a trustful and respectful relationship with each other, because 
geographical distance precluded them knowing each other well. Whilst I 
believe this is a valid argument, I do not believe that was the reason for 
pharmacists and GPs not developing (or further developing) their working 
relationship in this project. I believe that there were other factors which 
may have contributed to the community pharmacists and GPs working 
relationship not improving in the MMS, and the 'shopkeeper' image 
remaining significant. These will be discussed in turn. 
9.3.4 GPs' involvement in the MMS 
The first factor which I believe had an impact on the relationships 
remaining the same between community pharmacists and GPs, centred on 
the level of GP involvement in the project. Many community pharmacists 
reported that the participating GPs in their pilot site did not respond to 
their clinical suggestions and there was a strong sense they were not 
committed to undertaking a MMS. These reports were validated in some 
instances by the GP qualitative data, whereby GPs admitted that their 
practice pharmacist had dealt with any clinical recommendations made by 
the community pharmacist, so their involvement had been minimal. GPs 
also admitted that they had little input in to the project and had only ever 
attended the launch meeting, with some GPs stating they had not attended 
296 
any meetings. In these circumstances it was unlikely that GPs' perceptions 
of the community pharmacist would alter, or their working relationships 
develop, if they had minimal involvement with the community pharmacists 
in the MMS. 
9.3.5 Clinical interventions identified by community 
pharmacists 
The second factor which I believe also had an impact on attitudes and 
relationships not altering, centred on the nature of the clinical 
recommendations made by the community pharmacists. Pharmacists 
reported they had often only recommended minor, clinical interventions to 
patient's CHD medication. This was supported by the GP qualitative data, 
whereby GPs stated they believed that the majority of their CHD patients 
were already on the correct regimen of medication. In a few instances, GPs 
reported that some clinical recommendations were inappropriate for 
particular patients. Other studies have shown that physicians often had no 
clear expectations of how pharmaCists applied their clinical knowledge in 
practice so they had no strong (or negative) expectations that pharmaCists 
could provide any clinical services (Smith et ai, 2002). These authors also 
concluded that a physician's experience indicated that pharmaCists were 
better at providing non-patient-specific drug information than providing 
information tailored to an individual patient's clinical Situation. As 
community pharmacists in this project only made minor clinical 
interventions, they had no opportunity to show GPs their potential role in 
reviewing medication, thus not changing GPs expectations or experiences 
of the community pharmacist's role. 
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9.3.6 Communication of interventions 
The third factor which I wish to discuss centred on how the community 
pharmacists communicated their interventions to the GP. This factor I 
believe had a major impact on the relationships not improving between the 
community pharmaCists and GPs. As discussed in the methodology chapter 
(refer to Chapter 5), the method of communicating clinical interventions to 
the GP was left to the discretion of the pharmaCist. Both pharmaCists and 
GPs confirmed that the majority of interventions were communicated via 
post, with some GPs reporting they had no face-to-face contact with the 
pharmacist. Although the majority of the GPs claimed they were happy to 
receive recommendations via post, some GPs indicated that having verbal 
contact or meeting face-to-face gave the opportunity to discuss patients in 
more detail. They also stated it would have given them the opportunity to 
explain in more detail why certain clinical recommendations were not 
followed. 
The lack of verbal or face-to-face contact initiated by the community 
pharmacist may be explained by a number of factors. These included; lack 
of urgency surrounding the clinical recommendations, time pressures on 
both community pharmaCists and GPs, and a lack of confidence by the 
community pharmacist to speak with the GP. A small number of 
pharmacists stated they were often reluctant to speak with the GP as they 
lacked the confidence to challenge their prescribing deCisions and feared 
that the GP would retaliate if they did speak with them. 
Lambert (1996) argued that communication between pharmacists and 
physicians could be problematic because each party's professional identity 
was at stake when the two professions interacted. He argued even if a 
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physician did not feel their 'turf' was being threatened by a pharmacist, 
pharmacists' reports of problems and recommendations for alternative 
drugs could be interpreted as criticism, and this in turn could be 
intrinsically threatening to a physician's professional identity. 
Several studies have alluded to personality traits or factors that may 
predict whether pharmacists will interact with physicians (Lambert, 1996; 
Nimmo and Holland, 1999b). For example, Lambert (1996) investigated 
the effect of demographic factors, relative power, social distance and types 
of verbal politeness strategies used by pharmacists when reporting 
allergies and making recommendations to physicians. His findings included 
older pharmacists were more likely to make recommendations than 
younger pharmacists, perhaps because they had more experience and were 
more confident. Community pharmacists were more polite and therefore 
less likely to make recommendations than hospital pharmacists, and some 
pharmacists managed the threat of the physician by abstaining from the 
recommendation entirely. 
Nimmo and Holland (1999b) concluded from their work that the personal 
and social characteristics of pharmacists were two major factors that 
predisposed pharmacists to reacting in a certain way to changes in 
practice. Their review of published studies exploring the personality traits 
of pharmacists suggested that about one practitioner in five had a fear of 
interpersonal communication. 
Whilst this thesis did not set out to specifically look at personality traits, I 
would argue in this project that some pharmacists choose to communicate 
their recommendations by post as this was a less threatening act than 
having verbal contact with the GP, where the GP could potentially challenge 
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their recommendations. Some pharmacists also admitted that to avoid 
speaking with the GP they had sometimes asked the practice pharmacist to 
liaise with the GP on their behalf. 
Using McDonough and Doucette's CWR model (2001), the majority of the 
pharmacists and GPs relationship within this project were at Stage 0, 
where exchange was minimal and interactions were discrete between each 
other. However, what was evident was that by not having much verbal or 
face-to-face contact, this allowed little opportunity for new or existing 
relationships to be strengthened between the pharmacist and GP, and 
relationships did not have the opportunity to move onto higher stages of 
the CWR model. 
Bradshaw and Doucette (1998) stated that the lack of face-to-face contact 
with the rest of the primary healthcare team was a conSiderable barrier to 
pharmacists taking on new roles. A number of other studies have shown 
that communication can be problematic between pharmacists and 
physicians (Chen et ai, 200lb; Wilson et ai, 2002; Cheung et ai, 2003; 
MacRae et ai, 2003). For example, Chen et al (200lb) found that in 
Australia, pharmacists and GPs communicated via the telephone to discuss 
clinical issues, but a collaborative scheme had little impact on the 
frequency and rate of communication between GPs and community 
pharmacists. They suggested that in order for community pharmacists to 
adopt a more professional role, alternative communication arrangements 
needed to be identified to allow discussions about clinical issues to occur. 
They suggested face-to-face case conference meetings as one such 
alternative. 
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This is not just an issue that occurs in primary care. Cheung et al (2003) 
assessed the attitudes of junior doctors towards pharmacists and how the 
interaction between them could be improved. All the doctors appreciated 
the presence of a pharmacist on their ward, and the majority of doctors 
stated they would have liked more personnel contact rather than just 
reading a note attached to the drug chart. Doctors found it difficult to have 
regular contact with pharmacists and found it annoying when they were 
bleeped by pharmacists. They stated more personnel contact with 
pharmacists would have allowed them to discuss medication changes more 
openly. 
Likewise, role specification, trustworthiness, and relationship initiation were 
also positively aSSOCiated with increased physician/pharmacist collaborative 
practice (Brook and Doucettte, 2004; Zillich, 2004, 2005). However, once 
again without regular communication, particularly in the initial stages of 
the project, then these issues were also not addressed. If pharmacists had 
been required to collect patient data from the practice then this may have 
provided an opportunity for the pharmacist to initiate a relationship with 
the GP. In these instances, pharmacists would have needed to discuss with 
the GPs what information they required from the patients' medical records. 
This would have potentially allowed the GP to understand the role of the 
community pharmacist in the MMS, and the opportunity to inform the 
pharmacist what the practice needs was. Likewise, it would have started to 
allow the community pharmacist and GP to start trying to build a trustful 
relationship. These data also suggested that each GP interviewed had a 
preferred method of communication with the community pharmacist. This 
Suggests that community pharmacists and GPs should discuss and decide 
at an individual level the method of communicating clinical 
recommendations. 
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9.3.7 Established relationships between participating 
pharmacists and GPs 
These data suggest however, that where there was an established 
relationship between the community pharmacist and the GP, the GP was 
more supportive of community pharmacists extending their role. The 
importance of having a good relationship with the GP was also reflected by 
almost all pharmacists stating that having an established relationship with 
the GP impacted on the success of a MMS. There were examples given by 
pharmacists that by having an established relationship (or when the 
relationship improved) with the GP, this had a positive effect on the GP 
regarding the community pharmacist's clinical capability. Likewise, 
pharmacists acknowledged that when they did have the opportunity to 
meet with their local GPs, this allowed them to build relationships with 
them and made contacting and conveying information to the GPs much 
easier. 
There are conflicting findings concerning how improving the relationship 
between GPs and pharmacists can affect the attitude of GPs towards 
pharmacists' clinical role (Adamcik et ai, 1986; Bogden et ai, 1998; Chen, 
2001a; Muijrers et ai, 2003). Muijrers et al (2003) concluded that 
improving the relationship between GPs and pharmacists would have a 
positive, significant affect on the attitude of GPs towards the pharmacist's 
care-providing function. Likewise, Bogden et al (1998) stated that 
improving the relationship between the pharmacist and physician played an 
important factor in their intervention of managing patients with 
hypertension. This was demonstrated in this project by several GPs stating 
that if they did not have an established relationship with their community 
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pharmacist then it was hard to have trust and confidence in them. This was 
particular evident when GPs reported their local pharmacy had a succession 
of locums so their level of trust and confidence in the community 
pharmacist in that instance had not been that good. It was also concluded 
that it was difficult to follow advice unless the GP believed it to be good 
advice. 
Ambler (2003) acknowledged that without trust and respect, the 
professional relationships between community pharmacists and GPs may 
not be strong enough to sustain joint working relationships in two 
geographically distant locations. She concluded that if this was the case 
then getting to know one another was the key, but could be made more 
difficult by the increased trend for both professions (but particularly in 
community pharmacy) towards an increasingly mobile workforce, more 
locums and part-time working. 
This analogy can also be demonstrated by looking at the relationship 
between GPs and practice pharmacists. All the GPs interviewed, who had 
practice pharmacists working in their practices, were generally supportive 
of them undertaking clinical activities and accessing patients' medical 
records. All these GPs reported they had a good or excellent working 
relationship with their practice pharmacist and held them in high esteem. 
9.3.8 Community pharmacist and GP collaboration 
Despite the GPs being more supportive towards community pharmacists 
extending their role where there was an established relationship between 
them, these data indicated that GPs expressed contrasting views about 
community pharmacists undertaking a MMS. Six GPs interviewed were 
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generally positive and supportive of community pharmacists undertaking 
the service, however, eight GPs expressed more ambivalent views, whilst 
the remaining seven expressed predominately negative views. These mixed 
views were supported by the pharmacist and GP qualitative data, and the 
GP quantitative data undertaken for the MMS. For example, the qualitative 
pharmacist data indicated that some GPs did not respond to their clinical 
Suggestions, whilst the qualitative GP data stated some GPs found the MMS 
both time consuming and laborious, with the pharmacist simply duplicating 
work already carried out within their practice. The quantitative GP data 
undertaken revealed as the study commenced, nine per cent of GPs 
participating did not believe that community pharmacists should extend 
their role, but this had increased to 17% by the end of the intervention 
period (The Community P h a r m a c ~ ~ Medicines Management Evaluation 
Team, 2004). 
Similarly, participating GPs argued there would be a mixed reaction from 
most GPs concerning closer working relationships with community 
pharmacists. When asked about this, five GPs believed that the GP 
population would welcome more collaboration. This group argued that this 
was mainly because such services had the potential to reduce the GPs 
current workload, and they acknowledged that GPs currently did not have 
the time to undertake regular reviews of medication. The remainder of the 
GPs believed their peers would either be suspicious of having closer 
collaboration, or view collaboration as potential 'interference' creating more 
work for them. The interviewed GPs were very candid in their responses to 
why they believed fellow GPs would be against greater collaboration with 
community pharmacists. The r e a ~ o n s s cited included; concerns about 
maintaining a hierarchy within the current division of labour, feeling 
threatened by community pharmacists questioning their clinical decisions, 
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losing control over their patients, whilst others referred to the personality 
of some GPs, where some GPs believed that they had greater knowledge 
than a community pharmacist. It was acknowledged that if this were the 
case, then it would be unlikely that GPs would undertake collaborative 
projects with community pharmacists as they would not be willing to 
accept pharmacists' advice. 
Whilst participating GPs openly acknowledged how the GP population would 
react to collaborative work with community pharmacists, it is more difficult 
to determine whether they also shared these views. It is less clear from the 
data whether they felt threatened by community pharmacists questioning 
their clinical decisions, or whether they viewed community pharmacists as 
professional equals. What can be concluded is that several of the GPs 
interviewed indicated that they saw a MMS outside the scope of a 
community pharmacist's expertise. These GPs acknowledged that whilst 
community pharmacists could provide beneficial advice regarding drug 
interactions, they were not the most appropriate person within the primary 
health care team to be making clinical recommendations. These GPs 
believed it was outSide a community pharmacist's remit and could 
potentially lead to conflict between the two professions. 
Furthermore, some of the participating GPs went on to specify roles that 
they believed community pharmaCists could undertake, if they wanted to 
extend their role. Tasks identified included; managing patients' repeat 
prescribing, managing patients' medication post hospital discharge and 
participating in a referral system, whereby GPs referred patients 
(particularly the older population) to the community pharmaCist for their 
input. It should be noted that the roles identified by the GPs in this project 
usually had little self-autonomy and were seen to benefit the GP by 
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reducing their workload. Several GPs also referred to community 
pharmacists prescribing, arguing they believed it would be difficult to 
manage their patients if more than one person was prescribing for them 
because it could lead to patient confusion, and raised an issue over who 
would ultimately have responsibility over the patient. 
This finding is supported by the literature which has investigated GPs' 
views on the extension of the community pharmacist's role (Ritchey and 
Raney, 1981; Spencer and Edwards, 1992; Ellis et ai, 1992; Bleiker and 
Lewis, 1998; Ewen and Triska, 2001; Hughes and McCann, 2003; Howard 
et ai, 2003). As reported in Chapter 2, these studies demonstrated that 
although GPs generally favoured community pharmacists extending their 
roles, and often welcomed a greater degree of collaboration with them, 
they all identified roles which they believed were appropriate for 
community pharmacists to become more involved with. For example, GPs 
were generally supportive for community pharmacists to carry out an 
additional role in areas such as reporting adverse drug reactions, 
maintaining patient drug profiles, counselling on OTC or prescribed 
medication and supervising repeat prescribing schemes. However, they 
were generally not supportive of community pharmacists having a more 
significant clinical role, such as prescribing, therapeutic drug monitoring, or 
running pharmacy screening programmes in blood pressure or cholesterol 
monitoring. There was a general trend in these studies that GPs were least 
supportive of tasks that allowed the pharmacist the opportunity to make 
independent decisions regarding a patient's treatment. 
The majority of these studies identified in the literature asked GPs to 
comment about the extension of the community pharmacist's role 
hypothetically, as opposed to looking at actual examples of them 
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undertaking a multidisciplinary project. It could be argued that GPs in 
these studies may have had reservations because they may not have had 
exposure to community pharmacists undertaking these extended roles. 
This was not the case in this project, as the GPs did have some exposure 
and experience of community pharmaCists undertaking extended roles. 
However, these data suggest that this has had little impact in altering their 
views about what they deemed as appropriate roles for community 
pharmacists to undertake. Hughes and McGann (2003) concluded from 
their study, that GPs who had previous contact with pharmaCists through 
interdisciplinary projects did not have a more positive view of community 
pharmacists. They argued that contact with pharmaCists in prescribing 
support roles may have just reinforced the GPs' perceived view of the 
community pharmaCist, for example that of a 'shopkeeper' and they 
continued to be resistant against community pharmaCists undertaking roles 
such as prescribing. 
I believe that the response of participating GPs towards the community 
pharmaCist's role extension in the MMS was seen as boundary 
encroachment. That is, as community pharmacists in this project 
attempted to extend their boundaries by having a greater input into 
managing and reviewing medication for patients (roles that have 
traditionally been the GP's responsibility), GPs responded by identifying 
roles that did not threaten or had little impact on their autonomy and 
professiona lism. 
These findings are also supported by literature which suggests that GPs 
often see the extension of the pharmaCist's role as boundary encroachment 
(Eaton and Webb, 1979i Adamcik et ai, 1986i Gilbert, 1997, 1998a-c, 
2001i Britten, 2001i Edmunds and Calnan, 2001). For example, Gilbert 
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(1998a-c) has described the South African situation where community 
pharmacists have tried to expand their role but were often only permitted 
to do so, when the medical profession did not see a task as its exclusive 
domain. Adamcik et al (1986) concluded that physicians were more 
antagonistic towards the expansion of pharmacists' clinical activities in the 
community setting rather than in the hospital setting, as pharmacists 
working in a community setting typically exercised far more autonomy and 
had freedom from direct supervision compared to hospital pharmacists. 
Whilst this thesis can not comment on this (as only community pharmacists 
had participated in the project), it may offer some explanation as to why 
GPs were opposed to community pharmacists undertaking more extended 
roles. 
Similarities can be drawn with other studies that have looked at 
collaboration between GPs and community pharmacists. In Edmunds and 
Calnan's study (2001), the participating GPs accommodated some of the 
initiatives to develop the community pharmacist's role, such as helping 
patients to manage their medicines better or repeat dispensing schemes. 
However, there were also reports that some GPs were unhelpful, 
obstructive and felt threatened by some pharmacists' roles, such as 
screening cholesterol levels or monitoring BP. In their study there was also 
evidence of widespread support from the GPs for community pharmacists 
conducting extended adherence projects in the older population because 
GPs perceived a need amongst this population for help with adherence, 
which they did not have time to do. Like Edmunds and Calnan (2001), the 
GPs in this project were also supportive for community pharmacists to have 
a role in reviewing medication in the older population and welcomed 
pharmacists' interventions when it fulfilled a support function and they 
could delegate responsibility. 
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Edmunds and Calnan (2001) concluded that GPs were supportive for 
pharmacists to have a bigger role in areas where there were limitation and 
exclusion for the community pharmaCist, as they were not a threat to GPs' 
autonomy and control. I would also conclude that in this project, GPs saw 
the community pharmacist as a group to which they could delegate tasks 
to, but they discriminated between tasks that crossed the boundary into 
their territory and those which did not threaten their autonomy. 
I also believe what can be detected from these data is how the GPs used 
more subtle measures to prevent the community pharmacist from 
encroaching into their territory. In these instances, the GPs were able to 
appear sympathetic towards the difficulties community pharmaCists faced 
trying to conduct medication reviews, for example, having a lack of clinical 
information but used patients' welfare as a reason why these difficulties 
would always be barriers when there was often no strong evidence to 
rationalise this. The measures used by GPs to prevent encroachment will 
be discussed in turn. 
9.3.9 Access to patients' medical records 
As reported in Chapter 2, a more active pharmacist involvement in patient 
care has been less successful in the community setting mainly due to the 
pharmacists' lack of access to patients' medical records (Cotter et ai, 
1994). It is therefore no surprise that the lack of access to patients' 
medical records was shown to be a major limitation for community 
pharmacists to undertake a MMS in this project. In many instances, the 
pharmacists reported that they did not have suffiCient clinical information 
to conduct a full medication review on the patients they saw in the project. 
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Over a third of the GPs interviewed acknowledged that community 
pharmacists would be able to undertake a MMS, providing they received 
training and had supervision. However, they stated the lack of access to 
patients' medical records could be a potential limitation for them to fully 
undertake this role, and acknowledged without access to medical records, 
pharmacists had often duplicated clinical recommendations already carried 
out by the GP. This argument wasfurther supported by the GP quantitative 
data, which revealed that at the beginning of the project 37% of GPs 
believed access to patients' medical records was required to undertake a 
medication review, but this had increased to 98% by the end of the 
intervention period (The Community Pharmacy Medicines Management 
Evaluation Team, 2004). 
However, despite GPs acknowledging this fact there were mixed opinions 
from GPs whether community pharmacists should have access to patients' 
medical records. Firstly, there were practical concerns held by the GPs 
regarding how community pharmacists could gain access to the medical 
records, particularly if they were not based within the GP practice, as 
records would not be able to leave the practice. Likewise, GPs stated that 
only community pharmacists that were known to the GP should have 
access to records. However, practical concerns were very much secondary 
to the issue of confidentiality. The majority of GPs voiced varying concerns 
about patient confidentiality being maintained if community pharmacists 
had access to more than just patient medication details. Edmunds and 
Calnan (2001) also found that GPs strongly resisted community 
pharmacists looking at patient records, largely on the grounds that they 
believed access would be a breach of patient confidentiality. LikeWise, 
whilst several GPs acknowledged that pharmacists were bound by a code of 
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confidentiality, they still had reservations about letting community 
pharmacists have access to medical records. I believe these responses 
showed that GPs were in a position to act as a 'gate-keeper' to patients' 
medical records and choose who was permitted to have access to them. In 
doing so, they were able to prevent community pharmacists encroaching 
onto their territory because they knew how difficult it would be for 
community pharmacists to undertake medication reviews without them. 
Whilst I would agree that the practical reasons put forward by GPs were 
legitimate and they were justified to have some concerns, it does not fully 
explain why GPs had no concerns letting practice pharmacists have access 
to medical records. The data obtained in this thesis however, does not give 
definitive explanations as to why GPs allowed practice pharmacists access 
to patients' medical records. As previously discussed, I believe GPs viewed 
practice pharmacists and their clinical capabilities differently to that of 
community pharmacists. This fact alone may offer an explanation as to why 
GPs were happy for practice pharmacists to access patients' medical 
records. 
I would also hypothesise that most GPs were not so threatened by practice 
pharmacists because they were based within the GP practice, and GPs were 
able to decide and oversee what work they were undertaking. This is in 
contrast to community pharmacists, where GPs are not a position to 
oversee the community pharmacist's work. It may also be due to the fact 
that practice pharmacists are often employed by the GP practice, so again 
they are much more under the control of the GP. 
Lack of access to patients' medical records highlights the difficulties faced 
by community pharmacists attempt to reprofessionalise, particularly if they 
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are not located near the GP practice, or have not fostered a relationship 
with their local GP. The latter point is particularly pertinent due to 
community pharmacists' positions often being filled by locum pharmacists. 
This also raises issues surrounding the future use of electronic national 
care records. As part of the Government's pharmaceutical public health 
strategy 'Choosing health through pharmacy' (Department of Health, 
200Sa), it is envisaged that pharmacists will have a greater contribution to 
public health. In time, every person will have an electronic national care 
record, which will provide pharmacists with more clinical information about 
a patient and will also enable pharmacists to inform other health care 
professional of their interventions they have made. For example, that they 
have given advice on smoking cessation. If this is to be successful then it is 
important to overcome GPs resistance to community pharmacists having 
access to patients' medical records. 
9.3.10 Undermining the GP/patient relationship 
Edmunds and Calnan (2001) concluded in their study that there was some 
evidence that doctors saw pharmacists' participation in clinical activities as 
crossing the boundary into their professional roles and consequently 
undermining the doctor/patient relationship. The GP qualitative data 
indicated that there were mixed opinions from GPs about community 
pharmacists providing medication reviews. The interviewed GPs did not cite 
any advantages that extra collaboration with community pharmacists could 
have on patient care, other than suggesting it might help reduce GPs' 
workload. Conversely, several GPs had concerns that it could confuse 
patients over who had overall responsibility for their care. In a similar vein, 
a few GPs reported that they had been unhappy about the pharmacist 
recommending clinical changes to their patients because they felt it had 
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put them in a difficult position, as patients were expecting changes to be 
made as a result of seeing the community pharmacist, and had in essence 
undermined their authority. A small number of GPs also had concerns that 
community pharmacists often did not know patients well enough to make 
decisions about their medication. However, almost all the GPs interviewed 
thought the MMS had had a positive impact on patients, in that it allowed 
the patient to have the opportunity to discuss medication issues with 
another health professional, particularly if they were fearful about 
discussing medication issues with their GP. GPs also stated community 
pharmacists usually had a more informed view than the GP whether 
patients were actually taking their prescribed medication and they also 
admitted they often did not have time to undertake medication reviews 
with patients. I believe that some GPs in this project may have seen the 
activities of community pharmacists as undermining their authority and 
perhaps used arguments such as community pharmacists not knowing their 
patients well enough, as a reason why community pharmacists should not 
be conducting medication reviews, even though they had cited benefits 
towards the community pharmacist having a greater input into reviewing 
patient's medication. 
9.3.11 GP and nurse collaboration 
The data suggests that many pharmacists held concerns that within the 
primary care setting, nurses were encroaching on roles they could 
potentially conduct. Many pharmacists interviewed saw nurses as 
threatening their opportunity to extend their role and believed that they 
were competing with nurses when trying to secure extended roles for 
themselves. They were also frustrated that GPs appeared to support nurses 
in undertaking new roles within the primary health team. There was some 
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indication from the GP data that GP practices had practice nurses 
conducting extended roles, and several GPs admitted that nurses had been 
able to extend their role within the primary care setting with support from 
GPs. Pharmacists therefore believed that GPs were more encouraging 
towards primary care nurses expanding their role and delegating tasks to 
them. As a consequence, pharmacists feared that nurses were in a 
stronger position, as they were cheaper to employ and less threatening to 
the GPs. 
The literature is conflicting regarding pharmacist and nurse role extension. 
Competition between pharmacists and nurses was demonstrated in 
Adamcik et al (1986) study, whereby nurses who had worked with a clinical 
pharmacist were significantly more supportive of pharmacists undertaking 
clinical activities but they did not support clinical role activities which 
directly threatened their role. However, Gilbert (1997) described the 
formation of a 'therapeutic alliance' between the nurse and community 
pharmacist to form a 'united front' against the medical profession. The 
partnership developed between these two professions allowed the 
pharmacists to expand their professional activities without invading the 
nurse's professional domain. 
I would argue that the pharmacists in this study saw doctors and nurses as 
forming a 'therapeutic alliance' against the pharmacy profession. This may 
have been due to GPs and nurses having a more established relationship, 
so the GP was more favourable towards nurses extending their role. 
However, it may also have been a subtle way of the GP preventing 
community pharmacists from encroaching into their territory because they 
were able to control the activities of practice nurses more than the 
community pharmacist. 
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9.3.12 Summary 
A number of attitudinal barriers have been identified between the 
community pharmacists and GPs. Whilst some community pharmacists 
believed GPs perceived them as fellow health professionals, some 
community pharmacists believed GPs perceived them as 'shopkeepers', 
were frustrated by GPs not having a clear understanding of their current 
role with regard to patient confidentiality. They were also frustrated that 
GPs supported nurses extending their role within the primary health team. 
Likewise, GPs had a poor understanding of a community pharmacist's role 
and some GPs expressed a concern that commercial interests could affect a 
community pharmacist's advice. 
Almost all pharmacists and GPs stated they had a good working 
relationship with each other prior to the MMS commencing, although they 
often had little face-to-face contact. The project had a limited impact on 
improving relationships between community pharmacists and GPs, with 
relationships and GPs' perceptions remaining unaltered in many instances. 
This was mainly due to the limited or non-existent contact between the two 
professions throughout the project so the opportunity to improve 
relationships did not arise. 
The data suggests however, that where there was an established 
relationship between the community pharmacist and the GP, the GP was 
more supportive of community pharmacists extending their role. The 
importance of having a good relationship with the GP was also reflected by 
almost all pharmacists stating that having an established relationship with 
the GP impacted on the success of a MMS. There were examples given by 
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pharmacists that by having an established relationship (or when the 
relationship improved) with the GP, this had a positive effect on the GP 
regarding the community pharmacist's clinical capability and made 
contacting and conveying information to the GPs much easier. This finding 
is supported by the literature, which suggests that improving the 
relationship between GPs and pharmacists can have a positive effect on the 
GPs' attitudes towards the pharmacist's clinical role (Bodgen et ai, 1998; 
Muijrers et ai, 2003). 
The GPs in this project expressed conflicting opinions towards community 
pharmacists extending their role and having a greater degree of 
collaboration with them. What can also be concluded is that some GPs 
identified specific roles which they believed community pharmacists could 
undertake if they wanted to extend their roles. These roles usually had 
little self-autonomy and were seen to benefit the GP by reducing their 
workload. I believe the response shown by GPs towards the community 
pharmacist's role extension in the MMS was seen as boundary 
encroachment. Whilst GPs acknowledged a number of barriers community 
pharmacists faced if they wanted to undertake full medication reviews, I 
have argued that GPs were able to use some of these barriers to their 
advantage to prevent pharmacists undertaking this new role. For example, 
by stating they would have concerns over pharmacists having full access to 
patient's medication records whilst acknowledging how difficult it was to 
undertake a medication review without them. 
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9.4 SECTION THREE 
9.4 Introduction 
I have argued in the previous section of this chapter, that participating GPs 
viewed the attempted role extension of community pharmacists as 
boundary encroachment. In the final section of this chapter, I discuss the 
factors that were identified by community pharmacists as barriers against 
them undertaking a MMS. I argue that the majority of the participating 
pharmacists experienced the barriers identified; yet a small proportion of 
the participating pharmacists overcame them and conducted a full MMS. I 
posit that the difference between the pharmacists that managed to 
overcome the identified barriers lay in their motivation and aspirations, and 
support this assumption by looking at the literature on pharmacy 
innovators. 
I conclude this section by arguing that community pharmacists saw this 
opportunity at role extension as an opportunity towards greater job 
satisfaction, and were not actively encroaching on the GP's territory, as 
they had neither the organisational means nor the motivation to do so. 
Conversely, community pharmacists in this project were more concerned 
that primary care nurses were encroaching on potential roles they could 
conduct and believed GPs were encouraging nurses to do this. 
9.4.2 Barriers identified by community pharmacists 
Community pharmacists identified a number of barriers which they 
believed prevented them from fully undertaking a MMS. The key barriers 
317 
were identified as: lack of GP engagement, lack of access to patients' 
medical records and a host of organisational barriers, such as lack of 
consultation space, time constraints, lack of remuneration, requiring a 
second pharmacist and not being situated near the GP practice. These 
barriers were identified by the majority of participating pharmacists and 
were identified as barriers throughout the course of the project. The 
quantitative data undertaken for the larger study also supports these 
findings, with 83% of pharmacists reporting that they had conducted this 
service in their own time, 97% believed that protected time was needed to 
undertake this type of service and 72% believed a second pharmacist 
would be required (The Community Pharmacy Medicines Management 
project, 2004). 
The barriers identified in this project are similar to those reported in the 
literature. For example, Chen et al (1999a) identified three main categories 
of barriers that pharmacists faced when practising in the ambulatory 
setting. These included: cognitive barriers (whereby pharmacists received 
inadequate education and training to conduct a new role), attitudinal 
barriers (these centred around the pharmacist's fear of contacting 
prescribers and perceived interprofessional conflict), and situational 
barriers (these included factors such as inadequate remuneration, time 
required to develop and deliver new professional services, limited 
information about the patient and architectural barriers). 
Other authors investigating the restraints impacting on pharmaceutical 
care implementation have also identified similar barriers (Miller and 
Orteimer, 1995; Trinca, 1995; Bell et ai, 1998a; Rutter et ai, 2000; 
Rushton, 2001; Rossing et ai, 2001). In Bell et al (1998) study, which 
aimed to ascertain pharmacists' attitudes towards pharmaceutical care and 
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its implementation, the authors, found that the degree of implementation 
was restricted, although many pharmacists were eager to develop 
professional roles. The pharmacist qualitative data in this research 
indicated that pharmacists were positive about the concept of conducting a 
MMS and identified the need to undergo this role extension. However, 
whilst viewing the MMS as a positive experience, few pharmacists 
conducted a full MMS due to the identified barriers discussed at the 
beginning of section three. 
The Departments of General Practice and Primary Care in Aberdeen (2003), 
conducted a systematic literature review on the change and evolution in 
community pharmacy. They concluded that there was a consensus that 
pharmacists were in favour of providing pharmaceutical care and extended 
services. However, a prominent feature in the literature was barriers to 
providing such services, and therefore creating an appropriate supportive 
working environment would be a vital process if pharmacists were able to 
undertake such extended roles. They also concluded that financial 
implications of providing extended services were highlighted as a major 
deterrent to changing work practices. Inadequate and inappropriate 
funding systems based on dispensing volume were the cause of many 
pharmacists not changing working systems or professional practice. 
Inadequate remuneration was identified as a barrier by some interviewed 
pharmacists, who stated that they would not be conducting follow-up 
interviews on patients due to an inadequate payment. Likewise, during the 
course of the focus groups and interviews, pharmacists stated many 
pharmacists would not undertake a MMS unless they were adequately 
remunerated, nor would they invest in a confidential area in their 
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pharmacy unless they were guaranteed that this service would generate a 
profit. 
Whilst the participating pharmacists in this project all identified and 
experienced similar barriers, what can be detected from the data is that a 
small proportion of pharmacists had found ways to overcome some of the 
barriers and conduct a full MMS. Whilst the majority of pharmacists stated 
they did not see GPs face-to face to discuss patients, or accessed patients' 
medical records to obtain the clinical information they were lacking, a few 
pharmacists reported that they had done this. For example, a few 
pharmacists had arranged to go into the GP practice. This had enabled 
them to access medical records and receive more information about a 
patient's medical history, which in turn helped them to conduct a full 
medication review. Likewise, despite experiencing time pressures some 
pharmacists still managed to follow patients up over the twelve-month 
intervention period and met with GPs to discuss patients. One pharmacist 
stated that pharmacists should not receive remuneration to conduct a 
medicines management role and therefore did not see this as a barrier. 
It could be argued that the lack of GP engagement often had practical 
consequences for the pharmacist. Lack of feedback from the GP made it 
difficult for the pharmacist to follow up patients (which sometimes had an 
adverse effect on the patient's confidence in the pharmacist) and caused 
considerable frustration and disappointment for the pharmacist. Bradshaw 
and Doucette (1998) argued that the reactions and attitudes of GPs could 
either hinder or facilitate an expansion of the pharmacist's role. Likewise, 
Mrtek and Catizone (1989) argued that community pharmacists would only 
embrace more clinical roles when other health professionals were at hand, 
with whom they could interact as respected peers. Whilst I believe that the 
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attitudes of GPs and other healthcare professions was a major factor in 
helping community pharmacists successfully undertake a medicines 
management role, I believe that this project demonstrated that the 
individual motivation and aspirations of a community pharmacist also 
contributed as a major factor towards successful role extension. As such, I 
believe the lack of motivation shown by the majority of pharmacists in this 
project largely limited their ability to fully undertake a MMS role. 
9.4.3 Motivation of community pharmacists 
Participating pharmacists stated their main motivational factors to become 
involved with the MMS was the opportunity to move towards a more 
clinically orientated role, have greater contact with patients, increase their 
job satisfaction and prove that community pharmacists could do more than 
'dispense'. Similarly, Rutter et al (2000) found that pharmacists aspired to 
have a greater contact time with patients/customers and decrease the time 
they spent dispensing on a day-to-day basis, along with the opportunity to 
extend their role to provide new services. 
However, as previously discussed it is interesting to point out that these 
data suggest that only a minority of the community pharmacists fully 
utilised this opportunity and conducted a full medicines management role. 
for example, only four pharmacists stated they had conducted formal 
follow-uP interviews with patients over the twelve month intervention 
period. This finding reflects the literature on service innovation in 
community pharmacy practice. Despite strong drives within the pharmacy 
profession and external factors such as Government polices for community 
pharmacists to extend their roles, much of the literature available for 
innovation is characterised more by the efforts of individuals and 
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occasionally groups, rather than coherent and structured professional 
development (Hepler, 1987; Tan et ai, 1996; Higby, 1997; Bell et ai, 
1998b; Holland and Nimmo, 1999a; Rushton, 2001). For example, Hepler 
(1997) and Higby (1997) have both stated that rather than changes in 
pharmacy practice occurring simultaneously throughout the profession, 
there has been an uneven adoption of new practice models within the 
pharmacy profession. Holland and Nimmo (1999a) have also stated 
'Pharmaceutical care is as much a dream as a reality' and as a 
consequence a major proportion of pharmacists in both community and 
other health care settings still perform distributive fu"nctions, rather than 
undertaking a pharmaceutical care role. 
Holland and Nimmo (1999a-b, Nimmo and Holland 1999a-b, 2000) 
examined pharmacy practice as it evolved in the USA and then attempted 
to develop a framework for understanding innovation in the pharmacy 
environment. Nimmo and Holland (1999a) stated a changeover to 
pharmaceutical care was accomplished in stages, and the progression 
towards the pharmaceutical care model might not be under the control of 
the individual pharmacist. They also acknowledged that in order to achieve 
a change in practice, the pharmacist might not only need to acquire new 
knowledge and skills, but might also have to be professionally 'resocialised' 
and given time to incorporate themselves into the new model. Likewise, 
they stated the efforts to encourage practice change should be focused on 
the individual pharmacist, because the decision to change ultimately rested 
with them rather than the organisation or the profession. They proposed 
the Holland-Nimmo practice change model and posited three key elements 
for promoting innovation. These were: a practice environment conducive to 
change, availability of appropriate learning resources and effective 
motivational strategies for the practitioner. 
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The model proposed that regardless of the nature of a proposed change in 
practice, these three elements simultaneously had to be satisfied before 
the change could be implemented. If any of the elements were not met, or 
were not met simultaneously with the others, it was predicted that the 
process of achieving change would falter. These authors also suggested 
that there were two major factors shaping receptiveness to practice 
change, the practitioners' personalities and their current state of 
professional socialisation (Nimmo and Holland, 1999b). 
Applying the Holland-Nimmo practice change model to the participating 
pharmacists in the MMS, it could be postulated that practice change did not 
occur in the majority of cases, because these three elements had not be 
met simultaneously. Whilst community pharmacists had received training 
to increase their knowledge on CHD (so it could be argued that there had 
been the availability of appropriate learning resources), it could be argued 
that a practice environment conducive to change and effective motivational 
strategies for the practitioner had not always occurred. For example, some 
pharmacists stated that they had difficulty following up patients because 
they were not allocated a second pharmacist or given a locum, as had been 
the case in the initial patient consultations. Regarding the pharmacists that 
had conducted a full MMS, then their personality and professional 
socialisation may also have been an important factor. However, it is 
difficult to comment on this, as the thesis did not look at these factors. 
The research reporting these innovations has mainly focused on describing 
the process and outcomes of service development and has rarely analysed 
the individual and structural factors associated with practice change. 
Several studies however, have looked at whether there are 'identifiable 
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characteristics' within pharmacists that have adopted innovative change 
(Tan et ai, 1996; Bell et ai, 1998b; Doucette and Jambulingham, 1999; 
Rushton, 2001; Tan and Blenkinsopp, 2003). 
Rushton (2001) aimed to identify the characteristics that influenced the 
adoption of an 'extended role' in community pharmacists within the UK. 
Her data suggested involvement in 'extended roles' activities, were more to 
do with the pharmacist's professional orientation than the settings in which 
they worked. The greater the level of perceived autonomy the pharmacist 
had, the greater the level of involvement in the 'extended' role. Closely 
linked to perceived levels of autonomy was the position of the pharmacist 
in the pharmacy. For example, owners and managers were more likely to 
undertake 'extended roles' than locums. However, where roles required 
skills not traditionally associated with the community pharmacist's role, for 
example, the provision of screening services, then pharmacist involvement 
was relatively low. Rushton suggested areas that could facilitate the 
process of role expansion. These included establishing means by which 
pharmacists were able to leave their pharmacies to work with other 
professionals, and to have link supports between the community 
pharmacist and the Pharmaceutical Advisor. 
The points made by Rushton (2001) are pertinent due to many 
pharmacists being employees. Pharmacists in this project who were 
employed, particularly for multiple chain companies commented they had 
often received a lack of company support. Unless companies also engage in 
service development then it is difficult for these pharmacists to leave the 
premises or provide the provision of new services. 
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Sell et al (1998b) used the behaviour pharmaceutical care scale (SpeS) to 
assesS pharmacists' efforts to provide pharmaceutical care. They found 
that pharmacists routinely screened patient records and validated 
prescriptions, but rarely documented activities relating to patient care, 
evaluated health status or engaged in interprofessional interactions to 
optimise patient care or satisfaction. 
This was clearly demonstrated in this project, with many pharmacists 
stating that they had rarely communicated with the GPs face-to-face to 
discuss clinical recommendations. Likewise, many pharmacists had not 
formally followed-up patients with interviews; rather they had seen them 
on an opportunistic basis. 
Tan et ai's (1996) explored the hypothesis that innovation was related to a 
set of largely generic characteristics possessed by those who promoted 
professional change, together with appropriate elements in the work 
environment. They suggested that the achievement of organisational 
excellence was found in the match between the characteristics of 
individuals that fitted those required by the internal and external 
environments of an organisation. They suggested that they would expect to 
find specific characteristics of pharmacists that were significantly 
associated with superior performance in the particular organisational 
contexts which demanded those characteristics. Using the critical incident 
technique, a structured interview and the Kirton Adaption Innovation 
Inventory (Kirton 1987 - see Tan et ai, 1996) the authors explored the 
characteristics of what they termed 'leading-edge practitioners' (LEPs). 
They noted that LEPs were more likely to initiate more actions, be more 
patient-centred, more effective soft net-workers, more focused on staff 
developments and more effective influencers than a control group of 
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pharmacists. They suggested that LEPs were more likely to be more pro-
active and have more positive and developed attitudes to inter and intra-
professional practice. 
Furthering their research on innovation in community pharmacy, Tan and 
Blenkinsopp (2003) defined innovators as 'Early Adopters' of new practices 
initiated or sponsored by Health Authorities or peTs in response to an 
identified need. Table 9. summarises the characteristics of Individual 
innovators that they identified through their work. They stated all the 
interviewed and visited individual innovators showed evidence of vision and 
action orientation. All were effective communicator/influencers and were 
patient-centred. In addition, they were self-confident and showed evidence 
of focusing on their own learning. They were effective practitioners at 
balancing the professional and the commercial and were entrepreneurial, 
as well as effective users of resources. 
In the USA, Doucette and Jambulingham (1999) have developed and 
validated a measure of entrepreneurial orientation (EO), which they found 
to be positively correlated with the up-take of speCialised services (e.g. 
specialised compounding, asthma and diabetic care management, and 
compliance monitoring). They suggested that high levels of EO were a 
useful indicator of whether a pharmacy would develop a new and 
innovative service. The traits associated with EO were pro-activeness, 
innovativeness, risk taking, autonomy, competitive aggression and work 
ethic. 
The literature has suggested that 'innovators' are more likely to share 
certain characteristics such as being more patient-centered and being 
action orientated. The pharmacist qualitative data did reveal that some 
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pharmacists interviewed had undertaken a number of other local pharmacy 
initiatives prior to undertaking the CPMMP. Likewise, several of the 
pharmacists were members of the LPC and had been responsible for their 
pilot areas putting in a bid to take part in the CPMMP. It could also be 
argued that some pharmacists appeared positive in their attitudes to 
interprofessional practice and some were very patient-centered. However, 
it is difficult to draw any conclusions from the pharmacist qualitative data, 
whether the motivated pharmacists in this project also shared these 
identifiable characteristics, as the thesis did not set out to specifically look 
at this. 
Table 9. Individual Innovator Characteristics 
IN NOVATOR CHARACTERISTIC 
Leadership 
Vision 
Optimism 
Flexible 
Positive professionalism 
Seeing the 'big picture' 
Action-oriented 
Strateaic persoective 
Networking with non-oharmacy contacts 
Professional networking/leadership outside the pharmacv 
Information-seeking 
People focus 
Effective communicator 
Empathv 
Patient-centred 
Team approach/seeks consensus with staff 
Resolves conflict 
Open/trusted 
Personal drive 
Self-confident/positive 
FocuS on own learning and development 
Business focus 
commercial/professional balance 
Shares information 
Understanding of organisational dvnamics 
Effective use of resources 
Entreoreneurial 
Breadth of innovators 
From. Tan and Blenklnsopp (2003) Understanding Innovation In Community Pharmacy- A 
Final Report. Royal Pharmaceutical Society of Great Britain. 
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Whilst the work surrounding service innovation is important, I believe there 
is a tendency for this type of research to view innovation as an isolated 
issue. For example, Holland and Nimmo did not refer in any depth to the 
historical and structural context in which innovation must be promoted. It 
is important to acknowledge that there are other issues that may impact on 
motivation and innovation, such as interprofessional relationships and role 
encroachment. These factors might also shape pharmacists' perceptions of 
their scope to innovate and their willingness to engage in extended roles. 
As these data have shown in this thesis, community pharmacists' 
progression is interdependent with other health professionals. Abbott 
(1988, 1993) suggested that rather than focusing on one profession, 
systems of professions should be focused on, as developments in one 
profession could directly (or indirectly) affect all other professions in the 
same system. He suggested the dynamics in professional relations were 
not only dependent on the activities of individual professions, but also on 
the behaviour of other professions in the context of technological and social 
changes within the same environment. 
9.4.4 Community pharmacists' views about boundary 
encroachment into GPs' territory 
I now wish to discuss how I believe the pharmaCists in this project viewed 
their chance at role extension. Whilst I have argued that GPs saw the role 
extension of community pharmaCists as encroaching on their territory, I 
believe the qualitative pharmacist data suggested that the pharmaCists saw 
this project as an opportunity to have a greater clinical role, rather than 
the opportunity to encroach into the GPs territory. Pharmacists stated their 
main aims for participating in the project, was for the chance to improve 
relationships with patients, have a closer working relationship with their 
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local GPs and to demonstrate that community pharmacists could undertake 
new roles. Pharmacists stated they often told patients whilst conducting 
medication reviews that they were 'simply helping the doctor out' and the 
doctor would still have overall responsibility for their medication. Likewise, 
pharmacists often stated they did not feel confident to be making clinical 
recommendations. 
Edmunds and Calnan (2001) concluded when reviewing studies in which 
pharmacists were undertaking extended roles, those community 
pharmacists saw a new role as survival, rather than a chance to take power 
away from GPs. They argued that despite pharmacists wanting to pursue 
more clinical roles and have more involvement with patients, they saw an 
extended role as helping patients with adherence issues rather than taking 
on more of a clinical role, and did not seem to want to encroach on the 
GPs' territory. Adamcik et al (1986) also stated there was variability 
amongst pharmaCists about their thoughts on extending their role, with 
young women tending to be more supportive of the expanded role 
activities than men. They concluded this might be due to women being 
more comfortable with person-to person contact and with the 
interprofessional interaction demanded of a clinical role. They also 
speculated that woman could pose less of a threat to male physicians' 
autonomy and authority, and this might make it easier for women 
pharmacists to take on more clinical activities. Stein (1967) stated that 
nurses had been able to wield considerable power and autonomy by 
'tactful' interaction with male physicians. Adamcik et al (1986) postulated 
that women pharmaCists might also play this game, thus gaining more 
freedom in undertaking their own roles. 
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As previously discussed, GPs suggested a number of roles which they 
believed would be more appropriate for community pharmacists to 
undertake. As such, they were happy to relinquish some tasks, for 
example, managing repeat prescriptions to the community pharmacist. 
However, I do not believe this data has indicated that many GPs were 
willing to relinquish a medication role to the community pharmacist. 
Mesler (1991) stated that pharmacy's clinical role had developed through a 
slow process of encroachment and task delegation, which was taking place 
simultaneously, and that many physicians had become aware of the need 
for such assistance from pharmacy and were therefore relinquishing some 
tasks to them. However, I do not believe the qualitative pharmacist and GP 
data indicated that this process had occurred either. Whilst GPs frequently 
indicated there were roles that community pharmacist could undertake, I 
believe they did not relinquish these roles because they required assistance 
from pharmacists, but rather it was a convenient way of reducing their 
workload without having their autonomy threatened. Likewise, the lack of 
motivation exhibited by the majority of the participating pharmacists 
meant that there was little evidence of pharmacists encroaching on GPs' 
roles in this project. I would postulate that due to community pharmacists' 
lack of motivation, along with the organisational barriers they faced that it 
would be unlikely that community pharmacists would accept those roles 
that GPs were happy to relinquish to them. 
As discussed in Chapter 2, boundary encroachment has also occurred to 
community pharmacists by physicians threatening the dispensing function 
of community pharmacists (Spencer and Edwards, 1992; Gilbert, 1997, 
2001). Whilst no pharmacist interviewed made reference to physicians 
encroaching on their territory, as previously discussed some pharmacists 
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had concerns that nurses within the primary care setting were undertaking 
roles they could potentially conduct. As such, pharmacists viewed this as 
potential boundary encroachment and feared that nurses were in a 
stronger position to undertake extended roles as they were cheaper to 
employ and less threatening to the GPs. 
9.4.5 summary 
The participating pharmacists identified a number of barriers which they 
believed prevented them from fully undertaking a MMS. The key barriers 
identified were, lack of GP engagement, lack of access to patients' medical 
records and a host of organisational barriers, such as time constraints and 
lack of remuneration. These were identified as barriers throughout the 
course of the project and are similar to those identified in the literature 
which has investigated the restraints impacting on pharmaceutical care 
(Miller and Orteimer, 1995; Trinca, 1995; Bell et ai, 1998a, Chen et ai, 
1999a; Rutter et ai, 2000; Rushton, 2001; Rossing et ai, 2001). 
Despite the main motivational factor given by pharmacists for undertaking 
this project as the opportunity to extend and develop the community 
pharmacist's role, there was a lack of patient follow-up and often initiative 
demonstrated by the participating pharmacists undertaking the MMS. 
However, a small number of pharmacists successfully conducted a full MMS 
despite identifying these barriers. This could indicate that the pharmacist's 
motivation is also a major factor towards successful role extension for the 
community pharmacist, and the majority of pharmacists in this project 
were largely responsible for limiting their ability to undertake a MMS role 
due to their lack of motivation. This finding reflects the literature on service 
innovation in community pharmacy, where much of the literature for 
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innovation is characterised by the efforts of individuals rather than 
coherent and structured professional development (Tan et ai, 1996; 
Hepler, 1996; Higby, 1997; Bell et ai, 1998b; Holland and Nimmo, 1999a; 
Rushton, 2001). 
From a sociological perspective, whilst I have argued that some GPs viewed 
the role extension of community pharmacists as boundary extension, the 
data suggests that pharmacists viewed the project as an opportunity to 
have a greater clinical role, and they had neither the motivation nor 
organisational means to encroach on GPs' territory. Conversely, community 
pharmacists had concerns that nurses within the primary care setting were 
encroaching on roles they could potentially undertake. 
9.5 Conclusion 
This thesis set out to critically assess the views and experiences of 
community pharmacists and GPs involved in a MMS after its introduction. It 
aimed to explore how relationship and perceptions of each other could 
influence community pharmacists carrying out a MMS, from the viewpoint 
of both community pharmacists and GPs. 
Whilst the data has suggested that there were good relationships between 
many community pharmacists and GPs, this thesis has identified a number 
of attitudinal barriers that existed between the two professions. These 
included professional hierarchy, GPs' lack of awareness of a pharmacists 
training and role in health care, and concerns that commercial interests 
could potentially affect a community pharmacist's clinical abilities. 
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Furthermore, although some GPs were positive about working 
collaboratively with pharmacists to deliver a MMS, other GPs in this project 
expressed more cautious opinions towards collaborative working. Concerns 
identified included pharmacists' lack of knowledge about a patient's clinical 
history, anxieties about the potential loss of control over patient 
management, increased work load and the scope for boundary 
encroachment was also referred to. GPs in this project were also generally 
unwillingly for the community pharmacist to have full access to patients' 
medical records due to concerns over patient confidentiality being 
maintained. 
From the view point of community pharmacists, this research suggests that 
they were more positive about the concept of the MMS than the GPs, but 
were conscious of many GPs' attitudes towards community pharmacists. 
However, despite many pharmacists viewing the MMS as an opportunity to 
develop their role, many pharmacists did not fully utilise this opportunity. 
Community pharmacists identified a number of barriers (both attitudinal 
and organisational) that they believed prevented them from fully 
undertaking a MMS. Whilst the pharmacists in this project identified similar 
barriers, some pharmacists had managed to conduct a full MMS. This 
Suggests that the individual aspirations and motivation of a community 
pharmacist also contributed as a major factor towards successful role 
development for the community pharmacist. I believe the lack of 
motivation shown by the majority of pharmacists in this project largely 
limited their ability to fully undertake a MMS role. However, as previously 
discussed it is important to acknowledge that there are other issues that 
may impact on a pharmacist's motivation and innovation, such as 
interprofessional relationships with their local GPs. 
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From a sociological perspective I have argued that GPs viewed the role 
extension of the community pharmaCists as potential boundary 
encroachment. Whilst GPs were willing to delegate some tasks to the 
pharmaCist, these were usually roles that had little autonomy and were 
seen to benefit the GP by reducing their workload, rather than utilsing 
community pharmacists' skills in reviewing patients' medication. However, 
I have argued that community pharmaCists viewed the MMS as an 
opportunity to have a greater clinical role, and there was little evidence of 
the pharmacists actively encroaching on GPs' territory, largely due to a lack 
of motivation exhibited by the community pharmacists. Conversely, 
community pharmaCists had concerns that nurses within the primary care 
setting were encroaching on potential roles that they could potentially 
undertake. 
The introduction of this MMS had a limited impact on improving 
relationships and attitudinal barriers between community pharmaCists and 
GPs, with relationships and GPs' perceptions remaining unaltered in many 
instances. I have postulated that this was mainly due to the limited contact 
between the two professions throughout the project so the opportunity to 
improve relationships and break down attitudinal barriers did not arise. 
However, little consideration was given in this project regarding the 
importance in helping community pharmaCists and GPs to foster better 
relationships. This is a pertinent point as these data suggest that where 
there was an established relationship between the community pharmaCists 
and the GPs, the most positive feedback about the MMS was given by both 
professions. 
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This piece of research has highlighted attitudinal barriers between 
community pharmacists and GPs, along with a series of organisational 
barriers that need to be addressed in order to accomplish effective 
collaborative working and allow community pharmacists to undertake a full 
MMS. Future research is needed in order to evaluate how these barriers 
can be overcome. Chapter 10 provides an overview of the literature that 
has looked at strategies and approaches to try and help break down 
attitudinal barriers between pharmacists and physicians and develop 
relationships. 
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10. EPILOGUE 
10.1 Introduction 
In this chapter I wish to give an overview of the literature that has looked 
at initiatives and strategies that have been suggested, or used to break 
down attitudinal barriers and enhance collaborative working between 
pharmacists and physicians. 
The data has suggested that the MMS had a limited impact on improving 
relationships between community pharmacists and GPs, with relationships 
and GPs' perceptions remaining unaltered in many instances. I have 
postulated that this was mainly due to the limited contact and 
communication between the two professions during the MMS. As I 
discussed in chapter 9, I believe insufficient emphasis was placed on 
encouraging community pharmacists and GPs to meet in this project and 
address any attitudinal barriers that existed between them. 
Likewise, role specification, trustworthiness, and relationship initiation have 
all been positively associated with increased physician/pharmacist 
collaborative practice (Naccarell and Sims, 2003; Brock and Doucette, 
2004; Zillich et ai, 2004, 2005). This was reflected in this project, by GPs 
stating that if they did not trust a community pharmacist then it was 
difficult for them to have faith in the pharmaceutical advice given to them. 
Similarly, pharmacists stated that if GPs trusted them then it was much 
easier to convey information to them and GPs were more likely to listen to 
their advice. However, without regular communication, particularly in the 
initial stages of the project, then these issues were also not addressed. The 
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next section of this chapter focuses on the approaches that have been used 
to encourage collaboration between pharmacists and physicians. 
10.2 Addressing collaborative issues 
Reebye et al (1999, 2002) suggested a number of approaches that could 
encourage collaboration (which they termed positive territorialityls) and 
minimise resistance against collaboration (which they termed negative 
territoriality) between pharmacists and physicians. The approaches focused 
on three different areas, each will be discussed in turn. 
10.2.1 Interaction between pharmacists and physicians 
As previously discussed, the participating GPs had a limited knowledge of 
the community pharmacist's role and training. Reebye et al (1999, 2002) 
Suggested that tensions between pharmacists and physicians may arise 
because of physicians' mistaken or limited perceptions of pharmacists. In a 
similar vein, lack of understanding of the pharmacist's role could be one of 
the factors that might lie behind the negatively perceived attitudes of some 
physicians. Adamcik et al (1986) suggested that regardless of how another 
person's social role was perceived, the opportunity to gain first hand 
experience in interaction with that person, allowed the potential 
opportunity for negotiation. If pharmacists and physicians had the 
opportunity to interact directly, for example, via face-to-face 
communication, then previously held stereotypes could be questioned and 
attitudes and values may be changed. Reebye et al (1999, 2002) 
15 Territoriality involves an attempt at enforcing control or access to an area and to things in 
it, as pharmacists i n c ~ e a s e e th,eir roles then t ~ e i r r territory expands. If role expansion is 
accepted by the phYSICian, ~ h l ~ ~ can, b,e, perceived ,to be 'positive territory'. If the physician is 
threatened by the pharmaCist s activities then thiS can be perceived as 'negative territory'. 
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suggested that structured, or even informal, professional meetings 
involving the two parties could be a way forward to Induce collaboration. 
The literature suggests that pharmacist/physician meetings have been 
used to promote patient-centred care to increase interprofesslonal 
relationships (Chen et ai, 1999a, 1999b; Reebye et ai, 2002). For example, 
work in Australia (Chen et ai, 1999a, 1999b), has highlighted the 
importance of breaking down professional barriers prior to community 
pharmacists and GPs undertaking a collaborative service looking at 
medication regimens. They constructed a conceptual framework which 
community pharmacists and GPs could apply in their local environment to 
assist in the smooth implementation, dissemination and establishment of 
new cognitive services within primary care. The model was derived from 
two theoretical models: the Diffusion of Innovations model and the Linkage 
model 16 • In their study, community pharmacists and GPs had an initial 
meeting to discuss the potential for collaboration review, followed by the 
formation of a medico/pharmacy committee to oversee all project 
activities. Meetings were also held to show both parties the proposed 
medication review process. After the community pharmacists had received 
training to undertake medication reviews, both parties had regular 
meetings to discuss the medication reviews. The authors concluded that 
collaboration between community pharmacists and GPs was the key to the 
successful establishment of new clinical pharmacy services in the primary 
care setting. They stated their model encouraged face-to-face 
16 The Diffusion of Innovation model, proposed by Rogers (1983) conceptuallses optimal 
processes for the effective development, dissemination and implementation of interventions 
which aim to induce widespread behaviour change for the overall benefit of society. The 
linkage model, developed by Havelock (1969) represents a strategy for overcoming barriers to 
effective development, diffusion and implementation of the innovation, by the Incorporation of 
collaboration and strategic planning activities between the provider of the innovation 
(resource system) and the user of the innovation (user system) (In Chen et ai, 1999a). 
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interprofessional communication, which in turn helped breakdown barriers 
and helped fostered collaboration between the two professions. 
Reebye et al (2002) have described the situation in the Netherlands. In the 
Dutch system, pharmacotherapy consultation groups (PTC) have been set 
up by the Royal Dutch Pharmacy Association for the Advancement of 
Pharmacy and the National General Medical Association. Most PTC groups 
consisted of five to twelve GPs and one to three community pharmacists, 
who met around six times a year to exchange information about drug 
therapy and work towards guidelines. Community pharmacists and GPs 
were expected to attend these meetings and could gain continuing 
education points by doing so. The whole process was supervised by a 
steering committee of representatives from national organisations of GPs, 
health insurance companies and the Ministry of Health. The authors stated 
the PTCs sessions had enhanced the process of communication between 
physicians and pharmacists in the Dutch primary health care setting. 
Reebye et al (2002) stated the main advantage of these collaborative 
meetings was that it increased face-to-face professional Interaction 
between pharmacists and physicians, and allowed integration of expertise 
from both professions to target optimal prescribing and dispensing. The 
sessions tended to focus on general prescribing Issues rather than the care 
of individual patients. However, limitations of these meetings were noted 
as pharmacists wanting more Interactive meetings, focusing on practical 
issues concerning patient care. 
As previously discussed, in this project community pharmacists and GPs 
were invited to attend a launch meeting which aimed to give an overview 
of the CPMMP. Subsequent meetings were held during the course of the 
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project which provided participants with an update of the progress of the 
project, but participation was voluntary. Little consideration was given 
regarding the importance in helping community pharmacists and GPs to 
foster better relationships by holding joint meetings before the project 
began. Had this been done, it may have allowed some perceptions and 
attitudinal barriers to be broken down and had a more positive effect on 
the participating pharmacists and GPs. likewise, these meetings would 
have allowed the pharmacists the opportunity to discuss with the GPs what 
information they required from the patients' medical records. This would 
have potentially allowed the GP to understand the role of the community 
pharmacist in the MMS, and the opportunity to Inform the pharmacist their 
practice needs. This may have helped ease some of the GPs' concerns 
surrounding community pharmacists having access to the patients' medical 
records. 
10.2.2 Training of pharmacists and physicians 
As previously described in chapter 3, pharmacists received training from 
CPPE prior to undertaking the project. Whilst pharmacists stated they 
believed they had a good CHD knowledge as a result of the training, some 
pharmacists still feared challenging GPs' prescribing decisions. Likewise, 
GPs openly admitted they had a poor knowledge surrounding a 
pharmacist's training and knowledge base. The second area that could 
potentially have had an impact on collaborative working was through the 
provision of interprofessional (or multiprofessional) shared learning17 
17 Shared learning is usually inte,rpreted as students from different professional backgrounds 
learning together (Crow and Smith, 2003). Interprofesslonallearning denotes activities 
involving two professional groups, whilst multi professional learning denotes activities involving 
three or more professional groups. 
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and/or team teaching 18 • This would potentially allow professionals to 
develop knowledge about each others roles, allow high levels of 
interpersonal skills to develop, and an understanding of the contribution 
that each health profession could make to patient health outcomes. It has 
been suggested that multidisciplinary training at both undergraduate and 
postgraduate level may help to improve some of the attitudinal barriers 
which currently exist between healthcare professionals (Horsbourgh et aI., 
2001). Likewise, Parsell and Bligh (1999) have suggested that 
multidisciplinary learning was a potential tactic that may help build mutual 
respect rather than foster competition between the professions. 
Some studies (Carpenter, 1995; Hind et ai, 2003) have looked at attitudes 
between healthcare professionals. Carpenter (1995) demonstrated the 
existence of interprofessional stereotypes amongst health care 
professionals by looking at the stereotypical views of a small group of 
nursing and medical students. They found effective working relationships 
within multidisciplinary clinical health care teams were Influenced by Inter-
group stereotyping, with positive stereotyping enhancing collaborative 
teamwork. They concluded interprofessional education had the potential to 
challenge professional misconceptions. 
Likewise, Hind et al (2003) looked at interprofessional attitudes of health 
care professionals towards their own and other professional groups. At the 
beginning of their pre-registration training, doctors, dieticians, 
physiotherapists, pharmacists and nurses showed signs of high 
identification with their professional group and a strong willingness to 
engage in interprofessionallearning. However, unlike Carpenter's (1995) 
18 Team-teaching is usually interpreted as the teaching of a single group of students by tutors 
from different professional or academic backgrounds (Crow and Smith, 2003). 
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work, students who were positive about their own group also viewed other 
groupS favourably, and the positive relationship between heterosterotypes 
and professional identity was not expected. The authors concluded this 
finding might have been due to the students perceiving themselves as 
belonging to a much l a r g ~ r r group that incorporated all of the students 
included in the study. The students were in their first-year of study and 
were therefore unlikely to have had much contact between professional 
groups at this stage of their course. Therefore the degree and type of 
contact may have proved to be an important factor affecting attitudes held 
about each other. 
Studies have also been conducted to look at the views of healthcare 
students towards interprofessional learning and teamwork (Horsburgh et 
ai, 2001; Leipzig et ai, 2001). Horsburgh et al (2001) looked at the 
attitudes of first-year medical, nursing and pharmacy students towards 
interprofessional learning. At course commencement, the majority of 
students reported positive attitudes towards Interprofessionallearnlng. The 
benefits of shared learning included the acquisition of team working skills 
which were seen to be beneficial to patient care and likely to enhance 
professional working relationships. However, professional groups differed: 
nursing and pharmacy students indicated more strongly that 
interprofessionallearning would lead to more effective team working, 
whilst medical students were the least sure of their professional roles, and 
considered that they required the acquisition of more knowledge and skills 
than nursing or pharmacy students. 
Leipzig et al (2002) also compared the attitudes of second year residents 
(physicians), advanced practice nurses and master level social workers 
towards working together on interdisciplinary healthcare teams. Trainees 
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from each of the professions agreed that interdisciplinary teamwork 
benefited patients and was a productive use of time. Although students 
from all three disciplines were positively inclined toward interdisciplinary 
teamwork, medical students were the least so. The authors concluded that 
exposure to interdisciplinary teamwork might need to occur at an earlier 
point in medical training than residency for physicians as certain attitudes 
had been formed by this point in training. 
Several other studies have concluded that students form attitudes early on 
in their training. Henderson et al (2002) looked at medical students' 
attitudes towards general practice, in the context of undergraduate 
attitudes towards general practice. They concluded medical students ended 
their undergraduate years with a more positive attitude towards general 
practice, and postulated that this could be due to the greater contact with 
GPs they had received during their undergraduate training. They concluded 
that a more balanced, community-based curriculum promoted positive 
attitudes to general practice. 
Likewise, Kritikos et al (2003) studied students' perceptions of ten 
occupations within the medical and allied professions. These included 
community pharmaCists, dentists, dietitians, GPs, hospital pharmaCists, 
medical specialists, nurses, occupational therapists, physiotherapists and 
social workers. Students perceived the health care professions along three 
major dimensions relating to empathy, potency and expertise. On the 
empathy dimension, students rated community pharmacists the highest 
and medical speCialists the lowest. On a potency dimension, students rated 
medical specialists the most powerful, community and hospital pharmacists 
significantly lower, and dietiCians as the lowest. Regarding expertise, 
students rated medical speCialists the highest and dieticians as the lowest. 
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This again suggests that early on in their training healthcare students have 
started to form attitudes about each others role. 
Greene et al (1996) has described a joint therapeutics teaching sessions 
with final year pharmacy and medical students. Interdisciplinary pairs of 
students were assigned a patient with common medical and therapeutic 
problems such as arthritis or diabetes to carry out a series of tasks such as 
obtaining clinical and drug histories. Almost all students who took part in 
this study found the sessions to be useful and there was considerable co-
operation and little 'professional rivalry'. The authors suggested that small 
group problem-based teaching was most effective at encouraging 
interaction between students. They also stated that multi-disciplinary 
teaching, if frequent enough during training, could serve to break down 
unnecessary barriers between the professions when the students entered 
practice. 
The pharmacist acting as a team teacher to medical students has been 
described in the literature (Henley & Wenzel- Warnhoff, 2000; Owen and 
Gibbs, 2001; Cheung et ai, 2003). Owens and Gibbs (2001) argued that 
the pharmacist as an undergraduate educator was a professional colleague 
whose input at undergraduate level could help to overcome attitudinal 
barriers, and facilitate more effective interprofesslonal relationships in the 
future. The authors described a pilot study In which medical students 
explored the role of the community pharmacist by medical students 
arranging to visit the local pharmacy with predefined and discussed 
learning objectives. The evaluation demonstrated that this experience 
changed the medical students' perceptions and understanding of the role of 
the pharmacists. They felt encouraged to make more appropriate use of 
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the pharmacist in the future, whilst becoming aware of the undervalued 
feelings of the pharmacist. 
Henley & Wenzel- Warnhoff (2000) have also evaluated a pilot study of 
medical students being taught under the direction of a clinical pharmacist. 
Medical students found pharmacists teaching about OTC medications 
useful, and although only 60% of the medical students felt the pharmacy 
trip was worthwhile, they showed significant improvement in their 
knowledge. Likewise, Cheung et al (2003) found that 75% of hospital 
doctors questioned indicated they would be happy to attend tutorials run 
by pharmacists to help increase their knowledge about medication therapy, 
and 50% of the doctors interviewed stated they would prefer a pharmacist 
to teach them about drug therapy. 
The literature that has been described has mainly concerned 
interprofessional or team teaching of pharmacy and medical students at an 
undergraduate level. However, there is no reason to suggest that the 
principles described could not be applied to the postgraduate setting. I 
believe that by using either interprofessional training or team teaching in 
this project, this may have helped address some of the attitudinal barriers 
that existed between the two professionals. For example, joint training 
sessions may have allowed the pharmacists and GPs to utilise their clinical 
knowledge more beneficially surrounding a patient's care, and may have 
provided each profession with an insight into each others knowledge base. 
Likewise, the literature suggests the pharmacist acting as a team teacher 
had a positive impact on medical students learning. If GPs could have 
acted as either a team teacher to the community pharmacists, or acted as 
mentors (a role they currently have in supplementary prescribing for allied 
health professionals) to the community pharmacists this may have 
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encouraged a more positive relationship between the two professions. It 
should be noted that the GP qualitative data suggested that some GPs 
believed that community pharmacists would be able to undertake 
medication reviews if they received support and mentoring from their local 
GPs (refer to chapter 7). I believe if GPs had acted as team teachers or 
mentors then it would have encouraged relationships to build, and could 
have helped some community pharmacist's overcome their fear of 
communicating with GPs. As the GP was providing the teaching It may have 
allowed them to feel less threatened by the community pharmacist 
undertaking a medicines management role, because they would have had a 
greater understanding that community pharmacists were primarily wanting 
to undergo this role extension as an opportunity for greater job 
satisfaction, rather than as a chance to take roles away from GPs. If these 
attitudinal barriers could be resolved it could help address the issue about 
community pharmacists having access to patients' medical records. 
10.2.3 Fostering relationships between professional organisations 
at national and International levels. 
The third area that Reebye et al (2002) stated could help address 
collaborative relationships was through fostering relationships between 
pharmacists and physicians organisations at a national level. There are a 
number of examples that illustrate this strategy (Ruth et ai, 1994; Liddell 
and Lloyd, 1994; Anon., 1997; Boivin and Brown, 1997). 
In 1996 the Canadian Medical Association, along with the Canadian 
Pharmaceutical Association, produced a joint statement to promote optimal 
drug therapy by enhancing communication and working relationships 
among patients, physicians and pharmacists. This national agreement 
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stemmed from mandates by the provincial governments, as well as the 
college of physicians, and aimed to promote good co-operation on a local 
and national level between the physician and the pharmacist (Boivin and 
Brown, 1997). 
In Denmark, the Danish Medical Association and the Danish Pharmaceutical 
Association signed an agreement on good pharmacy practice between 
physicians and pharmacists, to try and increase co-operation between 
pharmacist and physicians and ensure quality surrounding patient care 
(Anon, 1997). 
As previously reported within the Netherlands, the jOint meetings between 
pharmacists and physicians came about because of co-operation at national 
level involving governing bodies of pharmacists and GPs. 
In Australia, The Royal Australian College of General Practitioners and the 
Pharmaceutical Society of Australia took the decision to release a joint 
statement on interprofessional communication as a national Initiative (Ruth 
et ai, 1994). The statement gave practical methods on how to enhance 
GP/pharmacist interaction. For example, GPs would use the prescription as 
the principal means of direct communication with the pharmacist using an 
enlarged range of abbreviations and conventions19 agreed between the two 
professions. GPs would also indicate the purpose for which the drug was 
prescribed as part of the directions, which helped the pharmacist provide 
the relevant information and counselling to the patient. Likewise, the joint 
statement stated that both professions should use verbal communication 
19 For example, NT - New/Replacement Treatment. This would indicate to the community 
pharmacist that the patient would need to fully counsel the patient on the new medication. If 
it replaced another medicine, the prescription would Indicate which medicine the new 
treatment replaced and the pharmacist would withdraw any unused repeat prescriptions for 
the superseded medications. 
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(either face-to-face or via telephone) to convey information to the other, 
particularly if it was of an urgent or confidential nature. Pharmacists would 
also use a written referral form (again, agreed by both professions), for 
communicating non-urgent information to the GP. The form was designed 
so that the GP could acknowledge referral when appropriate. It was hoped 
that this expanded and enhanced communication would lead to patients 
receiving more consistent and relevant Information about their 
medications, and enhance relationships between community pharmacists 
and GPs (Liddell and Lloyd, 1994). 
If the NHS is to enhance interprofessional collaboration this piece of 
research suggests that community pharmacists need to be more effectively 
intergrated into the primary health care team. Tactics at both a strategic 
and local level need to be implemented to try and help foster relationship 
building between pharmacist and GPs. 
10.3 Summary 
This piece of research has highlighted a series of organisational and 
attitudinal barriers that need to be addressed in order to accomplish 
effective collaborative working between community pharmacists and GPs. 
Therefore, in order to develop and establish the provision of new services 
in the primary care setting, there is a need to nurture the development of 
close working relationships and address attitudinal barriers that may exist 
between community pharmacists and GPs. Tactics that may be used 
include, regular structured or informal meetings (prior to and during a 
collaborative venture), interprofessional or team learning, and fostering 
relationships at a national level. The aim of all these strategies is to allow 
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regular communication to occur, gain a greater understanding of each 
professions role and to develop trust between the two professions. 
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Appendix 2 
community Pharmacist Semi-Structured Interview Questions 
(Pilot Data Collection) 
1. Why did you decide to participate in this project? 
Establish motivation to participate - changes in practice, financial, who 
e.g. PDGs/PCT, owner of pharmacy? 
2. Before you were approached to participate in this project, did 
you have any prior knowledge of medicines management? 
3. How would you define medicines management? 
4. What do you see as the effects of medicine management? 
5. How do you see this project working in practice? 
Has it worked? 
If there are problems, what are they and how have they occurred? 
What have been the benefits? 
6. Do you feel that in the future this is a realistic role for 
pharmacists to carry out? 
Why? 
7. If this role does continue, do you see this having an effect on 
any other areas of your role? 
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Do you perceive these changes to be beneficial or detrimental? 
8. Have you ever participated in any other community pharmacist 
research projects before? 
. If yes, how do you feel past experience will help you undertake this 
project? 
9. How do you feel about pharmacists taking a more active role In 
patient care? 
Do you think this will create more job satisfaction for you? 
If yes/no - why? 
Do you think this will create more job satisfaction for pharmacists 
generally? If yes/no - why? 
10.00 you think pharmacists have the necessary knowledge and 
expertise to undertake this expanding role? 
11.Did you feel you had a good knowledge of coronary heart 
disease and the NSF for CHD, prior to training received for the 
medicines management project? 
What information sources do you use? 
Do you keep up date with current guidelines/recommendations? 
12.Did you feel you received adequate training from this project to 
enable you to carry out your duties? 
13.What was the training like? 
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Were there areas that were covered in too much/too little detail? 
How could it be improved? 
14.How did the patient consultations go? 
Good points/problems? 
15. What is your working relationship like with the doctors In your 
area? 
Has the relationship improved/worsened since commencing the 
project? 
16.How do you feel about potentially challenging a doctor's 
decision? 
Do you feel you have the necessary skills and experience to 
challenge a doctor's decision? 
17. Do you ever challenge doctors' decisions? 
18. How does it make you feel? 
What would you do if you felt a patient's medication needed 
altering and the doctor refused to change it? 
19.Have you ever had any urgent interventions? 
What did you do? 
20.00 you have any concerns about using patient's medical notes? 
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21.Do you have any concerns with having to document your 
recommendations? 
22.1n what ways do you feel this project will alter your relationship 
with your patients? 
23.How do you feel about providing health promotion advice for 
patients with CHD? 
Do you think health promotion advice is effective - examples? 
Have you received any training, or do you have any strategies in 
giving health promotion advice? 
24. What do you hope to achieve from taking part in this project, 
personally and for your pharmacy? 
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Appendix 3 
Focus Group Confirmation Letter Sent to Community 
Pharmacists 
Dear (Pharmacist's name) 
Re: The Community Pharmacy Medicines Management Project -
Pharmacist Feedback Meeting. 
On behalf of the Research Team, I would like to invite you to a pharmacist 
feedback meeting. This will be held at: 
Venue: 
Date: 
Time: 
Finger buffet will be provided. 
The aim of the meeting is to get feedback about your views and experiences of 
the project so far. This will form part of the ongoing evaluation of the project 
currently being carried out by the Research Team. 
If you are unable to attend or require any further information, then please do 
not hesitate to contact me on 0115 8467321. 
Thank-you in advance for your help 
Yours sincerely, 
Stacey Sadler 
Research Fellow (Nottingham) 
On Behalf of the Research Team 
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Appendix 4 
Focus Group Invite Letter Sent to Community Pharmacists 
Dear (Pharmacist's name) 
Re: The Community Pharmacy Medicines Management Project -
Pharmacist Feedback Meeting 
Thank-you for agreeing to attend the pharmacist meeting to provide feedback. 
I am pleased to confirm the meeting will be held at: 
Venue: 
Date: 
Time: 
Finger buffet will be provided. 
As discussed, the aim of the meeting is to get feedback about your views and 
experiences of the project so far. This will form part of the ongoing evaluation 
of the project currently being carried out by the Research Team. 
If you are now unable to attend or require further information, then please do 
not hesitate to contact me on 0115 8467321. 
Thank-you in advance for your help. 
Yours sincerely, 
Stacey Sadler 
Research fellow (Nottingham) 
On behalf of the Research Team 
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Appendix 5 
Community Pharmacist Framework Topics for the Focus Group 
Introduction: 
- Introduce 55, DS /PB & role in meeting. 
Reiterate purpose of the focus group. Encourage input/opinions/examples 
of experiences. 
Explain re: taping - stress importance of not speaking over each other. 
Focus group ground rules: based upon social conventions & basic research. 
- Any questions? 
Begin recording: 
- Ask attendees to introduce themselves (name & up to 2-3 sentence 
summary of their thoughts of the experience to date - will help transcriber 
with voices, get them all involved. 
NB: Encourage examples! Encourage input from everyone. 
1. How have the patient conSUltations gone? (30-35mins) 
Aim to ascertain: 
Li kes/ disli kes ... positives/ negatives etc 
- Whether made medication interventions 
Whether lifestyle interventions made 
Whether had concerns with challenging doctors' prescribing decisions 
If they (pharmacists) feel health promotion advice is effective 
Remuneration -difficulties/plus point to project? 
If require extra information on forms 
If any home visits 
How long patient consultations have taken? 
Patient's perception of the service e.g. asking questions/patient's 
knowledge of their condition 
Summarise and give opportunity to comment 
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2. Why did you choose to participate in this project? (S-10mins) 
Aim to ascertain: 
What motivated them (e.g. financial? no choice? increased job satisfaction? 
increase clinical skills?) 
(Probe) whether they would do this service if no payment 
What they hope to achieve from taking part. 
Summarise and give opportunity to comment. 
3. How do you feel about undertaking a more active role in patient 
care? (lSmins) 
Aim to ascertain: 
Whether pharmacists should be doing this role and why. 
What they feel their limitations are. 
How it affects their relationship with (1) patients and (2) GP's (establish 
what their current relationship is like) 
Likes/dislikes, benefits/concerns about expanding role. 
Summarise and give opportunity to comment. 
4. How has the project worked in practice? (20-25mins) 
Aim to ascertain 
Good/bad practical points 
(Find out) when/where have been doing interviews 
Whether participating pharmacists feel this is a realistic future role 
If they believe medicines management can work/is it value for money? 
Summarise and give opportunity to comment 
5. What was your prior knowledge of medicines management 
before commencing this project? (5-10mins) 
Aim to ascertain 
Feedback about the training sessions 
Whether pharmacists would require training to undertake expanding role 
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Appendix 6 
Community Pharmacist Semi-Structured Interview Schedule 
1. How have the patient consultations gone? 
Aim to ascertain: 
_ Likes/dislikes ... positives/negatives etc 
_ Whether made medication interventions 
_ Whether lifestyle interventions made 
_ Whether had concerns with challenging doctors prescribing decisions 
_ Do they (pharmacists) feel health promotion advice is effective? 
_ Remuneration -difficulties/plus point to project? 
_ Require extra info on forms 
- Any home visits 
- How long have patient consultations taken? 
- Patient's perception of the service e.g. asking questions/pt's knowledge of 
their condition 
2. Why did you choose to participate in this project? 
Aim to ascertain: 
What motivated them (e.g. finanCial, obligation, increased job satisfaction, 
increased clinical skills) 
(Probe) Whether they would do this service if no payment 
What they hope to achieve from taking part 
3. How do you feel about undertaking a more active role in patient 
care? 
Aim to ascertain: 
Whether pharmacists should be doing this role and why. 
What they feel their limitations are. 
How it affects their relationship with (1) patients and (2) GPs (establish 
what their current relationship is like) 
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Likes/dislikes, benefits/concerns about expanding role. 
4. How has the project worked in practice? 
Aim to ascertain 
Good/bad practical pOints 
(Find out) when/where have been doing interviews 
Whether participating pharmacists feel this is a realistic future role 
If they believe medicines management works/is it value for money 
5. What was your prior knowledge of medicines management 
before commencing this project? 
Aim to ascertain 
Feedback about the training sessions 
Whether pharmacists would require training to undertake expanding role 
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Appendix 7 
community Pharmacist Semi-Structured, Follow-up Interview 
schedule 
1. Can you give your overall impression of the medicines 
management service? 
Can you sum up your experiences of the project? 
Overall, has being involved in the project been a positive or a negative 
experience for you? 
How has it impacted on your relationship with patients? Why? 
Do you think the service has enhanced your status as a health 
professional? In what ways and why? 
Would you take part in other studies / service development projects? If 
not, why not? 
What motivated you to take part in the project initially? 
2. Do you think that this model of medicines management works in 
community pharmacy? 
If not, which aspects do you think do not work? Why is this? 
What has been the major problem with this model of medicines 
management? 
How could it be improved? 
Do you think pharmacists should be providing a medicines 
management service in this form? 
What are the barriers (if any) to them providing these services? 
3. Do you think the service represents value for money for the 
government? 
Financial costs vs. clinical benefits 
Did you feel the pharmacist payment was adequate for the amount of 
work you had to do? 
4. Has this project improved your relationship with your local GPs? 
How? 
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If not, why not? 
5. What was your relationship like with your GP pre- medicines 
management? 
6. Do you think having an established relationship with your local 
GPs, impacts on the success of a medicines management 
Service? 
Why? 
7. What have you achieved by taking part in this project? 
What did you hope to achieve? 
If didn't achieve this, why not? 
8. What was the outcome of your clinical or lifestyle interventions? 
a) Followed up 
b) Do not know 
c) Not followed up - if not, why not? 
Get examples of the kind of interventions that were made 
9. Have you followed-up the patients that you initially interviewed 
on subsequent occasions? 
How have you done this? Arranged interview, or done it 
opportunistically? 
If not, why not? Establish reason e.g. lack of time, patient did not 
require one 
Did lack of money affect whether you would re-interview patients? 
10. What impact do you think your consultation had on patients' 
understanding of health promotion messages? 
11.00 you think your consultation affected patients' health 
behaviours or compliance with medication in any way? 
Get examples 
If not, why not? 
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Can a 30 minute interview have much of an impact on a patient's 
health behaviour/compliance? 
Do you think the consultation improved patient's knowledge about 
medicines/CHD? 
Do you think your approach to the consultation is different in any way 
to that of GPs? In what ways? 
12.What style of patient consultation did you adopt? 
Did your consultation affect patient concordance in any way? 
Examples 
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Appendix 8 
Letter Sent to Practice Mangers Requesting GP Interviews 
Practice Address 
Dear (Practice Managers Name) 
Re: The Community Pharmacy Medicines Management Project 
As part of the on-going evaluation of the Community Pharmacy Medicines 
Management Project it is important for us to obtain the views and experiences 
of the GPs taking part in the project. Their views will form part of the final 
report about how the project has worked in practice. 
I am writing to ask if you could inform the GPs in your practice that they may 
be contacted by Stacey Sadler, a Research Fellow in Nottingham, to take part 
in a telephone interview. The interview would take place at a time convenient 
to them and would take approximately 20 minutes to complete. Miss Sadler 
will be contacting them in the next few months to see if they are willing to do 
this. 
If you or your GPs have any queries about the interview, please feel free to 
call me on 0800 015 1419 or Stacey Sadler on 0115 8467321. 
Thank-you in advance for your help 
Yours sincerely, 
Mariesha Jaffray 
Trial Co-ordinator 
On behalf of the Research Team 
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Appendix 9 
GP Semi-Structured Interview Schedule 
Outcome measures: Professional satisfaction, perceived benefit/effect on other 
aspects of role e.g. workload. GET EXAMPLES! 
1. How do think this project is working in practice? 
If there are problems, what are they and how have they occurred? 
What have been the positive points of the project? Why? 
2. How has this project impacted on your day-to-day workload? 
Have you received much contact from pharmacists during the project? 
Has there been adequate time to meet up, phone/e-mail etc with 
pharmacists? 
Has there been adequate time to read paperwork/ 
recommendations? 
3. When you have received recommendations from the community 
pharmacist, what have you done? 
Have the recommendations been appropriate? - get examples 
If not, why not ..... get examples 
Did you feel your CHD patients were already on the recommended 
regimen of drugs? 
If so, have you been surprised at the interventions made by 
pharmacists? 
4. What is your working relationship like with the pharmacists in 
your area? 
Does your practice have a practice pharmacist? If yes how do they 
differ from community pharmacists? 
Has the relationship improved/worsened since commencing the 
project? 
How would GPs as a population react to a closer working relationship 
with pharmacists? 
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5. What do you think about the pharmacist's role in reviewing 
patient's medication and having an increased input into patient 
care generally? 
Advantages/disadvantages - what are they? 
Is it a good thing? 
Why do you think community pharmacists role is changing? 
6. Do you think pharmacists have the necessary expertise/training 
to carry out this role? 
If no, what do you feel they lack? 
Can they provide this MMS without having access to patient notes? 
Are there specific areas in which you feel pharmacists could have more 
of a beneficial role? 
7. Do you feel this project will involve a 'shift in roles' between 
pharmacists and doctors? 
If yes, what do you think the changes will be? 
If no, why not? 
Will it affect your job? 
8. Do you feel that a community pharmacy is an appropriate 
setting to review patient's medication? 
Is it private enough? 
9. Have you received any feedback from your patients about 
this project? 
Have patients liked it? 
Has it increased their knowledge? 
Have you had feedback from other colleagues? 
lO.Why did you decide to participate in this project? 
Your motivation to participate e.g. changes in practice, financial, 
obligation? 
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11.Would you support the project being rolled out nationwide? 
Would you support it for other disease states? 
Would you support it continuing in CHD in this PCT? 
If not, why not? 
What are the likely limits on it being funded in a PCT? E.g. costs in 
relation to other services? Priorities in relation to other services? 
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Appendix 10 
GP Semi-Structured Interview Schedule (Version Two) 
Outcome measures: Professional satisfaction, perceived benefit/effect on other 
aspects of role e.g. workload. GET EXAMPLES! 
1. What do you know about this project? 
How did you get involved? 
Did you feel obliged to get involved? 
Did you go to the meetings? 
How involved were you in the development of the project? 
2. How do think this project is working in practice? 
If there are problems, what are they and how have they occurred? 
What have been the positive pOints of the project? Why? 
3. How has this project impacted on your day-to-day workload? 
Have you received much contact from pharmacists during the project? 
Has there been adequate time to meet up, phone/e-mail etc with 
pharmacists? 
Has there been adequate time to read paperwork/ 
recommendations? 
4. When you have received recommendations from the community 
pharmacist, what have you done? 
Have the recommendations been appropriate? - get examples 
If not, why not.. ... get examples 
Did you feel your CHD patients were already on the recommended 
regimen of drugs? 
If so, have you been surprised at the interventions made by 
pharmacists? 
5. What is your working relationship like with the pharmacists in 
your area? 
Have you done any previous projects with the community pharmacist? 
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Do you trust/have confidence in your community pharmacist? 
Does your practice have a practice pharmacist? If yes how do they 
differ from community pharmacists? 
Has the relationship improved/worsened since commencing the 
project? 
How would GPs as a population react to a closer working relationship 
with pharmacists? 
6. What do you think about the pharmacist's role in reviewing 
patient's medication and having an increased input into patient 
care generally? 
Advantages/disadvantages - what are they? 
Is it a good thing? 
Why do you think community pharmacists role is changing? 
7. Do you think pharmacists have the necessary expertise/training 
to carry out this role? 
If no, what do you feel they lack? 
Can they provide this MMS without having access to patient notes? 
Are there specific areas in which you feel pharmacists could have more 
of a beneficial role? 
8. Do you feel that a community pharmacy is an appropriate 
setting to review patient's medication? 
Is it private enough? 
9. Have you received any feedback from your patients about this 
project? 
Have patients liked it? 
Has it increased their knowledge? 
Have you had feedback from other colleagues? 
10. Why did you decide to participate in this project? 
Your motivation to partiCipate e.g. changes in practice, financial, 
obligation? 
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11.Would you support the project being rolled out nationwide? 
Would you support it for other disease states? 
Do you think this type of service is sustainable? 
Would you support it continuing in CHD in this PCT? 
If not, why not? 
What are the likely limits on it being funded in a PCT? E.g. costs in 
relation to other services. 
Priorities in relation to other services. 
Who should fund a MMS? 
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